<SEC-DOCUMENT>0001558370-25-011471.txt : 20250814
<SEC-HEADER>0001558370-25-011471.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814070553
ACCESSION NUMBER:		0001558370-25-011471
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		251214253

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20250630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.0.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 8/14/2025 8:45:15 AM -->
<!-- iXBRL Library version: 1.0.9292.28120 -->
<!-- iXBRL Service Job ID: f31fea05-5b4b-4b03-ad43-ff0fad6e9499 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:plx="http://www.protalix.com/20250630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>PROTALIX BIOTHERAPEUTICS,&#160;INC._June&#160;30, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" xs:nil="true" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_cOJM3k19jEKfhTTecRZJkg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" xs:nil="true" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_4U70dJ4GK0W4puB6oxSofA"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityCentralIndexKey" id="Tc_kZ_6tRgi40qD0m3HqGY9Fw_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:CurrentFiscalYearEndDate" id="Tc_DmY_RMzHM0ifweaXqHkASQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:DocumentFiscalYearFocus" id="Tc_8ep4FMvZY06pYa_cC5vnAQ_4_1">2025</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_6j1qiv0cgEyyA-yQJOpFqg_5_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:AmendmentFlag" id="Tc_BKs-kREKDUWBkH2Mur8iHA_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_segment_EaaV5hI0qEadWpzP0cmK2A" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="INF" name="us-gaap:NumberOfOperatingSegments" id="Hidden_aiZWtzxgnU-JSOrCWSBBBw">1</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20250630.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gv3VRwsmA06TTm6sQUN6DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BEtiHKEg5kuzpUuHsr_wSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qLRTrEx8eUKQia7ENmBkMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2LLqvubzfE2_bgUOB4p5ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_Jmty4GTo6k21zaIY9WJ2NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_z3i-FDaHlE-BZ9GIL0jWNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n5C0Tv5uoUusGQMN1w0I-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oBjoUu4mDkqIlAPbHCD0BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YOsx-bZkqUqqRJ-r5Udi3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9h5JLRuXP0SrzhRzTBu5HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bNcrB3tI4keRMneOxkJ39w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_AdauIPbP4UuVFiRvmL4s7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ShmDYwDjqEWRMkqNQoAC2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FH48IkEeXkKYk6m4HHmdOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_NTtOh_tj50iF28Xo4DEnjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JAoE3eeC006wm5kUxnCZQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_afsyJr4hf0OEKhekB3AHYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_6_coWg2e90CjjtM9azRMBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_mBt_DhnwSkaQSv72fYtQQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_iejKZn67F0Sf2DaGIlWrig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Ry9eJBFRY0aWUriRJJoWPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_lOvXmD6MgESV0B-omrPS4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_YHDGlfD_AUaicoScEusHeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_GrF2myzJiEqbTvJY60IqmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_c_PLLEX5ekOtxFhMT3jjag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_W2wc6JkTt0WlVF693XXzxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_Nr4z7GCvjkSm2YfF7bwdZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember__Vfwx-5_M0Cu0g0xtW7Dkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_LpkP8tV3j0qgmNzcnf0nig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_r_xBq1FYmEe1hu9bPCmlCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_71I2lv4f9kWJWcfI-ONvvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_yAabyI-paEuRtn18CZC1RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_Qa6aQzsVJ062wE77uGETpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_vu813cbeqECqUyYxxfs3Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_ls4KWM6TWU2ieTyrmZgYpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_rUd6RnaD1Ea21Qe6MwDvwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_BskKyxhG5ketf2PCSTzhyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_6_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFHYyBQEPE2I_t5p2bioTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_8_14_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_kUAPHqMvy0ainpcMZtiRig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_8_14_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_DphnniDSq0SBx-JnoOYjZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yRXKgj1-r0me-ISDulhcmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iTnaGMElH0yBObH0OL-TXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rW77dB4dWESXNLR4EYGmyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GYqZURE_wUWCBx0IiGtJdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_J-bqAQI5xUiCwzpV-Gys5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIdlrBTkX0WJBo8z2nuPEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5IUo4MDNeU-PF-knaxHuhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tD6aS3nTtkSRjdsTuc_j0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gnSYRAKnVUCk2W-avLWlNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F5dDIxgUX02lMffBZpl-QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K54wRCnebE-ZiUifv4iNAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_YPPSNBqug0mazz_yBXPpwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_12_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_KdZmUKvKIEagwl1U2B1ZLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_wf2iuAS66kiC7r9Ko2A7aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_SSEd4QlqZ0ixMnchHstv9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_6_30_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_OSrevicPJEyApi98O9HZYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_H3oHw-vHw0emnoAUC9JBzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_xTNzdzPaT0qCf53ldUBTUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cCx29kPpekObSCYrlCS5HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaZNoHa79k-oQmE30hl7Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M2e2ab-8O0Wf_GeW-n8L5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BTZY9KQhX0ONpZ7wFZENbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IMn_qGh8rUiSVtUpQ531fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wzsUdUWAf0Cbd6Wi9_SGbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ETC7kP5_4Eeir_fPIkYRjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CkeeA2C0XEG0WPbHArw-rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-20</xbrli:startDate><xbrli:endDate>2025-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2W9cGUF6_ESGJ2hjWELYOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_H8A_3lY72U6nRHPcehodwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_FzEf68MnnECijIQBxIjdcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_17_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_DSLkWT434UONxCiW0FQpqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_1NEZJ566u0G9wZB2EoTpTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_1_2025_fYC8XQZBJkm4PqOx0h4hqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_R6tg8LdwCUeUoAN2h0xL2A"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_ZMevQBZ1KEOi7rMSOC56JQ"><xbrli:measure>plx:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_EaaV5hI0qEadWpzP0cmK2A"><xbrli:measure>plx:segment</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_8DGpfWJ6u0yrb1j10aB90g_10_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_E59k4yziiUa67x_HxpXThA_24_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_1cUpthGGJEqf6itNfIU1ZA_18_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_1gTmG3hllU66Zqf80x33Nw_32_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_JUsHG8EYSEWT6N4MJbloMQ_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_rM1xId7NxkWW208M0pKjng_21_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_qBTNBNI8cE-e-oypr6TgsQ_26_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_MHpHHWRQRUW2J_oQ3TlEYQ_12_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_5YdKmLQiKkezM06rF9KC3g_13_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_hlYrSjoLfkmyEVTMYIoDcw_27_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_VvyQGZl5rE-JlitgqqJ8gg_34_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_SimVJaL030ORTwulZYu9zw_20_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_R6K5a9hlw0WIYzXuvs9mOw_15_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_iNSN0warEkSepi8qJ6f5lw_29_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:9.2pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f4b911a2_9311_4ad1_a505_d65f5117b66a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:DocumentType" id="Narr_v27Ua5ytwkWaXkxlsYTPMw"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:DocumentQuarterlyReport" id="Narr_zpqmh-1sTkCN4NwzSGoAiw"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:DocumentPeriodEndDate" id="Narr_Hs2UOoK0EkigRFJdicpwyA"><b style="font-size:8pt;font-weight:bold;">June&#160;30, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:DocumentTransitionReport" id="Narr_aFaMN9W0W0ac3zsKbgntyw"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityFileNumber" id="Narr_XMIFlgmdrEO8CCTcJ4rV4g"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityRegistrantName" id="Narr_hpZWivxxXUa7ed8wORdmYQ"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_ORqsYSOlo0qGLBNGJBQ2qA_1_1"></a><a id="Tc_xl05fe1qnUiv-cGP1hOxLA_2_0"></a><a id="Tc_dKDCqJ46jkWXWaJPzQGKgw_2_1"></a><a id="Tc_dqVBvoVlmE-aUGiw5SNOAQ_4_0"></a><a id="Tc_vywNpi9tV0KPtszwWKPKrg_5_0"></a><a id="Tc_pxPF2nQuy0isGZBpXacbyQ_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_qvBBsVyFRki5h1sXt7PfKg_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityTaxIdentificationNumber" id="Narr_ib9PUXWHf0eMIWSckxY2Rg"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityAddressAddressLine1" id="Narr_D7S7SqupzU-pjDTiH3Pxtg"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityAddressAddressLine2" id="Narr_KmDWrM7ETkuOXmgEVElzxw"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityAddressCityOrTown" id="Narr_27_-6j2Ui0CHoSY0LN-hGQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityAddressStateOrProvince" id="Narr_K_GVvhQSWkGVKY5MVuNdWg"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityAddressPostalZipCode" id="Tc_mzC_mhp5Y0ujYWsWhuZOzg_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:CityAreaCode" id="Narr_ViFkkS48QUu655tpdOeRJA"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:LocalPhoneNumber" id="Narr_-75lLX_ZpkmddED0v0XeYA"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_bg0-R3yfGE2xqaibY8eaNQ_1_0"></a><a id="Tc_rG3tiqooWE2l0fXbsIWdOA_1_2"></a><a id="Tc_-0V3K87iWUeBzK1tZGoihQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:Security12bTitle" id="Tc_pz2-9OcpxEq2CkmxLTP1zA_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:TradingSymbol" id="Tc_4QDRQsKIQEexJ0DXR7wWYA_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:SecurityExchangeName" id="Tc_NEeTDIuDCU2ywFpiyNKlhA_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityCurrentReportingStatus" id="Narr_g510MsPjukCHIbrQHDHSkQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityInteractiveDataCurrent" id="Narr_VRta75Evbku7IxM7K13mzA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_WVKS1joXBUuG2UizeuvGjw_1_0"></a><a id="Tc_7-EMmlBtNUapYB8GOSHlNA_1_1"></a><a id="Tc_MYOsDx5L9UWvdwX9iU8iQA_1_2"></a><a id="Tc_SV9I_E5nnUCzLkxE0Mc9uQ_1_3"></a><a id="Tc_dnKcTYsYekm9kzJXxoV29A_2_1"></a><a id="Tc_RT1E77Jir0SQalv51HEAIg_2_2"></a><a id="Tc_j366r72v_kmG8FKhday9KQ_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityFilerCategory" id="Tc_BObzVYBzUkCtPQN9DP6aTA_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntitySmallBusiness" id="Tc_IodOZtfmgkGJMgydISo8BA_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityEmergingGrowthCompany" id="Tc_Kze4C0xGg0mNTqXm4mYTkg_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="dei:EntityShellCompany" id="Narr_jTcWcpimbEGL0py4rt-7vQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On August&#160;1, 2025, approximately <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_8_1_2025_fYC8XQZBJkm4PqOx0h4hqA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_CT8oyPXhc0KUPIXEvwKF1g">79,732,115</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_40bada46_bd9f_4c80_8e35_4c6f1c96a847"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-style:normal;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; As of June&#160;30, 2025 and December&#160;31, 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Six and Three Months Ended June&#160;30, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in </span><span style="font-style:normal;font-weight:normal;">Stockholders&#8217; Equity </span><span style="font-style:normal;font-weight:normal;">(Unaudited) &#8211; For the Six and Three Months Ended June&#160;30, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Six Months Ended June&#160;30, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-style:normal;font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">37</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b90f68b4_1992_4159_915f_84780616bc30"></a><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_ppmnMb1kWkivS0dYN5aCvw_1_2"></a><a id="Tc_vPTYfpkgEU2MIWHgb7IayA_1_5"></a><a id="Tc_EkQYo8pKG0Ov1H49Fa9QEA_3_0"></a><a id="Tc_hmYcTubPH0u8-xts2Lq6-w_5_0"></a><a id="Tc_EHtYH5t5e0u4mC3FT4uldw_6_0"></a><a id="Tc__EBKonfg5k-tjVJb_eF6XA_6_2"></a><a id="Tc_jiLUno58sk-5UsuS8-Uwmw_6_5"></a><a id="Tc_aEFAvvqjVkS0ok83cYI0cg_7_0"></a><a id="Tc_fURmGjHu4EamTmpQ6bH2Mg_8_0"></a><a id="Tc_TIPsVDUFm0WfqOgR0verNA_9_0"></a><a id="Tc_eSeoPmOULkyRmBxLLAEcIw_10_0"></a><a id="Tc_sDVJL2WkWEKeC8i2nE4IFw_11_0"></a><a id="Tc_daB5CibvrEOiyFpfMZqleg_11_2"></a><a id="Tc_5pcMXxuCgk-n6JmF4Y7vMg_11_5"></a><a id="Tc_opfzFc3-2keW9Gmq8YbuDQ_13_0"></a><a id="Tc_CxeGP3GH5ESHpmi5CX67Ew_14_0"></a><a id="Tc_vKHJzy5jWkGfLKHQ1RGiOw_14_2"></a><a id="Tc_n7ykM8jbH0-1UcbbZD5BHA_14_5"></a><a id="Tc_3HZu-vEv_keIXtbuNZ_WmQ_15_0"></a><a id="Tc_Qkc8aDO2skeNvvqUnQaOhw_16_0"></a><a id="Tc_4dkg6Kah10muXyJh0k2jMQ_17_0"></a><a id="Tc_E3Y2gcp-pUGbzjTEElDxxw_18_0"></a><a id="Tc_zAF18ku9s02BLH1zI8QCpw_18_2"></a><a id="Tc_18x1eSoYQ0alEt8sc4lgXw_18_5"></a><a id="Tc_ZxSle4sRbk2YEsx2H1bKow_20_0"></a><a id="Tc_PIu-ULfyWk-Z9ttVukmJ7w_22_0"></a><a id="Tc_UYpw7gksdEiR7yNFzfmnFA_23_0"></a><a id="Tc_ew85kp98CkSUYfZSY0g2ag_24_0"></a><a id="Tc_o3fUQADpEU2YQ-5ZtAbKig_24_2"></a><a id="Tc_uNDll6gHsEerIy2uMAGDEA_24_5"></a><a id="Tc_0rH5lRARokyUdvd-nW2knQ_25_0"></a><a id="Tc_vb4aT3vxcUmoaok_aAL1Rg_26_0"></a><a id="Tc_rIDPYXzbNU-VEQvIgWxvtw_27_0"></a><a id="Tc_1qgbirWU702DC2kJ29iXvg_27_2"></a><a id="Tc_KDsCkFq20UWglPaU8-wVHA_27_5"></a><a id="Tc_lZZLowjrMEy7XhPIuBRDGA_29_0"></a><a id="Tc_d3Z7_oy7o02TF4QckseXrg_30_0"></a><a id="Tc_AYql9DjwmEG-ZytJ9b_lLQ_30_2"></a><a id="Tc_HJRPSfta_02KO6ny7RpMtg_30_5"></a><a id="Tc__O3ulZ4r80iHA9kgeoc_hQ_31_0"></a><a id="Tc_5rkYcF3ffEKPNgG3tIDd5g_32_0"></a><a id="Tc_lMs1qj_mzE2YTbGT9s-eQQ_32_2"></a><a id="Tc_bU0GugdFp060xv_Xbm4XJw_32_5"></a><a id="Tc_aWGSN62WSEaHnTTMUIF6MA_33_0"></a><a id="Tc_PY_kYwZRlU-Hn1AvuthLAg_33_2"></a><a id="Tc_GBdr8SvGg0yyAbWGIv9-Kg_33_5"></a><a id="Tc_H9mrwH8HNE-P61r-QI7CHA_35_0"></a><a id="Tc_tZAmKwCjikq7dqFU9v9rcg_37_0"></a><a id="Tc_XkM3Ux1bUkSCECHUug1p3w_38_0"></a><a id="Tc_ObbemAsBAEG5E-Y0jZ3uuA_38_2"></a><a id="Tc_UGK6wjpfsUqyZYUD4JZQHA_38_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_XfAfRvdhsUOoizLeLGejAQ_6_3">17,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_v1W4phlgE02DkDq58-I5pA_6_6">19,760</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_qNIKoWPI3U6uprF3Bl5i4g_7_3">15,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_cdm9dUmhSEGuTRYuiVRxiQ_7_6">15,070</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_BK2F2gXxX0-r480hVimJSA_8_3">9,443</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_wIHtag8aYEO4eqaAMcnifQ_8_6">2,909</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_Vb84A8yWaUW5HCok-Tjl5A_9_3">1,513</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_6dxKD7sKtkepYRV6Nv5vCA_9_6">1,096</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_Mh-YSV3sA0iWnPmGu4-pZA_10_3">21,131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_0JvZdd0Xpka1XrcmUWqs4w_10_6">21,243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_krv5d6X93ka8Be34jAc6KQ_11_3">65,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_doCgr-5_Kki-ifknwp36nQ_11_6">60,078</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_Q8m0TvZJpkWEomDFO8I6XQ_14_3">520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_PE6oGEJ5skG5810NjfUgbw_14_6">462</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_U9WoFAu_L0yro9tEuAgJ6A_15_3">4,746</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_Cak5XelPv06qMvxnDm8a4w_15_6">4,591</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_R4qXwVESIE-ELF0x0nYeYA_16_3">2,738</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_kBLWp95tPEaMB0mWobx_tQ_16_6">2,856</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_L17wekQGHkOZ9B_iWHBsXg_17_3">4,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_PYGiS7XGVUO-DsY3oooB6g_17_6">5,430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_XeouVCUKw0as3cFsx8ZL_g_18_3">78,486</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_ODLBcq1A70C61-Zvja3KnQ_18_6">73,417</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS' EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_TPtzeHpuUkSZ3cutDUqQBw_24_3">6,689</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_XmcRuLU3O0umxwwHKKfUgA_24_6">4,533</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_sI50Z7KyfUKtBffgtQ2Dew_25_3">15,930</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_xYi1yx6MPU6f6xpniwWL-w_25_6">19,588</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_qng1FHGABki1GYCtUqzAFA_26_3">1,472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_KNSMm4m6gUKt6PjkJf69pQ_26_6">1,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_tiGR7UPWZkCYVCXQH8-jEQ_27_3">24,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_zh-CofGns0iRxLUCMbWbSg_27_6">25,621</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_r8MSCMCXhUq8TLe3KnvLYw_30_3">615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_c6d38trI4USXCzyo_FrQUw_30_6">559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_IW3EQgYK_Eewhq1YMlQ5DA_31_3">3,877</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_v9IqnyB7GEmJruy5LcPKWw_31_6">4,026</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_dcFk0a5cTEOZEjx8vhjiTA_32_3">4,492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_6S2zxPPrREOxkLjDJp4oGQ_32_6">4,585</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_rGyYIR1H_Eqnhn2-sWBWcQ_33_3">28,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_czI1t7LEdESqvSuOEvcclg_33_6">30,206</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">STOCKHOLDERS' EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_aEsDXpMdsUOVTdRA3_GQvg_37_3">49,903</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Bf4gkZIyz0CUZpjHJGI7kQ_37_6">43,211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total liabilities and stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_qgnLB2nZoUOy6uh7rc3QeQ_38_3">78,486</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_QmpbyklLgkaa-6iAAXf-jQ_38_6">73,417</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c8d2178f_b4b5_4137_bff6_0bc83f73c635"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt -13.5pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_nNR3TglcN0OnoZtZ4BKoTg_1_2"></a><a id="Tc_nbEuOxdfFUinQjgmZj633w_1_8"></a><a id="Tc_q2c9LJgVgEeB8JJ52qASbw_2_2"></a><a id="Tc_4CJloFpvV0u4ZR9pjs0KAA_2_5"></a><a id="Tc_-UATdlAEvEWvIdsKF8XEXw_2_8"></a><a id="Tc_VUqmdy6zbkCRKDslolQReg_2_11"></a><a id="Tc__q0iqSI9zkew8bx3NnTmng_3_0"></a><a id="Tc_wpwA19gUOUaGXauVlbZKaQ_3_2"></a><a id="Tc_wQI8lOftx0uOAV2xy0RFtQ_3_5"></a><a id="Tc_N42tRNAFAEGNNoGmFaTtwA_3_8"></a><a id="Tc_Klweat0wxEmTUN8NKJlang_3_11"></a><a id="Tc_7dwwiOSMa0OAxhBB_UikrQ_4_0"></a><a id="Tc_Cxj8xlNs-UmHcknTKBPbgw_5_0"></a><a id="Tc_voYgh1CrgU-UZ0WI6CgHYw_6_0"></a><a id="Tc_NlgAPk42Y02k-D5tSXlVzA_7_0"></a><a id="Tc_6kQz4Gn3aEyKG6id5vH5fw_8_0"></a><a id="Tc_78iA8L-TRkaWA55Y6Z5iuA_9_0"></a><a id="Tc_q-qe6sI6O0StaJiFgvSMCA_10_0"></a><a id="Tc_OhH5LzxIpEaEO3x9sZsTBA_11_0"></a><a id="Tc_ajlE9zYNlUmf112BTCrxOA_12_0"></a><a id="Tc_CVR2nGtnMk2duLeehiY_AA_13_0"></a><a id="Tc_Ziv34_KqvUmeAS3Tvpluig_14_0"></a><a id="Tc_N37JlRMt4Ui61Bcw-OCB3Q_15_0"></a><a id="Tc_ZBS7jxfOg0SJmSIRwEQhHg_15_2"></a><a id="Tc_PUiAp2fgnk2YPQ5uWOR65A_15_5"></a><a id="Tc_-Pf_S7zpSUurCT2Etmr2jA_15_8"></a><a id="Tc_p_8lGusdn0yAxb6EkEEM6w_15_11"></a><a id="Tc_-XP6SvZ6pU-baSFqmmfy6Q_16_0"></a><a id="Tc_g5mzbxT5YUiOpnLJcxLt5w_17_0"></a><a id="Tc_eukRU6hA5kCunREVPE1VPQ_17_2"></a><a id="Tc_heZ6lpU5vE24eOuuCkEEwQ_17_5"></a><a id="Tc_l_rtdtkNDkSMeRNZZKLpkg_17_8"></a><a id="Tc_eUlZFRMbxU-_cfMej1jQFA_17_11"></a><a id="Tc_8TZkx7n5bkuMMObOiLLoWQ_18_0"></a><a id="Tc_ydSoCHau6k2pqRNqNRbNEw_18_2"></a><a id="Tc_uPKJLB3Fx0yWx3SCxeqfhw_18_5"></a><a id="Tc_mwLKRSxE1kyEZeB_FekmAg_18_8"></a><a id="Tc_SkwnpvN_okOTtAuWj0FUxQ_18_11"></a><a id="Tc_ajL01oyZmk2vAObyidX4vQ_19_0"></a><a id="Tc_UAiMvbaNJ0qiaJE2zX0M3A_20_0"></a><a id="Tc__o9EoKs1aUuNFYvoGQV2Ig_21_0"></a><a id="Tc_Lyk6Tgqyukmu7Zw_e8nR_w_22_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.82870865%;padding-left:0pt;padding-right:0pt;width:101.65%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_c_PLLEX5ekOtxFhMT3jjag" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_aYvIVecp9kGKZ16a1ynqdQ_3_3">25,435</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_ls4KWM6TWU2ieTyrmZgYpw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_aaM7xZBmIUaO0xoajaMfdQ_3_6">16,981</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_iejKZn67F0Sf2DaGIlWrig" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_JjN9mxVvYk25xGleGcylkQ_3_9">15,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_r_xBq1FYmEe1hu9bPCmlCg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_3Mj_gVSNs0SR6bil_Xlhjg_3_12">13,304</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_W2wc6JkTt0WlVF693XXzxw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_LwCqYSRcYkKq3znyCmThxg_4_3">336</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_rUd6RnaD1Ea21Qe6MwDvwg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_XQCYccu6v0mdI_0oBGnhGQ_4_6">241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Ry9eJBFRY0aWUriRJJoWPw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_orv1hfT9j0Cfvhw57_nW3Q_4_9">218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_71I2lv4f9kWJWcfI-ONvvA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_BKT6pk9df0mY7Qwt-wLGSg_4_12">170</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_Pmfw0Ct390KvWLUgBSacNQ_5_3">25,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc__xmdKYGzjEWf460DxWO6Vg_5_6">17,222</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_3WwxLKj3Qk2aUCH79GDufQ_5_9">15,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_JNXura3V8U2MPnDx_p0s4Q_5_12">13,474</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_1BRXHpcsjU2pq6Fr4jQOAA_6_3">14,050</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_9tWH2TaIhESbW2ZU1uW2bQ_6_6">12,058</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_xX8N4tb6E0a5hSWcIR_mCw_6_9">5,870</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_nPJZFkZ8EU-33-R5xc5g1A_6_12">9,456</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_9hlBhEXU3EaTTGQauGdKMg_7_3">9,467</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_hPusIP1hokK08EBdm12crg_7_6">5,848</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_6FDSy3QAV0OqyBjiAs6p1w_7_9">5,992</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_2YKlNncOfkWKjYhaN2oUOw_7_12">2,961</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_bOdZaVYWi0Wq6JqP5gxU-A_8_3">5,227</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_G9iPz86CWk-wcHvVDg7w6g_8_6">6,599</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_ZLqzMca8FUaU4ZORHpag7w_8_9">2,624</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_HqQUnxkYLkyijh6QGpfHFw_8_12">3,484</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING INCOME (LOSS)</b></p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_NZjsDLRfSU21RRfu9UP0cQ_9_3">2,973</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_uLupgl8y4UyAOJei55sRqA_9_6">7,283</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_cbU8MA8PoEWVRCYM2oKabA_9_9">1,172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc__97YrPCNF06mCIfPYfcypA_9_12">2,427</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" scale="3" id="Tc_0hCx40NqxEaw6rjkd3QRnw_10_3">628</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" scale="3" id="Tc_03gVTmHJYku5Mt_VeBXGBg_10_6">757</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" scale="3" id="Tc_jIMahEj0WEqo3Ku9VJHoGQ_10_9">783</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" scale="3" id="Tc_Yr0kBO_VeEaUeMfOR55M6w_10_12">367</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_DHEHG-GdvEC_PGP6mbYsBw_11_3">530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_hk_YM8lkEUujW-eryseAnA_11_6">1,035</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_JNmegZ8T5E2zb-3pFoTzsA_11_9">272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_UnjcR7XEK0mpo7yNJHj6Fw_11_12">522</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME (EXPENSES), NET</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_1ykIRShRWUWN0QU3P--wPw_12_3">98</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_-RrNtfQA5UOI2-alZbDv7Q_12_6">278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_fsc6GCcAG0Gp-YJuV90hPw_12_9">511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc__EYne7KCNE6y_bCR-ARAsw_12_12">155</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">INCOME (LOSS) BEFORE TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_BQtW1CMkrEGBZ3-eNcdOhw_13_3">3,071</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_gZISIvjn6UyS8XRvXhCkdw_13_6">7,005</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_JVRi3LlGlkSAoyu6qh0_dA_13_9">661</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_EN3y4vyNEEKVaPyd-3TPqg_13_12">2,272</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TAXES ON INCOME (TAX BENEFIT)</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_cc6v-05UtEyDtUrNn_zBjQ_14_3">384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_xLcSIa1SF0ykiVabl9QYvQ_14_6">207</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_XIxVB7PP7kSnuN73hb5g4g_14_9">497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_rL74p3mtL0Sn1zZgijORog_14_12">69</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCOME (LOSS)</b></p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_EsNW05bpYUS7_RB0E3sAKA_15_3">3,455</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_MMF2DVfJJkqILiE7KOgFWw_15_6">6,798</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_Bf-vhMBgzkKstI7fcmkKHw_15_9">164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_MuOzqmiF2keLl9eP4kxunQ_15_12">2,203</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EARNINGS (LOSS) PER SHARE OF COMMON STOCK:</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">     BASIC </b></p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_YeAEsMS6VkW0-f91KshgKw_17_3">0.04</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_h7sy8-KJl02XngE6yiyY8w_17_6">0.09</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_mDd4W2sJIk-3Dk-T-vqEJA_17_9">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_u8UHjIL9MEirauk6mYkJSQ_17_12">0.03</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">     DILUTED</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_T_08yqbWhkyZh__tB8shgg_18_3">0.04</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_NzVpyhRH8EqSWRF0JcWzVQ_18_6">0.09</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_Gd_0H_MeGEeTLvwqbidR4g_18_9">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_Q0e1DPDBnEiA3KRBQu5dDQ_18_12">0.03</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING EARNINGS (LOSS) PER SHARE:</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">     BASIC </b></p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_GlyPTYfi00ilVlOyCGA9tg_21_3">77,651,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_nHy8My-5eky9bVAyUWK9pQ_21_6">73,172,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_EOzH8LpQ5EytCVdpWSGV6A_21_9">78,663,884</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_TDp3qo6_xkmoP2vgR6DymQ_21_12">73,308,281</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">     DILUTED</b></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_njYHuMqUxEiBHR6ZRK5Qlw_22_3">77,651,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_quolZDTcykCWeOo1LBB3TQ_22_6">73,172,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_FzOtwOkcKEGzkyYZcuft4Q_22_9">81,271,610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_rEWI0Rc3n0WSygxudIa9CA_22_12">73,308,281</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_fac46261_6b3d_48cf_92d5_e6dcc678f2dc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_1uGbkRoDiE2XGx-86gnz0w_1_7"></a><a id="Tc_t1loNCpp_kKKzpsRqPqWZw_2_2"></a><a id="Tc_ShPDiBkrIUmuEOvSideSLw_2_4"></a><a id="Tc_u5ItLcKH802jKgs966WKEA_2_7"></a><a id="Tc_FI8pyLWd3kudDZAuZR6BMg_2_10"></a><a id="Tc_wKAMeMwV9kevpPiDgH661Q_3_2"></a><a id="Tc_qkjf91r6IkO9XGFZFKFomA_3_4"></a><a id="Tc_jMwrDi33106inJPK5KuyLQ_3_7"></a><a id="Tc_UybRLqfDC0iJc7B-EQcqQg_3_10"></a><a id="Tc_c0fUzjhk10GleW6KuL8kcw_3_13"></a><a id="Tc_HtAnzgUGk0WND1PlhNoxSw_4_2"></a><a id="Tc_gKIEGxBrUEixmzgHYlG_6w_5_2"></a><a id="Tc_jK_ZjQmtb0GPLOGegf6WEQ_5_4"></a><a id="Tc_99il95s9zk6I-CfTNqdLtA_6_0"></a><a id="Tc_c8Cyjy0R00SwKGV8Aw7KyA_6_4"></a><a id="Tc_zOrDreXorketLWh23BYbhQ_6_7"></a><a id="Tc_uwATRgrbQUij4VVljl6p3Q_6_10"></a><a id="Tc_k_8L9NohlE-eCfAujnsg7A_6_13"></a><a id="Tc_hosR8whrBk27ZrVZyqiTIQ_7_0"></a><a id="Tc_-9fZWDJPf02Cezb4EBvdPA_8_0"></a><a id="Tc_DbP1s9Kbn0SXkjFxhrny0Q_9_0"></a><a id="Tc_ifcHj1_uvES_SP6cDgbZJQ_10_0"></a><a id="Tc_lsSDqnV5YkSIaQQipwEJeQ_10_5"></a><a id="Tc_2Dx9_uPHDkm84xkAefDkNQ_11_0"></a><a id="Tc_oq5lAHpXp0mvp8qT6nxdOw_12_0"></a><a id="Tc_mabO8mPeN0WaJ85FGMhERQ_12_4"></a><a id="Tc_ollAn8e7m0e97-FRceZS1w_12_7"></a><a id="Tc_rcYQb2ey8UeCuZUmIRa2rA_12_10"></a><a id="Tc_pRqChQ7RkES1BG2RFtpt5A_12_13"></a><a id="Tc_IwIVCD9dTEWT4053ysZ2xg_13_0"></a><a id="Tc_W4giopXLbkWhGnsaAEP-hw_13_4"></a><a id="Tc_npkLZ800zUiYIbexK56cXA_13_7"></a><a id="Tc_Fh6V2nSZkkekCXzT_ZJFHA_13_10"></a><a id="Tc_4QK_KdykKkm6XhcXhaAJww_13_13"></a><a id="Tc_aGRLuBbFE0-GMPzlye_QqQ_14_0"></a><a id="Tc_KgkV_3Y3RUapFwfbvUzn1w_15_0"></a><a id="Tc_DfLeN_LzykmTf5bA0ADZ4g_16_0"></a><a id="Tc_s8sNuGdv1kuMPNHgUxosAg_17_0"></a><a id="Tc_kW8VmQ_NqEeqMA6KZvuiZw_18_0"></a><a id="Tc_7QY-jwPumEOj71ildP8ypQ_19_0"></a><a id="Tc_JpuAp8GPrEet3WyPqhsYzA_20_0"></a><a id="Tc_PWgcWpcWDUScrzuPxMCqiQ_20_4"></a><a id="Tc_zy0uy2bGO0GuHpC2toOpcQ_20_7"></a><a id="Tc_GAlj2Tb_tEazPDlIx7YUJQ_20_10"></a><a id="Tc_UzrThDGxy0K92STzYdOlpw_20_13"></a><a id="Tc_nF9CyCVdekOqueeIqFgbyA_21_0"></a><a id="Tc_ncCVO_P_5keDQSIgdOr8HQ_21_4"></a><a id="Tc_WRww7PbzekWSE2oYg3-g2Q_21_7"></a><a id="Tc_8RtlZrG0_02VrOzoxcM-YA_21_10"></a><a id="Tc__XMEc4yVn0CBLcxftHCZ5A_21_13"></a><a id="Tc_Fa73KiOjHk2k9o5pUSH1aQ_22_0"></a><a id="Tc_9wrPCdpBFUKnu-Z8R2sU1A_23_0"></a><a id="Tc_chGwFas0TU-edhfjHcu09Q_24_0"></a><a id="Tc_sPHbm5IEnkOr8uvjUOfViw_24_5"></a><a id="Tc_won9wixcw0e-UJ1xIBLtSg_25_0"></a><a id="Tc_CVyRoh7wB0am1k2pzsCTzw_26_0"></a><a id="Tc_MAZecH6xEkWpJtYmYDSLdA_26_4"></a><a id="Tc_huaXUzuQeEeNu8ipk5deGA_26_7"></a><a id="Tc_89EzigDxnkC0c_IsS-3atg_26_10"></a><a id="Tc_RpIXZigmy0mDHEGFniE--g_26_13"></a><a id="Tc__OzWqEJNDkyVZ-1kFxsoAA_27_0"></a><a id="Tc_AbkIC3umxEKJ0mAYAhA-9A_27_4"></a><a id="Tc_nH_MIuu6-0CymskiCVFxGA_27_7"></a><a id="Tc_MGWR6XImK0KQj3pXSwH5XA_27_10"></a><a id="Tc_htMfnhDfrECIYRUjpzEuMQ_27_13"></a><a id="Tc_XG3TT4nRu0ivPj031JuVew_28_0"></a><a id="Tc_lVnE--RFy0yr1mqZUMJjQQ_29_0"></a><a id="Tc_muTawhWafEWq8H2WUkuv_w_30_0"></a><a id="Tc_GErHafA-dU2owLTViuFKGQ_31_0"></a><a id="Tc_WWkOX4V9fESEVaxnCn6HdQ_32_0"></a><a id="Tc_xC6P2EqSHkOTfPn96rf_wQ_32_5"></a><a id="Tc_NyEjtdUNBkSOgsjOcLueBA_33_0"></a><a id="Tc_-crCPWV6J0G-AKNnplYwJg_34_0"></a><a id="Tc_Vh3a-QzEL02f1lxD6Th7FA_34_4"></a><a id="Tc_aAhM_YYrcE-eUKECvHbrXQ_34_7"></a><a id="Tc_l9HLWOeQ3kGxio0bk-v5YQ_34_10"></a><a id="Tc_G_6V23A05UK0SM9xNlWU3A_34_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K54wRCnebE-ZiUifv4iNAw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_JUsHG8EYSEWT6N4MJbloMQ_6_2">72,952,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K54wRCnebE-ZiUifv4iNAw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wVAWmRz2R0WhnzUJRLTW7g_6_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_afsyJr4hf0OEKhekB3AHYw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_dafjpgEgbEaePj8ew_tZqQ_6_8">415,045</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JAoE3eeC006wm5kUxnCZQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_neWuVlVj0UyXIYUFm9FZ0w_6_11">381,549</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2023_SSEd4QlqZ0ixMnchHstv9w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UETTfFw0vEyIp_7WcG6xqg_6_14">33,569</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the six-month period ended June&#160;30,&#160;2024:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Initial adoption of ASU 2020-06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FH48IkEeXkKYk6m4HHmdOg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_DroN6LvDykepkfZqSLzfgg_8_8">393</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ShmDYwDjqEWRMkqNQoAC2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Smlu03_nxEORDotXYV2WMw_8_11">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_NTtOh_tj50iF28Xo4DEnjQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_XaK73bei1kSehfec9M63fw_8_14">169</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CkeeA2C0XEG0WPbHArw-rw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_024ACbkg60mMaJ5TsYefOA_9_8">833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_XC331I4PNk-GwW17yixA0A_9_14">833</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BTZY9KQhX0ONpZ7wFZENbQ" decimals="INF" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_8DGpfWJ6u0yrb1j10aB90g_10_2">340,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CkeeA2C0XEG0WPbHArw-rw" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_8PvpoFgHh0K2U-SyPiXp0A_10_8">1,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_5Ox-l6gSPU6nEOm2tpCDiQ_10_14">1,146</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GYqZURE_wUWCBx0IiGtJdw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_L2Qb1ipAxUaBtkjgvKhtMQ_11_11">6,798</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_0PxDgtXTe0Gjyj7GsXjrOQ_11_14">6,798</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gnSYRAKnVUCk2W-avLWlNQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_MHpHHWRQRUW2J_oQ3TlEYQ_12_2">73,292,674</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gnSYRAKnVUCk2W-avLWlNQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hp_X0lNc_Ua5A9jHJngLFg_12_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YOsx-bZkqUqqRJ-r5Udi3g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_dRyswdDTIkiOmohrr50rOQ_12_8">416,631</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oBjoUu4mDkqIlAPbHCD0BA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_J3qrhMI2CUW76e4WevLapw_12_11">388,123</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2024_wf2iuAS66kiC7r9Ko2A7aQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_BKD_2YVxL0ynwllJc9ml6w_12_14">28,581</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tD6aS3nTtkSRjdsTuc_j0A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_5YdKmLQiKkezM06rF9KC3g_13_2">75,850,275</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tD6aS3nTtkSRjdsTuc_j0A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_b7MRCZq5qEeLIbhHF-wyJQ_13_5">76</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n5C0Tv5uoUusGQMN1w0I-g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_XkeB1vuIWkaSnOVVf5B_vQ_13_8">421,528</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_z3i-FDaHlE-BZ9GIL0jWNQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_pg_vAhydcEa5NKDfUQXwSQ_13_11">378,393</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YyfMm_hW5kej_HurtyXrrg_13_14">43,211</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the six-month period ended June&#160;30,&#160;2025:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaZNoHa79k-oQmE30hl7Ug" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_R6K5a9hlw0WIYzXuvs9mOw_15_2">2,775,215</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaZNoHa79k-oQmE30hl7Ug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_pKRXtES6lkabiiGmpU366w_15_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wzsUdUWAf0Cbd6Wi9_SGbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_XSTyTSg9kkWAnWTnIu9NRg_15_8">6,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_3atokn--906d5NvXCjp19w_15_14">6,812</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wzsUdUWAf0Cbd6Wi9_SGbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_QQwy7x0Mj0K3398oDj_HKg_16_8">599</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_mPCCyholUEGckpWdiV8CGw_16_14">599</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wzsUdUWAf0Cbd6Wi9_SGbA" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_5hGR7ZUm0kKIgewaCWG3tg_17_8">368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_iNjsc0j0xk2LXOLDTRoluA_17_14">368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants and options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaZNoHa79k-oQmE30hl7Ug" decimals="INF" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" scale="0" id="Tc_1cUpthGGJEqf6itNfIU1ZA_18_2">1,106,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaZNoHa79k-oQmE30hl7Ug" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" scale="3" id="Tc_-17LUgHRR0eAU8w_F1adnQ_18_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wzsUdUWAf0Cbd6Wi9_SGbA" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" scale="3" id="Tc_bq83yUut00a35SpWOk6_ZA_18_8">2,367</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" scale="3" id="Tc_VhY-mc0t30WWOHErsUYtRg_18_14">2,368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iTnaGMElH0yBObH0OL-TXw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_fVcPjO4bGU2LyzSU_7EY-A_19_11">3,455</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_XvKZb8U8Qk6M6j-0vOWTQw_19_14">3,455</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIdlrBTkX0WJBo8z2nuPEQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_SimVJaL030ORTwulZYu9zw_20_2">79,732,115</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIdlrBTkX0WJBo8z2nuPEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_gSNky3RM0EyVL8PB-IlLwQ_20_5">80</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BEtiHKEg5kuzpUuHsr_wSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_fYwS2feQ4E2DMjYPxkr0XQ_20_8">431,671</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gv3VRwsmA06TTm6sQUN6DA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_tVaM6n_N0U-KgsLWkpru7Q_20_11">381,848</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pu3sH4OGekSPemHL-HJXgQ_20_14">49,903</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F5dDIxgUX02lMffBZpl-QQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_rM1xId7NxkWW208M0pKjng_21_2">73,052,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F5dDIxgUX02lMffBZpl-QQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MYKC3NQox0aAPVG0MuodEw_21_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bNcrB3tI4keRMneOxkJ39w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_SFyPkt0_n02jwWgkYcyZ4g_21_8">415,633</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9h5JLRuXP0SrzhRzTBu5HA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_JHxUCz8cEUi-mAQrTrtB1A_21_11">385,920</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_3_31_2024_AdauIPbP4UuVFiRvmL4s7Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Ptwxd6jwCUapH71ACmK_AQ_21_14">29,786</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended June&#160;30,&#160;2024:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ETC7kP5_4Eeir_fPIkYRjg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_UYHKzzfeL0m41hz4jQuj2g_23_8">333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_9FnxX2lprUaSxyU_zKIBAQ_23_14">333</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M2e2ab-8O0Wf_GeW-n8L5g" decimals="INF" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_E59k4yziiUa67x_HxpXThA_24_2">240,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ETC7kP5_4Eeir_fPIkYRjg" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_hRTLFcl9b0-f6gVr4hw-7g_24_8">665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_ZcMMEWxX0kuJVketf1a_IQ_24_14">665</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rW77dB4dWESXNLR4EYGmyw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_OOf1DqKce06fQt1ZcYdMiw_25_11">2,203</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HWY7xmTnFUmvR0kL0nq4xA_25_14">2,203</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gnSYRAKnVUCk2W-avLWlNQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_qBTNBNI8cE-e-oypr6TgsQ_26_2">73,292,674</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gnSYRAKnVUCk2W-avLWlNQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MkDmt2w8_EWnEUUVoHf_pQ_26_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YOsx-bZkqUqqRJ-r5Udi3g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VFQsudWaw0K8ZnsqGWdzHw_26_8">416,631</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oBjoUu4mDkqIlAPbHCD0BA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_5NvzsooDJ0yznifj2pF0IQ_26_11">388,123</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2024_wf2iuAS66kiC7r9Ko2A7aQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6cljebF3bk2DCYkIlMPRCQ_26_14">28,581</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5IUo4MDNeU-PF-knaxHuhQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_hlYrSjoLfkmyEVTMYIoDcw_27_2">78,133,829</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5IUo4MDNeU-PF-knaxHuhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_DxOt82Pe8UmcAkIJ8ymGoA_27_5">78</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2LLqvubzfE2_bgUOB4p5ug" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3wGWKwRDLEKoPp9RBviVQg_27_8">427,142</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qLRTrEx8eUKQia7ENmBkMA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_BnqkcfDNI06hjrBL25Aqow_27_11">382,012</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_3_31_2025_Jmty4GTo6k21zaIY9WJ2NA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_p1Afo8yRFku2tJvhIRVXNQ_27_14">45,208</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended June&#160;30,&#160;2025:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cCx29kPpekObSCYrlCS5HA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_iNSN0warEkSepi8qJ6f5lw_29_2">1,450,036</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cCx29kPpekObSCYrlCS5HA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_1okrwUogoESMoT03D1jHKg_29_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IMn_qGh8rUiSVtUpQ531fQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_SyTDUcgsvEuw3Ebtz-Nekg_29_8">3,949</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_XNbvdWSA3EqYfUe8Yw0DoA_29_14">3,951</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IMn_qGh8rUiSVtUpQ531fQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ozla6umCkEa8EEHl-zxZiw_30_8">263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_w_2cLLxW10yw9J6_7Aksmw_30_14">263</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IMn_qGh8rUiSVtUpQ531fQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_Im2Eg-CobEu6El_MFOJ3Fg_31_8">164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_B5pj9YStXUONAb1Hw3XVhw_31_14">164</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants and options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cCx29kPpekObSCYrlCS5HA" decimals="INF" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" scale="0" id="Tc_1gTmG3hllU66Zqf80x33Nw_32_2">148,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IMn_qGh8rUiSVtUpQ531fQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" scale="3" id="Tc_F-7taEekIEGt88QCc5Siuw_32_8">153</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" scale="3" id="Tc_aYMRxPZCkE2JG_Ci7IiuKg_32_14">153</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net income for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yRXKgj1-r0me-ISDulhcmw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_BFBZM0UuHkuS9Jgrohxpzg_33_11">164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_FShQEj2z7UqBmmkVT7k_7A_33_14">164</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIdlrBTkX0WJBo8z2nuPEQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_VvyQGZl5rE-JlitgqqJ8gg_34_2">79,732,115</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIdlrBTkX0WJBo8z2nuPEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hldhgVHRTES4iWt7EItNNA_34_5">80</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BEtiHKEg5kuzpUuHsr_wSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_q6omSpG8HkCq4Smi2mOwWQ_34_8">431,671</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gv3VRwsmA06TTm6sQUN6DA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_kbBsgg10DU-akIkg9nymRg_34_11">381,848</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_skaKqIx8bEWWu2EAuJNrKA_34_14">49,903</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">*Represents an amount equal to less than $1.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a2e03645_2643_4168_926d_13e04faf108a"></a><a id="_c3493724_079a_487d_a703_63d3836f1c6f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_s3SehukV90C99J1peCHZZA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Sswona3ipEOnprl2xSkUnQ">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of June&#160;30, 2025 and December&#160;31, 2024 &#8211; <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_d1JvnhEV7EKBaeakZOwTqQ"><ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_WVVDxZeTMUmavnJxHQ39Bg">185,000,000</ix:nonFraction></ix:nonFraction> shares.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_cd1507ab_3c46_45ac_bad2_d1f9a1c8f861"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_S9_o1QYH-kG2awMeSu-IVQ_1_2"></a><a id="Tc_YXJJ2abL7EWvi0W29mD69g_2_2"></a><a id="Tc_GJB_pGjCO0ynjcOgENTSiA_2_5"></a><a id="Tc_hGDhWAifik-xWQcYAbUk1g_3_0"></a><a id="Tc_bblNui7Yyku2dIJFNAZs3w_4_0"></a><a id="Tc_SyPMzJuQnk6POtGtofcVgg_4_2"></a><a id="Tc_hQVx9uTBF0uQYy3CzekRTw_4_5"></a><a id="Tc_e-pE6mXZe0KHWVqaNsGNGw_5_0"></a><a id="Tc_hv7gsB53s0S_ZY3YKMALfA_6_0"></a><a id="Tc_TGO5mxbStEmNluGrKh_T_g_7_0"></a><a id="Tc_I2NlwrsYsUG6n6kWuGo-8g_8_0"></a><a id="Tc_URC5VfpEokuFFAU2oHpTiw_9_0"></a><a id="Tc_LHabBcVlGE2Qxq9qt-4FkA_10_0"></a><a id="Tc_JAk_mfp06karnHb3pnpe0g_11_0"></a><a id="Tc_fvc0eoCM_kmlSFk83ATO8g_12_0"></a><a id="Tc_ZSmVLjFpr0SKp_ESoxx7Rw_13_0"></a><a id="Tc_BCXORZAlhku-hzeNg6lAIA_13_3"></a><a id="Tc_DajebE30eEW4MH3YswtpNw_14_0"></a><a id="Tc_ci2VP2vZKUK-CJcqbDStrQ_15_0"></a><a id="Tc_dX7zARZm6kmXC0_vLRN8Ow_16_0"></a><a id="Tc_PJ6PX0070Um_ECOBfOcZXA_17_0"></a><a id="Tc_slmMyBIydEeJ1b4Gts81_g_18_0"></a><a id="Tc_VW6kDv4KO0qV1ZDSfcmzng_18_2"></a><a id="Tc_ZXQ0rhVJkkOPIwjpmvrrZQ_18_5"></a><a id="Tc_-Ta0E-0C10qpQCuNxqOIiA_20_0"></a><a id="Tc_nnkYOwo98E6EHPMMkg_vQw_21_0"></a><a id="Tc_g2z8pCB0U0G5oA0Ys8-pKw_21_2"></a><a id="Tc_IeTWuhRXmkWebTxPgvrQvw_21_5"></a><a id="Tc_Ul3Gmna880Cn0PEGkyL9LQ_22_0"></a><a id="Tc_ppl02_A27kmTwUbcSWgOPQ_23_0"></a><a id="Tc_a_pErkouxU28pebAZuiONw_23_2"></a><a id="Tc_2ueetJCr4kGN1aFeFyQWyw_23_5"></a><a id="Tc_ol29nx1j2Ea4f7VhtUZ2aQ_25_0"></a><a id="Tc_SIOKomPHfUGs27vn1PeaqA_26_0"></a><a id="Tc_K70udCwgiUWyf710xi4Igw_26_2"></a><a id="Tc_tTpaYNKEVkSLGQzDHMvguw_26_5"></a><a id="Tc_3-PAwqU0G0WOHCQxHyQPgA_26_6"></a><a id="Tc_FpmLM0EM4kCG9Y8doB748Q_27_0"></a><a id="Tc_xQKOGtv2PUulQZXEOTkiXw_27_6"></a><a id="Tc_gWQabtEf5E6H2j8CPuzeOg_28_0"></a><a id="Tc_q5hMC1HDuUm3eRfvJBWlEA_28_2"></a><a id="Tc_24mGpX3FAUy6VNbpWSHbrw_28_5"></a><a id="Tc_TQ3sPgkyuUCHqrGAC2yuoQ_28_6"></a><a id="Tc_UGHfxqnrnUqr6CpH6a0f9Q_29_0"></a><a id="Tc_30CThjRWC0maujGIDTKiDg_29_2"></a><a id="Tc_F_AwIHXWiUSgz3BUIQWi8Q_29_5"></a><a id="Tc_4Gg6fjBU6EyyOZH8-Ra4Cw_30_0"></a><a id="Tc_uEt4FIr00kOWJOnjIb-o2A_31_0"></a><a id="Tc_649b0cYMEkOZ-uzT8iSHWg_32_0"></a><a id="Tc_isr6c_niAEuXJ0NWXy5n7w_32_2"></a><a id="Tc_W2-ACl8fOUa6JJLbE_KfYw_32_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_xoBNeGDTb0qnuGX1zydAng_4_3">3,455</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_E6TxyAqxn0aC-A5kL9SR1Q_4_6">6,798</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_6NdSqOVbh0ev9ztC9tQhfw_6_3">967</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_OTCnovG2GkydY8dpIc-C6w_6_6">1,979</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_QCROzJ6UH0iFBIDFcD8ksA_7_3">706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_s4jxBl1j3kKLvvFdBISJIw_7_6">641</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial expenses (income), net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="3" id="Tc_XuUSspnRekyDF63hRd3Ybg_8_3">108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_DMt0raUWakSyVkHMM9DUkg_8_6">975</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_U-IX74UbOEmS4oK2GuSUHw_9_3">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_pvBtU-g3gEmVrmJVAvSZeQ_9_6">16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_4n3x1VIbwk6WL15XjSgXgg_10_3">118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_T4eLBi7QTUyJN5SMbhOYxA_10_6">207</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_GaUaYmhREU6ca9bZ70LZwg_11_3">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_bPHUPQXuFEKUMylZ-YjyrA_11_6">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_itGeyFW9y0aBkjQWTHWgdg_13_6">12,695</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in accounts receivable-trade and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_ug_HVYlOIkWUCbkqbGcqpQ_14_3">6,919</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_oZv3JsJeUkGNNRdgseHpsQ_14_6">5,308</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating lease right of use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_EceABrrcakCBfMo4rUjiJA_15_3">38</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_gTVi4FqW-kiz6yIeK6UD4w_15_6">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_ieg84KiavUSIoNUAWt8cRg_16_3">112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_iDgU_sH2TkuIuaFjlveIjw_16_6">1,674</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_ApmJ0Y3rRUewruzak9OdDQ_17_3">1,894</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_37C5tQvawU-g3EjTasHxCg_17_6">199</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash provided by (used in) operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_-Jb-HXlMA0yj2-j5b4kxZA_18_3">10,291</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_xy9Hq5vaNky9uMuhIFciLA_18_6">578</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_pvbDJoXv6kWhb71jwIHD2Q_21_3">737</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_7ud9DQBwTESYugTJPTYkzg_21_6">770</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts funded in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_MwlVo52WU0W551YEoD8OCw_22_3">13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_LIVg8kR2G0Kbt15htrPqiA_22_6">16</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_4HXYCX6A6kOp0MQcK3E-Zg_23_3">750</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_MJYPFfBpzUK43W2dNNKoIQ_23_6">786</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_3DKu_9q6wE2AuztEMlRZcQ_26_3">6,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of warrants and options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ProceedsFromWarrantsAndStockOptionExercises" scale="3" id="Tc_EmDYICjHPkaCg1xuTRsoyg_27_3">2,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_vHO_jOCF1U-4A2WR45N5WQ_28_3">9,180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_06OcfJGy-ky0uwKfs6s6Mg_29_3">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_7liFiRmH80yoD_yF0Ya9RQ_29_6">27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DECREASE IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_yxhmdiG4f020A_V3ymh5uA_30_3">1,865</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_0xbnDcCwEkCANPyqgl5Vvg_30_6">235</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_JvJL961hFk2oK_5TJay7XQ_31_3">19,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2023_SSEd4QlqZ0ixMnchHstv9w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_DfTt87h7MU6guM_5P81ZJg_31_6">23,634</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_GdCuc5FiVESKgoE6AuotSg_32_3">17,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2024_wf2iuAS66kiC7r9Ko2A7aQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_v9GY2soSUkW7-8FjnqErCA_32_6">23,399</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_zINoK9iQGU2pQSmQpZJKHg_1_2"></a><a id="Tc_hUarC4GPUEuwT8-E7znuvg_2_2"></a><a id="Tc_1zeCGsdUnU-4C3z2ESvkIw_2_5"></a><a id="Tc_Zvg0MLFWnk2TSO8a1Ustgw_3_0"></a><a id="Tc_KmE0miDHWEioayFZb7gmdA_4_0"></a><a id="Tc_7wEvLcl3h0SIARDf1wXO4w_4_2"></a><a id="Tc_brd_ft2PoUChzWHikeARpw_4_5"></a><a id="Tc_YaJE9jrjW06ra9E_AfykSw_5_0"></a><a id="Tc_IMUS_9MVL0671ZdAN2dvmA_5_2"></a><a id="Tc_xgAN0bzmGEik7hpe0TRKGQ_5_5"></a><a id="Tc_tIFIyG37ik-0fC1gGBUGUQ_7_0"></a><a id="Tc_RS0iYTt2ZkSxELpn5Z0WRg_8_0"></a><a id="Tc_Dz0mcIBVgEayMAuepq0Pdg_8_2"></a><a id="Tc_2rX7SRrgekqTE2rbCd0WBQ_8_3"></a><a id="Tc_JMxpHTTqHkWW5h9FQgb_DQ_8_5"></a><a id="Tc_Wc8X4AmMDkCcU4oJ6Bq62A_9_0"></a><a id="Tc_iEQv7wXf7Eq_NfU-vFYtQw_9_2"></a><a id="Tc_vTfuXkRZokK9yu9UXpLGsA_9_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_DLolvX-r9Eqwj-VYD-CXpA_4_3">378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_lf5kNO5dPkS300lLYQev9w_4_6">121</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_i63YZGj-uEmfsc8S1yX06g_5_3">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_vrMnariiQ0OZbl7JIhmOXw_5_6">258</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc__vfFgxvVu0iwfyX9owP0zg_8_6">766</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:InterestReceivedNet" scale="3" id="Tc_aCQoKK2NYkKPDsOra0-5gA_9_3">220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="plx:InterestReceivedNet" scale="3" id="Tc_lkrzcdELk0O-B5pZgqXYSg_9_6">56</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_woFg3WAEqkeXrFIy2yvMAQ" continuedAt="Tb_woFg3WAEqkeXrFIy2yvMAQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_E4UhmIKRuEKi86osR_ioLA" continuedAt="Tb_E4UhmIKRuEKi86osR_ioLA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#8220;Company&#8221;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients and children four years of age and greater with Gaucher disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Elelyso was first approved by the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. In May 2023, both the European Commission (&#8220;EC&#8221;) and the FDA announced the approval of Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia, Singapore, Australia and Taiwan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases (neutrophil extracellular traps).</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio through <ix:nonFraction unitRef="Unit_Standard_agreement_R6tg8LdwCUeUoAN2h0xL2A" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="INF" format="ixt-sec:numwordsen" name="plx:NumberOfGlobalLicensingAndSupplyAgreements" scale="0" id="Narr_Mr0ik3J3UkepsdGTd-vlEg">two</ix:nonFraction> exclusive global licensing and supply agreements. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October </p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_woFg3WAEqkeXrFIy2yvMAQ_cont1" continuedAt="Tb_woFg3WAEqkeXrFIy2yvMAQ_cont2"><ix:continuation id="Tb_E4UhmIKRuEKi86osR_ioLA_cont1" continuedAt="Tb_E4UhmIKRuEKi86osR_ioLA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_1NEZJ566u0G9wZB2EoTpTg" decimals="2" format="ixt:num-dot-decimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_SnVcygBGO0S1QcQLV3_y5Q">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;">On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). After giving effect to the sales under the Sales Agreement in January 2025, <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_YPPSNBqug0mazz_yBXPpwQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_2r_2E-D9QEiR5vZrhruxDQ">no</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g" contextRef="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_YPPSNBqug0mazz_yBXPpwQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_qKxxs9zHK0uRxEO4new4Jw">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;) remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_3_17_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_DSLkWT434UONxCiW0FQpqQ" decimals="-5" format="ixt:num-dot-decimal" name="plx:CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" scale="6" id="Narr_3jS8bLUjb0-BfKsW9QUP7g">20.0</ix:nonFraction>&#160;million. As of June&#160;30, 2025, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_FzEf68MnnECijIQBxIjdcg" decimals="-5" format="ixt:num-dot-decimal" name="plx:CommonStockValueOfCapitalSharesReservedForFutureIssuance" scale="6" id="Narr_geruRghsR0SAZ0STM8urlw">15.7</ix:nonFraction>&#160;million in shares of Common Stock remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel. In October 2023 Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and attacked civilian and military targets. The infiltration was accompanied by extensive rocket attacks by Hamas on industrial, civilian and military targets throughout Israel. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#8217;s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel, as discussed above. In June 2025, Israel launched significant aerial attacks on military and related sites in Iran, and the Iranian military responded with missile and drone attacks in Israel, which was followed by strategic bombing by the U.S. Air Force. The U.S. action was followed by a cease fire with Iran which remains in effect as of the date hereof. Although ceasefire negotiations are on-going with Hamas and the level of military activity has decreased in recent months compared to previous levels, it is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The Company&#8217;s facilities are recognized as an &#8220;essential enterprise&#8221; in Israel which means the Company operates or can be operated for the purposes of state defense or public security or for the maintenance of essential supplies or services, allowing the Company to maintain operations during emergencies. However, the situation could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of June&#160;30, 2025, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p></ix:continuation></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_woFg3WAEqkeXrFIy2yvMAQ_cont2" continuedAt="Tb_woFg3WAEqkeXrFIy2yvMAQ_cont3"><ix:continuation id="Tb_E4UhmIKRuEKi86osR_ioLA_cont2"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_5SXqhbhMS0uObp36imacdw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;) on March&#160;17, 2025. The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_vgtdJKXbhk2vRNOntGDOVw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Net earnings (loss) per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of Common Stock outstanding for each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:DebtPolicyTextBlock" id="Tb_CDiL3nD89k6p_RihxvSkNw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its <ix:nonFraction unitRef="Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ" contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_J-bqAQI5xUiCwzpV-Gys5Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_vFkCTZvdIEe6BoIjZU3H7w">7.50</ix:nonFraction>%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.</p></ix:nonNumeric><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">New accounting </b><b style="font-weight:bold;">pronouncements</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_9uP82DbmvkOUi92sJ_m10A" continuedAt="Tb_9uP82DbmvkOUi92sJ_m10A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_woFg3WAEqkeXrFIy2yvMAQ_cont3"><ix:continuation id="Tb_9uP82DbmvkOUi92sJ_m10A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2024, the FASB issued ASU&#160;2024-03 &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures<span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="Tc_U-Igb2SlGEaYxNL7Ndl1Gw_1_2"></a><a id="Tc_B-S6jRhEWEeZ8LYNo5VQUw_1_5"></a><a id="Tc_N4qka0zkM06Lgyhkprn9mw_2_0"></a><a id="Tc_jGE6F-T4s0m96LRfrLfJFA_2_2"></a><a id="Tc_I8dBSxuxike1kdDbvsMZbw_2_5"></a><a id="Tc_Y-RCrFZ2ckK9yzpt2rdX3w_3_0"></a><a id="Tc_tC2TrJxHk0Gpq-ZMYRHZsA_3_2"></a><a id="Tc_MtQadb4b_0mBYTKQz3YqFg_3_5"></a><a id="Tc_4kt7GSiDrUyPufP5c4qrCg_4_0"></a><a id="Tc_h4BbVDnwXUeUHw6yxCB50g_5_0"></a><a id="Tc_oZvR8Sz2N0GM-hI23K3oMQ_6_0"></a><a id="Tc_-_av-0LGuUSecU-B3MqaVw_6_2"></a><a id="Tc_h02CYqhY_Um1ihvNsumTBQ_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_XFtGlW-Vu028LI60m-_aKg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Group_5mfmd0-jrECNWCRmPNfXFw" continuedAt="Group_5mfmd0-jrECNWCRmPNfXFw_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at June&#160;30, 2025 and December&#160;31, 2024 consisted of the following:</p></ix:nonNumeric><ix:continuation id="Group_5mfmd0-jrECNWCRmPNfXFw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_8Fl06kS0AUqy2MBWAg2jDQ_3_3">4,357</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_oApzV49rx0CejzqKWauFKA_3_6">4,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_7P0U4pJG0EK0v2Ru8t9hsg_4_3">8,144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_uYFprKC6P0aSDZZI3wYKng_4_6">11,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_6IdiTZWt4EmowQpLF3I0QA_5_3">8,630</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_aiO6wd1_uk2CozCciC7UVQ_5_6">5,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_Q8pHAirHek6-VX6dj4lnsg_6_3">21,131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_lMC-_FSEf0iD6bnu93x7yw_6_6">21,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_HL45UST1nUOytQfUPOQ5MQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is identical or close to their carrying value.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_5DyqU5yZk0Wa69eXONBmDA" continuedAt="Tb_5DyqU5yZk0Wa69eXONBmDA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 4 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the three months ended March&#160;31, 2025, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_BskKyxhG5ketf2PCSTzhyw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_1ANNu_dmGEa0Bss_ldBkfw">908,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_BskKyxhG5ketf2PCSTzhyw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_SGba7zzPS0yrrgfnPXvGIw">2.1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from such exercises. The remaining warrants expired on March&#160;11, 2025. Accordingly, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as of March&#160;12, 2025, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="As_Of_3_12_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_KdZmUKvKIEagwl1U2B1ZLA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_NDIoPPH0vkKQLi0JhqYy3w">no</ix:nonFraction></span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants remained outstanding</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the six months ended June&#160;30, 2025, the Company sold, in the aggregate, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_H8A_3lY72U6nRHPcehodwA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_-Jd1WUEGkEa8QVFPpdJh-Q">2,775,215</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock under the Sales Agreement. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company generated </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">gross proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_H8A_3lY72U6nRHPcehodwA" decimals="-5" format="ixt:num-dot-decimal" name="plx:GrossProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_snts2Gr8FU26Qjj8lMja2w">7.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in connection with such sales (issuance costs were </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_H8A_3lY72U6nRHPcehodwA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_B4oD44dAfkSgd6pOosMmYA">0.2</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million).</span></td></tr></table></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_5DyqU5yZk0Wa69eXONBmDA_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the six months ended June&#160;30, 2025, the Company issued, in the aggregate, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFHYyBQEPE2I_t5p2bioTg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_unrLzfg3YEm7Ih0sCra2nw">198,625</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of options to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFHYyBQEPE2I_t5p2bioTg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_EABleRMm1US_tPFTPRXrlQ">198,625</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock by certain current and former employees of the Company. The Company received cash proceeds equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFHYyBQEPE2I_t5p2bioTg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="Narr_DFOAMuSDGkiZ5dqLoL2rPw">0.3</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in connection with such exercises.</span></td></tr></table><div style="margin-top:10pt;"></div></ix:continuation><a id="_6decb5fe_5bf4_42a7_8c51_83efe763b9f1"></a><a id="Tc_sR59p2v7CU6YIEyqgbOXUw_1_2"></a><a id="Tc_y-JiqJeVGkyi01RIx562TQ_1_9"></a><a id="Tc_HH_u7R2ALk-uZZF2GZoGFA_2_0"></a><a id="Tc_y1pHes07iE6Unw0HGWy-Bw_2_2"></a><a id="Tc_Jp7W-wY5RUeJviA7QAEjCw_2_5"></a><a id="Tc_Sjg2n-6VrEWju4pE0KcV4A_2_8"></a><a id="Tc__fMyTSOFXESbbdqgz1PJ_Q_2_11"></a><a id="Tc_XY8bTjbYLUS_US0aTuzZ8g_3_0"></a><a id="Tc__WxZirhyRkat0H-mCnLnBw_4_0"></a><a id="Tc_g4KOTJaYRE2L1dUZ5OOyFQ_4_2"></a><a id="Tc_UWe9k1YBzUS7Q8Xx1-a-lw_4_5"></a><a id="Tc_rJNjPiIOEESxQItX6_Vs2A_4_8"></a><a id="Tc_0z9-etJHMUev7-jqC0N8RA_4_11"></a><a id="Tc_arX567Q2dUeVMVBcCR4QeA_5_0"></a><a id="Tc_fxc8SkHuGEaX0eQi_LX0_g_6_0"></a><a id="Tc_fBUzvAQ89Eax0_bciPGDxQ_7_0"></a><a id="Tc_Jjb0DsR9JE-T6K1KQ9e46A_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_iHyEK0sxdkK7rnVEbWHBXQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; EARNINGS (LOSS) PER SHARE</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_9mGTyPMlQEOe6S7rlCyzjg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted earnings (loss) per share attributable to common stockholders were calculated as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for basic and diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_F8freIaE3EqGzySL814VRA_4_3">3,455</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3zW86VaBSkustABP0kNpeg_4_6">6,798</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_-79aeVUiz0eW6mccYTuxAQ_4_9">164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_BVASvn3xrEaN4btBP2gcWw_4_12">2,203</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Ng4HO3U-KUGfcod_5rrA4w_6_3">77,651,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_tCDLG7wul0KoJvAX76bAgw_6_6">73,172,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_EUZkuQmzM06Tx1M1mQ9PqQ_6_9">78,663,884</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_oa4q9Z7AdUuj9o9LIJOaWQ_6_12">73,308,281</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of stock options and restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_dLptJM0nQ0enRPxRlbPcIQ_7_9">2,607,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_d_rUZt_qw0ier9Bd21WHug_8_3">77,651,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_8E5eeyc6FUy8U1PQZXqcLA_8_6">73,172,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_t0QVohfS7kmpUC12Dtma0A_8_9">81,271,610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_7eIHHKFy00qS9JYLdW-ltw_8_12">73,308,281</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_OSrevicPJEyApi98O9HZYw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_BQKWBlougUShm6K6mFWGOQ">12,936,429</ix:nonFraction> shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock and warrants for the six months ended June&#160;30, 2025 because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_Jd2vQXzHM0yf_bHD3xyvTw">2,365,709</ix:nonFraction> shares of Common Stock underlying outstanding stock options for the three months ended June&#160;30, 2025 because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_H3oHw-vHw0emnoAUC9JBzA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_r7UWY4uXQk21FKhtN2u54Q">31,744,960</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_xTNzdzPaT0qCf53ldUBTUQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_A2kbDg8J9U-gSDeP39oQmA">31,791,645</ix:nonFraction> shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock, warrants and the 2024 Notes for the three and six months ended June&#160;30, 2024, respectively, because the effect would be anti-dilutive.</p></ix:nonNumeric><a id="Tc_9B5jih9J30anYNAZwIrw2g_1_3"></a><a id="Tc_cjNJ5oPvY0K4Ca88uNSamQ_1_8"></a><a id="Tc_XvFCkwzw3kiRTUCNAd13rA_2_0"></a><a id="Tc_KOmq0QWj1USfOE_q7tR-7w_2_2"></a><a id="Tc_aPkNJBGqt0Oj1LLfFENcbw_2_5"></a><a id="Tc_1q9IKeNqGkuqDyd_POpaTQ_2_8"></a><a id="Tc_kzAuDfnjwUC0ha5z48pdgA_2_11"></a><a id="Tc_QGt9Pc7CNUOpWlKTRD_f0Q_3_0"></a><a id="Tc_gHYXWCHCI0KYPvsICZ5ajg_3_2"></a><a id="Tc_kROlHMHhB0mqWGjpquoEfA_3_5"></a><a id="Tc_uP3q85gNmUSxydsFckTYpg_3_6"></a><a id="Tc_sQcXgaYlDUG4i6MVr3BVmA_3_8"></a><a id="Tc_jBPm6irvM0e0IldFct__yw_3_11"></a><a id="Tc_pJVn04c2REqnejWWRbxUDg_3_12"></a><a id="Tc_pYYMaRmmxESDnIoGavjm1A_4_0"></a><a id="Tc_SCB6O_B2rUmEDWvStczmOw_4_8"></a><a id="Tc_Ss-FtWMWEEuKz38MKrEixw_4_11"></a><a id="Tc_mAcp2RGkdkuNM2H3Xyg_Ng_5_0"></a><a id="Tc_M1iT0WD5SEyUE_xZF_vwQg_5_2"></a><a id="Tc_EKeEycxa4kimqteNLxXwhg_5_5"></a><a id="Tc_q4uPJCgUMUOQTCLD8BrUsg_5_8"></a><a id="Tc_AFtdlLjEU0uc81tdNsI__Q_5_11"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_HqmhOi8HjUej0VtXhdaGOA" continuedAt="Tb_HqmhOi8HjUej0VtXhdaGOA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; TAXES ON INCOME (TAX BENEFIT)</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Group_BNfUwtRf8ku4ofF0J65BZw" continuedAt="Group_BNfUwtRf8ku4ofF0J65BZw_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p></ix:nonNumeric><ix:continuation id="Group_BNfUwtRf8ku4ofF0J65BZw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_xZgT5HmG0E69Fj7_8vDu-g_3_3">266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_NAtsWuunT0SqQWPHVzyRXA_3_9">266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:50.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_kfx4rB8H6kaAwrozXXp6XQ_4_3">118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_ZfisHjACr0-ArwFeOFj0Ug_4_6">207</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_dpgudmlYU0iOo3_z6-FwGw_4_9">231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_mBdbZW4ar0Gc8VMZd3FfMw_4_12">69</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income (tax benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_TzACwMOSB0y-3iAsPB59iA_5_3">384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_G11UkH6hX0aReEWTU5jAKw_5_6">207</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_VViQ9mCPAEeDkxtavF4RJg_5_9">497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_Ei-LXCaPk02D_XCxC_8hRg_5_12">69</ix:nonFraction>)</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Narr_nr698p2f5EGCpYf4mmo0DA">13</ix:nonFraction>% for the six months ended June&#160;30, 2025 compared to an effective tax rate of (<ix:nonFraction unitRef="Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ" contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_KRHB0nQFHUS651PGpgl6XA">3</ix:nonFraction>)% for the six months ended June&#160;30, 2024. For the six months ended June&#160;30, 2025, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of <ix:nonFraction unitRef="Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ" contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_DPyuy7_V402Rv_Eq5c3YAg">21</ix:nonFraction>% was the result of forecasted profits derived primarily from U.S.&#160;taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;), which was enacted in December 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On July&#160;4, 2025, tax reform legislation was enacted in the United States through the passage of H.R.1, One Big Beautiful Bill Act (&#8220;HR1&#8221;), which includes significant corporate tax changes, including a restoration of the current deductibility for domestic research expenditures beginning in 2025, with transition options for previously capitalized amounts. The Company continues to evaluate the impact that the new legislation will have on the consolidated financial statements.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_HqmhOi8HjUej0VtXhdaGOA_cont1"></ix:continuation><a id="NOTE_7"></a><a id="_f10d0571_9307_4863_b1ac_d02a1bb9aefb"></a><a id="Tc_6MwYFj7NDUaW4i-2nquXTg_1_2"></a><a id="Tc_ke3bpbUmskaUPDVqwXd3wg_1_8"></a><a id="Tc_o5AH2quT-E6jV1z1hVje8A_2_0"></a><a id="Tc_ubkKpaNt4ke8Z8d-IrkMwQ_2_2"></a><a id="Tc_UAgHuws_z0qyEUK-mLjrFw_2_5"></a><a id="Tc_9zgaP6pwl0-xXqJJZGJ4aA_2_8"></a><a id="Tc_3m0qHguU4UqRQlmy5vlVwg_2_11"></a><a id="Tc_f4Bx8ye_GUW_NjWJBYQiTg_3_0"></a><a id="Tc_eCUPrD8DoEykExToTj-d5Q_3_2"></a><a id="Tc_HJtYdFX2dEaWa-7yCAAwkA_3_5"></a><a id="Tc_l7gv275UeEW9r3h5hNAZ-w_3_8"></a><a id="Tc_OWefu5byAk6R2DneT0wTfA_3_11"></a><a id="Tc_t94ASrmzp0aG5LRT6NcACw_4_0"></a><a id="Tc_jGJiouF5YkG24PQPQAYHZw_5_0"></a><a id="Tc_4tydbBPm6Em6NJMsu9aa7A_6_0"></a><a id="Tc_ZBpFHeO4gEKM01DGfUgw4w_7_0"></a><a id="Tc_OsOt4KkX2kqqkqd07_JwuA_7_3"></a><a id="Tc_btwmZx8UAUGRG_eMTZzU-w_7_9"></a><a id="Tc_a23ghC3d8kCa8fJ1RixRNQ_8_0"></a><a id="Tc_XMYK3AUax0u3cmvhHVEpTw_9_0"></a><a id="Tc_-eCpPUnf106EJpFePQ5qxA_10_0"></a><a id="Tc_crNns8AZIk25wenjOAP58Q_11_0"></a><a id="Tc_huiCoqm36EevsoMhn6be9w_12_0"></a><a id="Tc_TqM6Y5oT4kKXRUuOTpI1Aw_13_0"></a><a id="Tc_9L6iK6Rv8EWDE1gHYRMtGw_13_2"></a><a id="Tc_nBb1q0yv2kGADb4EiiLQtg_13_5"></a><a id="Tc_D7HCiM6ZeUmzcIR9XHiGUQ_13_8"></a><a id="Tc_XolJa713nE6KME42glZHGg_13_11"></a><a id="_efea1927_263e_4853_975e_490fff50e12e"></a><a id="Tc_7pykZZcDuUSTD49kWz1-gg_1_1"></a><a id="Tc_hafgNfhikkWNJIXJQ75mwg_1_7"></a><a id="Tc_836k493x80KCNU85Y3NIAw_2_0"></a><a id="Tc_tHauxzZhj0Kqp5_nWk0QDQ_2_1"></a><a id="Tc_jxCFGrDvfkuciPMuGIqxjA_2_4"></a><a id="Tc_1s61GJSjeUOVrXF2XYbQlA_2_7"></a><a id="Tc_uwG6Rfo-k0elJTI3SxZQ6A_2_10"></a><a id="Tc_0UOOZLYqdUW1MEYhAuSjtw_3_0"></a><a id="Tc_t842BvDEMEKl9VSM7c4bUA_4_0"></a><a id="Tc_PUUgXOCyZEKRGiI6SAxYTQ_4_1"></a><a id="Tc_eGhog1p400m-P54EEPv2LQ_4_4"></a><a id="Tc_1LR5lErENkCrw1ozSNgZHQ_4_7"></a><a id="Tc__uSvM2JNU0KhfhKwC54ThQ_4_10"></a><a id="Tc_T7cdGQmwEUyefQswfL-MTQ_5_0"></a><a id="Tc_HNKcsOPcCEyt11YXK9zhVg_5_1"></a><a id="Tc_E-pUK9vOikauRPXH81yO1A_5_4"></a><a id="Tc_a-0pDag_40GqjdCAD16_vg_5_7"></a><a id="Tc_XvT_fsnn-UuxmmlmWDH4hQ_5_8"></a><a id="Tc_Cn0xiWwMP0u1i9wVqpc_BQ_5_10"></a><a id="Tc_M0dwGRklPUSaX5N3RZ_h4Q_6_0"></a><a id="Tc_X9VWqil56kyl2z3lEYPyxQ_7_0"></a><a id="Tc_vf8A7OrgPE-Kfxm6iD7exg_7_1"></a><a id="Tc_HEy619NDnkGQsQeeBLjtVA_7_4"></a><a id="Tc_C-2aiQfPGk2MQXznwekuGQ_7_7"></a><a id="Tc_WuqrkGewRkSGCm2Y9icRgQ_7_10"></a><a id="Tc_Vl1wim0gVUK6mfGiXhwkFA_8_0"></a><a id="Tc_6-_0c-W1EUaY8O3HS6cOuQ_8_1"></a><a id="Tc_BYHWG4_ESUaB-AfMqD-qgw_8_4"></a><a id="Tc_W27oDS1eGkyWmCLo9EFVGA_8_7"></a><a id="Tc_pFsOXjrpJkmKCra40wd03A_8_10"></a><a id="Tc_fTpzL7vD0kS1S8aQQzq6bQ_9_0"></a><a id="Tc_Gpd6j5jxHkGxKCyIT_4-oA_9_1"></a><a id="Tc_QNQrPI3TTUOhcb571q4Gmw_9_4"></a><a id="Tc_q-edbrnaIkiDugdiEmmt6w_9_7"></a><a id="Tc_PXQBL_SADU65DAftNxc-bw_9_10"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_VgaFp2RcoUWjw-HW_nJLvg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SEGMENT INFORMATION</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company operates in Israel as a </span><span style="-sec-ix-hidden:Hidden_aiZWtzxgnU-JSOrCWSBBBw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> operating segment. The Company&#8217;s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.</span></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="Tb_Q1vpxTm6702NDGaaGPgumQ" escape="true"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Segment information:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from customers</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_hZJ4MqPiuE2r1MBzkHKigA_3_3">25,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_f8kmu7iFy0ayRKShU9uOVA_3_6">17,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_tzhbvyn8MkC52y2g-uY0EA_3_9">15,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_r2rRQR-GAEWQWJtz4b31Ww_3_12">13,474</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee salaries and related expenses</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_0i9a4FtZDUutXu3qR3BqOw_5_3">10,649</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_NqPKTRWLYEiAesJv0-NEfA_5_6">10,357</ix:nonFraction></p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_iKvV-I1pakylOU2EYgWFzw_5_9">5,444</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_ER0RH9SlnEGgMSO3EwBaQw_5_12">5,213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-contractors expense</p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="Tc_I-0D9zV0B0GUzOOwqkN4kQ_6_3">7,463</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="Tc_o4F8azEvE0isM8UXQ9xYgw_6_6">4,764</ix:nonFraction></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="Tc_Fwc67k2etU6rb7PRV96NFw_6_9">4,773</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="Tc_BpOF2D1s60yfjx8kyXN7cQ_6_12">2,609</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_SJoliR-fpEaQ53c822d2ZA_7_6">761</ix:nonFraction></p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc__pu69sqn-0u46gWuhZE8nA_7_12">379</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_NcFTSI0GOE-V_OfR0AktfA_8_3">528</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_fOLh-NQWWUONYxnCZ9veJw_8_6">757</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_8c1b9ZTlVEajjyKwWEgqcA_8_9">272</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_epPbcno_20qjWi_F2RCJpA_8_12">374</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_-4ijikXqx0ajeD3KP3PxdA_9_3">706</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_CRcfRlLwg0---noMOe8IFg_9_6">641</ix:nonFraction></p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_9Gv3da9OK0Gqctu2KkMG9Q_9_9">360</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_2GKLzywQ002OuX7Qw8k82w_9_12">319</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment expenses*</p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_KXpaHKcDBEu25-4UpyaH6Q_10_3">10,552</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_dF2qORBR5UuORH9T3cYghg_10_6">8,461</ix:nonFraction></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_1cw5eeoLPkGKCd5vPu4pIQ_10_9">4,692</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_ysunOtYrZEqwMpEXGAWg1A_10_12">7,600</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income (loss) before taxes on income</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_7Jf8pvOSO0ykUO8QLptDcA_11_3">3,071</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_yWAGsCiJHEOL6aiuqAUt2w_11_6">7,005</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_RGqQP3oiN0unyiqhV8FVfA_11_9">661</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_wd8HhYEvckK7Hz5i1NpFLA_11_12">2,272</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxes on income (tax benefit)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_S7saCiF1CUSB2ceFk5M4_w_12_3">384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_4oeC_D-wPUCJBNPxRPCb4g_12_6">207</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_s9uMJuMMIkeC0FhChiNZMg_12_9">497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_IDRwQRpqwEaaN_XlRRah3w_12_12">69</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net income (loss)</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_7zBAfkjxvk2c_lh4txk0pA_13_3">3,455</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_7kBV7VjuSkOK8d4Xb-7-gw_13_6">6,798</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_yW65z1RslU6mR7-LRxQjvg_13_9">164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_j_2C1Us46EysWCi1_LYr-Q_13_12">2,203</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;">* <ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_yb07mZVDHUulKOJ25TrVaw"><ix:nonNumeric contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_kSbwOFa_rEKTjIBPrR1TAQ"><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_oVKpKdrwhka1akezzI6fsA"><ix:nonNumeric contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_qC9n0gkZ9k-H5PHkg6Z4SA">Other expenses included in net income includes raw materials, rent and utilities and others.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="Tb_5w6SzUPYgUW7zyptUDZ3kA" escape="true"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Gaucher disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer (Ireland)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_lOvXmD6MgESV0B-omrPS4Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_s4-KtEov1UKtU4C3M-pt2g_4_2">12,626</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_yAabyI-paEuRtn18CZC1RA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_sNoob_g9nUuJps3Mevt26A_4_5">8,001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_6_coWg2e90CjjtM9azRMBg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_DPFTb9DNGkCSBSckbmV_BA_4_8">5,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_Nr4z7GCvjkSm2YfF7bwdZg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_N27CjTqen0-mA8X67_UZHQ_4_11">6,874</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiocruz (Brazil)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_YHDGlfD_AUaicoScEusHeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_hxfKIqEXUUm3cYlD94FxrA_5_2">3,016</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_Qa6aQzsVJ062wE77uGETpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_uRFFP769RkiRl9CpB5DuJQ_5_5">7,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember__Vfwx-5_M0Cu0g0xtW7Dkg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_46bWuVZzG0ybOv3TF8-X1g_5_11">4,716</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Fabry disease:</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi (Italy)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_GrF2myzJiEqbTvJY60IqmQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_Y2WplVQKuEGD1R5G-hxMlw_7_2">9,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_vu813cbeqECqUyYxxfs3Wg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_eIyFfjOUkEKy2hJN6BQo9g_7_5">1,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_mBt_DhnwSkaQSv72fYtQQg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_cO504aYBmkyA7UF2tZkSYg_7_8">9,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_LpkP8tV3j0qgmNzcnf0nig" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_fymEMkZquUq1pZvzDnwh9w_7_11">1,714</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_c_PLLEX5ekOtxFhMT3jjag" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_FVKkpoihTkOlMfebkyOhUg_8_2">25,435</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_ls4KWM6TWU2ieTyrmZgYpw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_od5hk-9rgUuFchs8-FPReQ_8_5">16,981</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_iejKZn67F0Sf2DaGIlWrig" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_ynvn_rT9Tk6go1ZMwUPVlA_8_8">15,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_r_xBq1FYmEe1hu9bPCmlCg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_WxAv5RoqCEWNbagHxiCUWA_8_11">13,304</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_W2wc6JkTt0WlVF693XXzxw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_GNGekzq-EUG7ssbqA_8k4Q_9_2">336</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_rUd6RnaD1Ea21Qe6MwDvwg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_IJYuAfgwTU22KrpaN-KWbw_9_5">241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Ry9eJBFRY0aWUriRJJoWPw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_yvVR1HQvkUmEZUSV_Gq50g_9_8">218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_71I2lv4f9kWJWcfI-ONvvA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_vBuIp_qYKEaClaLQaLB8JQ_9_11">170</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Long lived assets are located in Israel.</span></td></tr></table><div style="margin-top:10pt;"></div></ix:nonNumeric><a id="Tc_2oCUb7K0806pxm42w5vW-w_1_2"></a><a id="Tc_y9iVrgImYkmVyNhicpOhuw_1_5"></a><a id="Tc_elLwjJ5diEmx8lF94V76Gg_2_0"></a><a id="Tc_qkeD0mxOP0ihW7BsZfYEyQ_2_2"></a><a id="Tc_2KgDhEQ2O0iyQT6atTkzIA_2_5"></a><a id="Tc_R_eHBYdBy0yBbgq3r9_V8w_3_0"></a><a id="Tc_a6-kPCCf8k-P08dLBXOmAw_4_0"></a><a id="Tc_dSSUBJqdGkaAD8PU7A-foQ_4_2"></a><a id="Tc_UvpWFPL3V0WR44hyjz2xeA_4_5"></a><a id="Tc_RBGdvEkbW0CYrYIgCgVk9A_5_0"></a><a id="Tc_zaiMY8SrwkWmIpgbGkpwdQ_6_0"></a><a id="Tc_GZsl9yoap0K5dm431Z2ZNw_7_0"></a><a id="Tc_G0xhUUkWvUaS7QV0KrRt9g_8_0"></a><a id="Tc_Osh8DOgLv0qapGNwrxLVJA_9_0"></a><a id="Tc_uwi-yqw0XUWbSgJbhn0zBQ_9_3"></a><a id="Tc_OS59kIS3CUS4_o3dWqva3Q_10_0"></a><a id="Tc_g9ab-Z_5H0yIMS-r_ZDjrQ_11_2"></a><a id="Tc_fxFi1JB-kUahd8RIvaJZ7w_11_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_eTJ64BGxZkCu3snMM-ee3Q" continuedAt="Tb_eTJ64BGxZkCu3snMM-ee3Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="plx:SupplementaryBalanceSheetsInformationTableTextBlock" id="Tb_OhOEhaaVrkaWpDPW1fu8wQ" continuedAt="Tb_OhOEhaaVrkaWpDPW1fu8wQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_MqZQx3rTDEGBuuZwKm59sw_4_3">1,527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_O_CV6GcgSEq2P22tfLuR8Q_4_6">1,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_srsKrp2LakqzQjqjhbQULQ_5_3">2,209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_hNpL06ST9k674XLaI_dmsQ_5_6">1,811</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_hDQCssK0x06vGHDW7nqPng_6_3">7,311</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_OufxySyxGkCoyAFZFm1XTw_6_6">9,568</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_KQ7LXB_b2UC0XZwTKnkyhA_7_3">763</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_KX8ig6UbBUa9C2A4OCgVbw_7_6">1,080</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_NEVP0yvPHU-QjhCPfSaAZg_8_3">3,742</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_qpFTtn3YbEWJs8x9YOGgUw_8_6">3,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable to customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">-</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="plx:PayableToCustomerCurrent" scale="3" id="Tc_OXt8nZ9g8kGup90mUftlUw_9_6">2,056</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_HXeOHaoTakOb7MbeKpg6sw_10_3">378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_BWM9oTSnXE2WqwLzbzE9eg_10_6">254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_dYud74kTMkehs6HAisjrUg_11_3">15,930</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_-akLPMdizkeKP6tMhWHU_w_11_6">19,588</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_eTJ64BGxZkCu3snMM-ee3Q_cont1"><ix:continuation id="Tb_OhOEhaaVrkaWpDPW1fu8wQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ" name="us-gaap:SubsequentEventsTextBlock" id="Tb_2UTDmpAotk-CpVb4PZEtsw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 9 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the end of the quarter ended June&#160;30, 2025, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_7_1_2025_To_8_14_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_kUAPHqMvy0ainpcMZtiRig" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCustomers" scale="6" id="Narr_j4UXtjX8dUeCdjKMNTAGMg">1.4</ix:nonFraction>&#160;million from sales to Pfizer and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="Duration_7_1_2025_To_8_14_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_DphnniDSq0SBx-JnoOYjZA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCustomers" scale="6" id="Narr_QtWXhi5sDUKbQZSzHcehwA">7.8</ix:nonFraction>&#160;million from sales to Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On July&#160;20, 2025, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonNumeric contextRef="Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_xbkGmc7wDUiQZVFhWFt7qg">10-year</ix:nonNumeric> options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ" contextRef="Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_t-mbo8lje0-oOlRRA1bbgw">597,990</ix:nonFraction> shares of Common Stock, in the aggregate, to the Company&#8217;s incoming Sr.&#160;Vice President and Chief Financial Officer under the under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g" contextRef="Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr__ifj5iKkPk6OiGhy_4qAvg">1.45</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_F1MsSGRD2Eyc-qX-JLaR3w">three-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_installment_ZMevQBZ1KEOi7rMSOC56JQ" contextRef="Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg" decimals="INF" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_81y6vS_Xoky14KrpnzmMOQ">12</ix:nonFraction>&#160;equal quarterly increments. Vesting of the options is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<span style="direction:rtl;"><ix:nonFraction unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA" contextRef="As_Of_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2W9cGUF6_ESGJ2hjWELYOw" decimals="-5" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_cIRC1Eshu0-VKfibNPlUbQ">0.6</ix:nonFraction></span>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c4d7c62a_9ed6_4497_98e7_8453d0a13c7a"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2024. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company, our subsidiary or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors, including those set forth in this Quarterly Report on Form 10-Q.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the commercialization of Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa-iwxj), our approved product for the treatment of adult patients with Fabry disease;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to Elfabrio&#8217;s market acceptance, competition, reimbursement and regulatory actions, including as a result of the boxed warning contained in the FDA approval received for the product;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possible disruption of our operations due to the war declared by Israel&#8217;s security cabinet against the Hamas terrorist organization located in the Gaza Strip, the military campaign against the Hezbollah and other terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers, and the risk that the current hostilities will result in a greater regional conflict; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the regulatory approval and commercial success of our other product and product candidates, if approved;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our expectations with respect to the projected market of our products and product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>delays in the approval or potential rejection of any applications we file with the FDA, European Medicines Agency, or EMA, or other health regulatory authorities for our other product candidates, and other risks relating to the review process;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with global conditions and developments such as <span style="background:#ffffff;">new or increased tariffs, new trade restrictions, </span>supply chain challenges, the inflationary environment and tight labor market, and instability in the banking industry, which may adversely impact our business, operations and ability to raise additional financing if and as required and on terms acceptable to us;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity or debt markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic partnerships;</div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer and Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the amount and sufficiency of our cash and cash equivalents and short-term bank deposits;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, top-line or preliminary data from clinical trials that we announce or publish;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance Fiocruz with its purchase obligations under the Brazil Agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the inherent risks and uncertainties in developing drug platforms and products of the type we are developing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug products to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given these uncertainties, you should not place undue reliance on these forward-looking statements. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product, the FDA or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical or biotechnology company for the drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On June&#160;30, 2025, we announced that we had been added to the Russell 3000<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Russell 2000<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Indexes, effective as of the U.S. market close on June&#160;27, 2025, as part of the 2025 Russell indexes annual reconstitution.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On July&#160;21, 2025, we announced the appointment of Gilad Mamlok as our new Senior Vice President and Chief Financial Officer, effective August&#160;24, 2025, succeeding Eyal Rubin. To ensure a seamless transition, Mr.&#160;Mamlok has joined the company and is working alongside Mr.&#160;Rubin. After his tenure as Chief Financial Officer ends, Mr.&#160;Rubin will continue to be available to as necessary until October 2025.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are a commercial stage biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced via our proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> plant cell-based protein expression system. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. Our unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To date, we have successfully developed two commercial products, both of which are enzyme replacement therapies (ERTs): Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients and children four years of age and greater with Gaucher disease. Elelyso was first </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">approved by the FDA in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. Elfabrio, which we referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia, Singapore Australia and Taiwan. We have licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer, and in Brazil to Fiocruz. Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil. We have partnered with Chiesi for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our partnership with Chiesi is governed by two exclusive global licensing and supply agreements for Elfabrio for the treatment of Fabry disease with Chiesi; the Chiesi Ex-US Agreement and the Chiesi US Agreement, or collectively, the Chiesi Agreements. Under the agreements, we have received certain upfront payments and development cost reimbursements, and remain entitled to potential milestone payments and tiered payments for drug product purchased by Chiesi from Protalix Ltd. See Commercialization of Approved Products--Elfabrio (pegunigalsidase alfa/PRX-102) &#8211; Chiesi Farmaceutici.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of our agreements with Chiesi, Chiesi is solely responsible for the global commercialization and medical programs of Elfabrio, including patient acquisition and retention, and distribution of Elfabrio to patients. We are responsible for manufacturing of Elfabrio drug substance and product delivery to Chiesi. Operationally, Chiesi conducts its own internal commercial forecasting to guide inventory needs. To date, since approval in 2023, Chiesi has placed bulk orders for Elfabrio. As a result, the orders we receive from Chiesi may not be timed in relation to Chiesi&#8217;s pace of patient acquisition and retention. Our sales of Elfabrio to Chiesi may not reflect patient demand for Elfabrio. In addition, on a period-to-period basis, there may be variations in the orders placed by Chiesi resulting in variability in our period-to-period results as we, in turn, recognize revenues from sales of Elfabrio upon delivery of the drug product to Chiesi. There may be periods during which no orders are placed by Chiesi, whether as a result of inventory de-stocking or other factors. We do not anticipate that these Chiesi ordering patterns will change until the demand characteristics for Elfabrio stabilize, the launch of Elfabrio matures and Elfabrio&#8217;s share of the market for Fabry disease treatment grows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the Amended Pfizer Agreement, we have licensed to Pfizer the global rights to market and sell Elelyso in all markets, excluding Brazil. We sell drug substance to Pfizer for the production of Elelyso, subject to certain terms and conditions and Pfizer retains the revenues generated from such sales. See Commercialization of Approved Products--Elelyso &#8211; Pfizer and --Alfataliglicerase &#8211; Funda&#231;&#227;o Oswaldo Cruz (Fiocruz).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our sales of Elelyso to Pfizer and Fiocruz are structured in a manner similar to Chiesi. We sell the products at a fixed price directly to Pfizer and Fiocruz who maintain product in inventory, and we recognize revenue from those sales upon delivery. The timing of such sales does not directly reflect patient demand and, on a period-to-period basis, there may be variations in the orders placed by each of Pfizer and Fiocruz resulting in variability in our period-to-period results. There may be periods during which no orders are placed by either Pfizer or Fiocruz, whether as a result of inventory de-stocking or other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to Elelyso and Elfabrio, we are developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase&#160;I, or PRX-119, for the treatment of NETs-related diseases, and a number of other technologies and preclinical assets. We have completed a phase&#160;I First-in-Human clinical trial of PRX-115 and we are currently in the advance stages of preparations for a phase&#160;II clinical trial of PRX-115 which we expect to commence in the second half of 2025.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:238.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Product Pipeline</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20250630x10q005.jpg" alt="Graphic" style="display:inline-block;height:238.15pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:540pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our proprietary ProCellEx platform is being used to manufacture both of our approved and marketed products as well as PRX-115 and PRX-119.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are committed to leveraging our track record of success as we progress with the development of treatments for rare and orphan diseases. In addition, we continuously work on the further development and enhancement of our ProCellEx technology. Accordingly, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. We are also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expression in suspension. We are the first and only company to receive FDA approval of a protein produced through plant cell-based expression, and with the approval of Elfabrio, we now produce two commercial proteins through our platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins. The system plays an important role in the execution of our corporate strategy as it allows us to develop and produce tailored complex recombinant therapeutic proteins and to genetically engineer and/or chemically modify such proteins pre- and/or post-production. The engineering and modification of the therapeutic proteins have the potential to provide added clinical benefits by improving the biological characteristics (e.g., glycosylation, half-life, immunogenicity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We developed ProCellEx based on our plant cell culture technology for the development, expression and manufacture of recombinant proteins that are the essential foundation of modern biotechnology. We develop new, recombinant therapeutic proteins by using the natural capability of agrobacterium to transfer a DNA fragment into the plant chromosome, allowing the genome of the plant cell to code for specific proteins of interest. The agrobacterium-mediated transformed cells are then able to produce specific proteins, which are extracted and purified and can be used as therapies to treat a variety of diseases.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:199.65pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology can be utilized to express complex therapeutic proteins belonging to different drug classes, such as enzymes, hormones, monoclonal antibodies, cytokines and vaccines. The entire protein expression process, from initial nucleotide cloning to large-scale production of the protein product, occurs under Current Good Manufacturing Practice-, or cGMP-, compliant, controlled processes. Our plant cell culture technology uses cells, such as carrot and tobacco (BY-2) cells, which undergo advanced genetic engineering and/or chemical modifications, and are grown on an industrial scale in a disposable, flexible bioreactor system. Our system does not involve mammalian or animal-derived components or transgenic field-grown or whole plants at any point in the production process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cell growth, from initiating scale-up steps from a cell-bank through large-scale production takes place in a clean-room environment in flexible, sterile, custom-designed polyethylene bioreactors, and does not require the use of large stainless-steel bioreactors commonly used in mammalian-based systems for recombinant protein production. The ProCellEx reactors are easy to use and maintain, allow for rapid horizontal scale-up and do not involve the risk of mammalian viral contamination. Our bioreactors are well-suited for plant cell growth using a simple, inexpensive, chemically defined growth medium. The reactors, which are custom-designed and optimized for plant cell cultures, require low initial capital investment and are rapidly scalable at a low cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we continuously work on the further development and enhancement of our ProCellEx technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Plant Cell Production Advantages</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="plx-20250630x10q006.jpg" alt="Graphic" style="display:inline-block;height:199.65pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:205.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">ProCellEx</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;">: Protalix&#8217;s Differentiated Plant Cell Protein Expression Platform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="plx-20250630x10q007.jpg" alt="Graphic" style="display:inline-block;height:204.8pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Marketed Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have two commercial products, each of which is an ERT; Elelyso and Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Elelyso for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an ERT for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for children four years of age and greater. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in 23&#160;markets including the United States, Brazil, Israel and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen, liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1&#160;in 400 to 1&#160;in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Gaucher disease, that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, was $1.7&#160;billion in 2024, is forecasted to be approximately $1.7&#160;billion in 2025 and is forecasted to grow at a compound annual growth rate (CAGR) of approximately -1.66% from 2024-2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The current standard of care for Gaucher disease is ERT, which is a medical treatment where recombinant enzymes are injected into patients to replace the lacking or dysfunctional enzyme. In Gaucher disease, recombinant GCD is infused to replace the mutated or deficient natural GCD enzyme. Elelyso is the only alternative ERT treatment of Gaucher disease to Cerezyme and Vpriv.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Elfabrio, our second commercial product, was approved by the EC for marketing in the EU and by the FDA for marketing in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. According to the EMA, overall, the benefit/risk balance of Elfabrio is positive in the claimed indication (Fabry disease). Similarly, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease. The FDA noted its determination that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study, our phase I/II clinical trial of Fabry disease, with confirmatory evidence provided by the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">BALANCE</i> study. The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support the non-inferiority margin. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Since the approvals by the FDA and the EMA, Elfabrio has been approved for marketing in Great Britain, Switzerland, Peru, Israel, Russia, Singapore Australia and Taiwan for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack or have low levels of &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">, in blood vessel walls throughout their body. The ultimate consequences of Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">&#160;deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The standard of care for Fabry disease is ERT. Currently, the marketed ERTs for Fabry disease are agalsidase alfa and agalsidase beta, and now Elfabrio. Through an ERT, the missing &#945;-galactosidase-A is replaced with a recombinant form of the protein via intravenous, or IV, infusion once every two weeks. Fabry disease, if left untreated, will progress from a less severe condition to a more serious one. It can have a significant impact on quality of life due to presence of serious, chronic and debilitating complications, including cardiovascular and renal complications, and comorbid conditions such as pain can have a significant impact on the psychological well-being of Fabry patients and their social functioning. Fabry disease involves substantial reduction in life expectancy. Causes of death are most often cardiovascular disease and, to a lesser extent, cerebrovascular disease and renal disease. The life expectancy of Fabry patients is significantly shorter compared to the general population. Untreated male Fabry patients may experience shortened lifespans to approximately 50&#160;years, and 70&#160;years for untreated female patients with Fabry disease. This represents a 20- and 10-year reduction of their respective lifespans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The global market for Fabry disease, that includes agalsidase beta, Sanofi&#8217;s Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, agalsidase alfa, Shire&#8217;s Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Amicus Therapeutics&#8217; Galafold<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, is forecasted to be approximately $2.3&#160;billion in 2025 and is forecasted to grow at a CAGR of 7.39% from 2024-2030 reaching approximately $3.2&#160;billion in annual sales in 2030. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Regulatory Background of Elfabrio</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On November&#160;9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102, the name we assigned to Elfabrio internally prior to its approvals, for the potential treatment of adult patients with Fabry disease. The initial BLA for PRX-102 was submitted to the FDA in May 2020. However, in April 2021, the FDA issued a CRL in response thereto. No concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package were raised in the CRL. The FDA noted in the CRL that an inspection of our manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, was required before the FDA can approve a new drug. Due to travel restrictions during the COVID-19 pandemic, the FDA was unable to conduct the required pre-approval inspection during the review cycle. In addition to the foregoing, the FDA noted that agalsidase beta had recently been converted to full approval, a change in regulatory circumstances which had to be addressed in the resubmitted BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The PRX-102 MAA was submitted to the EMA in February 2022 after a meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. In February 2023, we, together with Chiesi, announced that the EMA&#8217;s Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion, recommending marketing authorization for PRX-102. As disclosed above, Elfabrio was subsequently approved by the EC for marketing in the EU and in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with ERT class labeling, and warnings/precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The warnings/precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">In December 2024, the EMA validated Chiesi&#8217;s Variation Submission for PRX-102. The Variation Submission seeks to add an additional dose and dosing regimen, 2&#160;mg/kg body weight administered every four weeks in adult patients with Fabry disease, to the current Elfabrio label.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our PRX-102 clinical development program was designed to show that PRX-102 has a potential clinical benefit in all adult Fabry patient populations when compared to the then marketed Fabry disease enzymes, agalsidase beta and agalsidase alfa. In preclinical studies, PRX-102 showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of anti-drug antibodies, or ADAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;III clinical program included three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. In the phase&#160;III clinical program overall, two potential dosing regimens for PRX-102 were analyzed; 1&#160;mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2&#160;mg/kg every four weeks. The phase&#160;III program was preceded by the phase&#160;I/II clinical trial, a dose range finding study in ERT-na&#239;ve adult patients with Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Phase&#160;III BALANCE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BALANCE</i> study (PB-102-F20, NCT02795676) was a pivotal 24-month, randomized, double blind, active control study of PRX-102 in adult Fabry patients with deteriorating renal function designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 administered every two weeks compared to agalsidase beta. The Clinical Study Report for the <i style="font-style:italic;">BALANCE</i> study, completed in July 2022, demonstrated a favorable tolerability profile. A total of 78 patients who were previously treated with agalsidase beta for at least one year with an eGFR slope at screening worse than -2&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year were enrolled in the study. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77&#160;patients were treated; 52 with PRX-102 and 25 with agalsidase beta. Approximately 40% of the enrolled patients were female.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one treatment-emergent adverse event (TEAE) compared to 24 (96.0%) in the agalsidase beta arm. The number of events adjusted to 100&#160;years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">TEAEs were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21&#160;(40.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11&#160;(21.2%)&#160;patients in the PRX-102 arm experienced a total of 13&#160;events compared to six (24.0%) patients experiencing a total of 51&#160;events in the agalsidase beta arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Assessment of immunogenicity, that is, the existence and development of anti PRX-102 antibodies or anti-agalsidase beta antibodies, in the study indicated that for the PRX-102 arm, 18 (34.6%) patients were ADA positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA positive at baseline, of which seven (87.5%) had neutralizing antibody activity. Only a small number of patients showed treatment-emergent ADA. At the end of the two-year study, 11 (23.4%) patients that received PRX-102 were ADA positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity. There was little change in the percentage of patients who were ADA positive, with a trend of reduction observed in the PRX-102 arm and stability in the agalsidase beta arm. The proportion of patients with neutralizing ADA decreased in the PRX-102 arm while it remained stable in the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Considering that in the trial patients in the PRX-102 arm were exposed for the first time to the novel enzyme, tolerability data appear favorable for PRX-102 and in-line with what was observed in the previous clinical studies of PRX-102.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of the direct, blinded comparison of PRX-102 to agalsidase beta, for the primary efficacy renal endpoints (i.e., eGFR change, eGFR slope) and for the main secondary endpoints (e.g., urine protein to creatinine ratio [UPCR] LVMI, MSSI, BPI) strongly suggest comparability in treatment effects between the two treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At the same time, a potentially favorable safety profile was identified based on lower rates of IRR, lower ADA positivity, and less premedication use in the PRX-102 arm compared to agalsidase beta. Overall, a positive benefit-risk balance was confirmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Phase&#160;III BRIDGE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIDGE</i> study (PB-102-F30, NCT03018730) was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of PRX-102, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with agalsidase alfa for at least two years and on a stable dose for at least six months. In the study, patients were screened and evaluated over three months while continuing agalsidase alfa treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE</i> study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22&#160;patients completed the 12-month treatment duration. In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, et. al., in 2019, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. The majority of TEAEs were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate TEAEs were nasopharyngitis, headache and dyspnea. An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent ADAs over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Phase&#160;III BRIGHT Study</i><i style="direction:rtl;font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIGHT</i> study (PB-102-F50, NCT03180840) was a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four weeks for 52 weeks (a total of 14&#160;infusions). The 2&#160;mg/kg every four weeks dosage has not been approved by the EMA, FDA or any other jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Enrollment in the study included 30 adult patients (24 males and 6 females) with mean (SD) age of 40.5 (11.3) years, ranging from 19 to 58 years previously treated with a commercially available ERT (agalsidase beta or agalsidase alfa) for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV infusions every two weeks to 2&#160;mg/kg of PRX-102 every four weeks for 12 months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the four-week dosing regimen as measured by eGFR and for lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>levels as a Fabry biomarker, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The final results from the <i style="font-style:italic;">BRIGHT</i> study indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without ADAs at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30 patients received at least one dose of PRX-102, and 29 patients completed the one-year study. Of these 29 patients, 28 received the intended regimen of 2&#160;mg/kg every four weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg PRX-102 every two weeks per protocol at the 11th infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Overall, 33 of 183 total TEAEs reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs led to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Study outcome measures show that plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change (&#177;SE) of 3.01&#160;nM (0.94) from baseline (19.36 nM &#177;3.35) to Week&#160;52 (22.23 &#177;3.60&#160;nM). Mean absolute eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>&#160;(1.39). Mean (SE) eGFR slope, at the end of the study, for the overall population, was -2.92&#160;(1.05) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year indicating stability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The study suggests that Fabry patients who are currently receiving ERT every two weeks may be successfully transitioned to PRX-102 2&#160;mg/kg every four weeks as an effective and tolerable alternative treatment option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week 52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Phase I/II Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;I/II clinical trial of PRX-102 (NCT01678898) was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult patients with Fabry disease. It was completed in 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the phase&#160;I/II study, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Results show that lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Extension Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two long-term open-label extension studies were available for patients who completed the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase I/II study. Overall, 126 patients who participated in our PRX-102 clinical program initially opted, with the advice of the treating physician, to enroll in one of the extension studies: 97 patients in the 1&#160;mg/kg every two weeks extension study (PB-102-F60, NCT03566017) (10 patients who completed an extension study from the phase&#160;I/II study, 18 patients who completed the <i style="font-style:italic;">BRIDGE</i> study; 69 patients who completed the <i style="font-style:italic;">BALANCE</i> study), and 29 patients who completed the <i style="font-style:italic;">BRIGHT</i> study in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the 2&#160;mg/kg every four weeks extension study (PB-102-F51, NCT03614234). Two of the patients in the 2&#160;mg/kg every four weeks extension study were treated with 1&#160;mg/kg every two weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">After the approval of Elfabrio in the US and the EU, sponsorship and administration of the extension studies was transferred to Chiesi. Over time, and as Elfabrio is approved for marketing in different jurisdictions, patients switch-out of the open-label extension studies. Most of them have transferred to a commercial setting; others withdraw for other reasons. Accordingly, the 1&#160;mg/kg every two weeks dosage extension study is now closed as most patients have transferred to commercial or expanded access programs. In addition, most of the patients that enrolled in the 2&#160;mg/kg every four weeks dosage extension study are now being treated with Elfabrio on a commercial basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Pediatric FLY Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi is sponsoring, with our collaborative efforts, a clinical trial entitled &#8220;Multi-Centre, Open-label Trial to Assess the Safety, Pharmacodynamics, Efficacy and Pharmacokinetics of pegunigalsidase alfa in Patients From 2 Years to Less Than 18 Years of Age With Confirmed Fabry Disease&#8221; (NCT06328608). Recruitment has commenced. The design of the study is based on the Initial Pediatric Study Plan (iPSP) agreed to with the FDA and the paediatric investigation plan (PIP) for Elfabrio, which has been accepted, as amended, by the Paediatric Committee (PDCO) of the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Japanese RISE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi is currently recruiting patients for its clinical trial entitled &#8220;A Multicenter Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Pegunigalsidase Alfa (PRX-102) in Japanese Patients With Fabry Disease,&#8221; or the <i style="font-style:italic;">RISE</i> study (NCT05710692). The aim of the <i style="font-style:italic;">RISE</i> study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned that a total of approximately 18-20 male and female Fabry disease patients between the ages of 13 and 60 years will be enrolled in the study which is being conducted in Japan. The study involves both the 1&#160;mg/kg every two weeks and the 2&#160;mg/kg every four weeks dosages.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization of Approved Products</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Elelyso &#8211; Pfizer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to market and sell Elelyso in all markets, excluding Brazil, pursuant to the Amended Pfizer Agreement. For the first 10-year period after the execution of the Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso for a fixed cost, subject to certain terms and conditions, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods, subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period. Any failure to comply with our supply commitments may subject us to substantial financial penalties. The Amended Pfizer Agreement includes customary provisions regarding cooperation for regulatory matters, patent enforcement, termination, indemnification and insurance requirements. We retain distribution rights to taliglucerase alfa in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Alfataliglicerase &#8211; Funda&#231;&#227;o Oswaldo Cruz (Fiocruz)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso, marketed as BioManguinhos alfataliglicerase in Brazil, is commercialized in Brazil through the Brazil Agreement with Fiocruz, which became effective in January&#160;2014. Gaucher patients in Brazil are entitled to receive ERT paid for by the Brazilian MoH. The Brazilian MoH clinical treatment guidelines (PCDT) state that BioManguinhos alfataliglicerase is the therapy of choice for newly diagnosed patients. BioManguinhos alfataliglicerase is currently estimated to be used by approximately 25% of Gaucher patients in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Brazil Agreement provides for a staged technology transfer which is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of BioManguinhos alfataliglicerase. Fiocruz has not satisfied certain purchase commitments under the Brazil Agreement. We have continued to sell BioManguinhos alfataliglicerase for a fixed price through purchase orders. We, on a continuous basis, discuss with Fiocruz potential steps to maximize sales of BioManguinhos alfataliglicerase sales to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Elfabrio (pegunigalsidase alfa/PRX-102) &#8211; Chiesi Farmaceutici</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the Chiesi Agreements, Protalix&#160;Ltd. has received $50.0&#160;million in upfront payments and development cost reimbursements of $45&#160;million, and is entitled to more than $1.0&#160;billion in potential milestone payments and tiered payments for drug product purchased </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">from Protalix Ltd. equal to 15%&#160;- 35% (ex-US) and 15%&#160;- 40% (US), depending on the amount of annual net sales in the applicable territories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Chiesi Ex-US Agreement, we granted to Chiesi an exclusive license for all markets outside of the United States to commercialize PRX-102. Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of the net sales of the drug product in each applicable territory as consideration for the supply of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The exclusive license to develop and commercialize PRX-102 in the United States were granted to Chiesi under the Chiesi US Agreement. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, capped at $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi agreed to make tiered payments of 15% to 40% of the net sales of the drug product in as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi amending the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;29, 2022, we entered into a Fill/Finish Agreement, or the F/F Agreement, and a Letter Agreement, or the Letter Agreement, in each case with Chiesi. Under the F/F Agreement, we agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide us with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The Letter Agreement changed the obligations of both us and Chiesi under the Chiesi Agreements with respect to, among other things, the evaluation, selection and establishment of an initial alternate source of commercial fill/finish services for PRX-102. In addition, the Letter Agreement amended certain provisions of the Chiesi Agreements to reflect the appointment of Chiesi as a supplier to our company of commercial fill/finish services and the potential establishment of an initial alternate source of commercial fill/finish services. Subsequently, in November 2024, we amended the agreement to provide that a different Chiesi facility may act as a secondary supplier of such services and that the F/F&#160;Agreement shall have an initial term of 10&#160;years, unless terminated earlier in accordance with the terms of the F/F&#160;Agreement. Prior to expiration of the initial term, the term may be extended by mutual agreement for an additional period of seven years upon mutual written agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Development Pipeline </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our corporate strategy includes development of treatments for rare and orphan diseases. To execute on the strategy, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. Our current pipeline of product candidates includes PEGylated uricase for the treatment of uncontrolled gout, Long Acting (LA) DNase&#160;I for the treatment of NETs and other technologies and preclinical assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">PEGylated Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of patients with uncontrolled gout. The uricase enzyme, which does not exist naturally in humans, converts urate to allantoin, which is easily eliminated through urine. This recombinant enzyme, expressed via our ProCellEx system, is designed to lower urate levels and improve clinical manifestation of the disease while having low immunogenicity and increased half-life of the drug in the blood. Pre-clinical data demonstrates long half-life, reduced immunogenic risk and high specific activity supports the potential of PRX-115 to be a safe and effective treatment for patients with gout. One-month multiple dosing toxicity studies in two animal species and a six-month multiple dosing toxicity study in one animal species were conducted to support single- and multiple-dose studies in humans.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:258.1pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have completed a phase&#160;I clinical trial of PRX-115 for the potential treatment of uncontrolled gout entitled &#8220;A Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels&#8221; (NCT05745727), or the <i style="font-style:italic;">FIH</i> study. The study was conducted at New Zealand Clinical Research (NZCR) under the New Zealand Medicines and Medical Devices Safety Authority (MedSafe) and the Health and Disability Ethics Committee (HDEC) guidelines. The completed study included eight sequential dosing cohorts, each composed of eight subjects (six active and two placebo), a 3:1 ratio. Subjects in each cohort, males and females aged 18 through 65, received a single dose of PRX-115 and were analyzed for safety, pharmacokinetics (PK) and pharmacodynamics (PD) (concentrations of plasma urate) for 85 days. Overall, 64 randomized subjects were enrolled across the eight cohorts; 48 subjects were treated with PRX&#8211;115 and 16 subjects were treated with placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Key results from the full <i style="font-style:italic;">FIH</i> study are as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Exposure to PRX-115 increased in a dose-dependent manner. Detectable PRX-115 levels were observed in plasma for up to 12&#160;weeks from subjects in cohorts 6, 7, and 8. See Figure&#160;1.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Figure&#160;1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20250630x10q008.jpg" alt="Graphic" style="display:inline-block;height:258.1pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:415pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>In all tested doses, a single dose of PRX-115 rapidly reduced plasma urate levels. The effect and duration of response were found to be dose dependent. Following a single dose, mean plasma urate levels remained below 6.0&#160;mg/dL for up to 12&#160;weeks at the highest doses. See Figure&#160;2.</div><div style="margin-top:10pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:277.8pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Figure&#160;2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="plx-20250630x10q009.jpg" alt="Graphic" style="display:inline-block;height:277.8pt;width:415.7pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>All randomized participants completed the study. PRX-115 was found to be well-tolerated. See Figure&#160;3.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Figure&#160;3. Overall Summary of Adverse Events*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="plx-20250630x10q010.jpg" alt="Graphic" style="display:inline-block;height:135.15pt;width:415.7pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;">*Number of subjects reporting at least one adverse event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Only 25% of the subjects treated with PRX-115 in the study (12/48) having reported study drug-related adverse events. The majority of such adverse events were mild to moderate and transient in nature. One subject experienced an anaphylactic reaction in cohort&#160;2 immediately following the commencement of the infusion (6 minutes) and, accordingly, was exposed to approximately 5% of the applicable PRX-115 dose. The reaction resolved completely and the subject continued in the study for follow-up safety assessments. Premedication with anti-histamines and steroids were administered to all subjects following the anaphylaxis event. No other subjects experienced a similar reaction and no other serious adverse events were reported in the study. No related adverse events were reported for subjects treated in cohorts 6 and 7, and only for one patient per cohort in cohorts 4, 5 and 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These results suggest that PRX-115 has the potential to be a promising treatment option for patients with gout. The results demonstrate that PRX-115 may offer an effective urate-lowering treatment with an added benefit of a potentially wide dosing interval, which may enhance patient compliance and treatment flexibility. Further studies are needed to confirm the long-term safety and efficacy of PRX-115 in the gout patient population.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have initiated preparations for a phase&#160;II clinical trial of PRX-115, and we expect to commence the study in the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gout is the most common inflammatory arthritis, affecting an estimated 14.9&#160;million adults in the United States alone. Based on market research we have commissioned, we estimate that approximately 25% of the gout population in the US and Western Europe do not have their gout controlled. Some of those patients cannot be treated with existing therapies; others stop treatment with existing therapies due to adverse events. In addition, such research shows that there are gout patients treated with existing therapies that continue to suffer from tophi despite having reached urate target levels. The risk of gout increases with age, and is more common in males. Gout results from sustained elevation of serum urate levels (hyperuricaemia). Urate levels may increase due to diet, genetic predisposition and environmental factors leading to the deposition of monosodium urate crystals and/or tophi in joints, tendons and other tissues, which triggers recurrent episodes of pronounced acute inflammation, known as gout flares. Gout leads to substantial morbidity, severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with a number of comorbidities, including hypertension, cardiovascular disease, renal impairment, diabetes, obesity, hyperlipidaemia and frequently occurs in a combination known as the metabolic syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Uncontrolled gout is when serum urate (sUA) levels are above the maximum medically appropriate level (6.8 mg/dL), as well as tophi formation and/or flares that cannot be treated with available urate lowering therapies. Currently available ULTs can be effective in treating gout. However, factors such as low adherence, under dosing, disease progression that causes high patient burden or patients that are not suitable for available therapy, require new, effective and safe therapies to treat these underserved uncontrolled gout patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegloticase) for treatment of chronic gout refractory to conventional therapy (gout patients who have contraindication/failure of other lowering urate treatments) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis and other major side-effects. The FDA label of Krystexxa was amended in 2022 to include co-treatment of methotrexate to prolong efficacy and increases tolerability in patients with refractory gout. Krystexxa is no longer marketed in the European Union. The EC withdrew the marketing authorization for Krystexxa in 2016 at the request of the marketing authorization holder which notified the EC of its decision not to market the product in the European Union for commercial reasons. We believe that new effective, safe therapies are needed to treat severe gout, chronic refractory and uncontrolled<b style="font-weight:bold;"> </b>gout, regardless of treatment history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate which we are designing to have an elongated half-life in the circulation for the potential treatment of NETs-related diseases. NETs, or Neutrophil extracellular traps, are web-like structures released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduce NETs toxicity. Our proprietary modified DNase&#160;I, which we have designed for long and customized systemic circulation in the bloodstream, may potentially enable effective treatment for these conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The administration of PRX-119 resulted in a decrease in circulating of DNA levels and significantly enhanced the survival of mice in both a CLP-induced sepsis model and an ARDS model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of June&#160;30, 2025, we hold a broad portfolio of 16 patent families consisting of approximately 68 patents in Europe, the United States, Israel and additional countries worldwide, as well as approximately 42 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Research &amp; Development </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consistent with our corporate strategy, we are focusing on new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">molecules and oligonucleotides, to take advantage of highly innovative opportunities. We are also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Three months ended June&#160;30, 2025 compared to the three months ended June&#160;30, 2024</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $15.4&#160;million during the three months ended June&#160;30, 2025, an increase of $2.1&#160;million, or 16%, compared to revenues of $13.3&#160;million for the three months ended June 30, 2024. The increase resulted primarily from an increase of $8.0&#160;million in sales to Chiesi, partially offset by a decrease of $4.7&#160;million in sales to Fiocruz (Brazil) and of $1.2&#160;million in sales to Pfizer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $0.2&#160;million for the three months ended June&#160;30, 2025, and June&#160;30, 2024. <span style="color:#212529;background:#ffffff;">Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. We expect to generate minimal revenues from license and R&amp;D services other than potential regulatory milestone payments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $5.9&#160;million for the three months ended June&#160;30, 2025, a decrease of $3.6&#160;million, or 38%, from cost of goods sold of $9.5&#160;million for the three months ended June&#160;30, 2024. The decrease in cost of goods sold was primarily the result of the decrease in sales to Pfizer and Fiocruz (Brazil) partially offset by the increase in sales to Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;">For the three months ended June&#160;30, 2025, our total research and development expenses were approximately $6.0&#160;million comprised of approximately $3.0&#160;million in subcontractor-related expenses, approximately $2.0&#160;million of salary and related expenses, approximately $0.2&#160;million of materials-related expenses and approximately $0.8&#160;million of other expenses. For the three months ended June&#160;30, 2024, our total research and development expenses were approximately $3.0&#160;million comprised of approximately $1.6&#160;million of salary and related expenses, approximately $0.5&#160;million in subcontractor-related expenses, approximately $0.2&#160;million of materials-related expenses and approximately $0.7&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total increase in research and developments expenses for the three months ended June&#160;30, 2025 was $3.0&#160;million, or 100%, compared to research and developments expenses of $3.0&#160;million for the three months ended June 30, 2024. The increase in research and development expenses resulted primarily from <span style="color:#212529;background:#ffffff;">preparations for the planned phase&#160;II clinical trial of PRX-115.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;"><span style="color:#212529;background:#ffffff;">We expect to continue to incur significant, increasing research and development expenses as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $2.6&#160;million for the three months ended June&#160;30, 2025, a decrease of $0.9&#160;million, or 26%, compared to $3.5&#160;million for the three months ended June&#160;30, 2024. The decrease resulted primarily from a decrease of $0.6&#160;million in salary and related expenses and a decrease of $0.3&#160;million in selling expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Financial Income (Expenses), Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses, net was $0.5&#160;million for the three months ended June&#160;30, 2025, compared to financial income, net of $0.2&#160;million for the three months ended June&#160;30, 2024. The increase in financial expenses, net resulted primarily from exchange rate costs and lower interest income on bank deposits partially offset by lower notes interest expenses due to the September 2024 repayment in full of all the outstanding principal and interest payable under the 2024 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Taxes on Income (Tax Benefit)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded tax expenses of approximately $0.5&#160;million for the three months ended June&#160;30, 2025, compared to a tax benefit of approximately $(0.1)&#160;million for the three months ended June&#160;30, 2024. The tax expenses or benefit resulted primarily from taxes on income mainly derived from GILTI income mainly in respect of Section&#160;174 of the TCJA. Effective in 2022, Section&#160;174 of the TCJA requires all U.S. companies, for tax purposes, to capitalize and subsequently amortize R&amp;D expenses that fall within the scope of Section 174 over five years for research activities conducted in the United States and over 15 years for research activities conducted outside of the United States, rather than deducting such costs in the current year. On July 4, 2025, tax reform legislation was enacted in the United States through the passage of HR1 which includes significant corporate tax changes, including a restoration of the current deductibility for domestic research expenditures beginning in 2025, with transition options for previously capitalized amounts. We continue to evaluate the impact that the new legislation will have on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Six months ended June&#160;30, 2025 compared to the six months ended June&#160;30, 2024</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $25.4&#160;million during the six months ended June&#160;30, 2025, an increase of $8.4&#160;million, or 49%, compared to revenues of $17.0&#160;million for the six months ended June 30, 2024. The increase resulted primarily from an increase of $8.1&#160;million in sales to Chiesi and of $4.6 million in sales to Pfizer, partially offset by a decrease of $4.3&#160;million in sales to Fiocruz (Brazil).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $0.3&#160;million for the six months ended June&#160;30, 2025, an increase of $0.1&#160;million, or 50%, compared to revenues from license and R&amp;D services of $0.2&#160;million for the six months ended June&#160;30, 2024. <span style="color:#212529;background:#ffffff;">Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. We expect to generate minimal revenues from license and R&amp;D services other than potential regulatory milestone payments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $14.1&#160;million for the six months ended June&#160;30, 2025, an increase of $2.0&#160;million, or 17%, from cost of goods sold of $12.1&#160;million for the six months ended June&#160;30, 2024. The increase in cost of goods sold was primarily the result of an increase in sales to Chiesi and Pfizer partially offset by a decrease in sales to Fiocruz (Brazil).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;">For the six months ended June&#160;30, 2025, our total research and development expenses were approximately $9.5&#160;million comprised of approximately $3.9&#160;million of salary and related expenses, approximately $3.8&#160;million in subcontractor-related expenses, approximately $0.4&#160;million of materials-related expenses and approximately $1.4&#160;million of other expenses. For the six months ended June&#160;30, 2024, our total research and development expenses were approximately $5.8&#160;million comprised of approximately $3.2&#160;million of salary and related expenses, approximately $1.0&#160;million of subcontractor-related expenses, approximately $0.3&#160;million of materials-related expenses and approximately $1.3&#160;million of other expenses.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total increase in research and developments expenses for the six months ended June&#160;30, 2025 was $3.7&#160;million, or 64%, compared to research and developments expenses of $5.8&#160;million for the six months ended June 30, 2024. The increase in research and development expenses resulted primarily from <span style="color:#212529;background:#ffffff;">preparations for the planned phase&#160;II clinical trial of PRX-115.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;"><span style="color:#212529;background:#ffffff;">We expect to continue to incur significant, increasing research and development expenses as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $5.2&#160;million for the six months ended June&#160;30, 2025, a decrease of $1.4&#160;million, or 21%, compared to $6.6&#160;million for the six months ended June&#160;30, 2024. The decrease resulted primarily from a decrease of $0.9&#160;million in salary and related expenses and a decrease of $0.5&#160;million in selling expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Financial Income (Expenses), Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses, net was $0.1&#160;million for the six months ended June&#160;30, 2025, compared to financial income, net of $0.3&#160;million for the six months ended June&#160;30, 2024. The decrease resulted primarily from exchange rate costs and lower interest income on bank deposits partially offset by lower notes interest expenses due to the September 2024 repayment in full of all the outstanding principal and interest payable under the 2024 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Taxes on Income (Tax Benefit)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded tax expenses of approximately $0.4&#160;million for the six months ended June&#160;30, 2025, compared to a tax benefit of approximately $(0.2)&#160;million for the six months ended June&#160;30, 2024. The tax expenses or benefit resulted primarily from taxes on income mainly derived from GILTI income mainly in respect of Section&#160;174 of the TCJA. Effective in 2022, Section&#160;174 of the TCJA requires all U.S. companies, for tax purposes, to capitalize and subsequently amortize R&amp;D expenses that fall within the scope of Section 174 over five years for research activities conducted in the United States and over 15&#160;years for research activities conducted outside of the United States, rather than deducting such costs in the current year. On July 4, 2025, tax reform legislation was enacted in the United States through the passage of HR1 which includes significant corporate tax changes, including a restoration of the current deductibility for domestic research expenditures beginning in 2025, with transition options for previously capitalized amounts. We continue to evaluate the impact that the new legislation will have on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our sources of liquidity include our cash balances and short-term bank deposits. At June&#160;30, 2025, we had $33.4&#160;million in cash and cash equivalents and short term bank deposits. <span style="color:#212529;background:#ffffff;">In September 2024, we satisfied the outstanding principal and accrued interest under the 2024 Notes with a cash payment of approximately $21.2&#160;million which was available primarily from the withdrawal of short term deposits. </span>We have primarily financed our operations through sales proceeds, equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the six-month period ended June&#160;30, 2025, we sold, in the aggregate, 2,775,215 shares of Common Stock under the Sales Agreement generating gross proceeds equal to approximately $7.0&#160;million. In March 2025, we amended the Sales Agreement to provide for the offer and sale of up to an additional $20.0&#160;million in shares of Common Stock. As of June&#160;30, 2025, approximately $15.7&#160;million in shares of Common Stock remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents and short-term bank deposits are sufficient to satisfy our capital needs for at least 12&#160;months from the date this report is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Net cash used in operations was $10.3&#160;million for the </span>six months ended June&#160;30, 2025<span style="background:#ffffff;">. The net loss for the </span>six months ended June&#160;30, 2025<span style="background:#ffffff;"> of $3.5&#160;million was increased by a $6.9&#160;million increase in accounts receivable-trade and other assets, a $1.9</span>&#160;<span style="background:#ffffff;">million decrease in accounts payable and accruals, and was offset by a $1.0&#160;million in share-based compensation and $0.7&#160;million in depreciation. </span>Net cash used in investing activities for the six months ended June&#160;30, 2025 was $<span style="background:#ffffff;">0.8</span>&#160;million and consisted primarily of the purchase of property and equipment. <span style="background:#ffffff;">Net cash provided by financing activities for the </span>six months ended June&#160;30, 2025<span style="background:#ffffff;"> was $9.2&#160;million and consisted of $6.8&#160;million proceeds from issuance of Common Stock under the Sales Agreement, net and $2.4&#160;million from the exercise of warrants and options.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;background:#ffffff;">Net cash provided by operations was $0.6&#160;million for the six months ended June&#160;30, 2024. The net loss for the six months ended June&#160;30, 2024 of $6.8&#160;million was increased by a $1.7&#160;million increase in inventories, a $5.3&#160;million increase in accounts receivable-trade and other assets and $1.0&#160;million of financial income, net, and was offset by a $12.7&#160;million increase in contracts liability and $2.0&#160;million in share-based compensation. Net cash used in investing activities for the six months ended June&#160;30, 2024 was $0.8&#160;million and consisted primarily of the purchase of property and equipment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Future Funding Requirements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Since our inception, we have incurred significant research and development expenditures which have not been offset by revenues. We have not generated significant revenues from sales of Elelyso, and commercial sales of Elfabrio only commenced in the middle of 2023. W<span style="background:#ffffff;">e have generated operating losses from our continuing operations since our inception although the revenues generated in the years ended December&#160;31, 2023</span><span style="font-family:'28mugxoulnobhnx';"> and 2024 exceeded our expenditures for the same periods.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">As the 2024 Notes were paid in full during the </span>year ended December&#160;31, <span style="color:#212529;">2024, we are no longer subject to the financial limitations related to such notes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As we increase our research and developments efforts with respect to our current and future product candidates, we expect to continue to incur significant expenditures. We cannot anticipate the costs or the timing of the occurrence of such costs. Although we expect the revenues generated from the sales of Elfabrio and Elelyso will increase, such revenues may not be sufficient to fund the expenditures. To the extent we need to obtain additional financing in excess of such anticipated revenues, it may be difficult for us to do so given the volatility of the price of our Common Stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts and (v) tax payments. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12&#160;months <span style="color:#212529;">from the date this report is issued</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Chiesi&#8217;s progress in commercializing Elfabrio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through sales of Elfabrio and Elelyso, corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the milestone payments that may become payable under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services and salaries expenses. We do not believe currency fluctuations have had a material effect on our results of operations during the three and six months ended June&#160;30, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have no off-balance sheet arrangements as of each of June&#160;30, 2025 and December&#160;31, 2024.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_525852bb_8d3c_44ce_8e3f_213b4d2e211a"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and more than 50% of our expenses and capital expenditures are and were incurred in dollars, and a significant source of our financing has been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Approximately 44% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:17.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#009999;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.581</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.725</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.597</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.694</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.700</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.372</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.759</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.372</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.759</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.647</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><a id="_7a9cd39f_c4fa_4451_9a02_1b9fea39a97c"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended June&#160;30, 2025 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c12e0933_77a7_4262_8f63_1e94a7b4efda"></a><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are not involved in any material legal proceedings.</p><a id="_02227ae9_6465_45e7_b5d6_2e0b8a8490ba"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 10pt 0pt;">There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2024<span style="background:#ffffff;">.</span></p><a id="_53390533_2092_49a3_a168_cbf221100d93"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_3ad4db62_6e8e_4223_a379_9dc164099b58"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_bc847556_8bfa_4af5_80c6_92657fc4945a"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><a id="_cc94c6d0_eb48_44a0_9a0f_cc97cfc975db"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">During the quarter ended June&#160;30, 2025, none of our directors or officers </span><ix:nonNumeric contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_DF_iPi24eUao-E3ffWckYg"><ix:nonNumeric contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_rpVsv0R8aUK_juQKVZm8Cw"><span style="background:#ffffff;">adopted</span></ix:nonNumeric></ix:nonNumeric><span style="background:#ffffff;"> or </span><ix:nonNumeric contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_qBfL0My1k0upycp94DX_wQ"><ix:nonNumeric contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_9P1rdKXnjESZreQD-QmO5A"><span style="background:#ffffff;">terminated</span></ix:nonNumeric></ix:nonNumeric><span style="background:#ffffff;"> a Rule&#160;</span>10b5-1 <span style="background:#ffffff;">trading arrangement or&#160;</span>non-Rule<span style="background:#ffffff;">&#160;</span>10b5-1<span style="background:#ffffff;">&#160;trading arrangement (as such terms are defined in Item 408 of Regulation&#160;</span>S-K)<span style="background:#ffffff;">.</span></p><a id="_824f8650_e477_498b_8566_ab2557f9c337"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022013560/plx-20220630xex3d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;15, 2022</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex3d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;7, 2023</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837025007063/plx-20250331xex3d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.7</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">May&#160;9, 2025</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837024003161/plx-20231231xex4d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;14, 2024</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.9</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837025009308/plx-20250613xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement With Gilad Mamlok dated June&#160;13, 2025</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;21, 2025</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250630xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250630xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250630xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250630xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="color:#333333;background:#ffffff;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 3pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 3pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_cd8593c1_4ea1_47ad_9d39_425644e024ca"></a><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;14, 2025</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;14, 2025</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>plx-20250630xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 8/14/2025 08:45:12 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;14, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>plx-20250630xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 8/14/2025 08:45:12 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;14, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>plx-20250630xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 8/14/2025 08:45:12 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2025 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;14, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>plx-20250630xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 8/14/2025 08:45:12 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2025 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2) </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;14, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>plx-20250630x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250630x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '=!#@# 2(  A$! Q$!_\0
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M"11Y@=-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME:._J#U1YU\8'^$$GP3^-:_#I8O^$A A_MHQ+-DM]N3J6^7&[=]VO9OV)?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** $(!!!Y!KFO"'PT\*^ ;C4)_#N@V.C3:
M@P>Z>TB"&9@206]>6/YUTU% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &-XRUJ7PWX/UW5X$
M66:PL)[I$?[K,D;, ?;(KYX@_:8\>Z;X(T;QSJ_A?29?"5_/Y+/97+_:$^=E
M)VMQU1L=NG3->[_%7_DE_C#_ + UY_Z(>OB.UTO6D^&7PO\ ^$EUR2;X;ZEJ
M#I)8VT8B-L5F<'>_.<DN?H3Z5ZF#I0J1?.ENOR>B\SQ\=6J4YI0;V;TMO=:N
M_374^[-1\9Z#H\%I-J&LV-A'=J'@-U<+'YBG&"NXC/4?G5C4_$.EZ+IZW^H:
MC:V5DV-MQ/,J1MD9&&)P<BOCGQ[X>U3QK^T#XYL(8=!GM]-TQ4B3Q '\JVMP
MB9:$*1AADG/;FJ.FV@UV]^"&@:]J$&N>'&EN420>8(9P)654(D53Q@)TZ<"A
M8.+47S;Z_*S?Z \=-.2Y=M/G=+[M3[1C\4:/+HQU=-5LGTL#)O5G4PC_ ('G
M%-L?%NAZIIEQJ-GJ]C=6%N"TUS#<(\<0 R=S X&!SS7QO\4-)\*:*MEX:\-:
MO=7'A:Y\6[=:MI 8X+)\@")&V@%-N_G+?=!SZZMYIECX3^*?QCT3PY$EKX?/
MA.:5[:V.8EE\E/R.6?\ 6E]4BXW3??;HK?YC^NS4N5Q6ED]>KOM]Q]4P?$'P
MQ<RF*+Q%I<D@B\\HMY&2(\9W=>F#G/I7*_%7XNP^$?AA>^+/#LUCKBP2)&I2
M821$D@$$J>HSTKY=TSX=>'GM?@.6TV)FUJ20ZBYZW(#@@/ZC!QCTI-;T^WT3
MP7\=M*LD%OIUKK-F(+9.$C!>7A1VX 'X"M/JE-2T=[/_ -NY60L;4FE>*5UW
M[QYD?97@_P <Z3XML;;[+J=C<ZB;9)KBTMKA7>(D G*@Y !..:YGX;_%"YUC
MPQJ&J^+I-'T40ZB]I$]O?QR1,H52N7#$!B2?ESG@<5X-_P ([HO@OXP?!1_"
ML$-I+?V:M>-;-DS!D^9G/.<@MS7#P1B7]F#7D/ ;QE@X_P!R.FL)!O1Z-KU6
MK1/UV:7O+6*?H_=3/N?2/$^C^())TTS5+/47MSME6UG60QG_ &@#Q4%EXT\/
MZEJC:;::WI]SJ"YS:PW2-(,=?E!SQ7R[I%KH_P -/CI\18+2R:WT2S\'>?)9
MV;F,O\EN6(/9B6;YO<UYSX4L+BR\2?!_68=+TC1+'4M=3[*;&21KZ6/[0BOY
M[LQR.2!TR">U9QP<9:IZ65ON;_0TECI1T<=;N_R:\O,^X)/B)X6AN6MY/$>E
M1SK+Y+1O>1A@_P#=()Z^U<CXF^/.D>&?BKI7@^X>S6*Z@:6>_DO%06S $JC*
M1U/&,D=:^6=3\*Z5J/@_X\:W=644^J:?JT2VERXRT(:Y(;;Z9!Q7;6GAG1]=
M^-OPK;5=.M;Q=2\-07-W]HC#"XE%N,.V>IX'Y5:PM.+O)MZ/_P!)N1+&59+W
M4EJONYN4^K]8\1:5X>6%M4U*UTY9FV1&ZF6,.WH,D9-067C#0M2TVYU"TUFP
MN;&VSYUS#<(T<6.NY@<#\:\._:\LK/4IOAS::B5%A/KJ1W&YMH\L[0V3V&,U
MYQJVEV/A7XD_&[0_#\26GA]?#'G&UMS^Z6;$'Z@O+Q[FL*6&C4IJ5]=?P:_S
M.FKBY4ZKA;33\4_\CZVM?&OA^]BGEM]<TZ:."(3S.ETA$<9Z.QSP#ZFJEW\1
M/#Z>&M3UNTUC3[ZTL(F>22*Z0H&Q\JE@3@DX ^M?%_B/P1IOAC]FCPAK%BDL
M=YXAO84U2<R$B2(&3:I'0*"!7<WGA+0-$^/7B;P[X?L[9_#MSX6DEO["/$D"
MNJ!XV(Z9W"-@?5O>M982FKVD^O3^7?\ X!A'&U':\5K;K_-M_P $]W^$GQGT
MOXG^"&\02/:Z2T);[5;/=J_V9=Q"ESQ@-M)&0.E;NJ>-[.Y\':UJ_AV_T[5Y
MK*VDD39=(8O,5255W!PHXZDCBOB6_LH]/_9>\,&P@MK5M8UHQ:E<GY?.V,_E
M+*1R5&6/MBNRTCPQ?>#]<^)]E=7V@V<TOA2X>?1- 280H1&NR3Y@5!P2?O9^
M;I5U,)34I.+M9NR]+?YF=/&U'&,9*]TKOUO;\CZ6\'_$NVN/"&BWWBJ_TC1=
M6OX6E-NE]&8R [#*-N(88 Y!-=+#XKT6YT=M6BU>QDTM?O7JW"&$=N7S@=17
MQIIN@V'B;6?V?M,U.V2[L9].D$L$GW7 D<X/MQ6=:>$?^$@TKXB>%].U;3M(
MCM/%L9T_2[^X$,%RVZ5/*4$\DA4X]A1+!PYG[UM>W3FL.&.J**]V^G?6_+S'
MW%HVO:9XBM#=:5J%MJ-N&VF6UF610?3()YK#\??$+2O!.BZI+-J5A%JL%C-=
M6UC<W"H\S*C,H"YR<D8XKR7]F34K&R\4>+?#\WA5?"GB2%8I[ZVLKDR63CH&
MC7)$9YZ9.<]>,#S:?0-'\9^.OCY=>*H(;G4=,M9CIWVEL&)4$GELF3_LQ]/7
MWKG6&C[22;T23];V_P SIEBI>SBXK63:ZZ6OY>1]'_"[XGQ^+OA1H_C#79+/
M1A=K(92TNR%"LKH!N8]]H_.NMMO$ND7NDMJD&J6<VF("6O$G4Q*!UR^<"OAB
M\34=7^'?P*T.V^R2V]U)=,+;4MWV227[4X7S<$$C!/YUM0>!;J3PW\1O"TWB
MGPUI$LNH6CC3;:>2"SBNLO\ N5,@Q\X4\*Q_U?/ KHJ8.',WS6U?W<UCFIXZ
MIRQ7+?1:^?+<^K_$/CVW;P1K&L^%[W3-:N+*(LH%VGDAN.'?< O&3R14VA^-
M[>/P1HVM>);S3M'FO+>-Y2;I/($A7)5'SAA]":^5M$N[30M!^*/AF_\ "D7A
MCQ5'H!DN/[.N3)9SQJ% 8)DA&.Y3G)SD].E4_%,MNUW\$Q<Z=%XFMH- 6271
M)IDB5AM'S$R$)SQ[G;]*A82+?+?Y^5F^]NA3QLDE*VMMM=[I=K]3ZFTOXV>"
M]7O]0MH-=ME6RE6&2ZF;R[=Y#_"DK85S_NDUT^C>)=(\1),VE:G9ZDL+;9#:
M3K)L/H=I.*^'_%_@+4O"_P '=#M=8ABLX-3\6?:(=,BG$RVL+H%V;E)&>#QG
MMZDUT/B6T7X>_$KXT:5X8@&EV$7AF)UMK;Y54D6^YOKB23_OHTY82FU[DOZ5
MO\QQQM1/WX]OQO;\CZZTOQAH6MWTMEI^LV%]>19+P6]RDCKCKD YKCOC'\8M
M/^''@[6[RQOM-O-?L$C==,FN%WMND13E =W 8G\*^6OAQX6U+0=1^$^N+?>'
M=%^UW(%LUBDQO=01G42)-@,"<$KD[0-W)],VU\/:+KWP"^)/B76889O%\.LK
MMN)G_?(3)&"HR<\AI./;VJU@J<9ZRNDU^=C)X^I*GI&S:?Y7^\^O];^*T/AG
MX.VWC;4(H1++IL-X+3S=@DEDC5A&I.3U)['I5SP/\5=$\8>!+/Q-)?65A \2
M/=(]TI6U=AG8[<8//?%><_$C3;74?V083<V\<[6_A^SFA+KG8XBC 8>AP3^=
M>-^(]"TN#P-\#].%I;VNB:Q<13ZJ8P$6>7Y%S(>YVENM94\/3J)K9\UOD;5,
M54I-/=<M_G=(^S]'U[3?$-I]JTN_MM1ML[?-M95D7/ID$\U1U7QWX<T.[EM=
M1U[3;&YB"L\-S=)&Z@]"03GFO"?@E96WAC]ICXB:!X>58/#"6,4WV> YACG'
ME<#T/SRC'M[5D^(O"OA_Q;^UGXIM?$-K!>6T>@K+'%<?=W")!N^H!)'I62P\
M>=IMVY>;S-GB9\B:2OS<OEZGTW+KFG0:3_:DE_;1Z;L$GVQIE$6T]&WYQ@^M
M8&O_ !,T+2?!.K>)+74[#4+2QAD=3%=ILDE5"RQ;AG#,0 !UYZ5\1:7>W6H?
M#'P1H5Y-(WA:7Q?+ ZNY$;19C."W8?.Y_P"!$UWNH^%M%TSXI?%W0M)L;8^'
MX_#4UX]FBAH8;B.+<C = RL3CTR:W>#C!OF??[E;\=3G6/E-+ECV7S=_PT/I
M3X:?%G2?B%X"MO$K3VFG+Y>^[@:Z5A:'<0 [<8R!GD#K70VWC'0;W29]4M]9
ML)]-@_UMW'<HT4?^\P.!U'6OBCQ/IR6'[//PLMM)@M;;^W-0SJ)8;8[F17(C
M\\K@D#)[]/I5O4?#FH>$(_BG87%[H-I)-H*R76B:"LRPH1)'LDPP*@X8C[V?
MG/'-.>#@W)IVU=EZ.Q,,=448J4;Z)M^JN?8]AX[\-ZI.T-GK^FW4RQF9HX;M
M'8(!DM@'H!WKS#3/VCH/$^C>-6TF/3$U;1)GBL8+G4$"7JJ?]9D[<+COG'O7
MB&E>%-)\.ZU^S]<Z?8Q6UQJZ$7\J#YKD/M5@Y[@J[#'H:3P[X6T6V^&7QNNT
MTVUCO[&YEMK:41@20Q'&47N!Q36%I1O=W[?^!6!XNK-*R2[_ /@/,?5V@^/+
M>+P5H^L>*+W3-%N;R%7<&[3R=Y[(^[##Z$USOQG^+TGP^\&:-KVB+9ZO%J&I
MPV0<R;HRCAR65E/)!3^=?.%V\7C&^^'WA[3=$T[5-9L?#22S3Z_/)]ABB*%C
MB)2 6P<[N>W]VN=L+B1_V=H+=I$:&#QS"(UB),:@QN2$S_#FKC@X\Z;[[>3=
MC.>.GR.,>V_FDGV/J31_CDK_ !?\6>%=9?3]*TK1X8WAO9I?+:1VV_*2QQ_$
M>E>G-KVFKJL6F&_MAJ,L7G1VAE7S73GY@N<D<'GVKY!\:^#V\;_%3XWV$2;[
MJ+2HKN 8R=\9C? 'J0"![FNT_9;U*X^)7C36O&M[&W^@Z7::);AQ]Q@BF7;]
M67/_  (^M85,/#D]HM+)7^:5OO9TTL5/VGLVKW;M\GK]R/2;'X[Z3>?&"\\#
M[K1%A@5DOC>+^]G+!?("8^]D],YXZ5VUWXU\/Z?JBZ9<ZYIUOJ+$*+66Z192
M3T&TG.37S]X=\):$/VPO$"RZ7:;8+!+^$-$/DN-R-YJ_[623FO"O'#1>)_#_
M (S\5:5HVDV.D?VQY:WVH3R2ZG),<'$9+8 Y)QC 'TS50PL*KBE=:+[V[$3Q
ME2DI7L]7;T2N??&I^,="T6ZEMM0UFPLKB*,3/%<7"(RH3@,03TR0,U0\2?$W
MPKX2BN6U77["T>WB,SP-.IEVXSP@.XDCH ,FOFV[\&Z=\3_VBO#%AX@1[RTD
M\*6UW-'O*F5PG&2.>K9KSF?PI<>--4\>:9I>AVNN:C>Z[BS\0RWT<1M$1SN&
MUV#XP0.!CZX%$<'!VYI=+O;O;_,)8ZHKN,5O9;]K[)?(^V+;XE>&I=%TW5)]
M7MM-M=03S+8:BXMG=<XSM?!KF/B9\=M(^'/B'PII<C6MV=;NEBEE-VJ"TA8J
M!,W!ROS9Y(!P>:^:_%GAC7O%GQJ\6:;='0KZXTG1(HV?Q!O,<4*Q1YFB"GAN
M=^>?OGCFJQ\,Z9=:7\"1>RV6O+<ZS)8SW@B<+/;+/$%B;S%4E5#,.1CDU4,)
M2O%MW3Z>J;1$\;5M)15FNOHTGI\_D?;%_P")](TK3(=1O=4L[2PF*B*ZFG5(
MW+#*X8G!R!D4X^(=+&J/IIU&U&H)%Y[6OG+YHC_O%<YQ[UX/^VA9P6'P4TNV
MM(DAM8-6MDCCC&%1!'(  /2J;W,5S^UEK!BD60)X6*,5.<':./UKDC04J?/?
M^;\+?YG;/$RA4]G;^7\6_P#(]WLO'WAK4;FVM[7Q!IEQ<7/^HBCNXV:7DCY0
M#D\@CCTI;_QYX;TNXN(+S7]-M)[=U2:.:Z1&C9AE0P)X) -?"]IX8T[2OA3\
M-=?MK98]9O/$K)+>#_6%%EPJ@]@,=/4FNY^(/A72]<\8_'K4+^S2ZNM.L[>2
MT>3GR791E@/7 QGZUT2P<%*W,[:_@TOU.6..J2C\*OI^*;_0^MK/Q9HFH:HV
MFVNKV-QJ"KO-K%<(TFW&<[0<XQ27WB_0],U2+3;S6+"UU"7&RUFN465L],*3
MGFOCO0?#VG^%;[]G?5=*MDLM2U2<B]N8^'G#.BD,>_#L/H<5R:^'=6\;V'Q(
MUN_E\/I'#J;"ZU/6!*;VVPWR^5MS@=!C:?2G]2C?XM/^#87]H3M\&OZ6N?6^
MK_'C1]&^+MMX*N'LXXI+4S2ZA)>*HBER0(BI'WCQWSSTKOM7\2:3H#P+J>IV
MFGM.2(A=3+'YA'7&3S7RIX:\+Z5K7[0/@T:S;66KM>>&XKV>XDB)6[F\L8G.
M\ EC@')&:[7]J#2;77?'7PJT^]B$]G<ZJT<L1Z.I"Y!]C64J$.>$%U3O^/\
MD;QQ%10J5'T:M\TO\SV;_A8OA46L-R?$FE"VF<Q1RF]CVNPQE0<]1D?F/6M#
M6/$FD^'K5+G5-3M-/MY#A);J=8U8^Q)YKXAN? /A\V7[0<W]EP!M"NDCTT!<
M+:AII0=@Z#A%'TJ?4[;7/'7C;X7Z0(]+OV'AB.6UMM?WM:RG8^]B%();Y2!_
MN#TK7ZG!O26G_P!KS&/U^:6L=>G_ (%RGVR_B#2X](_M5M1M5TS;O^V&9?)V
M^N_.,?C7E-K\=I]9^+&N^%]'33M0TVST9M1MKZ*?<)9 JG:6!V@9.#Z8KYDN
MXY[#X=:!X=NM;M=1\,R^+6CO38^8EO  (_W89U'R_-(>,COGBO3-&\.:-X4_
M:6\=:=H-K!9:<GAF5A!;_<5C&A;'IS1]5A34FW?1V^5O\Q?7*E244E;57^=_
MPT/>_A_\0)=5^'EMXA\4RZ7H\CO(LKP7B/;J Y5<2!B"2 ._6NGM?$VD7VD-
MJMOJEG-IB@EKQ)U,2XZY?.!7P]H$*:UX:^!^AZMAO#=UJ%TT\4AQ'))]H8 -
MSSP<?\"/K75?%5/A]X#\-^+M$\/27>LR7FLVT<VB&5X;*QGP^W&U1D$*00&.
M=J^E%3"1Y^5/5M[+2U[=PIXZ7L^9I626[UO:_8^HK_Q]I=QX5UK5=#U&QU=M
M/MI)2+>=9%#*I8!MIXSBJ/P>\>7'Q$^&VE>);^&&SFNT=Y(XB=B!6(ZGV%?,
M/P[TN^\-_%'XEZ3>6^E:=,GA&9YK+0]PM5;]R5X).6 8Y/J6KVW]F_\ Y-OT
M?_KTN/\ T)ZQK4(TJ<FM=OQ3_P C>CB)U:L4U;25UZ./^9Z39>/?#6HW-M;V
MOB#3+BXN?]1%'=QLTO)'R@')Y!''I4^K^+]"T"ZBMM3UFPT^XE&4BNKE(V8>
MH!-?"5GX8T[2OA7\,]?MK98]9O/$KI+>#_6%%EPJ@]@,=/<UL^)M U?Q]\1/
MC#=7)T"2+3;AH9+G7Q(9;6W5I AMPIXP$'.#_#ZG.[P4$_BT5_P:7ZF"Q\VO
MAU=K?--_H?;6L^(=+\.VJW.J:C:Z=;L=JRW4RQJ3Z DTI\0:8-(_M4ZC:_V9
MMW_;?.7R=O3._.,?C7Q%>V>O>,/&?PRT'[3H^OB+02]D-9$ILK@#S,N5.UB<
M)@9 _P!6.N*R-0BN=,^'6G>'KC6K6_\ #DOBS9>I8>:EO;\+F,,X'RY+GC(X
MS26!3LN;5_E=K]!O,)*[Y-$N_6R?ZGU3H7QO_P"$B^.4_@W3_L%]HB::+U-1
MMI?,+-QE<@[<#->BZ7XNT/7+V:ST[6+&^NX03)!;7"2.@!P20#D<U\K_ /"*
MZ!X<_:1\8Z1H\]IX:TN7PO,GVB-PD5J\D84OG/&"0>HK,^$FFV_PP^(/@BQ\
M0^'+&::Z9H](\3Z!>Y6Z$F?FF )\P8;&>,#L:)8:G)7@^B?KN$,55A*TU?WF
MK]MO+\SZ8\7^,=9T/Q]X5T>RM;"73=39UNI;FY6.9,?\\T+ OVZ ]:V#\0O"
MXG$!\1:6)C*8!&;R,-Y@ZIC/49''O7E7QF_Y+[\'_P#KXNO_ $%:^>-5\)Z5
M=_#?XO\ B">SCEU:S\1+%;7+#YH5,WS!3VSNY^E12P\*L(MNW_!E8TJXJ=*I
M*,5?U\HW/OPL "20 .<FLG2/%VA^(+F:WTS6+'4+B$9DBM;E)&4>I ->7?'S
M5=0LOV:K^XLW?[1+I]NDKKG.Q]H<Y]P3^=>!>$?"-]X9UOP!J4NL>%O#$5[8
M2 3Z>9EEN;8Q_O6G;E-R@D[F*@$$_P /&=+#*I!R<NZ^Y7-*N+=.<8QC=-)O
MYNQ]F6OC3P_?7\]C;:WI]Q>0!FEMXKI&= OWB5!R,=_2N'^&GQZTCXC^,?$V
M@0&VMY-+N!%:R+=!S?+\^YT7 X&T=,_>%?.'P]T2T^&/B_P=!XE\/Z=K%GJ%
MZ\>E^*-$OMQN"YVGS0"?,7Y@,'& 3UKI/A)IGAOPMX@^.NIW&EQK'HL\D=J+
M8>7-#$WVA62)ARF0%&1TX/:MY86G",W=O31_.W]7,(XNK4E!62UU7E9OM^1]
M167C7P]J6JG3+37-.N=1!(^R172-+D#)&T'/ !_*O._ WQXMM9\9^.]'\07&
MF:);:%J*V5G+-<"-K@;I 2=QY(V+T]:^4M-L+K3;OX7:Y;Z5HVA6E_JX>S-C
M*[W[IYN"9G9CD=0.!7:P^$O#/B#7/VA[[7+>WFO=.N)I+*2=L-$Q:?E1GJ65
M!GW]ZMX2G34N9WT^:?,D9QQM2JX\J2U^33BWV/H[Q9\4+S0?BUX+\*V]M;SV
M.NQ3227#$[TV*2-N..<4[X9_$B^U[PWJVJ^*O[)TB*TO&@2:VOHY(O+ &"[!
MB%;)Z$U\_P#PWO+R^\5?L^37[.UQ_9]\N7ZE%,JI_P".!:YOPUX7;QG\';G2
M;75M,M=5/BV:>VTW4[D1)J&U0#& 2"Q!=>G][W%#PL$N5]-W_P!O-7^Y"6,F
MY<ZZZI?]NQ=OO9]+?&3XT)X%^&A\4^')+#75^UQVP99M\7S9SRAZCC\Z[GPU
MXOTGQ/ HL=3LKVZ2-'GAM9UD:(D#J 21SZU\/>,M6TV/X7^,] _X1C_A%?$-
MMJUG+J%I:W)EM&/S &)<D)UZ GMSV'9ZKI4/PU^-T<7A6W&EF3P7-,XM\@NX
MA=BY/<Y16SZKFIEA(<ENNK^Y)E1QLW4OTT7HVVNWWGUE;>+]#O-7?2H-8L)M
M30D-9QW*-*".OR@YXK ^)WQ.TWP!X<U><:AI_P#;5K:/<0:?<7"J\I R!MSG
MG':OBGPGX6U*V\$^#O$JZAX=T-6U4-;:FB3'499@YS&Y0-D<=,>GKSU=MH.D
M>+]-^.NL>)K>&Z\064SFWDN6_>08+;-F3QT _ "F\%"$KN5TM_O2_4%CZDXV
M4;-[:]+-_H?6'PP\<OXT^&>D>*-22"P:ZMFN)PK8CB +9.3T "YYK2T_X@>&
M-6O(;2R\0Z7=W4W^JAAO(W=_H <GI7EOPU_Y-"B_[%Z\_P#09:^<;CPSH>B_
ML[> O$VDPPQ^,)M8;-S$_P"^9EFD 4C/8*G'OGO6:PT)U)J]O>LOG?\ R-7B
MITZ<':_N\S^5O\SZHT_XVQ1_%[Q;X5UJ;3M*TO2(8)(+RXF$;2/(JDJ2QQ_$
M>GI7HVH^(]*TC3DO[[4[2TL9 "ES-.J1L",C#$X.1S7R/XQ\(Z9XJ^+WQFNM
M6M$NYM/\/1W$ D'^KF\B([Q[C&/Q-95S>Q^(O!WP9\+V^CVNM:]+:27$"ZM.
MZV4:;G'SHI&\_NSU/ &,<U3PL)\KCIHK_P#@-[_@9K&3@Y*6NKM\FE;;S/L<
M>+]".BG6!K%B=*!VF]%PAA!SC&_.,Y(%5Y/B!X9AF,4GB'3$D#.A5KN,$,@R
MXZ]0""?2OB+2WFMO@5\8+(O:K%;:K:;8[ G[,C>< WEY).WY1^5=[J7PC\-:
M1XS^"^ABQ\^QU..:ZOXY7)%Q*88RQ;GH2HX'&*3P<(NSD^O_ *3S%+'5);17
MW_WG$^GU^(7A=H[60>(M+*73%(&^V1XD8=0O/)JYKGBC1_#*1OJ^JV>F+*2$
M-W.L6_'7&XC/45\)6_@G0W^$OQAU1M.A-]I6K10V,VWFW0S@$)Z9!(KKO%EQ
M_P + \9^&K&VT?3-3UFW\*V]S?:AXEN)&M50P*S%4##!&XG=SRV>,9+>#C?2
M3MU^Y/\ 42Q\[:Q5^F_=KMY'V)+KVF0:2-4DU"U33"H<7C3*(2IZ'?G&#]:C
MTWQ/H^LZ;)J%CJEG>6$>=]S!.K1I@9.6!P,#UKX(T2]GU;X2^ ]'U*=FT)_%
MTT$L98B,)B([?89D<_\  C7<?'O2?"W@/P_XVTSP3J-Q%/>7EDFK:/$A6TM8
M]K%2I"@?,V,_,>I&..!X%*7)S:M]O-+7[QK,&XNIRZ)7>NNS>GW'USI_C/0-
M6M;NYLM:T^[M[12UQ)!<HZP@#)+$'Y1P>3Z4@\:: ;>PG&M6!AU!F6TD^TIM
MN"#@A#GYB#QQ7Q[;>$-1\'^(M7CDO/#>GM=^$+UI-,T!9]MU!Y$FR5B05W;@
MIR6'';GEFC7$$W@K]G.VWH\BZI=%X\\A3=8Y'X&E]3B[6EH_\G_D"Q\]I1UM
M^L?\SWO2OVB;#Q%K/CC2-/&GK>Z);R2:=))?+LU!EC=SC. %&T9.3@$G(Q78
M>#?'OVGX>:7X@\5W&F:+/<JQE*7B-;@[V"A9-Q#94 \$]_2OF_PIX3T.R\0?
M'YH],M(9=,L;E;$B,!K=6@G#!/3(X.*P='L[?Q#<? '1-:19M FM96:WF/[N
M5_-?@C\%'XU;PU.6D=-O_26W^7WD+%58N\M?B]/B27W7^X^SAXIT9M&_M<:M
M9'2L9^V_:$\G_OO.*Y[QC\2;+3?AQKWB;0+RQUG^SK=Y5\F821EQ_"Q4\5\Q
M?$"W\$:!;0>#O"2R^);C4/%++'IM]*\5A97 *H8_E"[T^91]XC'.?7,\&VEU
MI&F_'G3+A+"V>#35\RVTG<MHC@L#Y:D_A6:PD>7GN_GVNO\ ,U>-ESJ%EVT?
M6S_R/K_P3XO&O_#S1_$NI&"Q%U81WEP=VV.+*!FY/0#WJ:V^('AB\E,<'B+2
MYI!$9]J7D9/E@9+=>@ )SZ5YO9?\FD1_]BK_ .T*^=!X!T'[!\!1_9L6[7+O
M9J+X^:Y4RQKM8]Q@D8I0PT*DYINUG;\W^@YXJ=*G3:5[J[_!?J?<>E>(=+UV
MQ:]T[4;2^LUR&GMYE=%QUR0<#%5]'\9:#X@N9;?2]:L-1GB&9([6Y21E'J0"
M>*^1M(U#2_ VC?M!63V,CZ'::C';PZ?:RF%5W2R(H!'('"YQV%4?A-I5[X?^
M._PW$UAH^CKJ&D2SI;Z,7R\+6\K*9RS'<YP#^ H^J*TG?977_@/,+Z]*\5R[
MNS_\"Y3ZB\<?%K1] \':SJ6DZKIFHZC9VTTL-H+E6,CQC++A3GCOCI4_@#XD
M6GB7P7X6U35;FSTW4M<MUDBM#*%,CGJL8)RW4?G7RUX!^'VCW?PB^*'BZXA:
M;6;66_MK:4N<0H5(; Z'.\]:QOA%JVI:3J2W7B& KJ(\'7,GA68D$0^7'(04
M7^\<.?S]:V>$I^SDD]5_DW;^O,Q6-J>TBY+1_P":5W_78^W(/&.@W6K/I<.M
M6$NI)D-:)<H901R?ESGC!S]*XCP=\>-&\7?$;Q!X626SA.GM&MK<K=J_VTE2
M6V+C^''.":^1_"7A/41X.\%>)I+SPWI(FU;=#J.)VU*>;S6!20KNXX]!P1Z\
M^B:)X"\.W/CGXUV<S:;X?-M"([*_N-L269D#AB&/W0V0#CL:F6$IT^9-WT_&
MZ7ZE1QE6IRM*UVOFFF_T/JW2/%VA^(+F:WTS6+'49X>9(K6X21D'3D \5K5\
M??!.VA^&WQ*\(:7XA\+V=MJ-Y;O!IGB#0[S=%>HRD[ID!(?.>&XQP<< C[!K
MBQ%%49)1=TST,-6=>+<E9KH%%%%<IUA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!2UK2;?7]&O\ 2[Q6:TO;>2VF56VDHZE6 /;@
MGFN.NO@=X2O/AQ:^!IK*630+5_,AC,[>8C;V?(?KG+M^!Q7?45<9RC\+\S.5
M.$M9*_3Y'G/B;]GWP/XP>PEU;2I+FYL[=+5;H74J2R1JNT"1E8%^!U.35_Q'
M\%O!GBKP[INAW^B1'3M,&+)()'B:WXQ\K*0?KD\]>M=O15>UJ:>\]"?8TM?=
M6N^AP<7P,\#P^#'\*C08FT5Y?M#1-(Y=I?\ GH9"V[=[Y]NE-\/? OP9X5T#
M6-(TO2C;V^KP-;WLIGDDFE1E*XWL20,'C%=]11[6HTUS/7S#V-)-/E6GD<'#
M\%/"T"^$U2UG"^%]QTT?:&^0D@G=_>Z=Z@N_@/X0OHO$D<UG.\?B&YBNM04W
M#8D>,L5QZ#YCD#UKT.BCVM3^9_T[_GJ'L:?\J_I6_+0X#P?\"?!'@37FUG1M
M&$&H[2D<LD\DODJ1@B,.Q"C''%5%_9Z\&)X0N/#2V=RNE3W_ /:3H+I]QGP!
MG=G./E'%>E44_;5+WYG_ ,,+V%*UN56].^YQK?"3PS)XMU7Q'+9-/J.IV']F
MW0ED9HY(,(-NSIT1>?:N9T_]E[X=Z3=V=U9Z/-;W%I=QWD,@O)6*,AW*HW,<
M+GG Z\>@KUBBA5JD=I,'0I2WBON//&^ WA%]'\4Z8;6X^R>)9UN=147+9=U?
M>"I_AY]*?XE^!'@SQ;9Z';ZEIDDO]C6ZVEE+%=2Q21Q*H 4LK MP!U]_4UZ!
M12]M43NI/^M/R&Z%)JSBON^?YZGB?[1GPWU#Q])X$L[+2Y-2TZUU9&OU60+Y
M=OP&))(/3/3FNLT+X$>"_#?A_6M'T[2VM[764,=ZYN)'EE7GC>S$CJ>E>@45
M7MI\BIIV2(^KT_:.HU=O^M#D%^%'AAO -OX,N-.%YX?@C\M+>X=F8#)(._.X
M$$GD'-0>!?@SX0^' O#H>DB&2\3RIY9Y7G=T_N9<G"^PKMJ*CVD[-<SUW-/9
M4[I\JNMM-CS*Q_9O^'NGV.IV,6A%K+40!-;RW4SH,'(* O\ (<]Q@U>\/_ G
MP7X6T/6-*TS2FMX-6@:VO)6N)))I(R"-N]F) P>U=_15.M4>CD_O)5"DM5!?
M<<#9?!#PIIU]X6NX+6=9O#41ATXFX8A%)).X?Q=3UJG/^SMX$O(=<BNM(:Z7
M6+S[?<F6X?<)@6(9"""GWVZ>M>E44>VJ;\S_ *U_/4/84K6Y5]WE;\M#D_ /
MPL\,_#.&Z3P_IWV1[I@T\TDKRRRD=,NY)P,GBL;Q=^S]X%\<>()-:U?1?.U&
M5 DLD=Q+$)0!QN56 )'N.PSFO1:*7M:BES\SOW&Z--QY.56[6. N?@3X+OO
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MX'/%?0]%:0KSA)S3U:M<SGAZ<XJ%M$[V.,N?@]X.N_!$'A&30X#H$!W16H+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJU_=-
M9VWF* QWHF#_ +3A?ZU9H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** *&M_\> _Z[0_^C%J_5#6_^/ ?]=H?_1BU?H ***Q-
M;\;>'O#5Y!::OKFG:7<SC=%#>721,XSC(#$9&>* -NBJ)UW35U&VL#?VPOKF
M,S06WFKYDJ#JRKG)'N*O4 %%%% !1110 4444 %%4!K^F,^H(-0MB^G &\7S
M5S;#;N!DY^7Y>>>U5?#_ (T\/^*VE71=;T_5FB ,BV5TDI0'ID*3B@#9HHJ&
M\O(-.M)[JZFCMK:!&DEFE8*B*!DL2>  !G- $U%4+#7M-U2YGM[._MKNX@5'
MEBAE5VC5QN0L > PY'J*?<:S86FHVNGS7MO%?709H+9Y ))0OWBJ]3COB@"Y
M115.36+&+5(M->\@3498S-':-(!*Z X+!>I />@"Y1110 4444 %%%% !111
M0 445S^G?$+POJ]W/:V/B+2KRY@5GEA@O(W=%7[Q(!R ._I0!T%%5=-U.SUF
MQAO;"ZAO;.8;H[BW<.CCU##@U:H ***I2ZUI\.JPZ9)>VZ:E-&98[1I )70=
M6"]2!ZT 7:*** "BBB@ HHHH **** "BBB@ HHHH ***BN;F*RMI;BXE2&")
M#))+(P544#)))Z "@"6BN>L/B)X6U6SO+NR\1Z5=VUFF^YF@O8W6%?5R#\H]
MS6[;W$5W!'/!(LT,JATD0Y5E(R"#W!% $E%%% !16/J'C#0M)GNX;W6;"TFM
M(UFN(Y[A$:%&(568$_*"2 ">I-:T<BRHKHP=& *LIR"/6@!U%%% !1110 44
M44 %%%% !1110 4444 %%%<_9?$+POJ6HRV%KXBTJYOHMWF6T5Y&TB[<[LJ#
MGC!SZ8H Z"BJFEZK9:W80WVG7<-]9S#,=Q;R!XW&<9##@\@U;H ***HWNN:=
MIMY;VEW?6]M=7(=H89955Y B[G*@G)VCDXZ"@"]163IWBW1-8GMX;'5[&\FN
M(3<0QP7".TD0.TNH!Y4'C(XS6M0 4444 %%%% !1110 4444 %%9NK^)-)T!
M[5-3U*TT][N3RK=;J98S*_'RKD\GD<#UI?\ A(]*_MO^QO[2M/[7\OSOL'G+
MY^S^]LSG'OB@#1HHJE9ZUI^H7MY9VM[;W-U9LJW,$4H9X21D!P#E21ZT 7:*
M@O;VWTVTFNKN>.UMH5+R33.$1%'4DG@"JMCXBTK4[U[2TU&UNKI(4N&@AF5G
M$;C*.0#G:>QZ&@#1HHJMJ.I6FCV,U[?7,-G9PKNEGG<(B#U+'@"@"S14-E>V
M^HVD-U:SQW-M,H>.:)@R.IZ$$<$5-0 45CWOC#0M-N9[>[UFPMIX)(XI8I;A
M%9'D&8U()X+=AW[5L4 %%5-0U6RTE(GO;N"S2:588VGD"!Y&.%49ZDGH*;I>
MM:?K<<TFGWMO?1PRM!(UO*'"2+]Y#@\$9Y% %VBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH H:W_ ,> _P"NT/\ Z,6K]4-;_P"/ ?\ 7:'_
M -&+5^@ KY=^-OA_PKXD_:C\.VWC*UT^ZT-/"%Y++_:6WRHR)3\^6^Z1S@CD
M5]15QOC;X.>"?B/J5IJ'B?PU8:W>6J>7#+>1[RBYW8'MDYI-:I_ULT/HU_6]
MSXV^''B+6])\-^%;ZTO;"RGM?#.NC0]3U8QIY<"7:);EII/N@!F4 D#&WM6O
MHOQC\8:TOAOP3/\ $+4=&U*^U::/5-8O;:U\^R1;998T25&,4B.=Q#  XP,5
M]?WWPV\+:D+<76@V,R6]D^G11M"-B6SXW1!>FT[5X]JQ1\ ?AT/"Q\.#P;I/
M]B&?[2;+[.-GFXQO]<XXSZ53=_Z\[D_U^!\@:C^T+\0;E-6U5/B!;JWAJVTS
M[/96=NJPZX9I LC8D17R0<_*!C:<#O4OB3]H'XF:)I_B&PAUR=M3\(+>1ZC.
MT*GS3-=QQVI.0%)6-V9<\?+S7V)>?!7P'J&IZ5J%QX2TF6\TI$CLIC:KF!4^
MX%]AV]*TY_AYX:NIM=EFT.RFDUU8TU,R1!OM:HNU!(#UP"0*7_!*;[>1\@^#
M?BI\2_%5[HGA1_%%YITTOB06']IW#6DUZ;5[1Y&6582R!U*$H3CDCKBO0_@C
MXL\=ZU\:-2\&ZUK=]<VO@Z2^>_GGB4?;TE=19AB .B%V&/[M>V:!\'O!7A6#
M3H=(\-:?IT>G7+7EJ+>+;Y4S(4,@_P!HJ2,GM5/X9?#";P)J/B/5M3UR;Q'K
MFNW*S7%]- D)6-%VQ1!4XPJ\9[U5U?\ KR)MI;^NI\I67[1GBW4_B!J3:9XH
MU74-$U&QUN2W-U8V]M;Q^1;R/"UN@9I059>6D(W8Z=<);_&CXC>%/ OB-[CQ
M==:Q=77AK2-6@OKJ"('3GNIUBD*X7!4*?XN^#]?JV#X"_#RUU2ZU*#P?I4%_
M=>=YUQ% %9_-0I(#CLRLP(]S6@/A)X-%M<6W_".6#6]Q81Z7+$T6Y7M8SE(B
M#_"IY%0M%_7G_P  J^O]>7_!/G+X5VD]C:?M(V]SXD;Q;-':(IU9P@:;_0IL
M!MGRY484D>E>4^#/!?C'PA\)X_B?I&D:9X$@TSPIY$%]I4RO<ZM)))'B690H
M QR><G( R:^XO#'PC\&^"]*U/3-#\.6.EV&IQB*\M[:/:LZ[2N&]>&8?B:T)
M/ 7AZ7P</"CZ3;MX<$"VPTXK^Z$8((7'H,"GU;79+\&OU!=+]W^G^1\6?$#X
MO_%'X=^-KC28?%=_JKZ):65X\MS]B@MKMIR'E\_S"C",9V*$R1CD^M[6/B;X
MJ\5:1XWO]1\;Q+:7Z^(M)/@Z>(;HXH+.1D:,HA(=>&8N0".]?6WB#X1^"_%>
MLZ?JVL>&=-U+4K!56VN;F .\84Y4 GJ!V!J&3X+^!I=:U75V\*Z8=3U6&2WO
M;KR ))XY%*R*3_M D'US0]4UZ@G9I^A\FZIXFU_1=<U"V\/:LWA^\O[SPEIS
MW]I;Q&41S63!LDK\_0$!LXQQBJ^K?%3Q3HVDZ%KUU=)K_B/05\4V4&I75K&9
MG%OY"QR$A>" Q) P#CG-?8,OPF\'SW(N)/#]DTPEM9PY3G?;KM@;KU13@4^W
M^%GA*TE22+P_9*R-=.N8\C-SC[1P>OF;1N]<4/5M^OXK3]11T2\K?K_P#Y)U
M/XS>)?"?A:;2I/BO/KNI:D^FR6LFG:=%/J"&>%I)859MD"*<#:Q9R "".>+7
M[.'CS6_B+\8_ 6J^(;N2]U)-"U:U,\RHLC+'=!5W[/E+8ZD<5]*Q_L_?#>+P
M_-H:>"]'&DS3BZDM?LR[&E&0'/N 2/QK4\.?";P?X0U"VOM%\/66FW=LDL4,
MMO'M,:R-ND4>@)YIKXK^OY6$_AM_6YUM%%%(84444 %%%% !1110 5^=7PN^
M$GB#QGHZ>(-/\/:5HNFZ)JNJWESXHCG'V^]1?,!MB@4':<[>21@GZ']%:P]$
M\$Z%X<T*XT;3-+M[+2[AI7EM8EPCF0DR$C_:R<TFMQI]/ZZGPO\ "#XI>)/A
MC\.S93>+[N/29?!JZI9 :?'<-I\[7XMU6%,KNR'_ (VQDYZ#%:6C_&_XE:OX
M+\0Z;#XGNH;VPUZVMUFU"6Q@U:6W>%VDBBR?):0%00HR<$C.:^NU^"?@1+/[
M)_PBVFFU^P?V7Y+0Y7[+Y@D\K!_AW@-]:HI^SO\ #2/1;G2%\%Z0-,N9(Y9;
M80#8SQ@A&QZ@$C/N:TDT[O\ K>_Y:$)-?UY6_,^1/$7[3GCR_N-.D\/^(+^Y
MMM,TBWNOM,D%G9Q7TIG9)6NEE?A1M,?[MC\PSD9Q7O\ XAG-S^V+\/9BI0R>
M%+QRIQD9<''%>DZA\#O &JG1S=^$-)N/['016 >V7%N@.0JCTR2<>I-=#<>$
M=&NO$UIXAETZ&36[2!K6"](_>1Q,<L@/H34]4_7\;C:NK>GZ&O1112&%%%%
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MU_\ %T?VA^T!_P! SP'_ -]77_Q='L_-?>']K+_H'J?^ ,]JHKQ7^T/V@/\
MH&> _P#OJZ_^+H_M#]H#_H&> _\ OJZ_^+H]GYK[P_M9?] ]3_P!GM5%>*_V
MA^T!_P! SP'_ -]77_Q=']H?M ?] SP'_P!]77_Q='L_-?>']K+_ *!ZG_@#
M/:J*\5_M#]H#_H&> _\ OJZ_^+H_M#]H#_H&> _^^KK_ .+H]GYK[P_M9?\
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MWA_:R_Z!ZG_@#/;Z*\,D\0?'N)L-IG@7/7@W7_QRF?\ "2?'K_H&>!OSNO\
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MP;\(QWOB.Z?2A/)XA.=2$\KNLW)/ )PO)/W<5#X&^!W@GX<:E+J&@:(EI?2
MK]H>625E4]57>QVCZ5UG]H7/_0+N?^^XO_BZ5;^Y(8G3;@8&0"\7//3[_P#G
M%+FE:URE@,(IQJ>RCS1;:?*KIMW;3MNWJ_,O451-_<A0?[-N"3VWQ<?^/TYK
MV=7D T^=@N<,'CPW/;YOYU)W%RBJ']H7/_0+N?\ ON+_ .+H_M"Y_P"@7<_]
M]Q?_ != %^BJ*7]RS '3;A0?XB\7'_C]*+ZX,9;^SK@," %WQY/7G[_;'ZT
M7:*I"^N"ZC^SYP#C+;X\+]?F[4W^T+G_ *!=S_WW%_\ %T 7Z*H?VA<_] NY
M_P"^XO\ XNC^T+G_ *!=S_WW%_\ %T 7Z*IM>SAW4:?.0N<,'CPWT^;^=--_
M<[ ?[-N"22-N^/(]_O\ ^<4 ,U[_ )!I_P"NL7_HQ:?5#7KVX^Q.O]GS[1+'
MA]\>#^\7_:SS3OM]Q_T#;C_ON+_XN@"[15+[?<?] VX_[[B_^+IPO)RZ V$X
M!QEMT>%^OS?RH MT53%]<;2?[.N,@@;=\>3_ ./?YS2?;[C_ *!MQ_WW%_\
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M_P#BZ ([C_7/]:CJ">\G,DA-A.#GH7CR?_'J8+N8E!]BF ;J=R?+SW^;\>*
M+5%5!>3D$_89@1VW1\_^/4GVVX_Z!\__ 'W'_P#%4 7**I_;;C_H'S_]]Q__
M !5*MY.QYL9EX)R6C_\ BJ +=%5/MD^T'[#-G/3='Q_X]3A=3;B/L4P&,[MR
M8Z=/O?A0!9HJG]MN/^@?/_WW'_\ %4?;;C_H'S_]]Q__ !5 %RBJBWDY8 V$
MR@GJ6CX_\>H%Y.0?]!F&.@W1\_\ CU %NBJOVN;Y/]"F^;K\R?+SW^;\>/6F
MF]G!_P"/"<_\#C_^*H N453^VW'_ $#Y_P#ON/\ ^*I?MD^T'[#-G/3='_\
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M@"[15-;ZX.<Z=<# SR\?/_CU!OKC:#_9UQDDC;OCR/\ Q[_.* +E%5#>3AW
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MG_ANK0?^A8U'_O\ QT?\-U:#_P!"QJ/_ '_CKXVHH^JTNP?Z[9W_ ,_5_P"
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M"UJ'_?Y*LP_MS:%'&%/AG43C_IO'7QS11]5I=@_UVSO_ )^K_P !C_D?9/\
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M'1WFV[*W\RTO:Z[V9Z[XC\/>%?!.B^-]3L?#]KJQM[VQBM(M5AN8UMA-$[2
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M'+P-ZG/#?*O/L*CM/&>O6(@%OK%["(/,\H).P">8<R8Y_B/)]:A4II*\M?\
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MW[7_ )Y7O_@!/_\ $4?V_:_\\KW_ , )_P#XB@#2HK/37;:1PHCO 2<?-93
M?F4H&MVYC9_+O-H(4C[%-GG/;9D].OT]10!H450&M6YD1/+N\MC!^QS8Y]3M
MP/QZ4S^W[7_GE>_^ $__ ,10!I45F_V_:_\ /*]_\ )__B*/[?M?^>5[_P"
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M\SP+_AASP=_T&]<_[^0__&Z/^&'/!W_0;US_ +^0_P#QNO??[=MO^>5Y_P"
M,W_Q%']NVW_/*\_\ 9O_ (BCV]7^8/\ 5?)O^@:/X_YG@7_##G@[_H-ZY_W\
MA_\ C='_  PYX._Z#>N?]_(?_C=?0']L0;RGEW60"?\ CTEQP,]=N*0ZU;A
M_EW>"2/^/.;/&.VW/?\ SBCV]7^8/]5\F_Z!H_C_ )G@'_##G@[_ *#>N?\
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M\SPG_ABGPA_T&=;_ ._D/_QNC_ABGPA_T&=;_P"_D/\ \;KW;^V;?_GG=_\
M@'+_ /$TJ:M YP$N>A/-K*.@SW6CV]7^8/\ 5?)O^@:/X_YGA'_#%/A#_H,Z
MW_W\A_\ C='_  Q3X0_Z#.M_]_(?_C=>[G5X H;R[K!)'_'I+G\MOO3AJD)<
MKLN,@%O^/:3'3/7;^GX=:/;U?Y@_U7R;_H&C^/\ F>#?\,4^$/\ H,ZW_P!_
M(?\ XW1_PQ3X0_Z#.M_]_(?_ (W7NW]LV_\ SSN__ .7_P")H_MFW_YYW?\
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M?\\KS_P!F_\ B*/;U?Y@_P!5\F_Z!H_C_F>!?\,.>#O^@WKG_?R'_P"-T?\
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M!_JODW_0-'\?\SYYN/V)/!\+[1K6MGC/,D/_ ,;J/_ABGPA_T&=;_P"_D/\
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M>[?VS;_\\[O_ , Y?_B:/[9M_P#GG=_^ <O_ ,31[>K_ #!_JODW_0-'\?\
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M\"_X8<\'?]!O7/\ OY#_ /&Z/^&'/!W_ $&]<_[^0_\ QNO??[=MO^>5Y_X
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M^25TEV5V^["BBBLCR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .#"+_XJC_A<7@7_ *'#0_\ P81?_%5^7-%']DP_F8?VW4_D1^HW_"XO O\
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M']DP_F8?VW4_D1^F?_"W/!'_ $-NB_\ @='_ (T?\+<\$?\ 0VZ+_P"!T?\
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M .#"+_XJC_A<7@7_ *'#0_\ P81?_%5^7-%']DP_F8?VW4_D1^HW_"XO O\
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MT?\ C7YF44?V3#^9A_;=3^1'Z9_\+<\$?]#;HO\ X'1_XT?\+<\$?]#;HO\
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^R)\2T8@Z5:Y'_3]%_C2?\,C?$K_ *!5K_X'1?XU][S7BN[L(+HC/_/K+_\
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MC1_PR-\2O^@5:_\ @=%_C7WFMV&8*(+O)..;64?^RTHN@03Y%UQU_P!%E_\
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M3_M2OV7]?,/[&PW=_?\ \ ^#/^&1OB5_T"K7_P #HO\ &C_AD;XE?] JU_\
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M_P#Q-)]L'_/"[_\  27_ .)H_M2OV7]?,/[&PW=_?_P#X-_X9&^)7_0*M?\
MP.B_QH_X9&^)7_0*M?\ P.B_QK[R^V#_ )X7?_@)+_\ $TX70*%O(NL @?\
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MSHHCN<OC&;:0#KCD[>/QI!J<14MY5U@?].LN?_0:/[4K]E_7S#^QL-W?W_\
M .!_9F\!ZQ\./A9;:+KL"6^H)=32,D<BR#:QR.0<45Z;83K<0;U611DC$D;(
M?R8 T5YE2;J2<WNSV:=-4H*$=D6:***S- HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^ _\$\+_ .&Q_ 7_ #[Z[_X+C_C1_P -C^ O^??7?_!<?\:]THHYZ'\C^_\
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M ,$\+_X;'\!?\^^N_P#@N/\ C1_PV/X"_P"??7?_  7'_&O=**.>A_(_O_X
M>SQ'_/Q?^ _\$\+_ .&Q_ 7_ #[Z[_X+C_C1_P -C^ O^??7?_!<?\:]THHY
MZ'\C^_\ X >SQ'_/Q?\ @/\ P3PO_AL?P%_S[Z[_ ."X_P"-'_#8_@+_ )]]
M=_\ !<?\:]THHYZ'\C^__@![/$?\_%_X#_P3PO\ X;'\!?\ /OKO_@N/^-'_
M  V/X"_Y]]=_\%Q_QKW2BCGH?R/[_P#@![/$?\_%_P" _P#!/"O^&R? 0./L
M^NY]/[./^-+_ ,-D> O^??7?_!<?\:]:U'_D9=._Z]+G_P!#@JY1ST/Y']__
M   ]GB/^?B_\!_X)XS_PV1X"_P"??7?_  7'_&C_ (;(\!?\^^N_^"X_XU[-
M11ST/Y']_P#P ]GB/^?B_P# ?^">,_\ #9'@+_GWUW_P7'_&C_ALCP%_S[Z[
M_P""X_XU[-11ST/Y']__   ]GB/^?B_\!_X)XS_PV1X"_P"??7?_  7'_&C_
M (;(\!?\^^N_^"X_XU[-11ST/Y']_P#P ]GB/^?B_P# ?^">,_\ #9'@+_GW
MUW_P7'_&C_ALCP%_S[Z[_P""X_XU[-11ST/Y']__   ]GB/^?B_\!_X)XS_P
MV1X"_P"??7?_  7'_&C_ (;(\!?\^^N_^"X_XU[-11ST/Y']_P#P ]GB/^?B
M_P# ?^">,_\ #9'@+_GWUW_P7'_&C_ALCP%_S[Z[_P""X_XU[-11ST/Y']__
M   ]GB/^?B_\!_X)XS_PV1X"_P"??7?_  7'_&C_ (;(\!?\^^N_^"X_XU[-
M11ST/Y']_P#P ]GB/^?B_P# ?^">,_\ #9'@+_GWUW_P7'_&C_ALCP%_S[Z[
M_P""X_XU[-11ST/Y']__   ]GB/^?B_\!_X)XS_PV1X"_P"??7?_  7'_&C_
M (;(\!?\^^N_^"X_XU[-11ST/Y']_P#P ]GB/^?B_P# ?^">,_\ #9'@+_GW
MUW_P7'_&C_ALCP%_S[Z[_P""X_XU[-39?]4_T-'/0_D?W_\  #V>(_Y^+_P'
M_@GC7_#9/@'_ )X:[_X+C_\ %4?\-D^ ?^>&N_\ @N/_ ,57J5%'/0_D?W_\
M /9XC_GXO_ ?^">6_P##9/@'_GAKO_@N/_Q5'_#9/@'_ )X:[_X+C_\ %5ZE
M11ST/Y']_P#P ]GB/^?B_P# ?^">6_\ #9/@'_GAKO\ X+C_ /%4?\-D^ ?^
M>&N_^"X__%5ZE11ST/Y']_\ P ]GB/\ GXO_  '_ ()Y;_PV3X!_YX:[_P""
MX_\ Q5'_  V3X!_YX:[_ ."X_P#Q5>I44<]#^1_?_P  /9XC_GXO_ ?^">6_
M\-D^ ?\ GAKO_@N/_P 51_PV3X!_YX:[_P""X_\ Q5>I44<]#^1_?_P ]GB/
M^?B_\!_X)Y;_ ,-D^ ?^>&N_^"X__%4?\-D^ ?\ GAKO_@N/_P 57J5%'/0_
MD?W_ / #V>(_Y^+_ ,!_X)Y;_P -D^ ?^>&N_P#@N/\ \51_PV3X!_YX:[_X
M+C_\57J5%'/0_D?W_P# #V>(_P"?B_\  ?\ @GEO_#9/@'_GAKO_ (+C_P#%
M4?\ #9/@'_GAKO\ X+C_ /%5ZE11ST/Y']__   ]GB/^?B_\!_X)Y;_PV3X!
M_P">&N_^"X__ !5'_#9/@'_GAKO_ (+C_P#%5ZE11ST/Y']__ #V>(_Y^+_P
M'_@GEO\ PV1X"/\ R[Z[_P""X_XTO_#9'@+_ )]]=_\ !<?\:]@L_P#4CZU-
M1ST/Y']__ #V>(_Y^+_P'_@GC/\ PV1X"_Y]]=_\%Q_QH_X;(\!?\^^N_P#@
MN/\ C7LU%'/0_D?W_P# #V>(_P"?B_\  ?\ @GC/_#9'@+_GWUW_ ,%Q_P :
M/^&R/ 7_ #[Z[_X+C_C7LU%'/0_D?W_\ /9XC_GXO_ ?^">,_P##9'@+_GWU
MW_P7'_&C_ALCP%_S[Z[_ ."X_P"->S44<]#^1_?_ , /9XC_ )^+_P !_P""
M>,_\-D> O^??7?\ P7'_ !H_X;(\!?\ /OKO_@N/^->S44<]#^1_?_P ]GB/
M^?B_\!_X)XS_ ,-D> O^??7?_!<?\:/^&R/ 7_/OKO\ X+C_ (U[-11ST/Y'
M]_\ P ]GB/\ GXO_  '_ ()XS_PV1X"_Y]]=_P#!<?\ &C_ALCP%_P ^^N_^
M"X_XU[-11ST/Y']__ #V>(_Y^+_P'_@GC/\ PV1X"_Y]]=_\%Q_QH_X;(\!?
M\^^N_P#@N/\ C7LU%'/0_D?W_P# #V>(_P"?B_\  ?\ @GC/_#9'@+_GWUW_
M ,%Q_P :/^&R/ 7_ #[Z[_X+C_C7LU%'/0_D?W_\ /9XC_GXO_ ?^">,_P##
M9'@+_GWUW_P7'_&C_ALCP%_S[Z[_ ."X_P"->S44<]#^1_?_ , /9XC_ )^+
M_P !_P"">,?\-D^ ?^>&N_\ @N/^-'_#9/@'_GAKO_@N/_Q5>JS?ZY_J:91S
MT/Y']_\ P ]GB/\ GXO_  '_ ()Y;_PV3X!_YX:[_P""X_\ Q5'_  V3X!_Y
MX:[_ ."X_P#Q5>I44<]#^1_?_P  /9XC_GXO_ ?^">6_\-D^ ?\ GAKO_@N/
M_P 51_PV3X!_YX:[_P""X_\ Q5>I44<]#^1_?_P ]GB/^?B_\!_X)Y;_ ,-D
M^ ?^>&N_^"X__%4?\-D^ ?\ GAKO_@N/_P 57J5%'/0_D?W_ / #V>(_Y^+_
M ,!_X)Y;_P -D^ ?^>&N_P#@N/\ \51_PV3X!_YX:[_X+C_\57J5%'/0_D?W
M_P# #V>(_P"?B_\  ?\ @GEO_#9/@'_GAKO_ (+C_P#%4?\ #9/@'_GAKO\
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M_P"??7?_  7'_&C_ (;(\!?\^^N_^"X_XU[-11ST/Y']_P#P ]GB/^?B_P#
M?^">,_\ #9'@+_GWUW_P7'_&C_ALCP%_S[Z[_P""X_XU[-11ST/Y']__   ]
MGB/^?B_\!_X)XS_PV1X"_P"??7?_  7'_&C_ (;(\!?\^^N_^"X_XU[-11ST
M/Y']_P#P ]GB/^?B_P# ?^">,_\ #9'@+_GWUW_P7'_&C_ALCP%_S[Z[_P""
MX_XU[-11ST/Y']__   ]GB/^?B_\!_X)XS_PV1X"_P"??7?_  7'_&C_ (;(
M\!?\^^N_^"X_XU[-11ST/Y']_P#P ]GB/^?B_P# ?^">,_\ #9'@+_GWUW_P
M7'_&C_ALCP%_S[Z[_P""X_XU[-11ST/Y']__   ]GB/^?B_\!_X)XS_PV1X"
M_P"??7?_  7'_&C_ (;(\!?\^^N_^"X_XU[-11ST/Y']_P#P ]GB/^?B_P#
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M3K1GDSO8P+EL]<G'-(?#VE% ATRS* DA?LZ8!.,GI[#\J -"BLW_ (1K2/\
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MH O450.@:64"'3;3:"2%\A< GKV]A^5.&B:<'+BPM0Y4J6\E<X(P1TZ8X^E
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M"%?[-M-I()7R%P2.G;W/YT 7Z*S_ /A'=*_Z!EG_ . Z?X4?\([I7_0,L_\
MP'3_  H T**HKH.F(&"Z=:*'&& @7D9!P>/4 _A2'0-+954Z;:%5Z P+Q^E
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MNZ+_ .1?_BJ/^'BWC3_H7=%_\B__ !5?)M%'U6C_ "A];K_S'UE_P\6\:?\
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M^TSK #;0M((R<_,^/NH,<L>!Q0!=HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** %7[P^M:E9:_>'UK4H **** "BBB@ HHHH **** "BBB@ HHHH
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MUNXCOW%P(O+93*TSR>82,@#:21V%<)9?LZ^/-?\ A[:_">XT5?#WA_3M0O\
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MN]?U6V^+-IK,D&BZ.M[.N;=9@MLB6X.R2)XMI9V4GEB6!KZU$,:[,1J-GW<
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M7 /Y>PIPTFQ#EA9P!B"N[RQG&,$=/3BCGEW#DCV.6_X4MX _Z$K0/_!;#_\
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M_P"%+> /^A*T#_P6P_\ Q-=#:Z-8/ H:RMV R!F)>/TJ7^P]._Y\+;_ORO\
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MT52_L/3O^?"V_P"_*_X4Y=(L59&%G &3[A$8^7G/'''- %NBJ8T73PI46-N
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M6'3XYF:-E."#OC7/?[N>E'LL/>W(ON#VV*M?G?W_ /!.M_X:'\;?\_UO_P"
MJ?X4?\-#^-O^?ZW_ / 5/\*\XEMY8)FAEC:*53AD=2"#[@UV%W\+[FUU232E
MUK2[C6$3>-/B\_S&^3?M#-$$)P?[U$J.'CO%?<*-?%3VF_O-?_AH?QM_S_6_
M_@*G^%'_  T/XV_Y_K?_ ,!4_P *\\CTZZEM9+E+:9[:,X>98R44^YZ"M'4/
M">HV%]!:+";R>6VBNPMHK2$(Z!AD8SD C--T*"TY5]PEB,2]5-_>SLO^&A_&
MW_/];_\ @*G^%'_#0_C;_G^M_P#P%3_"N+/A74ET"766MV2RBN!:L64A@^,]
M,=!TY[FJ-QIEY:/$L]I/"THS&LD94O\ 3(YIJA0>T4)XC$K5S?WL]"_X:'\;
M?\_UO_X"I_A1_P -#^-O^?ZW_P# 5/\ "N,U3PM?Z-I%EJ%Y'Y"7<DD20R*R
MR IMR2"!P=PQSZUJ+\/I%L]+EGUO2[2;4X1/:VLQG#NI8J 6$1122I'+"I]E
MATK\J^XM5L4W;G??<W_^&A_&W_/];_\ @*G^%'_#0_C;_G^M_P#P%3_"N(N?
M#M[:L(GB<W?GO;M:K$YD5UQG^':>O0$GCH.*K+I-\]X;1;*X-V.3 (FWC_@.
M,TU0H/:*^XEXC$K1S?WL] _X:'\;?\_UO_X"I_A1_P -#^-O^?ZW_P# 5/\
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M10 4444 9LW^N?ZFF4^;_7/]33* "BBB@ HHHH **** "BBB@ HHHH ****
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M.V71OM\EQ'-#+-;W46]%#R(5&&)V]#GN.,YKQVBE]7CW_K3_ "#ZU+LOZO\
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M!;HJG_9-MZ2_]_W_ ,:/[)MO27_O^_\ C0!<HJLVG0,[L?,R^<_O7_QXIO\
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M"Y155=+MU=&'FY3&,S.>^?7G\:9_8UKZ3?\ ?^3_ .*H NT52_L:U])O^_\
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M_CQH_LZW_P">?_CQH Q:*VO[.M_^>?\ X\:/[.M_^>?_ (\: ,6BMK^SK?\
MYY_^/&C^SK?_ )Y_^/&@#%HK:_LZW_YY_P#CQH_LZW_YY_\ CQH Q:*VO[.M
M_P#GG_X\:/[.M_\ GG_X\: ,6BMK^SK?_GG_ ./&C^SK?_GG_P"/&@#%HK:_
MLZW_ .>?_CQH_LZW_P">?_CQH Q:*VO[.M_^>?\ X\:/[.M_^>?_ (\: ,6B
MMK^SK?\ YY_^/&C^SK?_ )Y_^/&@"I9_ZD?6IJLI:Q1KA5P/J:7R4_N_K0!5
MHJUY*?W?UH\E/[OZT 5:*M>2G]W]:/)3^[^M %6BK7DI_=_6CR4_N_K0!5HJ
MUY*?W?UH\E/[OZT 5:*M>2G]W]:/)3^[^M %6BK7DI_=_6CR4_N_K0!5HJUY
M*?W?UH\E/[OZT 5:*M>2G]W]:/)3^[^M %6BK7DI_=_6CR4_N_K0!AS?ZY_J
M:96VUA Q),?)]S2?V=;_ ///_P >- &+16U_9UO_ ,\__'C1_9UO_P \_P#Q
MXT 8M%;7]G6__//_ ,>-']G6_P#SS_\ 'C0!BT5M?V=;_P#//_QXT?V=;_\
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D5KR4_N_K1Y*?W?UH JT5:\E/[OZT>2G]W]: 'CI12T4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>plx-20250630x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250630x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $J M4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]3Y)EA&YV
M"KZL<4BW",I8.I7.,YXKFOB/JT.B^''N9VV1B9!N_&JUK>JWA^TFMI (YY=P
M)/7-<_UBE[25+F]Y)-KR9;A-14[:,Z0Z]IJQS2'4+4)#D2,9EPF.N3GC%0P>
M*M&NAF'5["8>L=RC?R->:>,M$CO- U> $1/=6[1LZX/4KS[FO*/!OV+P9XTN
M-!OF2XMM_E)<*NT@YP-R_P"!XK5R2:UT?4R3[[GU!/XOT*V;;-K6G1'T>[0?
MS-5SX_\ #"MM/B/20>N#?19_]"KP'XJ?#5+BXBDACX)P2!TKYR\?>%9O#U\=
MR%6 Q]5K.<Y0E:PTTS]"QX_\,-T\1Z2?I?1?_%4[_A._#7_0PZ5_X&Q__%5^
M8EI(RR8Y'M6H\Y6*L5B&^AKRH_29O'WAE%+-XBTE5 R2;Z( ?^/4D?Q \,2H
M'3Q'I#H>C+?1$'_QZOS#\1WNS0;LYY9=H_$U/:,-.TJUA!QLC --UVE>PE&[
M/TW_ .$\\-?]##I7_@;'_P#%4H\<>'&Z:_I9^EY'_P#%5^87]K;6^]6C%XA2
MT@,TD@5%7<6/85G]9?8KD/TL/CGPXKJAU_2P[=%^V1Y/X;JOV^MZ?>8\B^MI
M\]/+F5OY&OS#\)^(I+K5FUN]^7(V6L+#.R/^]CU-?2W@7PYK&MV0N;BWBTR-
MD5X#>*4:?/(V8&3D9/'I6L:]W:QFTTKGUB&!&0<U&;N$,H\U,L< ;AR?05\\
MW\^K>%M)M+N[O[RR%S<&T@CMY9-QDY R#@ $@\UWL^I67A6RL]1U"Y>YORC0
M)&#G<S'HH[<CK_A6DZL:<7.>B0*+;21Z0+N)I3$LJ-* &*!AD ]#BH[?4[6[
M4F"XAF ."8W#8/X5X+J?CW6)/$-JNC6AN+[4=)6ZB1>/X)2@R>!]U?SKB(F^
M(;>-;NU\-?9(=,M+=9+B2\EV!YLME%]SCZ5Y6(S"K2A*<*=[6W:6YV4\,IR4
M92MN?6PNHV4,)$*GN&XIKWT$>_?-&NQ=[98?*OJ?;@U\06OQ%^+=I]@<:7<2
MP23O;2Q%=I1@1M(!Z@C(!H/QG\;MJ-_;WNAZE'+,ILV0VKG*\\YQ@#YFY]C7
MA+B.KI^XOZ27D>C_ &4W>U1?U<^W&U2T2986NH%E9MHC,@W$^F/6IY+A(5R[
M*@]6(%?.&@>*;CQ-XG\,?;(9;:\DU&59H6RI1E2,'W'->D)HMA-)XP>6W^T-
M'&P'VEVE .UONAB0O;IBOLZ-3VL%.UKGASBX2<6>CQ7$<X)C=9 #@E6S3R<5
M5TNS@LK&&.WAC@3:#MC4*,X]JEG?:IK8D^-OVU[R:3X@:-;F5C!'IP=8\_*&
M:1P3CUPH_*O-/$GPM/A[X7>'?&/]HB<:O,8OLGD[?*QOYW9Y^[Z#K7??ME2^
M9\1],_[!JC_R))5.Q^*_@35_A;X=\)>)]*UBX.E,TGF6,B("Y+=R>1AJ]JFY
M*E!Q/YXS6EA\1G&.AB9J+M[KDVDI>[V\K]#B]-^!_C;5_# \06NB/)IAB,ZN
M9%#O&/X@F<D<>E68O@#XYGT_3[V+1Q);WXC-NRSQY<.,CC=GIR?0=:]>\+?M
M3>$/"^C66F6OA[48(+>W-N6#QL6&,!B>I./<5A>&_CA8ZGX_^&[1-_9]GH]@
M;"Z;4I1' 6,9!;<,@=  2/3.!S2]I6N] CEF0VIQ^L.4G9.SZMI/=;*]_D>=
MZI\!?'6CSV$%SH;">^F:WMXTE1BS@$GH>!@$YZ5D>-_AAXF^'<ENNO:8]FMQ
MGRI%82(Q'4;E)&?:OIWXC_&CP[\-)O"IT>ZM=;DM;N>6XL[:\%PR1R*V27YP
M<N, _3I7GWCW]K2\U":S7PQ9FWCAW&2358TF+DXX"C@8]:4*M:5GRZ%8_*,C
MPBJ0>)DIQM9+WM[7[7Z]58RM!_9AGU/P-9>(+WQ):Z:][ ;B&%K=GC5<9&^0
M'"\>WYXKBM-^!_C;5_#K:W9Z))/IVUG6177=(@ZLBDY8<=ASVKU#P/\ M,Z#
MX2T<,='U4ZD48S6L=X6LIY6Y9PCD[,G)PH[]ZHW?[0WAOQ%H.GG6_#M__;.F
MP/!;)IM\UM;$-C&=I!&,#CFCFKIO053"</U*4.6KRRY=;-ZO35MIVZZ6//8/
M@?XVN?"Y\0QZ(YTSR3<!_,3>8\9W;,YQCVK8UG]GS7HM7T?3M#W:W/?Z9'J;
MD((5@5B1AB6QVZ\5Z)HG[4?AO2_",.CKH%[!)_9IM)&B9&7?MQNR?F.>O)[5
M%HG[5&EZ1JEH?[+O&L?[&@TZ=D*"598RQWKG((PQX--SK7T1<<OX=C&*EB6[
MVN^SZVTZ^=['A7B3P3K/@W7TT?7+-]/O&*G:V&!5C@,"#@C_  KVGQ%^R1+I
M.F:C/:>*(KN[L8%N9+:2S:,;#G^+<1GY3^7:O/\ XP_%B/XG>-K/5HK66ULK
M.-(HDF8-*P#9);'&3GI72_%G]I+4_&FI1V^B75YIWAQH8TGLG5 TC DMEADX
M(QQFJ?M9*-M'U//P\<CP\L2JUZD4TH:M-K6[Z+337\#/\0?LW>);7QA<Z%H2
M'7!;6\4\MT56!$W@D+\S=>/6L?3OV?\ QYJD]_!!H;&:QG%O/&TR*58@$=3R
M,$'(XKUF+]JGPW;>(]6U0:!>S27,-ND3ETW QC!!!R #ZCG]*BU/]J+0;N76
MI(=.U&-M0O;2Y7[HVK$(PP.&[[#^=1SUUI8]&>7\.RO-8AK5Z)]-;6NO3ON>
M=VG[.GBB7PMXDU>Z$-E+HKLDEC(09'*JK,<YP %;(/.>U9GPM^$<WQ%M=6U*
MYU6WT+0]+0-<WUPI?!/. H([<]>XKO/$7[0N@^(K/Q_87.DW[6?B!XIK9DD5
M7C=(8T&_GINC!XSD'%<?\)?BMIW@S1=?\/:_IDNIZ!K*@3+;/LE0@8X/'&/?
MM6B=7E=]SSIT,EAC*,83O3M+F;;U:;Y;V2LGIMT&ZK\#-5D\4PZ1X7OK3Q<D
M]N+I+FQD50B?]- 3\AY'4\Y_"K>C_L^:Y*?$\6MLVB76C62WHB:,2K<*=W1@
MV/X>O-=5X9_:*\->#_%KS:+X3.F:&]@MDYMR@NI&!XE8]"0..>O4D]*N:S^U
M#INM77B7S--O4M[W2UT^SW,K/NRY+OR /O#@>AK.4JVR1W4L)P_?VE2MK=^Z
MK\MK=&];7ZW\CS'XC?"P_#_QY8>&SJ(O3=1P2?:!#LV^8Q&-NXYQCUKT?Q/^
MR-=:3I.I3Z;XCBU*_L8UE>SDM3#N#= '+$9QG_ZU<+\5OBA8>/?B1IOB*SMI
MX+6VBMXVCFQO/EL2<8..AKI/B7^TMJ7B[Q+;_P!EW5[9>&%:!IM/945Y"C M
MEAS@XZ9Q5OVK4;?,Y*7]ATY8KVRYE=*%F[V=[M:]';>_H<U<?LZ_$"VU"VLG
MT/-Q<;BBK<1GA<98_-P!D<GN15-/@7XXD\22Z$-"E_M&*#[2RET">7D@,'S@
M\C'7K7H#?M(Z<WQ2US7)=.O;C0=6T]+![;S LT0"@%E.<#G/0]ZT#^U%HTE]
M-82:'>'PR=)_LQ%6<?:\?WB_N,#KD=:GGK+H;1P'#TF[XB2M*W>Z[_#L][]#
MC/&O[./B'PS/(MBRZI%;V"7MVY"PF#<6&W!8YQM/(K)A_9_\=W&N3Z3'HI:[
M@A2>4^<@15?.W+9QDX/&<UZG<?M2>';S4]1^TZ%?RZ7>:7%9-$)5$@9"Y/S9
MY!##GKQ3=7_:?\-^(+[6;/4-$U%M!U*"!6\B81SH\><\@]#\O?U]:2G770Z*
MV X=G+FAB&E?:_D_)Z-VU_ X+1OV;/%FH^']?U*ZBCTV;2LJ+.8CS)F !.#G
M &#G.>>U1:O^SWXA77;#2]"C?6I;C3HM1D<HL*PJY( )+$=5/UYXK;T_XY^&
MTT[QGI5QHFI)I.M1QI;HM\TTL908!9W)/)P>#[5O1_M-:%-/)97NCWTVBW6C
MV^G7'E2+'.KQ[\LI!Z$-ZCI0Y5KW2(AA>'ITU&56S[W=])/RM9JVMOD>;V?[
M/_CR^O+^TBT)_M-DZ)-$\J*1N^Z1DX(QW'I7'^)O#.I^#];N-(U:U:TU"W(#
MQ,0>HR"".""#7OVI?M5:;JEMK,1TJ\M5G%M%:;'5F$<;;B7.1R>>E>=>-_B5
MHGC7XSP^*Y[.Z&C!X'DM6"^:XC4#'7')'K6L)U7+WD>7C\%E%.E'ZG7<I.26
MNUFWKLMM->O8L_$']G[5? /@+1_$DUT+DWAC6XM%A(-LSKE03D[N>.@YQ6AI
M'[+OBBZ\+ZEJFI#^R;J%$>ULY0K&XW=BP;Y#G Y]:[+6_P!J_1/$MEKFGWOA
MN:*VN%4VDRN'?>AS&SJ3@8(4\'UJMXK_ &GM!\0>&/$=O;:/J%EJ^L6D<;3-
M,KQ)(HP,#/ 'L.?2L>>O;8]J6#X<5252-:\5'2-VO>2:;VZZ-=/D>5R? _QI
M&UZK:.=]I=I92()4R9F"E549^;A@<CC!JS??L_\ CK3=2TNQN=%\N?4I&BM_
MW\94N$+E20< X5NOI7?^(_VF]/U^?P>TNCS/#83K=ZK'E5-U*L812,'D#D\X
MZ 5T.H?M8^'+Z\T21-&U"&/3=0:ZVXC^9#%(@ QC!S(./;K5.=9?9.:&7\/2
MYO\ :6K-6UZ.U^G1.WJCS'2OV9O'-YK^GZ;?6":4EX7Q=32*Z(%^]D*3SZ#O
M4$O[./CB37-7T^PTO[:FGS>2UQYJ(LGRAEQENI5@<=LUW1_:<TN-="=-.OI9
M+#6)[^0.RC=%)YF%!SU D'MQ5WPM^TUX1\*W>JR6GAW4A]LU$WHDDDC=\,!O
M!)Z<@D >H%+GKK6QK' \.2:BZ[2OJ[ZVY=OAMN>3:#\"_''B1+IK'0Y&%K<-
M:2F21$VR*<,/F(S@]Q4NF_ 'QYJ_VXVNA/*MG,]O(?-0!G0X95R?FP>.*^C?
MAK\3_#'B^TO+[4-1L=*MX-:DU*"*\U 6\T>0>77HP^8]"0<US-K^UMI&B7.L
M6;:?=WD,.H7$UE<6;JBW",[%=V1D=>H[8J?;5FVE$Z/[#R*E2IU:V):4KZW6
MMO*VGZGA]G\$O&M]H$NL1:+(+.,.2))%20A"0^$)W'!![5PNZOHW2/VIM-A\
M.7UMJ.E7U]<7/GEK*5XI+4F1BW!(W@#/3FOG'CG"A1GH*ZJ<IMOG1\AFF'R^
MA&D\#5<VU[U^CT\D+NHW4E%;'SXNZC=244 +NHW4E% "[J-U)10 NZC=244
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M[7';$R'9\O,JL,9XR.#1[6H_M!_8N6_] \/_  %?Y#?^&7_AK_T+W_DU-_\
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M4W_Q=>K8HQ1[6I_,P_L7+?\ H'A_X"O\CRG_ (9?^&O_ $+W_DU-_P#%T?\
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MX9?^&O\ T+W_ )-3?_%UZMBC%'M:G\S#^Q<M_P"@>'_@*_R/*?\ AE_X:_\
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M#&(XY(XP-S'A4FD '^UZ@5?U+P'H^JWEY<7$,K&\7;<Q).Z13'9L#,@(!.W
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MMTQG(:1L%S;FW)Z_\\F*_KUJ&U^%OAZUN9+G[//-<2 AY9[F21FS$8>K,?\
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M'X&QW!N=0OE++ P>(QA6/)V%<#IV;/U%>%_$I[RWU'6%><F7.W"-T/F)@GZ
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MC>C#*G!YZ5Q.N?&&WT.[\36DMI*UUI4T44*I#*Z3!XT;+.J%4^^1R>WO2VU
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M--E\^UNI)(H&68*/*FD4/'$V&)W%2#QD?,,GFBS0'9T4@Z4M !1110 4444
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MU]J^BLE12?;]#PE=U';^M3],?^"7#(WP$UO9G UZ8$GN?*BKZZO?]6:^1?\
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M2!O7(8;AP<4O,;W')\,](3P['HV;AK5;U;\ON57:82B3)VJ% +#D  5/X<\
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M1)#( N4VM(@YQ]X4#ZB6WPCT6UCBACFO!:J\<DMMYH\NX:.0R1L_RYRK'/!
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M=%E>2%K.7S(EC56=G7;E0%=3DCH:$,2P^$^AZ5#!'8FYLTM[J2\A\J0?NW>
MPG&0> AX![^M7?#?@J/PI=.;&[D:WN))+B[25$!GF8(H?Y555PJ8PH&<Y.3S
M523XK^'$0'[5<,QD>/REM)3("D:R,2NW(&QU;)XP:H6'QCT>ZU75+:9XX(+*
M5HTE#L[7"A+=E9%"\Y-RB@9SG& <\ %NW^$>AVRZB%:Z_P!/:,S;I1_!<R7
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M%% !1110 4444 %%%% !1110 4444 %4-9_X]%_WQ5^J&L_\>B_[XH L6/\
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M<YJO\1D6A?ZF;_KH?Y5=O+.#4+66VN88[BWE4I)#*H9'4C!4@\$$=C5+0O\
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ML2#B/ D+ CY=NY<[L8W#U% &!IGP@C\-V:/IFH2O>VUW+?VQN$!3S6M1;A6
M_A  /'-;'B[X?6OCF/2EU.=U-HQ:580 MP"O*-GG;O$;X]8USQFII?B?X5@L
M?M<FMVT<'F-$2V00ZKO(*XSPI#=.G/2I5^(OAI[![Q-9MGMDD$.]&+98KN&
M!E@5^;(R, GH,T=D(Y6P^!ECIOV1X=6NC-;QVD?F2(C&0PF<EF&.K_:9,^A
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MI+" D2#.&0<'GOS73AL/'#0<5U.:O6==IL/AC\*U\*?:+B34;[4);DEF^TL
MH8L22% ')S7K6DZ:$(PH%/T[3-L:+CH.:Z'3[#!QBNI(P+%K!B+ 'Y4R2#<>
M?RK72TV1@=.*;]E!IV)1CBTXZ<4HL@16RMD1QCBI5M..>#2&<W/8 ]JH7>F
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M&R.-LR6Z,4^?Y2/L^1G(^?G.*K67P!2RU>TO8]8)2WNS<K&8,D@W33[<[O\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H:S_P >B_[XJ_5#6?\
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M/.;C3I-#9&U)1;0@Y6*21?.G_P!S!PO..3QQ5QKZ'QBL^EW4;RW$*;V1H]A
M[8[9 QR.O%7IM(TN&Y2UUOP_/87**Q\R-L\8R3]!BNDT?P=/H4*WFCQSWRW"
MJ8H+A>$3.2=V.,]!2A14(W2W)E.4GJS+UO1$TOP7\.K=&W"#4IGR_P![OC\>
M35@Z5K7B9;-6TJS6*V0QJ]R3(S?,2&Q]"*W/B-+HXT'PE;:W83B:6[E,,EC+
MEK5\ $YQSUQ7HWPI\-:/<>&(GTJ]NK^U$C*6O"3*C#[R'(&,>E2P/K__ ()Y
M:-<Z+\'-6AN71G;6)& CC" #RHN./I7TQ>_ZLUX[^R58)IWP[OXT& =0<_\
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M8]J[O_A&]/\ ^??_ ,>/^-'_  C>G_\ /#_QX_XT<Z#E9PP7!Z\4[;R*[?\
MX1S3_P#G@?\ OH_XT?\ ".6'_/#_ ,>-3S)BY&</M'&*".*[C_A'-/\ ^>'_
M (\:/^$<T_\ YX'_ +Z/^-',@Y&<$XSGCM526/@\\5Z.?#6G'_EW_P#'C_C3
M6\+::W6W/_?9_P :7,A\C/(KV+(.![UR_B'0AJ%LPQ\W8U[^_@O2)/O6I/\
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MP;U6'6-*UO4A96RQE9)-/"D[,&^X QC_ )>T^FUJ]:_M6?\ Y]U_,T?VK/\
M\^Z_F: /'(/AIKNC2>%]%BM8]0CM+K2Y[G49 <1"V4!O*)[';T.#ECP0<CH=
M3^'^K^(?%?B3=%;6.G3:C;7<5\V?M$GEVJ+M7 ^Z6RI).<;A@YS7H7]JS_\
M/NOYFC^U9S_R[K^9HN'_  QY]9?".]T^PT^QCGL3$MCIMI/-M8/$UJ^XM$,<
M[LXY(QUYZ5G'X,:R;J.7[5I_^A6EI;VTF7\RX:"\6X#3';P6"X.-V"2>:]2_
MM2?_ )]U_,T?VK/_ ,^Z_F: ."\)_#'6?#FL'49Y=-OGN3.MQ!(7V0![R6X#
M1?+DMB7:<XY13GC%4-"^#^K:%>Z9>K/IMU+IT$$$=M)O$4PCCGCW,=ORG$RL
M, XPP[@UZ9_:L_\ S[K^9H_M6?\ Y]U_,T >>:1\&[O2X[<&]MI)(M2LKWS0
MA#;(8PK(/3)S@=,58\5_"&Y\2:EJ5Q'?I9?;-26[\Z,$2QQ_86MB ?[VX[AV
MQ7=_VK/_ ,^Z_F:/[5G_ .?=?S- 'F=O\&]4AM;.3[9 +NTGA=8EN)?+F6."
M6(98K\I_>Y "'&T EN"%D^#.HQKIMK'-I]Q917=I=S-<F1G3R8O+,4><G8>O
M+<%F]>/2_P"U9_\ GW7\S1_:L_\ S[K^9H Q/AQX1O?"%E<6D\L0LQY:VMK%
M*TP@55VX\QU#L#Q@-G&.IKLZQ_[5G_Y]U_,TO]K7'_/ ?F: ->BLC^UKC_G@
M/S-']K7'_/ ?F: ->BLC^UKC_G@/S-']K7'_ #P'YF@#7HK(_M:X_P"> _,T
M?VM<?\\!^9H UZ*R/[6N/^> _,T?VM<?\\!^9H UZ*R/[6N/^> _,T?VM<?\
M\!^9H UZ*R/[6N/^> _,T?VM<?\ / ?F: ->BLC^UKC_ )X#\S1_:UQ_SP'Y
MF@#7JEJJ[[91_MBH$U2=NL 'XT\O)=%=ZA5'.!0!;M!BW044^)=L8%% #Z*3
M(I-PH =13=PHW"@!U%-W"C<* '44W<*-PH =13=PHW"@!U%-W"C<* '44W<*
M-PH =13=PHW"@!U%-W"C<* '44W<*-PH =13=PHW"@!U(1FDW"C<* &O&#VS
M49MU/45-N%&X4 0?95/:C[(OI4^X4;A0!!]D7TH^R+Z5/N%&X4 0?9%]*/LB
M^E3[A1N% $'V1?2C[(OI4^X4;A0!!]D7TH^R+Z5/N%&X4 0?9%]*/LB^E3[A
M1N% $'V1?2C[(OI4^X4;A0!!]D7TH^R+Z5/N%&X4 0?9%]*/LB^E3[A1N% $
M'V1?2C[(OI5BEH K?9%]*/LB^E6"0*3<* (/LB^E'V1?2I]PHW"@"#[(OI1]
MD7TJ?<*-PH @^R+Z4?9%]*GW"C<* (/LB^E'V1?2I]PHW"@"#[(OI1]D7TJ?
M<*-PH @^R+Z4?9%]*GW"C<* (/LB^E'V1?2I]PHW"@"#[(OI1]D7TJ?<*-PH
M @^R+Z4?9%]*GW"C<* (/LB^E'V1?2I]PHW"@"#[(OI1]D7TJ?<*-PH @^R+
MZ4?9%]*GW"C<* (/LB^E'V1?2I]PHW"@"#[(OI1]D7TJ?<*-PH @^R+Z4?9%
M]*GW"C<* (/LB^E'V1?2I]PHW"@"#[(OI1]D7TJ?<*-PH @^R+Z4?9%]*GW"
MC<* (/LB^E'V1?2I]PHW"@"#[(OI1]D7TJ?<*-PH A%N!VJ18]M.W"EW T
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M(_X3;7A_S&+W_O\ &C_A-M>_Z#%[_P!_C0!];_VJG]X?G_\ 7H_M5/[P_/\
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M[53^\/S_ /KT?VJG]X?G_P#7KY(_X3;7O^@Q>_\ ?XT?\)MKW_08O?\ O\:
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MDC_A-M>_Z#%[_P!_C2?\)MKW_08O?^_QH ^N/[53^\/S_P#KT?VJG]X?G_\
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M +53^\/S_P#KT?VJG]X?G_\ 7KY(_P"$VU[_ *#%[_W^-'_";:]_T&+W_O\
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MJ-Z-0CC>W%HX+2#/EDE5#_AG/X5K2^$8[/PY#IUS;^7JSW\8EE1-TB(WF*%
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** />_V?S_ ,4Y>?\
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MM;'2=USI;:J[RRNL=OB-F^SR,2 K@@ L>!G.!BG8#H_^&=O"G]Z__P"_X_\
MB:/^&=O"G]Z__P"_X_\ B:Z+X<>,)O&6A/=7*1QW4,[02I"/D5@%. 0S*W##
ME68>_4#KJ0'E_P#PSMX4_O7_ /W_ !_\31_PSMX4_O7_ /W_ !_\37J%% 'E
M_P#PSMX4_O7_ /W_ !_\31_PSMX4_O7_ /W_ !_\37J%% 'E_P#PSMX4_O7_
M /W_ !_\31_PSMX4_O7_ /W_ !_\37J%% 'E_P#PSMX4_O7_ /W_ !_\31_P
MSMX4_O7_ /W_ !_\37J%% 'E_P#PSMX4_O7_ /W_ !_\31_PSMX4_O7_ /W_
M !_\37J%% 'E_P#PSMX4_O7_ /W_ !_\31_PSMX4_O7_ /W_ !_\37J%% '$
M:#X*T[P,K66FF8PRMYK><^XYQCK@>E:>H_ZH_A5S5/\ C_3_ '1_6J>H_P"J
M_*@#E&_9\\+73&9VOM\AWG$XQD\_W:3_ (9V\*?WK_\ [_C_ .)KTR#_ %*?
M[HJ2@#R__AG;PI_>O_\ O^/_ (FC_AG;PI_>O_\ O^/_ (FO3R<4PRJ.I Q0
M!YG_ ,,[>%/[U_\ ]_Q_\31_PSMX4_O7_P#W_'_Q->CMJ%NDBQM/&)&^ZA<
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M$G^Z?Y4 0Z7S80_0_P S11I7_(/A^A_F:* &6W_(3O?^ ?R%7JHVW_(3O?\
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MQZ ?[*_ACI706\<R#$KK(WJJ[?ZFIL =J"..*S;-4K!4-Q9PW0 GBCF Z"1
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M>_\  /Y"HM=\06OAZ&W>YWL]S,(((84+R2R$%MJ@>RL?8*3VJ6V_Y"=[_P
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M7KI'M05!'(!HZ6'?6YXU8S>,-$^'>J3:O?7BW_\ HS-).B0>4H9/M 20S/\
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M]]"N:P/048'H* .E,\/_ #U3_OH4>?#_ ,]4_P"^A7-8'H*,#T% '3">$?\
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M/_/5/^^A7,8'H*,#T% '3_:H?^>J?]]"C[5#_P ]4_[Z%<Q@>@HP/04 =/\
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I_OH4V:>,PN ZG(QP<USJ*/05=M@/2@#5LEV6L:^F?YT5)#_JEHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20250630x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250630x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $T MH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4B<4;A2/
M]TUX3+XUUQOAW)=)JDWV\>+A8"4$;A#]N">7TZ;./I6M.FZCLO)??H95*BIJ
M[\_P5SW?<*-PKQN#XU:O+XA-K-H4":.VLW&B)>1W1,IE12ROL*XP0O/-9>G_
M !LUJW\.:7'IVD#5[R/19-9OI=0O-A$0=E 5@GS,2I[ 8%7["=KF7UF&W]=$
M>\9HS7D*?'&X.B:M?'2H@UD-+(3SC\_VME![<;=W'KCM3/#WQYN-?^(\N@1>
M'KHZ4MW+8_VC'%,P61,Y9SL\L*2,<.3SR*/J]7738/K-+37<]AW#UHW UX[X
MVU;4]9\9>(-/'B'4O#VF:'8PW.W1[<2W-P\F[YMNQF91@#:HY.:PKS]HN;1-
M*\.6^F65QXRN[BR:ZN+M+.>)I%24Q-B)8V*L65A\VU>.O-$:$YI./44L3"#?
M-I;^OU/?]PS2%@.]>.ZA\<-6M=7N_*\.Q'1[.\L;:XGFN3'.OVE5QB/;U4L,
M@D5BO^T/J^N3>(K;2_#L\,$%M>_8M2DBF\L20(QS(QCV ':<88\X!ZT+#U&K
MV!XFFG9L]]W"C(KY_P!)^,6KZ%IEOJ>N1-=W"^&;>_-O;W&8II))=JL04&&.
M1DYP.:]1TG6O$-UX8U677-,@TC48(W,9L[D3QN-F0RG (],$#D=Q4SI2AN7"
MO&;21U^X4;A7SA\(_%FN/X?3Q%J-QXROI(M*EO7.IK"NFSL$SA2HW<]JW8?V
M@=6L]/N)=4\-P074NG6E_80V]YO63SY5B19&*C;\[#/7BM)8>:=EJ9QQ4&KO
M0]Q+@=32[A7B5S\5M;NM2&FZCIZZ5>V.NV%C*+"\WK*)5+')*<K[<$^HI^D?
M'S46^SWFK:!#:Z1=0ZA+!-;W)DE8VI;=E"HP"%XY-3]7J6O_ %W']9IWM_6]
MCVK(HW"O +#]IZ\;PSJ&I7OA.\MY5, L0(9_*G,K85<M$"6'!.P,#GC-:^D_
M&W7]>_X1VUM?"WD:GJ=S<6\D5^\MNB") YD7?&&*D$XRH.:;PU5:M?UN)8ND
M[)/?_ACVC<*,BO"])^+?B%+*PM=-TN/6+Z[?4I"U_>[!&MO(1C<$Y&. ,>GU
MI]Y^T)JD^BR:IH_AV&YM;31H-5O?M-WY;1^:"55 %.[&.3Q[4/#U$QK%4VK_
M -?UJ>X[@*-PP/>O,?C&=1N?AG<:_INN:AH5U969NU6Q= LA*J=K[E.0/;'6
ML >/M;\"6\^G6<=QXK&F:?'K&JWNK7BQRK%("0D05 &(",><#MGFI5%R5T]2
MI5U&5FM#VW(H# UX_)\=+F>]EO+/14E\+VU[;Z?<WCW&VX66;9M*QXP5!D7/
M.>N!7.M\:O$'A;3KISIQUB(ZO?QM>W;O'#!%%*0D>Y48*<="V%XY-4L/4?03
MQ--=3Z"S2U1T;4DU?2[.^CV^7<Q+,NUPXPP!X8<'KU%7JYK-:,Z4^9704444
M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLM0M]2@6>TGBNH&Z20N'4_B.*LT#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(\5^)[
M#P?H5UJNHR-':VX&=BEF9B0%50.K$D #U-<WX?\ BSIVK7L]GJ5C?^&;N*W-
MWY6LQK%OA! ,@8,1@9&><C/-7?BCX0NO&GA*6RL9HX-0AGAO+9IP3&98I%D4
M-CG:=N#]:\P^(/ASQ9XDT;7]?U[3;32OL.@W=G;6%E<FZ>9Y%&YRVU<#"\*
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M ,) VE^< JZ>-2^V[U^S^46*YWY]OI5^V\7:)>6]I/!J]E-#=L5MY([A"LI
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M8_'_ ,(:I8VUY;7LJ03M;E6O;6:V)BF#&.50Z E"$;YNG!Y%+?4-M#C?@/\
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M:[B< [ER,$\UW'Q0^,%S\/\ 4HHK:SM-0AB-LUY%OE,\:33")6PD;*HZD%V
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M-;V*0C35>[\F1FW.%<!2#ERJ@]< &HM3^-WQ N+&+6=6\0VVGBX\(7]W:Z;
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M$\TSG"QQJ2S'T %>T_#W]FK4-8\J\\1R-IMF?F%JF#,_U/1?U/TKV[P-\*]
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ME=R6-Y!<1';)$X=3Z$'- 'US2U5TV^34M/M;N/[D\:R#\1FK5 !12$\9I-U
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MHHK<\\**** .Y^!W_)7/"O\ U_)_6OT)U1BFG7!!P0AY_"OSV^!W_)7/"O\
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MT;AEE1'!63:P!V$<C->.:AX5\>7\<(MK/4+:TN+V1Y)[5/L$]PC3VI,L\<;
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MB2S0+'\_!()(9AW89;G_ &C0&YR?@[5=%^S2+#HDPENXT$\"IYGEQ;5PK9.
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MV09R9,MG@;>IJQ=?LFZWJ$FKV,VLZ-;:2JZ@VFW=K9.+^=[J0R%;QB<.B'C
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MF4]5WQLK $<$ \@D'@UKT4K7#8IZ7I=MHVG6MC90):V=K&L,,$8PJ(HPJCV
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%%% !1110 5Q_P 5?A9H/QA\'7GASQ#:B>SG&Y)%XD@D'W9$/9A_];O7844
M?C'\?/@#XA^ GBV32]5C-QITK%K'4D7]W<)V^C#NM>85^X?Q&^&_A[XI^%KK
M0?$FGQW]A.#PW#QMV=&ZJP]17Y>?M(?L@>)?@9?3ZA9I)KGA%W)BU")/G@'9
M9@.A_P!KH?;H #Y_HHHH **** "BBB@#ZC_X)S_\G"I_V"[G_P!EK]$?C9_R
M2CQ/_P!>;?S%?G=_P3G_ .3A4_[!=S_[+7Z(_&S_ ))1XG_Z\V_F* /S^HHH
MH **** "BBB@ I*<B-*X1%+L3@*HR2:^B/@M^S-/JCV^M>+86M[,8>'3CP\O
MH9/1?;K]* .=^!'P&N/'UW'J^LQ/;Z!$V0I^5KHCL/\ 9]37V59V<-A:Q6UO
M$D,$2A$C0855 X %+:VD-E;QP01K##&H5(XP J@=  *FH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH 0]*X?Q)\*--\2ZW=ZI<75U'-<_9-R1E=H^SR^:
MF,CN>#[5W!Z5@:EX]\-:/K$6DW_B'2K+59=HCL;F]CCG?=]W"$Y.>V!S3C)Q
M=XD2BIJTD<[J7P=T[4+BXN$U"^M+F75UUE9H2F8Y@@3:,J1M*Y&#ZU1T[X!Z
M/I<VJ^3J.H_9+Z&XA2T+1^7;B8DR%<*"3D\;BV.U>FY-'6K56:5DS-T:;?-;
M4\TU#X":'J%E<P/=WJ22-9R13HR;X)+9"D;J"I!)#'(((.::_P #+&.#3VLM
M=UG3M1M8Y8'U&VF033QR,&=6RA R0,;0,=L5Z/%>02SS01S(\T1'F1JP+)D9
M&X=LCGFD@O[>ZFN(89XY9;=@LR(P+1D@$!AV."#SZTU6J;7_ *V%["F]>4X#
M5O@GIVJR:N6U;5(DU*&W25%E4D20!1',&92Q?"C.20?2LNY_9UTJ]@?[3KNK
MSW;Z@=1>[D:)G>0QB-@08]N"%].,\8KUJEH5:HMF#H4Y;HX7P3\)-,\"ZA87
M=E=7<[V>FG3(UG*D&(S&7)P!\V3CZ5N^&?"-KX7GU>2WDED.I7KWTOF$':[!
M00,#I\M;@H^M3*I*5VWN5&E"*22V_P"&.$N?A#IEQX=FTD7=[ 6U*358;R)U
M$UO.TA?<AQC@L1@@\=:YC6O@3<&X\/#2M9O8IH=2GU#4=7DF7[7)(\6S<OR%
M2> -N ,"O5M5UBQT*QEO=2O;?3[.+&^XNI5CC3G RS$ =:M1RK+&KHP=& (9
M3D$>HJHUIK5,F5&G+=?U<\JG_9ST!UT]H-0U*TNK>)H9[J*1#)=HTAD;S"RG
M!+$G*[3S70W/PFTJYT?Q1IK3W*P:^P:<JPW18C5!L..VT'G/-==%?VTM[-:)
M/&]U"JR20JP+HK9"DCJ =K8^AIUW?06$/FW,\=O%N"[Y7"C)("C)[DD >YH=
M6<M&_P"KW&J-.+T1YE8?"N\D^*]AXBU!HYK32M/%K!.\V^:\EQ@2RH$55*@N
M!C/7M70Z[\)_#_BGQ1)K>MV46L2&U6TCMKV-)(H5#$EE!'#'/)]A79CD=Z#S
M2=63:=PC1@DU;<\AE_9MT@:<]C9Z[K.G6\EK)8S+;2Q@2V[.SK&V4/"EV Q@
MXXYKIK?X1Z+;^,-.\1@SO?65@+!%+ (P *B0@#[X5F4'T8UVX&:4"FZU1[L2
MHTULCQ_3_P!F?0=.COXTU34I$N[&XT_:YB^2*5@QP0@)((ZMDUOZ[\&M,UV2
M]F>_O;:>YCM$$L#+NB-NQ:-URIYR><Y%>@X]Z,4W6J-W;!4*:5K'DL?[.VCQ
M>(WUK^T]0N+DW,EYY-P8S&TKQF-]Q"!B"#TSQVQ7*>!O@#X@.HF#Q?<13Z+;
MZ7<Z5!%!>-*3'*RD! 8U\L*$[ECTYXKZ%Q15+$5$K7(>&IMWL>71? 6QAT";
M3AK^KM+),DOVLM%N 5=JH8]GELN#T*G)YZUVG@;P?9^ _#-IHE@\TEM; X>=
M@78DEB3@ =2>  /:MP\&H%U&V-\]F+B(W:H)6MPX\P(3@,5ZXR",UG*K.>DF
M:QHP@[Q1:HI <TM9FP4444 %%%% !1110 4444 %%%% !4%Y90:A:RVUS#'<
M6\JE)(I%#*ZGJ"#U%3T4 ?%GQ_\ ^">.E^)WN=:^'<T6BZDY+OI%PV+64_\
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M=Q;-%%O*LN?E('/?(Z4W2OV@/"VJ>&]3UP_VA9V%BJ.7N[1D\]7.$,74-N/
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MD,T"X212002>20P(.3QBJLO[/VA23+<"^U%+S)D>Y#QEY)_/:<3'*8#!W;@
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-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>plx-20250630x10q008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250630x10q008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &N K0# 2(  A$! Q$!_\0
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M-2_[_FC_ (7'XW_Z&C4O^_YKCJ*[_9P_E1YGMJG\S^\['_A<?C?_ *&C4O\
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M#%\Q/T]*S#^PSJL6CWLS^(;4W\"LRV\:94@<C/H36:Q6%?5?<:/"8U=']_\
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M2_[_ )KCJ*?LX?RH/;5/YG]YV/\ PN/QO_T-&I?]_P T?\+C\;_]#1J7_?\
M-<=11[.'\J#VU3^9_>=C_P +C\;_ /0T:E_W_-'_  N/QO\ ]#1J7_?\UQU%
M'LX?RH/;5/YG]YV/_"X_&_\ T-&I?]_S1_PN/QO_ -#1J7_?\UQU%'LX?RH/
M;5/YG]YV2_&3QN"#_P )1J0/;]\:]E^ W[6.O:5XAM-(\5WK:GI5TXB^TSG]
MY"3P#GN.U?-%/@8QSQLO#!@01]:QJX:G4@XN)O1Q52E-24F?K[#(LL*.A!1@
M"".XHK"\ 3-=^"-"EDY=K*(D_P# 117Q,ERMH_0X/FBGW/A']LG_ )*_<?\
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M[PM=K\/ULO$5NZV=Q&UT(I#\B@#.ZJ_C7XH^$-0^.>DZM;^,AIUO%8^6+RU
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MZ_UI*6/_ %J?7^M)[,M;H_5SX<?\B%X?_P"O*+_T$44?#C_D0O#_ /UY1?\
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MPE.%+WI33;7D<F,K3K^[&#23\]3[2;XIP_#K]G[2M4L7LKV]@M8P+:24<GZ
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M-O@5X6O[VZCU*>*6":>(2JTCXZYP:^8-7^%OCO4=1N[B+PIJ=K#-(SB!8SA
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M $P/2C ]*6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH 3
M]*,#TI:* $P/2FR*&1E/<&GTAH Q[8[$91V8BBFV_23_ 'S10!9T+_CQ/^\:
MTJS="_X\3_O&M*@ HHHH **** "BBB@ KAO&F@RW7BOPSJ-K:>;/#-())><*
M-GRY]!FNYHH \I\$>'=?TWXEZI?ZG:*5NK1?,NTD+*6#'"CZ#M7H^I//;PF:
M*4*J8RI7.>0.M7ZI:Q_R#IO^ _\ H0HZ6#K<N*<@4M(OW1]*6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-:FZ-25-] G%PDXL6BBBLB HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ^#N;?4/%MH?^66IN0/3=S7IV>:Z<9)SKRD^IK6UFV+1117&8!1110 4444
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M8KXT^Z7Y&U;XD_)#J***Y3$**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !534K^'2K*:[GW^5$"S;%+'
M'T%6Z:RA@0PR#U!&0: /.Y_CKX92%F1KMGQD VS $_6J&G_M Z'=3;9X;F!
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M%N,8KV;1M1.KZ5:WIMY+0SQK)Y,XPZ9'0^] %^F2+YB,N2N1C(ZBGT4 >?\
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M&.4TJT*$I2O*^O+*VGR_(]6&58J<'-15EYK_ #/6,<YJ)[J&.01M,BR'HI8
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MS1!-&XR"1CK7N$,*6\:Q1HL<:C"JHP /05X%IO[./B[2?$&HZW:_$N]BU+4
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M<QM<0JQ0^V15E-+LXYO-6VB638(]P0 [?[OTIEEK-E?V%M>Q7,;6]R@>*0L
M&!]*SCXRLH_%4NA/F.=+<7)E8@*5)QB@">\\(Z)J5E'9W6E6EQ:Q'*120JRH
M>N0"*M1:-80O;/'9P1O;J4A*Q@&,>B^@JS+=10('DE1$/1F8 &DDNX8E!>:-
M 1D%F !% %>TT6PL+NXNK:RA@N;C_6RQH%9_J1UJ&Y\,:3>ZE%J-QIEK-?1?
M<N'A5G7Z$C-)HGB;3/$JW3:;=QW0MI3!+L.=KCJ*XKQ5\7KSPG).UYX/U5K*
M.41"\1DV/DX! )SBCK8#TH=*6HK:;[1;Q2[2F] VUNHR,X-2T %%%% !1110
M 4444 %(:6D- &);=)/]\T46W23_ 'S10!:T+_CQ/^\:TJS="_X\3_O&M*@
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MOT-1+#-KFI/F7EO]PG3=KPU1Z-15:._MIC'LGC;S1F/:P.X>HJS7*9!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %,D<(,DX]Z?5'5M+@UFPGL[C=Y,R[6V,5./8CI0K=1JU]1\^HVU
MK"\LLR(B#+$MP!5:V\1:;>3)%#>0R.Z>8JJP.5]:X"Z_9X\+R6TD<3:@CLN
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M@\2>"O"B:K<Z1IFJW+F\DM)/+D=47(7=VKV^N+^(7PG\/_$TV7]MPS.UFS-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M _"M.:NMXI_/_@%7J=E]_P#P#T#-'4\UYV/AEK-IG[#XSU2(=DG*R ?G2?\
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MF3<>&[!F/<1 ']*5\++HU]S_ ,@_=>9TUOKVG7:@P7]K,#TV2J?ZU>5PZY#
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&XT4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>plx-20250630x10q009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250630x10q009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '/ K4# 2(  A$! Q$!_\0
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M?^9CO_\ OZ:3_A;GC'_H8K__ +^FN1HKN]E3_E7W'G>VJ?S/[SKO^%M>,?\
MH8K_ /[^FC_A;7C'_H8K_P#[^FN1HH]E3_E7W![:I_,_O.N_X6UXQ_Z&*_\
M^_IH_P"%M>,?^ABO_P#OZ:Y&BCV5/^5?<'MJG\S^\Z[_ (6UXQ_Z&*__ ._I
MH_X6UXQ_Z&*__P"_IKD:*/94_P"5?<'MJG\S^\Z[_A;7C'_H8K__ +^FC_A;
M7C'_ *&*_P#^_IKD:*/94_Y5]P>VJ?S/[SKO^%M>,?\ H8K_ /[^FC_A;7C'
M_H8K_P#[^FN1HH]E3_E7W![:I_,_O.N_X6UXQ_Z&*_\ ^_IH_P"%M>,?^ABO
M_P#OZ:Y&BCV5/^5?<'MJG\S^\Z[_ (6UXQ_Z&*__ ._IH_X6UXQ_Z&*__P"_
MIKD:*/94_P"5?<'MJG\S^\Z[_A;7C'_H8K__ +^FC_A;7C'_ *&*_P#^_IKT
M7]E'X8Z!\3_%.IV7B"U:ZMX;?S$57*X.:N7'PI\.1_M0IX.%H_\ 81F">1YA
MSC;GK7)*I1C4<''5*^R.Z-+$2IQJ*>C=MV>7?\+:\8_]#%?_ /?TT?\ "VO&
M/_0Q7_\ W]->P_M$? *TT/QSHFA>!M*E>XO+=I3!YFXL0>O->8:S\!/'OA_3
MKN_O_#EU;VEJ,RRMC _6G3J8>I%2LE?O856EB:4W&[=NU[&;_P +:\8_]#%?
M_P#?TT?\+:\8_P#0Q7__ ']-:^D_L\_$/6]/CO;3PQ=O;R+N1F 7</7!-:WP
ML_9XUWQI\0&\/ZO9W6D16HWWCL@W1J>GYU3GAXIO33T(C'%2:2YM?4Y+_A;7
MC'_H8K__ +^FC_A;7C'_ *&*_P#^_IKO?VC_ (&O\,O%%I'H^GW!T6>..&&9
MSN,TV/F ]ZYN+]G7XBS6 O$\*7QA*[Q\HW$>N,T1GAY04]$GZ!.&)A-PU;7:
MYC?\+:\8_P#0Q7__ ']-'_"VO&/_ $,5_P#]_37+WEE/IUU+;74+P7$3;7CD
M&&4CL17U#^RG\#O"7Q-\':E?Z_8R7-Q#=>6C+*5PN/:G6G1H0]HXZ>@8>-?$
M5/9*3OZL\&_X6UXQ_P"ABO\ _OZ:/^%M>,?^ABO_ /OZ:^BM*_9ET"3]H74]
M!N+.1O#4%B+I(_,(/S< ;OK7-_M8?!CPW\-;?P__ ,(S8R02WLCHX,A<M@<
M5S1Q&'G.,%'5Z[(Z9X7%4Z<IREI%VW9XS_PMKQC_ -#%?_\ ?TT?\+:\8_\
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MMKQC_P!#%?\ _?TU]F:_^SQ\'/#%WIEIJ=H]K/J,GE6RO<-\[^E<!XN_9?\
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MN^(XN4@_X1>\+NN\8 QCZYJM8_ #X@ZE<7D,'A>^:2U;;*"@&#Z#/6IYL/\
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M1AO7!]A6EZ%[:7^1C;%6YO>M\S/_ .%M>,?^ABO_ /OZ:/\ A;7C'_H8K_\
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M'9?J?:O8M-_M=OV;=*'PW,?]I>3'M\O&[.?GS[U\3>+OBQXM\=0+!KFN75_
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M %%%% 'WG^QPVWX-P_\ 7Y-_,45'^QW_ ,D=A_Z_)OYBBOB,5_&EZGZ)@_\
M=X>A\M_M&_\ )8O$'_74?R%>:5Z7^T;_ ,EB\0?]=1_(5YI7U^'_ (,/1'PN
M*_CS]6%%%%=!RA1110 4444 %%%% !1110 45J>%_#EYXN\06.C:>JO>WD@B
MB5C@%C[UZ\/V-OB,>EC:G_MN*QG6ITW:<K'13P]6LKTXMGAM%>L>)OV9?&_A
M/^S_ .T+6!/MUPMK#MF!R[= :YKXD_";Q!\*;NSMM>ACBDND,D7EN&R <&E&
MM3DTHR3N$\/5@FYQ:L<91116QSA1113&%%%% !14EM;O=7$4$8R\CA%^I.!7
M>?$'X(>)_AGI%EJ6MV\45M=-MB,<@8DXS6<IQBTF]67&G.2<HK1;GG]%%%:&
M84444#"BNI\,_#+Q'XNTN]U/3M-DDTZSC:6:Z88C4#J,]S7+5*DFVD]BG&44
MFUHPHKT+X>_ ;QC\2[%[W1=-+V2G:+B9@B,?0'O5/XA?!SQ5\,&A_M[36MX9
MCMCG0[D8^F?6L_;4^;DYE<T]A5Y.?E=NYQ-%>T:7^R1\0=7TVVOK>SMS!<1K
M*FZ< [2,BN$^(OPRUSX6ZK#I^N11PW,T?FJ(WW#;2C6ISERQDFRI8>M3CSRB
MTCDJ**[[X=_!/Q-\3].O;W0[>*6"U.V4R2!2.,UI*<8+FD[(RA"527+!79P-
M%37EK)8W<UM*,2PN48#U!P:AJB-M HHHH **[GX:_!OQ'\6/MG]@013?9<>9
MYD@7&>E=G>?L@?$.QM9KB6SMA'"C2,?/'0#)K"5>E!\LI),Z88:K./-&+:/$
MZ*=)&8I&1OO*2#^%7O#^AW7B;6K/2[)0]W=R"*)6. 6/3FM[V5SF2;=D9]%>
MI:A^S=XSTWQ;IOAR:VMQJ>H0O/ @E&"J]3FN/\>> ]5^'/B&31=9C2*^C19&
M5&W##=.:QC5IS:497-IT*M--RBU8YVBBBMS ****0PHHHIB"BBB@845/864N
MI7UO:0@&:>18D!Z;B<#^=>UC]CCXC$ BRM<?]=Q6,ZM.G\;L;4Z%6M?DBW8\
M-HKJ?'_PR\0_#+44L]>L6M7D&Z-P<HX]C7+5I&2DN:+NB)1E!\LE9A1175_#
MSX:ZU\3]8DTS0XHY;J./S661]HV_6B4E%<TMA1C*<E&*NV<I16QXN\*W_@KQ
M!>:+J2+'?6K;)%5L@'ZUCT)J2NA2BXMI[A12J-Q '>O0O$WP*\5>$O!L/BC4
M+>%-+F"%'60%OFZ<4I3C&RD[7*C3G--Q5['GE%* 6( &2:['Q7\)_$'@OPWI
M>MZO;I:VNH\P(SCS",9R5[4W)1:3>XHPE)-I;'&T444R0HHKM/A[\(?%'Q/F
ME70=/:>*+B2=CMC4^F?6IE.,%S2=D7&G*H^6*NSBZ*[_ .(?P,\7?#&WBN=;
MTXQVDC;5N(FWIN]"1T-;?A?]EWX@>*](BU*UTE8;:9=T?VB0(S#UQ6?UBER\
M_,K&OU>LY<O([^AY+17=K\%O%*>.(_"5S9+9ZS*-T<<[A5D'^R>]<UXH\+ZC
MX-URZTC5;=K:^MFVO&W\Q[54:L).R9G*E.*O)6Z&31116ID%%%% !1110 44
M44 %%%% !1110!]W_L=_\D>B_P"OR;^8HI/V//\ DCT/_7Y-_,45\1BOXTO4
M_1,'_N\/0^7/VC?^2Q>(/^NH_D*\TKT_]I*WD@^,.NF1&02.KKD=01UKS"OK
M\/\ P8>B/A<5_'GZL****Z#E"BBB@ HHHH **** "BBB@"]H>MWOAO5K74].
MF:VO;5_,BE7JK>M?>/[(GQ"U_P"('@[6[O7=0DO[B"Y"1N^/E&W.*^ *^C?V
M:/V@O#WPB\+ZMI^KPW4LUU.)$,"@C&W'->;CZ+JTO=C>1ZV75U1K+GE:/X&7
M:?$[Q/XI^.&EZ3JNKSWFGV^M_NX)"-JX<@5];_$CPEX#\8>-M#T[Q/;B\U::
MWD6SMV)VE <L>.]? 6A^,+/3OBQ;^))5D-C'J)NRJCYMNXG\Z]Z\5_M0>%]:
M^+_A3Q/!;W@L-+MY8IE9!O)8\8%<6(P\VX>S5K)[=SOPV*ARS]JT[R6_:YT?
MAK]GOPA:?'_7] GT\7>DKIT=W!;RL?W;,W(S5;QS\*_AAJ_B^S\!>';06VO2
M7@-W,I),,0&6 /Z5FV7[5/A6W^,VI>*F@O387&G1VBJ$&_<IR>/2O'=6^,AL
M_CE<>.M$C8Q&Y\U(IN"R'@J:*=+$2DG)M6C^)52MA:<6H).\OP\CZ<?X2?!V
MS\9VWP_DT:5]9FMC,)R3T Z[O6L'X8?LU^&-.^)_BW0M7LEU>RM8HIK1IB<J
MK=CCO4?_  UO\.9]6B\33>&KG_A)HX#$LVT9 Q]W=Z5PWP__ &M!I?Q2U[Q'
MKMB[6.J1K$(K<Y:%5/RX]:RC3Q7+)*^W5];]#:53!J46[;]%TMU.W^$?P5\'
MZ_;_ ! ;4-&CG.G7\T5J6)_=J%) %-^'7P4\ ^%_A)<>,?%UB=1$F^4@9/EI
MN(55 [UH1_MC> [>WU>WM=&NK-+H,V^., RNRD%FK:^ 5]KVI_" J+"Q\3:9
M*\AAMGE"2*"Q.QP>*SJ2KQBY3NE==2Z<<-.<8PM)I/I]Q@_$KX0^ M(^$5EX
MD\.:3Y,LD]O)!<2$^9M9QUKUSXD:/X-US2?"UIXQ7S8IIDCM(23AY2@ZXKEO
MVD-9@T'X'VZ7\4.G7+3V^VQA8';M8$JOK@"O(/B;^TWX8\8/X,-G;WB?V/>I
M<3^8@&5"X.*SIPJXA1:OHWK\C:=2CAW*+LKI:=]>QL>/_P!EGP_=?&?P_I6E
M;M/TF^MWN+F%6S@)UV_6NMB^$WP;U+QC=?#^'2)4UFWM_-:8$@].H;UKS7XB
M?M9V%Y\0?#7B3PY:SLNGQO%<0W(V^8C'D"NG/[6WPZM=2G\2VWAJX_X2::'R
MVEV@$^Q;TKH<,4X1O?;IWOU.95,&I2M;?JNENA/\'OV;_#-OXB\<:-KU@FJC
M3KE!:S2DY$;)D=*S?A)\&_".O?"GQ5JE_H\<]]:75Y'#*Q.55"=H_"N6^$W[
M6<?A_P 9>)]4\264DT&M2K+_ */R8MHP%P>V*[:Y_:_\#-X;US2K+1KG3H[E
M)%B$48 =G!RS8Z'-.<<5=JS=[;?B32G@VD[I6OH_P/0OA#JOA<_L^2W4&F/'
MHT$$BW=OWE*CYR/K7P5XTOM*U+Q5J=UH=JUEI,LQ:VMVZHG85[]\#/VD_#G@
MKP!>>%?$NG7%S:R22$&$9#H_52*\"\;7VE:EXKU.YT.U-EI$LQ:VMVZHG85V
MX2E*G6J-IV>QP8VO"M0IJ+5UNNI]S_!#_0?V;+4>(;K_ (1^P$)V7UO)LD6,
MMP^>QK._:HADU#X7>&GL2M_HJWD#SW[-N?9QAO?/>O+_ (9_M0^&[?X:P^#O
M&NCRW]I#'Y.Z,;ED0'(!'K5;XO?M5V&N^'],T#PAI;6.G6DL<A-P!@A#E4"^
ME</U>M]8YN7K?RL>E]:H?5N7FZ6\[GT/)\5/!&I1^'=%B\275I/<!8+=;+='
MN8 #!)%>,_&O]FOQ7XV^(T<-CK?]I0-:^;$^I2?-&H;!3/?FI[/]JCX<:W!I
M-]K_ (5==9T[#Q-#&NU7QR5Q_6O(_B[^TCKOCWQ>-3T>YN=#M(8O(@CADPQ7
M.26([YIT,/6A4O!6WWU^XC$8K#SI6J2YMK)73^9Z;\(?V03:^-[RW\:^3=VU
MI LJ0VS_ "NS'N:]U^#W_"$)IWBB#P5:O9QVT[P74; A3(JD9&>U?)7P0_:7
MU/P!XJN;SQ%/=:W9740BE+ON=,'((S7L>C_M:_#;P]_:J:9H-W8B]9I97CC'
M[V0CDFEB:.)G)J5WHMM@PE?"PBG&T=7>^_WG/_!'X8^!O$R:[J&LZ7>ZYJOV
MR;]PD3>6H#' !Z$FNE^-/P!\&:%\/O\ A+-.T0Z;-I[1SS6CL<21[@&1AZXK
MF/A9^U=X7\+^$+K0]6TRZ ,TKK):\>8K,3SZ&IO''[3_ (6^(7PRU#PE8:?>
M6-[?*+:V63YE!+#;N;WHE'$^UND[77W#4\)[%JZ;L^FMS>\9?LZ^%O%MKX%U
M7PKID=O8WMU&;WRB2#"RY.?H>*\?_:RT#PIX.\7V6@^&M-BLGMX?,NFC).6;
MH/RKZD^ .G:_\-/A-);^,4BMET[?)$_FAOW6,CFO@KXD>+)?''CC6-:E;=]J
MN&9/9<X4?E6^#YYUFN:\8W^=SGQOLZ>'3Y;2E;IM8^F_V!NGBG_>C_E7<?%W
M4--T_3?$D]O\3+J#4$CDVZ6LR;0V,;,8S7@/[,'QRT+X/#6O[9BN9/MFSR_L
MZYZ>M>5?$CQ%;^+/'6LZQ:*RVUY<-+&'&& /K52PLJN*E)Z+04,9"C@XP6LM
M=.Q]3Z5\&/AU\*/AII_B3QO:RZK<W_EEW&2 T@R  /K2^,O@-H'@[QEX$\7>
M%U>WT^YU"%9+=FR!OY5AZ5S?A']JCPMK/@2Q\/>/]"DU$6@14DC7<K[/NDCL
M16=\0?VK++Q7XG\+Q6%A+9>&=(NTN'3_ ):2;>  /0"L53Q7M-;];]K>1K[3
M">S5K=+::W\SZ \9\_M-> _^P5=_^A"N#\5_!FQ^+G[3>LC5G8:9I]C;R21H
M<&0D$!<^E<KXA_:D\*ZI\8O#7BB*WNQ8Z;93V\JM&-Y9R",5BS_M5VND?&^_
M\5:99S7&B7]K%;7%O+\LGR]Q[UG3H5XI.*L^5KYW-JF)P\[J<DUS)_*QZ=8_
M![X2?$ZX\0^'=#TR2QU/23Y3W"Y7#]B/49KGO^%!>'?&'PBE32-+CC\4:?=B
MTN)HR<LR/ACCW'-)<?M:> O#,.K:AX6\.30ZYJ7SRR.@56?'5C7!?L^_M+V_
MP]U'Q"_B-+BXMM4F^U 0#.V4GGCTJHT\5RN2OI:R?XD2JX3G496UNFTM$NGS
M/8_B;^RIX<D\#VL7A_34AUBWE@$TB,29%R ^?U-<O\7OV=-)UG5=*\)^";"S
ML=8AMOM=[/-(02GW0/J3S53P;^V'ING>/?%6H:M'=R:/?NC642#+1A1C!':O
M%/B3\:M7\3_$K5?$NCW]UIBW&(HO+?:PB'0&KHTL5S)2>VOS?3Y&>(JX/D;B
MKWTLNRZ_,]I^"_[,46A?$6]T7QO:6NJ!]/%U"L;DA?GVYK=^%7P2\&ZYX[^)
M%E?:-'/:Z9?B*T1B<1KL!P*\7^"G[1-]X%\</J_B2:ZUN":W^S,SOND1<Y&,
M^]>YV?[9G@.TU+47MM%NK9+H;Y+A(P'FDQC+?A2KQQ2D[7=UT[CPT\&XQO96
M;T>]K%?X2?!7P%K'@'7=3UO2%E%I>W*F52=RQHQP!^%9WC[X+?#_ ,9_!.Y\
M7>#;"33I;6-I4+$@N%."K UWW[/6O6<_P;UW5IH#/I[W=U.\+#ED))(_*O(O
MB/\ M0^&9/AE<^$O!>C2Z='<J8G\P;5B4G+8]364/;RK-1;T:ZZ>=S>?U:%!
M2DE9I]-7VL?.?@S_ )&[1/\ K]A_]#%?IWXSTG6=5&DMI6MKHJ03B2XW*#YR
M8^Y7Y=^'[Z/2]>TZ\E!,5O<1RMMZX5@3_*OHC]HG]I?2?B3X;T^Q\./J%C<P
M3;Y'8E,KC&.#7;C:$ZTX<J[GG9?B*>'IS<GKIIW/9_CMX8T;XQ^.O"'A$WZ-
M) \EU>>0P+K$%QC/8DUJR?LR_#A@VF-X<:)1'Q>^;@Y^N>M?$/PN^)]_\-_'
M5IXC7=>NA*S1R.29$/49KZ8U3]K7X<ZB[ZG/H-_<:FT07RV8A<^G!Q7)5PV(
MH\L*;;2[=SNHXK"UG*I524GW[$_PA_9P\)Q>*?&NC:O9IJT.GW""VFD;E8V7
M...]:W@+0OAC=_$]M!\*6;)-:6\HO)XI&0[@V N<\UYI\(?VHM#\*ZCXKOM9
ML9H6U:8/!#:C<L:A< 9)KC/@?\9=&^'7Q1UKQ%J45P]G>"01K$N6^9LC-:2H
MUY.;DWLK>;L9PQ&'@H*"6K=_)7/8= _9XT+QK\8?&FI:UYKZ-IEP$2W\PDNV
MT$ECUP!5E/@W\+?C'X0UR;PC8RZ9>:8[Q";!7]XH)Y!Z@XK@_#7[6-IX:^*/
MB;4A8S7?AO691(8FXDC(&,XK:UG]J[P;X7\+:G8>!/#TEC>:B6:21T"J'88+
MGU/-1*GBKJU]E;LN]RXU<'RN]MW?35]K&KX&^!_@+P'\'4\5>,K)M1FD7?*R
MY/EY;: HKJ?VH?L!_9RMCI88:>6@, ;J$[5YA\.?VH_#<?PT7PKXWTF;4DA!
M4>6N5E7.1GT.:B^.'[2?A7XA_"M?#FCV-U93J\92-U 1%7MGZ4>RKRKIS3=G
M\K J^&C0DH-*ZMYW/&?@AX;B\6?%3P[IUPN^WDNE:1?51SBOHSX]?9_%'[1_
M@_PK?0"71X(XU-N>%;=_^JOF;X4^*E\%?$30M9D.(;:Y5I/]T\&OI/\ :%OK
M3PK\9_!?Q!??<Z+<0HQDAY^[T _ UVXB_MX^CMZGGX5KZM+_ !*_H>D77P(^
M$=AXWMM%FTI!JE_;M+!:;FV[%^\WUKB_!?PIT#P?\8?%VC0>&1XAL(X(9H89
M-I,&[G'-<UKG[4/A;4OC7X?\61V]X-.L+&:VD4H-Y9CQ@5Y]\3/VB]2O/B7J
M7B+P7J%UI5O>P11/N4!FVCO7%3HXF7NR;U77O<[ZF(PL?>BEH^BZ6/J?7/!>
M@QZ-?LOPQBB80.0^(_E^4\U5^!FG66E_L^;X[Y=$299I)[U ,P_,<GZ@5\AW
M'[2?Q&NK>2&7Q/=-'(I5EXY!&".E=S\$/VE=/\'^$KSPIXMTZ35-&G+$-'R0
M&^\I'<42P=>-)K?5?UJ.GC\/*JFM-'NEUMV/4?COX>UR;X/0:UH?BZ3Q#H,"
MI(\=S&K>:H;APW<YK/\ @9\;M2\<:S8P>--6_L2*Q=!810H8%NWZ;&X^8 =J
MY'XH?M0Z%=> H/"7@C2'T_3U*@M,,!%5MVT#W-;VE_M1_#W7](TIO%7A8MJF
MGL)(S!$-HD ^\,4U1J>QY90OJ[;70.O2]OS1J6T5][,?^U9<ZQX<^-?@_7ML
M<5G&R+;2QGYCAAN#5F_MR:!:"\\,^(H4"7%] 8Y<#[V ""?SKF_'/Q2N/VD_
MBSX7T[3K%K73K>X58HW.6(R"S-Z<"M7]MKQE9ZAXCT;PW9NL@TJ',S*<[7/
M7\JTHPG"=*+5FD[^AA7J0G3KRB[Q;5O4^9:***]X^;"BBB@ HHHH **** "B
MBB@ HHHH ^[OV//^2/0_]?DW\Q14_P"Q_;2VWP?M_-5X_,N977(ZJ3P:*^(Q
M7\:7J?HF#_W>'H=9\3_V>/#OQBL+2YO&DL-3B3:MY !N*^C#O7EW_# >E_\
M0UWG_@.E?4VD_P#(/A^E7,BIABZ]./+&6@5,%AZTN><-3Y-_X8#TO_H:[S_P
M'2C_ (8#TO\ Z&N\_P# =*^L<T9-:_7\1_,9?V=A?Y#Y._X8#TO_ *&N\_\
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M_P" Z4?\,!Z7_P!#7>?^ Z5]8Y-&31]?Q'\P?V=A?Y3Y._X8#TO_ *&N\_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !24M% "48I:* ,2^_Y"$O^ZO\ 6BB^_P"0A+_NK_6B
M@"_I'_(/A^E7*IZ1_P @^'Z5<H **** "BBB@ HHHH **BFF2WC:21UCC499
MF. *YUOB'HITR"_BN'N8;B5H8A!&6:1E^]@>U '3T5C/XJTQ/#XUDW ^P%=P
MD Y/.,8]<\8J30_$5GXAADDM2X:)MDD4J%71O0CM0!JT444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M8E]_R$)?]U?ZT47W_(0E_P!U?ZT4 7](_P"0?#]*N53TC_D'P_2KE !1110
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MCU%(751R0* NAU%1M,B]74?4TTW,2\F5 /\ >%.S"Z)<BC(J'[9!_P ]X_\
MOH4S^TK3_GZA_P"_@_QHY9=A<R[EJBJ?]KV/_/Y;_P#?Q?\ &L^?QAI5OJMI
MIQO(FNKG/EHC!NGKCI34)/H2YQ74W****DT"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,2^_Y"$O^ZO\ 6BB^_P"0A+_NK_6B@"_I'_(/
MA^E7*IZ1_P @^'Z5<H **** "BBDW#UH 6BBB@ HHI"0.IQ0 M%%-!##(.:
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M2CX27K1[9/&>N/ZGS%']*]'HJ?K57O\ @O\ (?U:GV_%GFZ?!Z4 A_%FMO\
M]MP*$^"T2MEO$NML/3[617H^?\YHS1]:K?S?@A?5J78\V_X4?I[2;VUW7&.<
MG-\W-.;X'Z2QR=4U<G_K]>O1\^]%/ZU6_F#ZK1_E/.V^"&B/C=>:FV/6\?\
MQI1\#_#Q3:TFHM];Q_\ &N[NKVWLH6DN)DAC7DL[  ?G7$ZG\7M&@F-KI23Z
M[>=/*LHRPS[MT%<U7,G17OU+'32RWVS_ '=._P"7S>R(T^!OAD*0RWK9];M_
M\:IWWPC\"Z'$T][OMXP.3/>,!_.I-WC_ ,6'@6_A>T;U_>SX_D#5O3O@[I*3
MK=:M+<:[=YSYE[(64'U"]!7+_:>,JZ44[=V[+[MSK_LW!T=:\E?M%7?W[?BS
MSZXL/!%W<F#P[X;OM?N!QNCD=8?Q<GFFZ/\ !77CK\.IB&QT7<Q98XRTQ@P,
MCDGJ:]ZM+*WL(5B@B2&->BQJ% I);Z""XAA>9$FESLC9@&?'7 [T+ZU4:=:J
MWULM%I^(.>%I)QHT4NEWJ]=/1?<30JZ0H)&#.% 8CN>YJ6BBN@Y@KSG7?VAO
MAKX9\3'P[JOC31['7%D6$V$UP!*'8@*N/4DBO1JX36/@AX U[Q"=;U'PAH]Y
MK#2+*;V:U4REU.0V['48% &1KO[3_P */#&L76E:KX_T.QU&U<QSV\MT-T;#
MJ#[U+X;_ &E/A=XOU/\ L_1O'>BZC>^6TODP7(+;5&6;Z 5+J7[.GPQUB_GO
M;WP+H=U=W#F26:6S5F=CU)/K5C0O@)\.O#5]]MTKP5HMA=[&C\Z"T56VL,,,
MXZ$4 5-(_:0^&'B!=1;3O'6BW@TV%KB[\JZ!\F,'!<^P-87Q=\8V=W!X*N+/
MQ9+H_A_5+AB^IZ=.%$D>S*X;!XKIM-^ 'PXTAKMK+P5HMJUU$T$YBM%7S(V^
M\I]0:D\0_#>WO[_PC'8V=G!I&BS,QL_+ C"%-H"KC%+J@Z,\GO?&%[HK:U#X
M7\8ZCXGTY-)FN)KNY;S/LLH^X5DP.3Z5WUY\3M;T?0]+%EH1U61=-ANKJ\NK
MM+>,Y0$A2WWFZ\5UWC'P?'JW@K6='TNWMK.6]MVB79&$7<1U.!7EWB#X*>(=
M1U6!BFEZK:-IL-D/[0DDQ9LB;69$!PV3SS3Z6'I_7R.E_P"%WG6--T >'M&D
MU75]8@:YCLGE6-8D4X8LYXZ\#UJ'5/CG+8PZ;9KH1M_$5XKNVGZC=);)$J'#
M,9&."">F.M8WA_X0^*/!.G^&K_2)M/N-;TFVEL9;>X)6&:)F+ @CH12^)/@_
MXE\07VF>(]231/$&NP12036%[$1;>6S9 4]<KZ]Z'N(@\0_&F]U>#PG>:';S
M->-J[6-YI=O,K"1PI^0N."N><UT3?''^S;6_M-8T.:S\26LT4"Z7'()/.:3_
M %91^F#Z]JR'^$/B2STO09M,;1['5+'46OW@MX3';@%<"/CD_6GWWP?\1>))
MKWQ%J=Y96OBHW$$]I';AFMXA#G:I)Y.<G)HT_KY;"1U_A#XBWVJ^(9?#^OZ(
MVA:R(/M448F$T<L6<$AAW!ZBN^KS;PGX0\1WGC7_ (2KQ2]C#=0VAL[:ST\L
MR(I.68L>I->DT=$,**** "BBB@#$OO\ D(2_[J_UHHOO^0A+_NK_ %HH OZ1
M_P @^'Z5<JGI'_(/A^E7* "BBB@#E_'UCXDU'1?LWA?4+72[Z1\/=W49D\M.
MY5>YKR2X_9=U#4F:\UCXF>(I[S[S20RB-!] .U>J?$OXEZ3\*_#O]LZRET]H
M)!%BTA,KY/3@5Y#>?MN_#Z:TFC6VUW<R,H_XES]Q4]VMQ]KG2_"SPOXETB\A
MGTSX@1^+_"XD:*:.^CW2H5X.V0=P>QKV?H*\+_8ZF^U?"1K@1R1K-J5U*JR*
M5;:SY&0:]T(S5RTT9FM=1:\[^*[S32:'91/'&)YW+FY=D@("9P[*0?I7HE5K
MRQM[^+R[J".XCSG;(H8?K4LL\JN]8NC\%H3'<2-= K'*[/A_+\W:S ]=N._I
M6_\ #LQ1:]XFM+"3S-(AEA^SE9#(H)3+ $D]Z[/^S+,Q^6;6'9L\O;L&-OIC
MTIUGI]MIT/E6EO%;1Y^[$@4?I3OJQ=#Q3]IK4;VTT_1HPJPV+7:?OMXW-)G@
M >U>L^$Y;V7P]8-J"".[\L!AG.?0_E7R_P#MGZ?XDU'7- :VF@7389%%O"LO
M[QICSN*^G%?2OP\U276?!>CW5SM%RULBRJIR X&"*ZYT:$*$:E.:E*3U2>JM
MIJ8^VJ3G[*<6E%:/O?4Z>BH;BXBM8FEFD2&->KR,% _$U!;:M8WK[+>]M[A^
MNV*56/Y UR&Y=KDO$?Q7\&^#]1_L_7?$^EZ1?;0_V>\NTC?:>AP3TK0\4^-=
M#\%V]M-KFJ6NF1W4RV]N;F0+YLK<*B^I->'^&?V>[_XF:YXPUGXS:5HNLQ:I
M+]GT[2%@21;2U0D(WFXW%V'/7B@#Z"TW4;35[&&\L;B*[M)EWQS0N'1P>X(Z
MU;KQ/6_V=)-)^'^F^&/AKXJU#X>QZ;,TUNUM^_1L_P #A_X?855^(_CCXL?"
M3P_H5QIWA6'XD6]M;@:Q/9R^3=LX."T470\<XH ]TK-U_7;3PYI-SJ%[*L4$
M"%R6.,^U>*>&/VOO#_C*\NM*T_P[X@@UZ%%/V&^LC%N=OX V2#CO72I\,]5^
M(,BW_C2]>),AX-*LWVQQ>FX_Q&NVGA^6TJ[Y8_B_1?J<,\1S7C17-+\%ZL2P
M^,NH^,[:-/"OAZXN;AAA[BY.R"$^Y[U;A^%VJ^)W%QXQUR6]7.?[/L28H!['
M')KL?#GA6U\,?:/LLDS^<5++(P(&!@8 '%;N<4YXB,)-8>-EWZ_?_D*%"4DG
M7=WVZ?<9FB^&]-\.VRP:?9PVD:]HT )^I[UICKTHZTI[5PN3D[R=V=JBHJR0
M@-!/%9'B#Q/IGABT-SJ5TEO&!QN/)]@.]<,^M^*/B,QCT>%] T5N#?7"_OY!
M_L+V^M<57$QIRY5[TNRW_P" CNHX2=6/._=CW>W_  7Y(Z7Q7\1M)\+,(&=K
MW4'XCLK8;Y6/T[5S*^&_$WQ$83:].VB:.QRNFVK8E<?[;_TKJ/"GP\TOPF#+
M!&;B]?F2[G.^5S]3TKJ,<5C["IB-:[LOY5M\WU-_K%+#Z897E_,]_DNGYF5H
M?AG3O#MFEK8VD4$2\@*@SGU)[FM4"G?2CI7H1C&"Y8JR/.E.4VY2=VPVCT%-
M,2'JBG\*?1560KD+6L+=84/_  $5 VE6<GWK:%OK&#_2KM(2:CDB]T-3DMF9
MDGAO2I?OZ;:M]85_PJI+X)T";._2+1L\_P"I6M[-)S4NC3EO%?<6JU2.TG]Y
MRTGPS\+/R=#M"<YXCQ6!J_P2T.]G^T6!ETBX51Y<EFY0JP.<GU^E>@75U#8V
MTD]Q(L,$:EGD<X"@=R:^1]7_ &F/%.H_&9H/"EJM_HLN+&W6Z#+ [9_UFX#U
MJZ654,6FG&*2UN[+Y7[E/,\1AFFIRU]7^![D/$OBSP$XCUVT.N:6.!J%DO[Q
M!ZNG^%=IX>\6:5XHM1/IMY'<*>J@_,OL1U%>>_:OC)<!U;3_  W ".,S2/7(
M:K\)OB;JVIQ:E:WF@Z%? Y::R5UW'_: X-3' UZ#_=U8RCV;U7HTM?F:/%X?
M$*]2#C+NEH_5=/E]Q]%9Z49KYRU_6/C3X2DA74=1TV2P& U]:V1DQ[L.M=!H
MEG\0O%-I]IL?B#I4L;#/[BR&5]B,\5U1C1<W3=:-UTU_R.1TZR@JBIOE?73_
M #T/;LT5XQ>>#O'EM ]W??%"WL[6,8DD^SHB+]23@5R_B/4$\+>&5U_6_CE'
M;:,9O)%[%Y;1M)_<!7.3[5T?5Z?6JON?^1S>UG_(_P #Z/Z4=/:OD?QMXXT?
MPGX6TKQ!<?%7Q7JNF:QG[')HNG&X,F.O"KQ67\39O%>BZ?HB>%U^(GBZZUJS
M\^*X0+%#; ]!,#R#[54</1DTO:K[F)U:B5^3\4?7VF:O9:S%)+974=U''(T3
M-$V0&'4?45:>>./[TBK_ +S 5\!?#7X>_$O1]82P\0>#?%<FF7LR[Y+'4! (
M2Q^:1N>:]2C\)VL/Q47PG/\ #[QO<Z4THC'B.34RUKC&=Q&<XK:OAL-1FXJK
MS+R5_P!3.G6K3BFX6]7_ , ^HI-;TZ'_ %E];)_O3*/ZU2F\::!;_P"LUFQ3
M_>N%_P :^;O">F^!]>\?ZAX:N/AGXNLS:>:!JE^CFUF"<_*V[OVJQX%UGX4>
M,+K7H!\-=>T[^QX9)YI-5TN5%E5,@^62?F)QT%<_+A5]J3^2_P S6];^5?>_
M\CWBX^*W@^U'[WQ)IJ_]O"FLNX^/GP^M6V2>*]/W?W5D)/Z"O*O _P 1_@GX
ME\*:[KVG^%9[+3]#0/=_;=$EC<*3QM5AEOPK=T'XS_!>^\!W?C&""TLM"LYA
M;S3W.E-$R.>@VE,T?[*NDG]R_P P_?>7XG62_M%^ 8^4UQ9_^N,+M_2JA_:4
M\'M_J/[2N?\ KG8R'^E0K\;?A)9^![3Q<VKZ3:>';J4P0WLEOL5G'\.-N<UK
MW'QF^'UCX>M]936=/DT^XC\V&6$K\Z^H'^-9SKX*E'FJ1:7FTOT-:=#$UGRP
MU?DFS)D_:/T?<!;Z#X@NB3@>7I[TR3X_7+1EX/ GB.90,Y:!4'ZFJ6H_'9K^
M6V@TH:=I,=VH:"ZUBZ2+S%)P&1,Y(K3_ .$0BUB\1/%7C(7MP^&&GV]PL,?/
M3Y0<D5Q?VA0G_N]!R\VVE^2_([UE\Z>N)K*/DE=_<M%\V<I-^U9<&]-E!X U
MB6Y!QY?FQD_D,U;U7XB_%S7[,'0_ :Z6''$E]<*6'X5ZKHNB^&_#B^381V5J
MR]0I7?\ B>M:K:K91_\ +W /^V@_QK18F"@_;0BOF_SN82@HR7L&W;ND_P +
M'SC;>"/BAJTXN==T6VU2;.1'<Z@5B'_ !Q78Z7I_Q7L(A#8:/X6TJ( 8",Q/
MXX%>HW7C'1[,?O=1@4^F[-8EY\7/#MGQ]K\T_P"PM>;_ &OE6$;M[._WO\V;
MSI8W$I*4I-=ME]R21S#:1\9;D'&O>&[/_MS=\?K0O@SXLSX^T>.],B]?L^FX
M_F:T9?CAIA;;#$">@,D@457;XLRW!/EW.G6Z^KS%C^0%'^LM%_P:;EZ4[_BU
M;\3'^S)KXI6]9?\ !*G_  J_Q[</FX^)5TO'W8+1%%>->+_ _P 2=(^+>DWL
M&O'5X=/E5K=KVX5&<'[XVCIFO:V\>BXXG\400CJ1;VY-<3>/%XA\:0V]EJ#W
MTMPP*S2*5Z=<^E>?C.*,YPU-3P.!YFVDU)16CW=D[FU'*L'5ERUZ]K:Z-O5>
MNA]$VSO);QM(NQV4%ESG!QR*GJ"VC\B")"<E5"D_05-UKWXR<E>2L<KT"B@<
M"N7U3XE>&-%OI+.]UJTM[J,X>)Y,%?K6L8RF[05S*4XP5Y.QU&:*XYOB_P"#
M5&?^$BL?^_E4M*^-_@_5+8S-K-O:D.R>7,V&X.,_0UM]6KVOR/[F8_6:-[<Z
M^]'>Y]Z/QKCO^%O>#O\ H8K+_OY6=XZ\9WTDV@:1X9N(/MNN.QCOG&](H5&6
M<#N<=*RG3J4[<\6K^1K"I"I?EDG8]$HKSG2=*\8>$-9BEOO$"^(/#[1N]W)=
MQK%+;8&0RXZCVJGI_P =;.\O+)YM$U*RT2^G^SVNL3*!#*Y.!QU /8FL]]$:
MGJ)Z4#I7A>@?':\TN#5Y=6TK4-2L;75Y;6748$ CMDW (".IZ]JZG7/C5;:?
MJ-]!IVA:CKEKIV#?WEFHV6^1N[_>(') I]+AY'IE%>97?QMMIM9MM,T/1+[7
MY[BS2^1K4JJ^4W&23TJ3X(>.=8\<^'[ZZUG3IK&6&]EB1I"I#*&P ,>G2@#T
MFBO*?'OC/Q5I/CWPS96MK%9Z!<WZV\UP[!I+C*DX4=A7JN:.EQ=;"T444#"B
MBB@#$OO^0A+_ +J_UHHOO^0A+_NK_6B@"_I'_(/A^E7*IZ1_R#X?I5R@ HHH
MH XKXJ:1XEUKPSY'A6:P@U/S5.[48A)'M[\>M?./@^/XS^-X]8ETRZ\*O!IU
MR]IYC6*#S9$^\ ,<#/<U]-^/?&J^!-(34)-+OM4B,@1TL(O,=!_>(]*^8+C2
M_ 'B3Q-?W.@_$O5O ;:G*9;O29E, =S]X@-TS[5*W=BNBN>Z?LZ^)=2\4?#M
M+C6)+5]3ANIK>X6SB$:(ZM@K@<?C7J=<9\*/"&A>!_!MMIGAVX6]L59I&N1*
M)#+(>68D=R:[.K>YG'8***Y#XE3&P\,SWB7EY:SQ_+"MG-Y9DD8X4'CGDTBC
MKL<8H[FO/_$-UJW@WX91EKV>[U4>5%)=R$,X9W 8_AFKO@F]NH]=\0:/<74U
M]#8/%Y4]PVYR'3)!/?FA+5BZ7/#?VMM7TO2=9T28W33:A%,DTMG&NXK&,_,?
M2O>?AG;V4?@S3;BR+&&\B6Y^9MW+#)Q7R-^U@&G^,-VL,%QE+2#?(T1$9)!P
M W0UD:#^W[J?@/2(O#>D_!?Q9XGMM%7[&^IV(7R9'7KCCWKH_L?#X.C'&4K<
MTV[VO?75WUMN;U/:6BYS33V756T/IW]HZ'1/''@J^^&T^K6]GXD\36TD6F6L
MD[1O(Z\[LI\P ZUX[\/?^"<?A'PKX-TRWN/$WB:+Q7'"!=:Q8ZM*A>3J=JDX
MP#7=?L_3>'/CCXB;XN7OA36= \916JZ<UIK<;+]C0\XASP<CJPKZ(KG,3XXD
M_P""?FKZGXT\,^(->^.7B_Q%_P ([>+=6%GJ,$#QI@YV^_'&>M?8]%% #"*Y
M+XI>()/#?@75+R!PEUY?EP9ZEVX 'O77'N*\M\2'_A//B;I^AI\^FZ+B\O,=
M&D/W%/\ .NG#14JG-+:.K^7^>QRXB34.5;O1?,XSP3\!;K1Y;7Q2;>%_$]I9
MR36;O<.%>X=>!(!U7H*[?X'_ !*\0>//#ER/&7AR3PEXEL+IK.YM7;,4S#D2
M0L?O(17IP&.!TKQK]IWX):W\:?"&FV_A7Q"/"OB?2[^.]LM58N5CVGY@54_-
MD<8/%36KRQ$W.>[*H48T(*$=D>R9&,T 8%?/>G^ /VAI=:TJ75/B7X:@TBU*
M?:8;#2',MR!][+.>,U2\5Z;K<'Q@76M/^(VOZRJ3*\?A"P6,6B@#&V1L9P3S
MUKAJUX48WF[?UT[G?1H5*\N6FK_IZL^B[J^M["!Y;B:.&-!EF=@ !7E^I_&,
M:_>76G>$C;7<MLI:YO[B4)!;J.K'GG%<]X*_9W9M3U'5_%&IW]_)J$S3MI\E
MV[QQ[OX?H/05U/@S]FWX>> =0U:^T?P_'%<ZK$T-X\LKR>;&W52&.,5PWQ&)
M_N0_%_Y'?;#83?WY_P#DJ_S_ ".6\.^(?AU]BU?Q1K'C33_%$VCJ)+ZZ682P
MV8/3"KG K43]JGX?W'PYO?&>DW5]K>A64ZVK_P!E6$LTI<] J 9(]Q7:>%?A
M%X+\$:?=6&A>%]+TRSN\?:(8+90LN/[PQS^-=)8Z58Z9;"WLK."T@'2*")47
M\@,5VTJ%.BK05OS?JS@K5ZE=WJ._Y+T6R/)=3_:+DD^'6G>*_#O@+Q/KZWT[
M0)IPM/(N(\?QNKGA32^+?B9\45\->'=0\*?#(:A?:C&7O++5-12W:Q.>%;KD
M_2O90 . ,"G5T&!X!\4%_:(O]6TR3P')X4TK3WLT:\AU56F=+C^)5(ZJ/6D\
M.7/[1UIJVB0:U9^"[_324&HW5O)+'*!_$47IZ8KZ HH \EL]<^,1^*,]G<^&
MO#@\!>8PCU&._?[;LQP3'C&<TWPGXQ^+=]XVU.QU_P !:5IOAN%)6M-2MM5$
MLD[#[@*8^7=^E>N44 >.>"?B+\4]43Q WB/X9PZ.;.!I+ 0:HDIO7!.$Z?+D
M=S53PM\9/B)J?@_Q'JNM?"34M)U/32!::6MY'(]]GJ4(XX]Z]NHH \8MOC=X
MF'PTG\2W?PL\10:G%<B :"IC:X=3_P M!SC:*J^(OVEKCPM\-M+\6ZA\.O%
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MY_*IPO%.!QU!8B@I-/M%]/.UOQ(J997IU/9SM?U7Y;_@//A[QM(.?$EJG/\
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M17?T47ZDG$_$'PM?^(M5\*3V2HT>G:B+F?<VW"!2./4UV]%%!04444 %%%%
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MOTWQ:/ >K227=[):'3PI\V,(,[SQT-9_@S]M>]\67M] WP]UBQ%M9RW8>92
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M  UMH[H7^MW,FMZCUW7!_=H?]E>E=G'&L2A44*HX"J, 4^BM!A1110 4444
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M$3Q2+!-$DB0\;R7P%7ZY-3>&_$_]NS7UM-9O8WUDZK-;NX?&X9!!'7BN=N/
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M%4='MA9:590 8$4*)^2@5=Z5Q5)<TY2[L[:<>6$5V05R'Q5UAM%\#ZC)$?\
M29E\B$>KN<"NO+=:\V^(!/B'QOX9T%3NB64WLZ_[*= ?QKS<9)QHR4=WHO5Z
M'IX**E7BY;1U?HM3K/!FBKX?\,:;8J,&*%0WU(R?UK<QGGVH P /:E[5TTXJ
MG!0CTT..I)U)N<MV[CJ***U)&9 X/4TA<!23P!574-2MM+MFGNI5BB7J6-<H
M9-4\;/MB\S3=()YDZ23#V]!7CXO,88>2I4XN=1[17YOLO4Z:5"51<TG:*W;_
M $[LNZIXLEN;EM/T2(7=WT>7^"+W)KG]3N8/"4R##:YXJNN(HSSL)[X_A45:
MU?7(_#SIX>\,VRW.KR#!"\K"/[[GUK7\(>#(O#HEN[F4WVKS\SWDG)/L/05A
M0RZ=6:Q./DI26T5\,?EU?FRYUXQ3IT%9=7U?KY>2*WA7P8VFSOK.M3"]UF4;
MGD;[D(_NKZ 5P>BJ?C1\4)=9D!?PKX;D,-FI^Y<W/\4GN%Z5L?&SQ9>>78^#
M=!?_ (G^N-Y6Y>MO!_'(?3BNY\&>%;+P1X:L-&L$"V]K&%SW9N['W)KZ^'^S
MTO:?:EHO)=7\]D>1+]]/EZ+?UZ+]3> Q2T45YYUA1110 4444 %%%% !1110
M 4AI:P/%?B_3?!NG->:C/Y:]$C7EY#Z*.YJ)24$Y2=DB7)15V:]W=PV4#SSR
M+%"@W-(YP *\QU#Q?K'Q)O)-+\)[K/2U.RYUJ1>".XB]3[U':^'];^*UREYX
M@$FE>'0=T&E(V'G'8R^WM7I^GZ=;Z5:1VMI"EO;QC:D<8P *XOWF)V]V/XO_
M "1A[U7RC^+_ ,C%\'>!]-\%V1ALXR\S\S7,IW2RMW+&NDZT4=:[(1C3BHQ5
MDC>,5%60T@# J"_U"WTRTENKF58;>)=SR,> *;J6IVFCV,EY>W,=I:Q+N>:5
M@JJ/4DU\_>+/'OB'X^K<^'/AW:_9M$W[;KQ/>*5C!!SB%?XCGO752I.H[[);
MLRJ5535MWT1ZO'\7_"(CG:YUJWL/(&YUO6\EMIZ$!N2*X_5?VIO",4QM]#AU
M+Q5=YPL>DVC2*3_OXP*Q/ '[*FCZ;JJZKXJBA\1:A''L$MT[S&1R<F0[N![
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MH;F*W^1]/LX1][V!ZU/VM/ZU0_LZ_P!:'T_\&;J.\\%0R1^%)/!B^:X_LN0
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M7 ]*6BI)(XXDBR$14!Y.T8J2BB@ I*6B@ HHHH **** "BBB@ HHHH ****
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M5JB^)]Y-\3?&EE\/M.D86$)6ZUN>,\+&#E8L^K5Z9JFM:/X&T2-KJ:*QLK=
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M0"I<5$ZS:Y(*T>W^?<<**B^:3O+O_D%&*6BL#H"BBB@ HHHH **** "BBB@
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MZ1\O\RE\-OA'X?\ AE9NNFPM<7\WS7.I7)WW$[=RS'^5=R!BJ']JG_GSN_\
MOU_]>C^U3C_CSN_^_7_UZXI2E-WD[LZXQC!<L59&A16?_:Q_Y\[O_OU_]>C^
MUC_SYW?_ 'Z_^O4EFA16?_:Q_P"?.[_[]?\ UZ8^MI&Z(UK=!GX4>5U_6@#3
MHK/_ +6/_/G=_P#?K_Z]']K'_GSN_P#OU_\ 7H T**S_ .UC_P ^=W_WZ_\
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M_?K_ .O0!H45F1:VDV_9:W3;6*G]UT([=:?_ &L?^?.[_P"_7_UZ -"BL_\
MM8_\^=W_ -^O_KT?VL?^?.[_ ._7_P!>@#0HK/\ [6/_ #YW?_?K_P"O1_:Q
M_P"?.[_[]?\ UZ -"BLPZXBRK&;6ZWL,@>5_]>G_ -K'_GSN_P#OU_\ 7H T
M**S_ .UC_P ^=W_WZ_\ KT?VL?\ GSN_^_7_ ->@#0HK/_M8_P#/G=_]^O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'_(/A^E7*IZ1_P @^'Z5<H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)N [
MB@!:*3</44;AZB@!:*3</44%@.XH 6D(K%\6^)(/"/AN_P!8N1NBM8RY4'&X
M] /Q.*Y3X5?$K4?'LNH1W^GV=O\ 9]K)-I]V+B/G^!B.CCN*%J&QZ-17D=U\
M9-6@\022QZ'"_A*'41I<VHFXQ,),X+!/[H.!6\_QR\"*TZ_\)+9Y@5F<9;@
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M* -.BLS^VO\ IW;_ +Z%']M?].[?]]"@#3HK,_MK_IW;_OH4?VU_T[M_WT*
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0VB+*6/4\FBKL4.%HH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>plx-20250630x10q010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250630x10q010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #A K4# 2(  A$! Q$!_\0
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M8U;_ *]K;_T UPU?4X>G!THMI;'QV)J3C6FE)[FK_P )EXF_Z&75?^__ /\
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MO;0BY2D_O/M+X+W%U??#'1;BZNKB[N)!(SS2N79CN/4T4WX'?\DHT'_=D_\
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M_P#9^DVB//$NEN'MY$?# ^Y[T*-7J^W_  0YZ2V11^)%PVGZ:MXVL3:;#&&
MBML>9-(1\J@_7M7/ZEX@UG3?#=E+*XM]6NXH8'F8?ZLLV-Q'KBNN\4^![/Q9
M=64]U<74,EF=T7D2;0&]<>M13^&K74FGTJ^:2]@-NH,DS9<D'@Y]:IPFW*W4
MB,X)1OK;<R?,O_AW9WU[J&MRZ[;[%\NWF $HD)P.1V-9/BKXA:G'9RV?V9M/
MU:":W?;#(&$D;MTS726/PMT6SM;R&3[3>?:E"/)<S%V"@Y ![8-2+\-=*\EU
ME>YN)GDCD:>:3<YV'*KGT%2X5+66B-%4I7N]7Z&6OQ.N(S-92:9_Q-UO%LT@
M64;&8KN!W>F*8?BA=R7EOIT.E*=4:Z:TEB:7Y$8+G(/<8K<O/A[I5Y)>2OYR
MSW,ZW/FH^&CD48!4]J6Q^'VEV%Q9W"><]Q;S-/YSOEI'88)8]Z?+6OJR>:A;
M8H_#_7M7UN^UU=22-4MKHQ1B-L[<#I61JMUJ>C^,8K>;4IYK.]BFR)@!#G:=
MJ)C^(5VND^&[;1M0U"[MWE!O7\R2-FR@;U [5D3> M-LYKC4 ]Q*T:R210RR
MEHXV93DJ.U/DG:/=$\\.:3Z,YX?VOXNUB]LK77)=$@TR"((L(&9&9 =S9[5J
MWGC2^TF4:=#;IJ]U:6@N;NX#A%*_[/J34^H_#K2O$JVMY,UQ;7#0(DC6LIC\
MQ<#AL=:LWWPYTF\\G8;BT\N'[.WV>4KYD?\ =;U%3R5$G;?U+YZ3M?;T_JYQ
MP^)=_'K6JZA;0->:3':6]QY4CA?*#=<#N:W+KXH/')=7$&FF73+-HTN9C( P
M+ 'Y1WQFM>3X=Z0T=]&J21QWD"6[JC8 1.F/2H[CX;:3<71E)G2-]AEMUDQ'
M*5^Z6'<\4*-5;,;G0?3^M#EM<^).M76AZM=:78Q0PVERMN+AY.6R1R!^-=IK
M7B)M#\,QW=QL2[D1412W!D8<<GM3&\!Z8VDZAIV)!;WLIFDPW(;V].E:<FAV
MEUI\-G=Q+>Q1@ ?: &)QW/O51C4L[O5I?\$SE.G=66B?^1YIX<\7:@O@UM4N
MKE;_ %"U:Z^;.1QTZ=JV_#MCJ^FQVNMWOB5[VVEMS//:2J-OW=V(_I6EI_@W
M2_#\MOI]K;C[+<&9I%;G=N'(^E)I'POT;1[[[3&;F8*K+'#-,6CC!&"%'TJ>
M2>GIW*=2G[UNK[?U8P[SXF74^D[WL6L8]0M99;"X20,WR@GYAV-1Z+\4;C3=
M)A&L63%QIZW:2K(&:7D#GT)-=#;_  RTBWWKNN)8_+:**.23*P*W4(.U3R?#
MS2)O*$L<DB1VGV(*S<>7G/Y^]+EK;W*YZ&UC U#XJ76D03I>:2([Y8XYHHEE
MRKH[8'/8C-6M#\2:]>_$"33[R"&"T6R68Q(^[:2>ON:N_P#"L=):WECFDN;E
MY-@\Z:7<X5#E5!]*V/\ A&;7_A($UA'ECNEA\A@K?*Z]@15J-2Z;9$I4K-17
M]:'&>*M4U/3?%DEW=G4(= A\J-9+6950,3R67J11?WNH:IJ&C:!8ZC)I45S%
M+<2740&\@,<*N:Z?5/ FG:MJ9O)WN,,RM);K*?*D*]"5JG-X-T_Q5HUH+KS8
M98&;RI[=RDB?,> 14\D[->8_:0O'T[%7^VM2\)VMCI<EROB'5+J9HX)&(3Y0
M,_.?45@3_$;4]0\1Z;]@MF#1PW"W-BT@";T[Y[UUJ_#728M-M[2(W$3P2&:.
MZ64^<'/4[JDL?A[I.GW%O-$LHEACDCW%\E_,^\6]30X57HF-3HJ[:NS%A^*4
MVI0VYTW2_/F^RF[G620*$4$C /<\4S_A9=[JTLT6D:>CJMB+LRS2;=N0>,=R
M"*U6^&&D_9[>*)[FW,,1A\R&7:SQDY*L>XK1L?!>F:;=2S6\3)YELMJ8\_+L
M']:.6L]V+FHK9&!I_BS4X_A3+KEVJM?K;M(I4Y!YX-8WA/7KVX\Z#4+B\>=D
M@N5ANBK<-_$I'8^E=[IOA6STW07T<&2XL6#+LF;=A3_#]*R(?!=AX9C,UNTT
MTTCQQ^9.^\J@/"CV%/DGS)WTL2YT^5JVK9@^'X]>\4)_;P\1M8K]J9!8E1Y(
M16QM/?)K1;XFNMPT_P#9^='6\^PFZ\P;O,SC.WTS5R;X6:++JQO?])13)YS6
MJ3$0E\YW;:L_\*[TG^TOM7[[RS-]H-IYG[GS/[^WUI*%2*27YEN=*3U_*QR?
MA?XA:C9JHU&!KFTGU&>W6Z:0;EP20,>@ K2C^*<OEV]U-IGE6%YY@M)?,!9B
M@)^8=LXK<C^'^EQPV\0$I2&Z>\4%_P"-NN?:H(/AGI$$I;-P\2AQ% \F8X=X
MPQ0=CS24:R5D_P"M!RG0DV['.#QYX@U.Z\*3164-I::G*<IYF690N<'TK:^)
MOGP:?#+::A>6M]-(MO;QV\NU6=CU(QSBM1O ^GFST>W1YHAI3;K>1'PPXQR>
M]:&JZ#;:Q=:?<7&\O8R^=$%.!NQCGUJ^23BXM]3/VD%)2BMK_P# .)\17VI>
M'[-;&"]87UU+;6KWT@R5RIRWUJYY]]\/-/OKG4-8DUZ+*+##* )0[' !/H:V
MM0T&S\23ZM97T?F0MY1&#AE(4X(/8U3L?ACHUG8WEL_VB[^U "26XF+OQTP>
MV*)0GS-Q_/\ 0(SARI2^>GZG,^*?B!J:VK6?V9K#5H+F M'#("LD;GIFM1?B
M=<9DLFTS_B;K>"R6 2?(6*[L[O3%:B_#72O*82O<7$S2I*UQ-)ND)3[HSZ5+
M=?#W2[N2[E;SDGN+@77G(^&CD P"I[<5'+6WN7ST+6L8:_%"[N+VUT^#2U.I
M27#VTL3RX5&49R#W%7_A[X@U;6I-<.IK&BV]TT4>QL[<#I5ZP^'^EZ?=6=S'
MYK7%M(TOFN^6D=A@EO6K^D^&K71;R_GMVEQ>OYDD3-E W<@=JN,:ETY/^M")
M2I<K4%_5SR[0?$^K7FO-'<WT\EM<"Y4^;CR9-I^41>X[UZM>:7#K6@M8W&[R
M+B$(^TX."!7/M\/M+T=I[Z$S,T:R-##))F.(M]XJ.V:X;QY_:-]XRCM+2#5+
ML+IZ,D>G3^7L;^\V>HJ+NC"TE>YI:-:I>#M8]<DT2TGT7^RY8_,L_*$)5CU4
M#%84'PTT>."XCG$]X9HQ%ON)"S(@Z!3VQ7E/B:XU>PU"TAU9=5NY+?35DG73
M[C84;/WF]:T==UC5_#O@G0-7BU1I=5<-&L6[S!+$W<XZE1WJ)5H.[E';_AC2
M-":249;GHR?#;2OL\B2M<7$LCQNT\TNZ0[#E1GT%3V_@/3K74I;N)[A4D=I&
MM1*?)W,,$[?>LS0_$=EH.AZ/9FZGO[J^CWQW&QG5W/\ >(Z#-9.@/XC>[\66
M[ZA')J*,FQV!\N(%3G:/85JW!-)1,;5&G>7];'0Z;\-=*TO4K2]ADNBUHS&"
M)Y24CW=0!Z5MWO\ R&=-_P"VG_H->:6\>M:S\/\ 1HH+@W%PUTYG9Y_*:15)
MX!KI_">I0ZG8:3)!'+"(S/&R2OO8,HP?F[U4)1^&*MU_(FI&7Q2=^AT<^@VM
MQKEOJK[OM4$;1)@_+@]>*J>(/!]EXAN(KB5Y[>YC4QB:WDV,5/52?2O(?"]O
MXAU36H[FRCU7*W[B2\DN ;8QACE=M=%9^.+W0_#\S)/!+<M>7&%NF9B54YPH
M'-9*M"2O*-EO^1JZ,XNT97>QUUS\-=&F2%8EFLQ'#Y!^SR%?,CSG:WJ*?<?#
MG1KA;A3"Z+-'''A&QL"?=*^AKG])^)&K>)?(_LVRM49;5+F=;F0KG<<84_AW
MJ(_%*_N/$$]G#II>SBG^S2,BL6!QRV[IBJYJ/;<GDK;7V\SI9?A[I\]C#!)/
M>/+#+YT=TTQ\U6Z9!^E:'AGPO9^%;2:WLS*R2RM*[2ON)8]3FO./"OCW4]#T
MG3Y+]([JPNKJ>%7#DS!@21GVXKHO#_C^_OM0TE;VT@2TU8,UL86)=,?W_P#Z
MU.$Z;::6H5*=5)INZ/MGX'?\DHT'_=D_]#-%'P._Y)1H/^[)_P"AFBOEZW\2
M1]90_A1]#QSXY_\ )6-6_P"O:V_] -<-7LOC[X9:AXU^)>NW4-_;VJ1QVR!7
M1B2-AK(_X9_U;_H,6G_?IJ^@HXFE"G&,GK8^<Q&%JU*LI16C9YC17IW_  S_
M *M_T&+3_OTU'_#/^K?]!BT_[]-6WUNCW,/J5;^4\QHKT[_AG_5O^@Q:?]^F
MH_X9_P!6_P"@Q:?]^FH^MT>X?4JW\IYC17IW_#/^K?\ 08M/^_34?\,_ZM_T
M&+3_ +]-1];H]P^I5OY3S&BO3O\ AG_5O^@Q:?\ ?IJ/^&?]6_Z#%I_WZ:CZ
MW1[A]2K?RGF-%=Y-\)3;SWD,OBC3(Y;-!)<(P(,2GH6'85H0_ 74KB%)8]:L
MWC<!E98VP0>AH^N4>XOJ5;^4\SHKT[_AG_5O^@Q:?]^FH_X9_P!6_P"@Q:?]
M^FH^MT>X_J5;^4\QHKT[_AG_ %;_ *#%I_WZ:C_AG_5O^@Q:?]^FH^MT>X?4
MJW\IYC17IW_#/^K?]!BT_P"_34?\,_ZM_P!!BT_[]-1];H]P^I5OY3S&BO3O
M^&?]6_Z#%I_WZ:C_ (9_U;_H,6G_ 'Z:CZW1[A]2K?RGC^B];[_KZD_I6E7;
M^'/@3JEU_:FW5K5?+OI8SF)N2,<UK_\ #/\ JW_08M/^_34?6Z*ZB^I5G]D\
MQHKT[_AG_5O^@Q:?]^FJG-\&9X+Z.RD\1:>EU)]V(HVXT_K='N'U&M_*>>T5
MZ=_PS_JW_08M/^_34?\ #/\ JW_08M/^_34OK='N/ZE6_E/']<_X]X/^NZ?S
MK2KM_$WP)U2TL[9FU:U8-<QIQ$W<UK_\,_ZM_P!!BT_[]-1];H]P^I5OY3S&
MBO3O^&?]6_Z#%I_WZ:FR? /4X8V=]:LT11DLT;  4_KE'N+ZE6_E/,Z*]$T_
MX*W6K1M)9^(;"X13M8QQL<&K7_#/^K?]!BT_[]-2^MT>X_J5;^4\QK-B_P"0
M]/\ ]<%_G7L'_#/^K?\ 08M/^_35D0? G5&\57-O_:UKN6V5MWE-CEJ?UNEW
M#ZE6_E.(HKT[_AG_ %;_ *#%I_WZ:C_AG_5O^@Q:?]^FI?6Z/</J5;^4\QHK
MT+4/@Q<:6T:W?B+3[<R'"B1&&:N#X ZJP!&L6A'_ %R:CZW1[B^I5OY3S&JV
MI?\ (/NO^N3?R->K_P##/^K?]!BT_P"_354UCX"ZK!I%](=7M2$@D8CRF[*:
M/K='N/ZE6_E/,]-_Y!]K_P!<E_D*LUZ%HWP%U6?1[&0:O:@/!&P'E-W45<_X
M9_U;_H,6G_?IJ/K='N'U*M_*>8T5Z=_PS_JW_08M/^_353L_@S/J%S+;VWB+
M3YIHOOHB,2*/K='N+ZE6_E//:*]._P"&?]6_Z#%I_P!^FH_X9_U;_H,6G_?I
MJ/K='N/ZE6_E/'[O_D-:?_NR?RK2KMM0^!.J1^(])@.K6I:592#Y3<86MC_A
MG_5O^@Q:?]^FH^M4>X?4JW\IYC17IW_#/^K?]!BT_P"_357OO@?>Z9;F>ZUZ
MQ@B'5GC8"CZY1[B^I5OY3SFBO2K;X$ZA>0)-!KEE+$XRKK&Q!%2?\,_ZM_T&
M+3_OTU'UNCW']2K?RGF-9OA__D%Q_P"\W_H1KV#_ (9_U;_H,6G_ 'Z:LCPG
M\"=4O-#AE75K506<8,3=F(H^MT=[B^I5]N4XBBO3O^&?]6_Z#%I_WZ:C_AG_
M %;_ *#%I_WZ:CZW1[C^I5OY3S&BO0F^#,Z:@MBWB+3Q=L,B'8VXU<_X9_U;
M_H,6G_?IJ?UNCW%]2K?RGF-9VN?\>L7_ %V3^=>O_P##/^K?]!BT_P"_35D>
M)_@3JEI8PNVK6K!KB->(F[FE];HO2X?4JR^R<117IW_#/^K?]!BT_P"_34?\
M,_ZM_P!!BT_[]-1];H]Q_4JW\IYC17IDWP%U*WB:236[..-1EF:-@ *@T_X)
MW>K0F:S\06-Q&#M+)&QP?2CZW1[B^I5OY3SJBO3O^&?]6_Z#%I_WZ:C_ (9_
MU;_H,6G_ 'Z:CZW1[C^I5OY3Q^R_Y#.I_P#;+_T$UI5V^F_ G5)?$6LPC5K4
M-%Y.3Y3<Y0FM?_AG_5O^@Q:?]^FH^MT5U%]2K/[)YC17IW_#/^K?]!BT_P"_
M353OO@Q<:7)$EWXBT^W:0X02(PS1]<H]P^HUOY3SVBO3O^% :J>1K%I_WZ:C
M_AG_ %;_ *#%I_WZ:CZW1[C^I5OY3R76/^07<_[AJO8Z+:)>QZF(_P#3'MUB
M+Y_A'.,5ZGX@^ VJVVBWLIU>U8+$20(FJQI_P#U633[9QJ]H T2G_5-Z"CZU
M1WN+ZG76B1Y.^@64FJ2Z@\.ZYEA\AR3P4],5FZ=\/]%TNXBFBMF8Q*R1K(Y9
M4#?> ':O<?\ AG_5O^@Q:?\ ?IJ9-\!=2MX7EEUNSCC0%F=HV  '<U'UFAO?
M\"UA<3LE^)Y'HN@V?A^S^RV492 .756.=I)R<>@IUMHMI:7E[=1QXFO,><V>
MN!@5Z:_PA>-K96\3::#< -%\K?.#T(K0_P"&?]6_Z#%I_P!^FJOK5'N+ZGB-
M=-_,\2F\#Z1<:7#8- P@A<R1E7(96/4@TZ'2;71[G2;.TB$-N@E 4?[M>U_\
M,_ZM_P!!BT_[]-6/J7P*U2'Q#HT)U:U)E\[!\IN,)FDL11Z,)87$-:K\3SO2
M-%M=#M6M[2/RXF=I""<\DY-8]Q\.M#ND19+5ODD>0,KD'+_>&?0U[I_PS_JW
M_08M/^_34?\ #/\ JW_08M/^_34GB*#5G^0UA<2G=+\3PAOAKH#0VT?V5E2!
M/+7;(1E,Y"MCJ,U97P+HZ:G]N2W:.;.XJCD(6 QDCN<5[/)\#;V.Z2W?7[%9
MW4LL91MQ ZG'I45C\&+C4Y)4M?$6GSO$<.J(Q*T?6,/_ $A_5L3_ $SQ?3_A
MSH.FW4=Q#:$O&695=RRAFZG'K5C2? ^CZ+??:[6UV3#(3<Q(C!ZA0>E>V?\
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MKVZ'K%>7>/O#NJW7BV2]MXKNYAELEAMU@4-&LH<$^9G^$BH/^$?M/^FW_?\
M?_&C_A'[3_IM_P!_W_QJ?8ZWN/ZQY'J=JKK:PB0 2!%#!>F<<U+7D_\ PC]I
M_P!-O^_[_P"-'_"/VG_3;_O^_P#C3]EYA[?R/0O%G_(MZC_UQ:K>D_\ (*LO
M^N*?^@BO(?$6@VBZ'?$>=GRC_P MW_QJSIOA^T.G6I_??ZI?^6[^@]Z?L=-Q
M>WUV/8*XSXJ:'K'B/PU-8Z683'(C^?$Y(:4;3A5(]37-?\(_:?\ 3;_O^_\
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M4,71,NTD^G'I78^-/$.I0:O:V-C<&R7[!-?/)Y8;<4&0G-'MNM@^KO:Y@_\
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M%'EA?*;?C;QU&*/:^0OJ_F9/_"2Z?_SV?_OR_P#\31_PDNG_ //9_P#OR_\
M\33K#QIK=PUE<FZ!74OM82W,0 @\H$KSWSC]:]"\+ZS_ ,)#X>L-1V[#<1!R
MOH>A_44>VTO8/J]NIYNOBS2Y))(UN6:2/&]1"^5STS\M2?\ "2Z?_P ]G_[\
MO_\ $UW&C?\ (W>(_I;?^@&D\=>*E\)Z')<C:UU)^[MU;[I<CC)[ 42K<O0(
MT'+J<1_PDNG_ //9_P#OR_\ \31_PDNG_P#/9_\ OR__ ,35.T^+6IR>#X;\
M&.ZNH=,:[G,2<2.9?+  ]!UI9/'OB%=0AT-6D?4)69V;8FZ-1'O S]TYH]MY
M#^KON6_^$ET__GL__?E__B:/^$ET_P#Y[/\ ]^7_ /B:ZN?7'NOA^NKB_:!D
M@\UYXXQEB.,8/J>*SM!US6M);PS#K-R+N351('_=A2C8W+T]N*?MM;6%]7TO
M<Y3Q%XDT]M#O@)GR8C_RQ?\ ^)JQIOB33QI]J#,_^J7_ )8OZ#_9KTSQ9_R+
M>H_]<6J2W,@\/P>5*D,GV9=LDGW5.T<FCVVFPO8:[GG'_"2Z?_SV?_OR_P#\
M31_PDNG_ //9_P#OR_\ \34C>*M6M[7Q+#>:E)%+I?EO#)Y*AY=PXXZ;2V,5
MIZ/JVL/OTW4=2\JXL]/6ZN[I8@#O;G '3 %+VOD5]7?<R/\ A)=/_P">S_\
M?E__ (FC_A)=/_Y[/_WY?_XFE;5?$:>!X]3?69/MU]<^78Q^2O*NV$W?AS7<
MZW-JFC^#[B6&:.XU&WMF9II%PI95)+8'N.E#K6Z!]7UM<X7_ (273_\ GL__
M 'Y?_P")J-O%FEQR)&URRR29VJ87R<=<?+73:+XMO'N/"JW3+*NL618[5QME
M5 Q/T(-:VM?\C;X=_P"WC_T"J]KY$NCYG#_\)+I__/9_^_+_ /Q-'_"2Z?\
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M[.'8?M9]S.62U6V:$>$I &<.7^WKOR!@?-UZ<58;4XVL19_\(HZVR@!8UOD
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M[TO_ *&:*\^?Q,]"'PHYW6/"MSK/Q!\12IJTEHH6V 185;_EF?6G?\*]O/\
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M:1T5;A6%N#CY<DY;.#S[T>TG8/9T[E#3X[;4(]XU^^@_?)"RSV2*59QE2>>
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M:M_X#?\ UZ.;S#E?8;_8>G_\^,'_ 'P*/[#T_P#Y\8/^^!3OM5]_T M6_P#
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M_P#GQ@_[X%.^U7W_ $ M6_\  ;_Z]'VJ^_Z 6K?^ W_UZ.;S#E?8;_8>G_\
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M*=]JOO\ H!:M_P" W_UZ/M5]_P! +5O_  &_^O3YO,.5]AO]AZ?_ ,^,'_?
MIC>'=,>1)&L+<NF=K;!QGK4OVJ^_Z 6K?^ W_P!>JL^M7-O>VMJ^AZJ)+C=L
M'V?^Z,GO1?S%R^18_L/3_P#GQ@_[X%']AZ?_ ,^,'_? IWVJ^_Z 6K?^ W_U
MZ/M5]_T M6_\!O\ Z]'-YCY7V&_V'I__ #XP?]\"C^P]/_Y\8/\ O@4[[5??
M] +5O_ ;_P"O1]JOO^@%JW_@-_\ 7HYO,.5]AO\ 8>G_ //C!_WP*/[#T_\
MY\8/^^!3OM5]_P! +5O_  &_^O1]JOO^@%JW_@-_]>CF\PY7V.X^%-M##X"T
MY4B55W2\*./OFBF_"JX:3P'IQ:WGB;?*"DJ[6'SGM17GSOS,]>E\")HO^1X\
M2?[MK_Z+-9'Q6FF@^'FNO;W<UA,+9MMS;QF1X_< <_E67XBU/6K+XA^(5LI[
M9(F2V.)(R3_JS43:_P")64@W-B0>"#":KV4I1T.;VT82U[G@GACXG^(?!/A#
MQ!_8J3:C<Q26P%V\S3VB;^&<%QD'N0>!7::#\2O'OBZSMHYYK.RC_LBYO+EH
MH/,\\J2J[3QMS[5W\=]K<4#PI_9:0O\ >C6UPK?4=Z<NJ:]& %?35 78,6^,
M+Z?3VJG1DP6(@NAY?'\9/%6DV&E0PR0VQAL+66*QFM6DDU)G;#*C?PXK;A^.
M6NRZI!I9,*:G_:%W%-;O;-^[A2/='DX]>_>NT.I:Z6B).FDQ?ZL_9ON?3TH_
MM+7//,V=,\XG)D^S?-^=-T9,/K$.QB_ 'XG:_P".VUJVUZ6&>>UVLDEO!L0
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M_P"_)J#4-6\2WUA<VQN[)1-$T>?)/&01_6FJ,KB=:-CN_#O_ " -,_Z]8O\
MT 5HUYGI^K>);&PMK87=DPAB6//DGG  _I4__"0>)O\ GZLO^_)H]C(%6C8[
MZ^:5+&X:$9F$;%!_M8./UKR[X:7,K:[IPBFDE:>PDDU$-(S;9O,(&0>A_I6G
M_P )!XF_Y^K+_OR:BAU77K9G:%]-B:0Y=DM\%CZG'6DJ,KC]O&UCTJBO.O\
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M\)!XF_Y^K+_OR:H:'>>)=&TV.T%Y8N%9CGR3W8G^M/V4K6%[:-[GJE%>=?\
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M_<21R2OILDD?*,]ODK]#VJ?8RN5[>)Z+;,[6\1DXD* M]<<U+7G7_"0>)O\
MGZLO^_)H_P"$@\3?\_5E_P!^33]C(7MHG7^+/^1;U'_KBU6])_Y!5E_UQ3_T
M$5YGXDU_Q(V@WX:YLBIB;.(C5G3?$'B4:;: 7-ECRDQ^Z/\ =%/V,K"]M&YU
M?Q"CN)/!NJ&VN9+65(&<-#]XX'0'M7''6(I$9=<O9[33;31X)2T;E&<L!N.>
MY[?C5YM>\22*5:XL64\$&$D&J=S-K%Y<)/-_9LKHAC&ZWR-I[$>E3[&1?MX&
MEX+O9--\,ZE>VQ-VDTKRV.G),))$7'"=>IZX[5QFBZYK$>@^+[N\:_CU"UOX
M9HQ=(4 )(_=J,].<8KI;>^UJSP(!I<(!R/+M0N#Z\4V]NM;U!%2>2P=1(LI'
MDD98="?6G[&5[B]O ]-A8R0HS#:S*"1Z5@ZU_P C;X=_[>/_ $"N;_X2#Q-_
MS]67_?DU0O+SQ+=:KI][]LL0;7S,+Y)YW+BFJ4KDNM&QZI17G7_"0>)O^?JR
M_P"_)H_X2#Q-_P _5E_WY-3[&0_;1+?Q+DS>>'X;F0Q:5+/(+IMY0<)E,D>]
M:GPWN+JZ\%Z;)>%FG*MR^<E0Q"G\L5SEQK'B"[C,<\FGS1_W9+?</R-/77O$
MB*%6YL54< "$X%'L9#]O$]&HKSK_ (2#Q-_S]67_ 'Y-'_"0>)O^?JR_[\FC
MV,A>VB=UX _Y%.U_ZZS?^AFBJ'PM>[E\"V#S.C3-),6*+@??-%826K.B+T1S
MGB;_ )*%KW_7.V_] -5JU]0\&Z-K?C_Q'->V*W$NVV^9G8?\LSZ&N \7W6G^
M%_&6FZ!#\.YM2_M%F6VNH]0"*^T9;@G(P*ZX58Q21R2HRE)R1U%%<5X-\1:!
MXR\0'3X/!*6]NER]L]Q)JR;U*'!/E;MQ%3:7XJ\$:IKWB/35\,RQ#2899HKA
MIVV7HC^_Y?S=CZU7MH"^KSV.OHKF?AC?:!\2&1QX.BTZTDA\Y)?[56=L'H"B
M-E?QKH]$T7PGK7B77M'30_*DTEHUDE:9]K[UW<?-QBCVL2?82'T50M+[X67T
MNIQP3V<CZ:I>Z ED^10<$]>>?2JDGB#X3KH*:NDUK):22-%'M>7<TBC)7;G.
M?PI>VAN/ZO,VJ*Y#0/&7PYU;3S?WFF1Z59"V2Y,L]R[$!W*J" <\D5MG5OA2
M-'BU3S[7['),;=7WRY,@ZKMSGCZ4_;1#V$S4HK$\3:Q\-_#7A.P\1&R6]TR^
MN$MX);=I#N+-C/7H*TM/;X9ZIK_]BVK6LNI=H1))R<9(!SC/MUH]M$/82+-%
M<AXX\3>#_!?C"/P^/"<VH3^4D\LD=R8]J,V!M#-ES["KWAWQ%\-/$6M:AIB6
M7V:YM+M;("=I5\R1AD!>:2K1>P.A-;G0T5A^)->^%WAO1WOYA;S?+*8H8Y)"
MTC1YW*.>.1C)XJSH5Y\.-:T>VOOL\-LTIAC:WDED+I)*N40X/)-/VT6'L)K<
MTZ*YCQ=?:)X=\676B6/@2?6FL[(7]S/#>;!'&21PK'+'CM5RU\0?"JX2'<88
MI9+5;PQ,TNY(R,Y;!P*7MHA]7F;=%5=1D^&6DPS27;6L2PK$SYDD)Q(,I@ Y
M.1Z5I^&_#O@7Q?IOV_2+:&]M-[1^9'))C<.HY-/VT1>PD5J*D\+_  _\/W?]
MK>=IRR>5J$T2;I7^51C ^]6W_P *S\,_] I/^_C_ /Q5#JQ0*C)F!16__P *
MS\,_] I/^_C_ /Q5'_"L_#/_ $"D_P"_C_\ Q5'MHA["1@45O_\ "L_#/_0*
M3_OX_P#\51_PK/PS_P! I/\ OX__ ,51[:(>PD8%%2>+/A_X?L[*U:#3EC9K
MN)"5E?E2>1]ZMO\ X5GX9_Z!2?\ ?Q__ (JCVL=P]C(P**W_ /A6?AG_ *!2
M?]_'_P#BJ/\ A6?AG_H%)_W\?_XJCVT0]A(P**W_ /A6?AG_ *!2?]_'_P#B
MJ/\ A6?AG_H%)_W\?_XJCVT0]A(P**W_ /A6?AG_ *!2?]_'_P#BJQ+?X?\
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MD_[^/_\ %4?\*S\,_P#0*3_OX_\ \51[:(>PD8%%;_\ PK/PS_T"D_[^/_\
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M*?LX[6%[6=[W-/\ X60/^@+?_D/\:/\ A9 _Z M_^0_QK,HI>RAV'[:9I_\
M"R!_T!;_ /(?XT?\+('_ $!;_P#(?XUF44>RAV#VTS3_ .%D#_H"W_Y#_&LG
MQ)XVEU6RABAT6]W+/'(=P X!R:?13]G%=!.K-]33_P"%D#_H"W_Y#_&C_A9
M_P"@+?\ Y#_&LRBE[*'8?MIFG_PL@?\ 0%O_ ,A_C1_PL@?] 6__ "'^-9E%
M'LH=@]M,T_\ A9 _Z M_^0_QH_X60/\ H"W_ .0_QK,HH]E#L'MIC-/\:RVN
MO:O>/HM[Y5T(=F ,_*I!S6M_PL@?] 6__(?XUF44_9Q["]K-=33_ .%D#_H"
MW_Y#_&C_ (60/^@+?_D/\:S**7LH=A^VF:?_  L@?] 6_P#R'^-'_"R!_P!
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M]LT4=P=JL]P)  ?3;WJ/XA?#?4/ >G275MI;:AHW]K6]Q_94#.Z.HCVL7 Y
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M#K+_ *_8?YUT-/VDK+4GV4+['#?\*\U+_H9'_P# */\ QH_X5YJ7_0R/_P"
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M3_PKS4O^AD?_ , H_P#&JNK>!]4LM+O+A/$;EX87D ^Q1]0I/K7H=9WB+_D
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MC?\ /V__ 'XD_P#B:.5]@YEW.6\=^./$NE^--,\/>'-/TVZFNK22[>34)'0
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M'#0?]RX_]!%=#7"ZIXPTF3Q7HDJW+F-$GW-Y$G&5&/X:W?\ A-M&_P"?M_\
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M $,T57^'5_!<>#[216.TRS8W*RG[Y[$45G*]S6.QU\'_ !_7?_ ?Y59]***
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MBB@ HHHH AO/^/67_=-/A_U,?^Z***?074?1112&%%%% !5:?_C]M?\ @?\
A*BB@19HHHH&%%%% !1110!4LO^/5?]YOYT445+-%L?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>plx-20250630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/14/2025 8:45:28 AM-->
<!--Modified on: 8/14/2025 8:45:28 AM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2025" targetNamespace="http://www.protalix.com/20250630" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:plx="http://www.protalix.com/20250630" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2025" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" id="DisclosureEarningsLossPerShareDetails">
        <link:definition>99940501 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" id="DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails">
        <link:definition>99940601 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" id="DisclosureSegmentInformationScheduleOfSegmentInformationDetails">
        <link:definition>99940701 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" id="DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails">
        <link:definition>99940801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>99940401 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails" id="DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails">
        <link:definition>99940602 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" id="DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails">
        <link:definition>99940702 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99940901 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>995210201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>995210301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>995210401 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShare" id="DisclosureEarningsLossPerShare">
        <link:definition>995210501 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit" id="DisclosureTaxesOnIncomeTaxBenefit">
        <link:definition>995210601 - Disclosure - TAXES ON INCOME (TAX BENEFIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995210701 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" id="DisclosureSupplementaryFinancialStatementInformation">
        <link:definition>995210801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995210901 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>99930203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" id="DisclosureEarningsLossPerShareTables">
        <link:definition>99930503 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables" id="DisclosureTaxesOnIncomeTaxBenefitTables">
        <link:definition>99930603 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>99930703 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" id="DisclosureSupplementaryFinancialStatementInformationTables">
        <link:definition>99930803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeStockIncentivePlan2006Member" name="EmployeeStockIncentivePlan2006Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_SupplementalInformationAbstract" name="SupplementalInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" name="SupplementaryBalanceSheetsInformationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_PfizerAgreementMember" name="PfizerAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_FiocruzMember" name="FiocruzMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" name="AccountsPayablePropertyAndEquipmentSuppliersCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" name="SeniorVicePresidentAndChiefFinancialOfficerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfGlobalLicensingAndSupplyAgreements" id="plx_NumberOfGlobalLicensingAndSupplyAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PayableToCustomerCurrent" id="plx_PayableToCustomerCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccountsPayableAndAccruedLiabilitiesOtherCurrent" id="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" id="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" id="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromWarrantsAndStockOptionExercises" id="plx_ProceedsFromWarrantsAndStockOptionExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SalesAgreementMember" id="plx_SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" id="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CommonStockValueOfCapitalSharesReservedForFutureIssuance" id="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="GrossProceedsFromIssuanceOfCommonStock" id="plx_GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" id="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SingleReportableSegmentMember" id="plx_SingleReportableSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" id="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" id="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>plx-20250630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/14/2025 8:45:28 AM-->
<!--Modified on: 8/14/2025 8:45:28 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSegmentInformationScheduleOfSegmentInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638907579270919735" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638907579270919735" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638907579270919735" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638907579270919735" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638907579270919735" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638907579270919735" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638907579270919735" xlink:to="plx_ShortTermBankDeposits_638907579270919735" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638907579270919735" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638907579270919735" xlink:to="us-gaap_AccountsReceivableNetCurrent_638907579270919735" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638907579270929727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638907579270919735" xlink:to="us-gaap_OtherAssetsCurrent_638907579270929727" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638907579270929727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638907579270919735" xlink:to="us-gaap_InventoryNet_638907579270929727" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638907579270929727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638907579270929727" order="2" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638907579270929727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638907579270929727" order="3" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638907579270929727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638907579270929727" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638907579270929727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638907579270929727" order="5" use="optional" weight="1" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638907579270939718" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_638907579270939718" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638907579270939718" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638907579270939718" xlink:to="us-gaap_LiabilitiesNoncurrent_638907579270939718" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638907579270939718" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638907579270939718" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638907579270939718" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638907579270939718" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638907579270939718" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638907579270939718" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638907579270939718" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638907579270939718" xlink:to="us-gaap_LiabilitiesCurrent_638907579270939718" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638907579270939718" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638907579270939718" xlink:to="us-gaap_AccountsPayableTradeCurrent_638907579270939718" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638907579270949715" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638907579270939718" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638907579270949715" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638907579270949715" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638907579270939718" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638907579270949715" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638907579270949715" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_CommitmentsAndContingencies_638907579270949715" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638907579270949715" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_638907579270949715" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638907579270959719" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638907579270959719" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638907579270959719" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638907579270959719" xlink:to="us-gaap_OperatingIncomeLoss_638907579270959719" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638907579270959719" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638907579270959719" xlink:to="us-gaap_Revenues_638907579270959719" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638907579270959719" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638907579270959719" xlink:to="us-gaap_CostOfRevenue_638907579270959719" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638907579270959719" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638907579270959719" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638907579270959719" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638907579270959719" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638907579270959719" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638907579270959719" order="4" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638907579270959719" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638907579270959719" xlink:to="us-gaap_NonoperatingIncomeExpense_638907579270959719" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_638907579270969721" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638907579270959719" xlink:to="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_638907579270969721" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638907579270969721" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638907579270959719" xlink:to="us-gaap_OtherNonoperatingIncome_638907579270969721" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638907579270969721" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638907579270969721" order="2" use="optional" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638907579270969721" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638907579270969721" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638907579270969721" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638907579270969721" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638907579270979718" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638907579270969721" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638907579270979718" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ProceedsFromWarrantsAndStockOptionExercises" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_638907579270979718" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638907579270969721" xlink:to="plx_ProceedsFromWarrantsAndStockOptionExercises_638907579270979718" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638907579270979718" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638907579270979718" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638907579270979718" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638907579270979718" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638907579270979718" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638907579270979718" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638907579270979718" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638907579270979718" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638907579271039726" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" xlink:to="us-gaap_ProfitLoss_638907579271039726" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638907579271039726" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" xlink:to="us-gaap_ShareBasedCompensation_638907579271039726" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638907579271039726" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" xlink:to="us-gaap_Depreciation_638907579271039726" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638907579271039726" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638907579271039726" order="4" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638907579271049751" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638907579271049751" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638907579271049751" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638907579271049751" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638907579271049751" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638907579271049751" order="7" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638907579271049751" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638907579271049751" order="8" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638907579271049751" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638907579271049751" order="9" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638907579271049751" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638907579271049751" order="10" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638907579271059724" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" xlink:to="us-gaap_IncreaseDecreaseInInventories_638907579271059724" order="11" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638907579271059724" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579270979718" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638907579271059724" order="12" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638907579271059724" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638907579271059724" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638907579271059724" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638907579271059724" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638907579271069728" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638907579271069728" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638907579271069728" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" xlink:to="us-gaap_NetIncomeLoss_638907579271069728" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638907579271069728" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638907579271069728" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638907579271069728" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638907579271069728" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638907579271079723" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638907579271079723" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638907579271079723" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638907579271079723" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638907579271079723" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638907579271079723" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638907579271079723" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_Depreciation_638907579271079723" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638907579271079723" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_InvestmentIncomeInterest_638907579271079723" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638907579271089726" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_InterestExpenseNonoperating_638907579271089726" order="4" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_638907579271089726" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_638907579271089726" order="5" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638907579271089726" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_LaborAndRelatedExpense_638907579271089726" order="6" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638907579271089726" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_Revenues_638907579271089726" order="7" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638907579271089726" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638907579271089726" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638907579271099727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_AccruedVacationCurrent_638907579271099727" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638907579271099727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638907579271099727" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638907579271099727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638907579271099727" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638907579271099727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638907579271099727" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638907579271099727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_TaxesPayableCurrent_638907579271099727" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_PayableToCustomerCurrent" xlink:label="plx_PayableToCustomerCurrent_638907579271099727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="plx_PayableToCustomerCurrent_638907579271099727" order="7" use="optional" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>plx-20250630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/14/2025 8:45:28 AM-->
<!--Modified on: 8/14/2025 8:45:28 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSegmentInformationScheduleOfSegmentInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20250630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_BR" xlink:label="country_BR" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_SalesAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - STOCK TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_SalesAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_GrossProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SingleReportableSegmentMember" xlink:label="plx_SingleReportableSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="plx_SingleReportableSegmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_LaborAndRelatedExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_PfizerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_FiocruzMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromCustomers" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>plx-20250630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/14/2025 8:45:28 AM-->
<!--Modified on: 8/14/2025 8:45:28 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Securities Act File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals - other:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Other, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Other</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Accounts payable and accruals - other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">GOODS</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and Service [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">LICENSE AND R&amp;D SERVICES</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues from customers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING INCOME (LOSS)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" xlink:to="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_lbl" xml:lang="en-US">Amount of expense related to nonoperating activities, classified as other, net of amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_lbl" xml:lang="en-US">Other Nonoperating Expense, Net of Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_lbl" xml:lang="en-US">FINANCIAL EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL INCOME (EXPENSES), NET</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">INCOME (LOSS) BEFORE TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Taxes on income (tax benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total taxes on income (tax benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">TAXES ON INCOME (TAX BENEFIT)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET INCOME (LOSS)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss) for basic and diluted calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for basic calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for diluted calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US">ASU 2020-06</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants and stock options.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants and Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants and options</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Number of shares issued as a result of exercise of warrants and stock options.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants and Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants and options (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial expenses (income), net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Changes in deferred income tax asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain on amounts funded in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase in contracts liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in accounts receivable-trade and other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in operating lease right of use assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ProceedsFromWarrantsAndStockOptionExercises" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromWarrantsAndStockOptionExercises" xlink:to="plx_ProceedsFromWarrantsAndStockOptionExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_lbl" xml:lang="en-US">The cash inflow associated with the amount received from holders exercising their stock warrants and stock options.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_lbl" xml:lang="en-US">Proceeds from Warrants and Stock Option Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_lbl" xml:lang="en-US">Exercise of warrants and options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">TAXES ON INCOME (TAX BENEFIT)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME (TAX BENEFIT)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementalInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementalInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Earnings (Loss) per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Taxes on Income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Schedule of Segment Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Schedule of Disaggregation of Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for supplemental balance sheets information.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplementary Balance Sheets Information [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Information of Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">All Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_BR" xlink:label="country_BR" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">BRAZIL</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SalesAgreementMember" xlink:to="plx_SalesAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SalesAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to sales agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Represents the number of global licensing and supply agreements.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number Of Global Licensing And Supply Agreements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number of global licensing and supply agreements</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expenses sharing percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares remain for sale</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" xlink:to="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Amount of increase in gross sales price of shares available for future issuance.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Increase in Gross Sales Price of Shares Reserved for Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Increase in aggregate gross sales price</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" xlink:to="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Aggregate value of common shares reserved for future issuance.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Value of Capital Shares Reserved for Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares remain available, total gross proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings (loss) per share, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants and rights outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrossProceedsFromIssuanceOfCommonStock" xlink:to="plx_GrossProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">The gross cash inflow from the additional capital contribution to the entity.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross stock issuance proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Stock issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Cash proceeds from stock options exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" xlink:to="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_lbl" xml:lang="en-US">Represents the information pertaining to outstanding stock options, unvested shares of restricted stock and warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_lbl" xml:lang="en-US">Outstanding Stock Options, Unvested Restricted Stock and Warrants [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_lbl" xml:lang="en-US">Outstanding Stock Options, Unvested Restricted Stock and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" xlink:to="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_lbl" xml:lang="en-US">Represents the information pertaining to outstanding stock options, unvested shares of restricted stock, warrants and convertible notes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_lbl" xml:lang="en-US">Outstanding Stock Options, Unvested Restricted Stock, Warrants and Convertible Notes [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_lbl" xml:lang="en-US">Outstanding Stock Options, Unvested Restricted Stock, Warrants and Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">NET EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net income (loss) for diluted calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Denominator:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Weighted average dilutive effect of stock options and restricted stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SingleReportableSegmentMember" xlink:label="plx_SingleReportableSegmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SingleReportableSegmentMember" xlink:to="plx_SingleReportableSegmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SingleReportableSegmentMember_lbl" xml:lang="en-US">Represents information pertaining to single reportable segment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SingleReportableSegmentMember_lbl" xml:lang="en-US">Single Reportable Segment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SingleReportableSegmentMember_lbl" xml:lang="en-US">Single operating segment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Employee salaries and related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Professional and Contract Services Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Sub-contractors expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US">Other segment expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xml:lang="en-US">Segment Reporting, Other Segment Item, Composition, Description</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xml:lang="en-US">Segment reporting description</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FiocruzMember" xlink:to="plx_FiocruzMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FiocruzMember_lbl" xml:lang="en-US">Fiocruz</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued Vacation, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Provision for vacation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Royalties payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income tax payable</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_PayableToCustomerCurrent" xlink:label="plx_PayableToCustomerCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PayableToCustomerCurrent" xlink:to="plx_PayableToCustomerCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PayableToCustomerCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable to customers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PayableToCustomerCurrent_lbl" xml:lang="en-US">Payable To Customer, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PayableToCustomerCurrent_lbl" xml:lang="en-US">Payable to customer</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Accounts Payable, Property And Equipment Suppliers, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Property and equipment suppliers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerAgreementMember" xlink:to="plx_PfizerAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:to="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_lbl" xml:lang="en-US">Sr. Vice President And Chief Financial Officer</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_lbl" xml:lang="en-US">Senior Vice President And Chief Financial Officer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="plx_EmployeeStockIncentivePlan2006Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">It represent the employee stock incentive plan for the particular period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">2006 Employee Stock Incentive Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCustomers" xlink:to="us-gaap_ProceedsFromCustomers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Proceeds from Customers</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Total proceeds from sale of products</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of award</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options to purchase shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award grant date fair value.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Grant Date Fair Value</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>plx-20250630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/14/2025 8:45:28 AM-->
<!--Modified on: 8/14/2025 8:45:28 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureEarningsLossPerShare" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShare" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureTaxesOnIncomeTaxBenefit" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSegmentInformation" roleURI="http://www.protalix.com/role/DisclosureSegmentInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSupplementaryFinancialStatementInformation" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureEarningsLossPerShareTables" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureTaxesOnIncomeTaxBenefitTables" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSegmentInformationTables" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSupplementaryFinancialStatementInformationTables" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSegmentInformationScheduleOfSegmentInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
  <link:presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638907579271429753" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638907579271429753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638907579271439769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638907579271439769" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638907579271439769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638907579271439769" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638907579271439769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638907579271439769" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638907579271439769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638907579271439769" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638907579271439769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638907579271439769" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638907579271439769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638907579271439769" order="7" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638907579271439769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638907579271439769" order="8" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638907579271439769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638907579271439769" order="9" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638907579271439769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638907579271439769" order="10" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638907579271449745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638907579271449745" order="11" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638907579271449745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638907579271449745" order="12" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638907579271449745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638907579271449745" order="13" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638907579271449745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638907579271449745" order="14" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638907579271449745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638907579271449745" order="15" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638907579271449745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638907579271449745" order="16" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638907579271449745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638907579271449745" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638907579271449745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638907579271449745" order="18" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638907579271459743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638907579271459743" order="19" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638907579271459743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638907579271459743" order="20" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638907579271459743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638907579271459743" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638907579271459743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638907579271459743" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638907579271459743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638907579271459743" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638907579271459743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638907579271459743" order="24" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638907579271469743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638907579271469743" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638907579271469743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638907579271469743" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638907579271469743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638907579271469743" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638907579271469743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638907579271469743" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638907579271469743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638907579271469743" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638907579271469743" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638907579271469743" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638907579271479742" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_638907579271479742" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638907579271479742" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638907579271479742" xlink:to="us-gaap_AssetsCurrentAbstract_638907579271479742" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638907579271479742" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638907579271479742" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638907579271479742" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638907579271479742" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638907579271479742" xlink:to="plx_ShortTermBankDeposits_638907579271479742" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638907579271479742" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638907579271479742" xlink:to="us-gaap_AccountsReceivableNetCurrent_638907579271479742" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638907579271479742" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638907579271479742" xlink:to="us-gaap_OtherAssetsCurrent_638907579271479742" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638907579271489751" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638907579271479742" xlink:to="us-gaap_InventoryNet_638907579271489751" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638907579271489751" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638907579271479742" xlink:to="us-gaap_AssetsCurrent_638907579271489751" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638907579271489751" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638907579271479742" xlink:to="us-gaap_AssetsNoncurrentAbstract_638907579271489751" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638907579271489751" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638907579271489751" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638907579271489751" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638907579271489751" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638907579271489751" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638907579271489751" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638907579271489751" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638907579271489751" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638907579271489751" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638907579271489751" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638907579271489751" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638907579271489751" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638907579271489751" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638907579271479742" xlink:to="us-gaap_Assets_638907579271489751" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638907579271499748" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638907579271499748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638907579271499748" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638907579271499748" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638907579271499748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271499748" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638907579271499748" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271499748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638907579271499748" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271499748" xlink:to="us-gaap_AccountsPayableTradeCurrent_638907579271499748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638907579271499748" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271499748" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638907579271499748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638907579271499748" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271499748" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638907579271499748" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638907579271499748" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638907579271499748" xlink:to="us-gaap_LiabilitiesCurrent_638907579271499748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638907579271509746" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638907579271499748" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638907579271509746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638907579271509746" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638907579271509746" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638907579271509746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638907579271509746" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638907579271509746" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638907579271509746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638907579271509746" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638907579271499748" xlink:to="us-gaap_LiabilitiesNoncurrent_638907579271509746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638907579271509746" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638907579271499748" xlink:to="us-gaap_Liabilities_638907579271509746" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638907579271509746" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638907579271499748" xlink:to="us-gaap_CommitmentsAndContingencies_638907579271509746" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638907579271509746" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638907579271499748" xlink:to="us-gaap_StockholdersEquity_638907579271509746" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638907579271519745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638907579271499748" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638907579271519745" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638907579271519745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637041422967477240" xlink:to="us-gaap_StatementTable_638907579271519745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638907579271519745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638907579271519745" xlink:to="srt_ProductOrServiceAxis_638907579271519745" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638907579271519745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638907579271519745" xlink:to="srt_ProductsAndServicesDomain_638907579271519745" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638907579271519745" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638907579271519745" xlink:to="us-gaap_ProductMember_638907579271519745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638907579271529754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638907579271519745" xlink:to="us-gaap_LicenseAndServiceMember_638907579271529754" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638907579271529754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638907579271519745" xlink:to="us-gaap_StatementLineItems_638907579271529754" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638907579271529754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_Revenues_638907579271529754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638907579271529754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_CostOfRevenue_638907579271529754" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638907579271529754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638907579271529754" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638907579271529754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638907579271529754" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638907579271529754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_OperatingIncomeLoss_638907579271529754" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_638907579271529754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_638907579271529754" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638907579271529754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_OtherNonoperatingIncome_638907579271529754" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638907579271539749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_NonoperatingIncomeExpense_638907579271539749" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638907579271539749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638907579271539749" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638907579271539749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638907579271539749" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638907579271539749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_NetIncomeLoss_638907579271539749" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638907579271539749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_EarningsPerShareBasic_638907579271539749" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638907579271539749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_EarningsPerShareDiluted_638907579271539749" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638907579271539749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638907579271539749" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638907579271549749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271529754" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638907579271549749" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638907579271549749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_638907579271549749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638907579271549749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638907579271549749" xlink:to="us-gaap_StatementEquityComponentsAxis_638907579271549749" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638907579271549749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638907579271549749" xlink:to="us-gaap_CommonStockMember_638907579271549749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638907579271549749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638907579271549749" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638907579271549749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638907579271549749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638907579271549749" xlink:to="us-gaap_RetainedEarningsMember_638907579271549749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638907579271559752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638907579271549749" xlink:to="us-gaap_EquityComponentDomain_638907579271559752" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638907579271559752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638907579271549749" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638907579271559752" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_638907579271559752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638907579271559752" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_638907579271559752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638907579271559752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638907579271559752" xlink:to="us-gaap_TypeOfAdoptionMember_638907579271559752" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_638907579271559752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638907579271549749" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_638907579271559752" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638907579271559752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638907579271559752" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638907579271559752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_638907579271559752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638907579271559752" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_638907579271559752" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638907579271559752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638907579271549749" xlink:to="us-gaap_StatementLineItems_638907579271559752" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638907579271569749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271559752" xlink:to="us-gaap_StockholdersEquity_638907579271569749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638907579271569749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271559752" xlink:to="us-gaap_CommonStockSharesIssued_638907579271569749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638907579271569749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271559752" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638907579271569749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638907579271569749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271559752" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638907579271569749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638907579271569749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271559752" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638907579271569749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638907579271569749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271559752" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638907579271569749" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638907579271569749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638907579271569749" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638907579271569749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_638907579271579750" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271559752" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_638907579271579750" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_638907579271579750" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_638907579271579750" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_638907579271579750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638907579271579750" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271559752" xlink:to="us-gaap_NetIncomeLoss_638907579271579750" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638907579271579750" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271559752" xlink:to="us-gaap_StockholdersEquity_638907579271579750" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638907579271579750" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638907579271559752" xlink:to="us-gaap_CommonStockSharesIssued_638907579271579750" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended" xlink:title="995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638907579271589757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638907579271589757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638907579271589757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_638907579271589757" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638907579271589757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" xlink:to="us-gaap_ProfitLoss_638907579271589757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638907579271589757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" xlink:to="us-gaap_ShareBasedCompensation_638907579271589757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638907579271589757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" xlink:to="us-gaap_Depreciation_638907579271589757" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638907579271599757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638907579271599757" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638907579271599757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638907579271599757" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638907579271599757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638907579271599757" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638907579271599757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638907579271599757" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638907579271599757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638907579271599757" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638907579271599757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638907579271599757" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638907579271599757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638907579271599757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638907579271599757" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638907579271599757" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638907579271599757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638907579271599757" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638907579271599757" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638907579271599757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638907579271599757" xlink:to="us-gaap_IncreaseDecreaseInInventories_638907579271599757" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638907579271609753" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638907579271599757" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638907579271609753" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579271609753" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638907579271589757" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638907579271609753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638907579271609753" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638907579271609753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638907579271609753" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638907579271609753" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638907579271609753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638907579271609753" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638907579271609753" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638907579271609753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638907579271609753" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638907579271609753" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638907579271609753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638907579271609753" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638907579271609753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638907579271619752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638907579271609753" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638907579271619752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ProceedsFromWarrantsAndStockOptionExercises" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_638907579271619752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638907579271609753" xlink:to="plx_ProceedsFromWarrantsAndStockOptionExercises_638907579271619752" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638907579271619752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638907579271609753" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638907579271619752" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638907579271619752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638907579271619752" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638907579271619752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638907579271619752" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638907579271619752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638907579271619752" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638907579271629755" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638907579271629755" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638907579271629755" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638907579271629755" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638907579271629755" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638907579271629755" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638907579271629755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638907579271629755" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638907579271629755" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638907579271629755" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638907579271629755" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638907579271629755" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638907579271629755" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638907579271629755" xlink:to="us-gaap_InterestPaidNet_638907579271629755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_638907579271639752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638907579271629755" xlink:to="plx_InterestReceivedNet_638907579271639752" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638907579271639752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638907579271639752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="995210201 - Disclosure - INVENTORIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638907579271639752" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_638907579271639752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="995210301 - Disclosure - FAIR VALUE MEASUREMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638907579271649761" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638907579271649761" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="995210401 - Disclosure - STOCK TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638907579271649761" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638907579271649761" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShare" xlink:type="extended" xlink:title="995210501 - Disclosure - EARNINGS (LOSS) PER SHARE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638907579271649761" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638907579271649761" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit" xlink:type="extended" xlink:title="995210601 - Disclosure - TAXES ON INCOME (TAX BENEFIT)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638907579271659763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638907579271659763" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformation" xlink:type="extended" xlink:title="995210701 - Disclosure - SEGMENT INFORMATION">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638907579271659763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638907579271659763" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" xlink:type="extended" xlink:title="995210801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION">
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967789587" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638907579271659763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967789587" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638907579271659763" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995210901 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638907579271669763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventsTextBlock_638907579271669763" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_638907579271669763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_638907579271669763" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638907579271669763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638907579271669763" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638907579271669763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638907579271669763" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638907579271669763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638907579271669763" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638907579271669763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638907579271669763" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="99930203 - Disclosure - INVENTORIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638907579271679756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638907579271679756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" xlink:type="extended" xlink:title="99930503 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638907579271679756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638907579271679756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables" xlink:type="extended" xlink:title="99930603 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638907579271679756" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638907579271679756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationTables" xlink:type="extended" xlink:title="99930703 - Disclosure - SEGMENT INFORMATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638907579271839770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638907579271839770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_638907579271839770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_638907579271839770" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" xlink:type="extended" xlink:title="99930803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638907579271849787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967854703" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638907579271849787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638907579271849787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_638907579271849787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638907579271849787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638907579271849787" xlink:to="us-gaap_TypeOfArrangementAxis_638907579271849787" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638907579271849787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638907579271849787" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638907579271849787" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_638907579271849787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638907579271849787" xlink:to="plx_AmendedPfizerAgreementMember_638907579271849787" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638907579271849787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638907579271849787" xlink:to="dei_LegalEntityAxis_638907579271849787" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638907579271849787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638907579271849787" xlink:to="dei_EntityDomain_638907579271849787" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_638907579271849787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638907579271849787" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_638907579271849787" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638907579271849787" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638907579271849787" xlink:to="srt_StatementGeographicalAxis_638907579271849787" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638907579271859771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638907579271849787" xlink:to="srt_SegmentGeographicalDomain_638907579271859771" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_BR" xlink:label="country_BR_638907579271859771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638907579271859771" xlink:to="country_BR_638907579271859771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638907579271859771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638907579271849787" xlink:to="us-gaap_DebtInstrumentAxis_638907579271859771" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638907579271859771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638907579271859771" xlink:to="us-gaap_DebtInstrumentNameDomain_638907579271859771" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638907579271859771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638907579271859771" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638907579271859771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638907579271859771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638907579271859771" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638907579271859771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638907579271859771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638907579271849787" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638907579271859771" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638907579271859771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638907579271859771" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638907579271859771" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember_638907579271859771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638907579271859771" xlink:to="plx_SalesAgreementMember_638907579271859771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638907579271869765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638907579271849787" xlink:to="plx_SignificantAccountingPoliciesLineItems_638907579271869765" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_638907579271869765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638907579271869765" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_638907579271869765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638907579271869765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638907579271869765" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638907579271869765" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638907579271869765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638907579271869765" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638907579271869765" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_638907579271869765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638907579271869765" xlink:to="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_638907579271869765" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_638907579271869765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638907579271869765" xlink:to="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_638907579271869765" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638907579271869765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638907579271869765" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638907579271869765" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638907579271869765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638907579271869765" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638907579271869765" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638907579271879765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638907579271869765" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638907579271879765" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638907579271879765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638907579271879765" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638907579271879765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638907579271879765" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638907579271879765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638907579271879765" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638907579271879765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_638907579271879765" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - STOCK TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638907579271889772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_ScheduleOfStockByClassTable_638907579271889772" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638907579271889772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638907579271889772" xlink:to="us-gaap_AwardTypeAxis_638907579271889772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638907579271889772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638907579271889772" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638907579271889772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638907579271889772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638907579271889772" xlink:to="us-gaap_EmployeeStockOptionMember_638907579271889772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638907579271889772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638907579271889772" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638907579271889772" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638907579271889772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638907579271889772" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638907579271889772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember_638907579271889772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638907579271889772" xlink:to="plx_SalesAgreementMember_638907579271889772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638907579271889772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638907579271889772" xlink:to="us-gaap_PrivatePlacementMember_638907579271889772" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638907579271889772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638907579271889772" xlink:to="us-gaap_ClassOfStockLineItems_638907579271889772" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638907579271899770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638907579271889772" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638907579271899770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638907579271899770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638907579271889772" xlink:to="us-gaap_ProceedsFromWarrantExercises_638907579271899770" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638907579271899770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638907579271889772" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638907579271899770" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638907579271899770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638907579271889772" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638907579271899770" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock_638907579271899770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638907579271889772" xlink:to="plx_GrossProceedsFromIssuanceOfCommonStock_638907579271899770" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638907579271899770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638907579271889772" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638907579271899770" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638907579271899770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638907579271889772" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638907579271899770" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638907579271909770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638907579271909770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638907579271909770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638907579271909770" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638907579271909770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638907579271909770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638907579271909770" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638907579271909770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_638907579271909770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638907579271909770" xlink:to="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_638907579271909770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_638907579271909770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638907579271909770" xlink:to="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_638907579271909770" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638907579271909770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638907579271909770" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638907579271909770" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638907579271909770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638907579271909770" xlink:to="us-gaap_NetIncomeLossAbstract_638907579271909770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638907579271909770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638907579271909770" xlink:to="us-gaap_NetIncomeLoss_638907579271909770" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638907579271919771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638907579271909770" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638907579271919771" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638907579271919771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638907579271909770" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638907579271919771" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638907579271919771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638907579271919771" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638907579271919771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638907579271919771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638907579271919771" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638907579271919771" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638907579271919771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638907579271919771" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638907579271919771" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638907579271919771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638907579271909770" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638907579271919771" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638907579271919771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638907579271919771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638907579271929771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638907579271929771" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638907579271929771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638907579271929771" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638907579271929771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638907579271929771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638907579271929771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638907579271929771" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638907579271929771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638907579271929771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638907579271929771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638907579271929771" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638907579271929771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638907579271939774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638907579271929771" xlink:to="us-gaap_SegmentDomain_638907579271939774" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SingleReportableSegmentMember" xlink:label="plx_SingleReportableSegmentMember_638907579271939774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638907579271939774" xlink:to="plx_SingleReportableSegmentMember_638907579271939774" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638907579271939774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638907579271929771" xlink:to="us-gaap_SegmentReportingInformationLineItems_638907579271939774" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638907579271939774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638907579271939774" xlink:to="us-gaap_NumberOfOperatingSegments_638907579271939774" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638907579271939774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638907579271939774" xlink:to="us-gaap_Revenues_638907579271939774" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638907579271939774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638907579271939774" xlink:to="us-gaap_LaborAndRelatedExpense_638907579271939774" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_638907579271939774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638907579271939774" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_638907579271939774" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638907579271939774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638907579271939774" xlink:to="us-gaap_InterestExpenseNonoperating_638907579271939774" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638907579271939774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638907579271939774" xlink:to="us-gaap_InvestmentIncomeInterest_638907579271939774" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638907579271949774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638907579271939774" xlink:to="us-gaap_Depreciation_638907579271949774" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638907579271949774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638907579271939774" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638907579271949774" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638907579271949774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638907579271939774" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638907579271949774" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638907579271949774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638907579271939774" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638907579271949774" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638907579271949774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638907579271939774" xlink:to="us-gaap_NetIncomeLoss_638907579271949774" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_638907579271949774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638907579271939774" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_638907579271949774" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638907579271959776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_3" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638907579271959776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638907579271959776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638907579271959776" xlink:to="srt_MajorCustomersAxis_638907579271959776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638907579271959776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638907579271959776" xlink:to="srt_NameOfMajorCustomerDomain_638907579271959776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638907579271959776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638907579271959776" xlink:to="plx_PfizerMember_638907579271959776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember_638907579271959776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638907579271959776" xlink:to="plx_FiocruzMember_638907579271959776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_638907579271959776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638907579271959776" xlink:to="plx_ChiesiMember_638907579271959776" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638907579271959776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638907579271959776" xlink:to="srt_ProductOrServiceAxis_638907579271959776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638907579271959776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638907579271959776" xlink:to="srt_ProductsAndServicesDomain_638907579271959776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638907579271959776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638907579271959776" xlink:to="us-gaap_ProductMember_638907579271959776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638907579271959776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638907579271959776" xlink:to="us-gaap_LicenseAndServiceMember_638907579271959776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638907579271969767" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638907579271959776" xlink:to="us-gaap_SegmentReportingInformationLineItems_638907579271969767" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638907579271969767" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638907579271969767" xlink:to="us-gaap_Revenues_638907579271969767" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422969008821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271969767" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422969008821" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271969767" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638907579271969767" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271969767" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638907579271969767" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638907579271969767" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271969767" xlink:to="us-gaap_AccruedVacationCurrent_638907579271969767" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638907579271969767" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271969767" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638907579271969767" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638907579271969767" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271969767" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638907579271969767" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638907579271969767" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271969767" xlink:to="us-gaap_TaxesPayableCurrent_638907579271969767" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_PayableToCustomerCurrent" xlink:label="plx_PayableToCustomerCurrent_638907579271979775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271969767" xlink:to="plx_PayableToCustomerCurrent_638907579271979775" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638907579271979775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271969767" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638907579271979775" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638907579271979775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638907579271969767" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638907579271979775" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638907579271979775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_2" xlink:to="us-gaap_SubsequentEventTable_638907579271979775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638907579271979775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638907579271979775" xlink:to="us-gaap_SubsequentEventTypeAxis_638907579271979775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638907579271979775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638907579271979775" xlink:to="us-gaap_SubsequentEventTypeDomain_638907579271979775" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638907579271979775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638907579271979775" xlink:to="us-gaap_SubsequentEventMember_638907579271979775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638907579271979775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638907579271979775" xlink:to="us-gaap_TypeOfArrangementAxis_638907579271979775" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638907579271989775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638907579271979775" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638907579271989775" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember_638907579271989775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638907579271989775" xlink:to="plx_PfizerAgreementMember_638907579271989775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638907579271989775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638907579271989775" xlink:to="plx_ChiesiAgreementsMember_638907579271989775" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638907579271989775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638907579271979775" xlink:to="srt_TitleOfIndividualAxis_638907579271989775" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638907579271989775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638907579271989775" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638907579271989775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_SeniorVicePresidentAndChiefFinancialOfficerMember" xlink:label="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_638907579271989775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638907579271989775" xlink:to="plx_SeniorVicePresidentAndChiefFinancialOfficerMember_638907579271989775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638907579271989775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638907579271979775" xlink:to="us-gaap_AwardTypeAxis_638907579271989775" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638907579271989775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638907579271989775" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638907579271989775" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638907579271989775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638907579271989775" xlink:to="us-gaap_EmployeeStockOptionMember_638907579271989775" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638907579271999772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638907579271979775" xlink:to="us-gaap_PlanNameAxis_638907579271999772" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638907579271999772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638907579271999772" xlink:to="us-gaap_PlanNameDomain_638907579271999772" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_638907579271999772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638907579271999772" xlink:to="plx_EmployeeStockIncentivePlan2006Member_638907579271999772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638907579271999772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638907579271979775" xlink:to="us-gaap_SubsequentEventLineItems_638907579271999772" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers_638907579271999772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638907579271999772" xlink:to="us-gaap_ProceedsFromCustomers_638907579271999772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638907579271999772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638907579271999772" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638907579271999772" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638907579271999772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638907579271999772" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638907579271999772" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638907579272009773" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638907579271999772" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638907579272009773" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638907579272009773" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638907579271999772" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638907579272009773" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_638907579272009773" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638907579271999772" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_638907579272009773" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250630.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638907579272009773" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638907579271999772" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638907579272009773" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,732,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,895<span></span>
</td>
<td class="nump">$ 19,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">15,503<span></span>
</td>
<td class="nump">15,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">9,443<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,513<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">21,131<span></span>
</td>
<td class="nump">21,243<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">65,485<span></span>
</td>
<td class="nump">60,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,746<span></span>
</td>
<td class="nump">4,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax asset</a></td>
<td class="nump">2,738<span></span>
</td>
<td class="nump">2,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">4,997<span></span>
</td>
<td class="nump">5,430<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">78,486<span></span>
</td>
<td class="nump">73,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">6,689<span></span>
</td>
<td class="nump">4,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent', window );">Other</a></td>
<td class="nump">15,930<span></span>
</td>
<td class="nump">19,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,091<span></span>
</td>
<td class="nump">25,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">3,877<span></span>
</td>
<td class="nump">4,026<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">4,492<span></span>
</td>
<td class="nump">4,585<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">28,583<span></span>
</td>
<td class="nump">30,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="nump">49,903<span></span>
</td>
<td class="nump">43,211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 78,486<span></span>
</td>
<td class="nump">$ 73,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 15,658<span></span>
</td>
<td class="nump">$ 13,474<span></span>
</td>
<td class="nump">$ 25,771<span></span>
</td>
<td class="nump">$ 17,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="num">(5,870)<span></span>
</td>
<td class="num">(9,456)<span></span>
</td>
<td class="num">(14,050)<span></span>
</td>
<td class="num">(12,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="num">(5,992)<span></span>
</td>
<td class="num">(2,961)<span></span>
</td>
<td class="num">(9,467)<span></span>
</td>
<td class="num">(5,848)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="num">(2,624)<span></span>
</td>
<td class="num">(3,484)<span></span>
</td>
<td class="num">(5,227)<span></span>
</td>
<td class="num">(6,599)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="nump">1,172<span></span>
</td>
<td class="num">(2,427)<span></span>
</td>
<td class="num">(2,973)<span></span>
</td>
<td class="num">(7,283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax', window );">FINANCIAL EXPENSES</a></td>
<td class="num">(783)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="num">(628)<span></span>
</td>
<td class="num">(757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME (EXPENSES), NET</a></td>
<td class="num">(511)<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE TAXES ON INCOME</a></td>
<td class="nump">661<span></span>
</td>
<td class="num">(2,272)<span></span>
</td>
<td class="num">(3,071)<span></span>
</td>
<td class="num">(7,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">TAXES ON INCOME (TAX BENEFIT)</a></td>
<td class="nump">497<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="num">$ (2,203)<span></span>
</td>
<td class="num">$ (3,455)<span></span>
</td>
<td class="num">$ (6,798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares)</a></td>
<td class="nump">78,663,884<span></span>
</td>
<td class="nump">73,308,281<span></span>
</td>
<td class="nump">77,651,330<span></span>
</td>
<td class="nump">73,172,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares)</a></td>
<td class="nump">81,271,610<span></span>
</td>
<td class="nump">73,308,281<span></span>
</td>
<td class="nump">77,651,330<span></span>
</td>
<td class="nump">73,172,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 15,440<span></span>
</td>
<td class="nump">$ 13,304<span></span>
</td>
<td class="nump">$ 25,435<span></span>
</td>
<td class="nump">$ 16,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">$ 336<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other, net of amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Adjustment</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance (ASU 2020-06) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (381,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">72,952,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">340,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,798)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(388,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,581<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">73,292,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(385,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,786<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">73,052,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">240,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,203)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(388,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,581<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">73,292,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(378,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,211<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">75,850,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(382,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,208<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">78,133,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(378,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,211<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">75,850,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,775,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised', window );">Exercise of warrants and options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised', window );">Exercise of warrants and options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,106,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,455)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(381,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,903<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">79,732,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(382,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,208<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">78,133,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,450,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised', window );">Exercise of warrants and options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised', window );">Exercise of warrants and options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">148,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 431,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (381,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,903<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">79,732,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock, $0.001 par value; Authorized &#8211; as of June&#160;30, 2025 and December&#160;31, 2024 &#8211; 185,000,000 shares.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued as a result of exercise of warrants and stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants and stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (3,455)<span></span>
</td>
<td class="num">$ (6,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">967<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">706<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses (income), net</a></td>
<td class="nump">108<span></span>
</td>
<td class="num">(975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Changes in deferred income tax asset</a></td>
<td class="nump">118<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase in contracts liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable-trade and other assets</a></td>
<td class="num">(6,919)<span></span>
</td>
<td class="num">(5,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in operating lease right of use assets, net</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="nump">112<span></span>
</td>
<td class="num">(1,674)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="num">(1,894)<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(10,291)<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(737)<span></span>
</td>
<td class="num">(770)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(750)<span></span>
</td>
<td class="num">(786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">6,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromWarrantsAndStockOptionExercises', window );">Exercise of warrants and options</a></td>
<td class="nump">2,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(1,865)<span></span>
</td>
<td class="num">(235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">19,760<span></span>
</td>
<td class="nump">23,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">17,895<span></span>
</td>
<td class="nump">23,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromWarrantsAndStockOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants and stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromWarrantsAndStockOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activity, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#8220;Company&#8221;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients and children four years of age and greater with Gaucher disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Elelyso was first approved by the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. In May 2023, both the European Commission (&#8220;EC&#8221;) and the FDA announced the approval of Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia, Singapore, Australia and Taiwan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases (neutrophil extracellular traps).</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio through two exclusive global licensing and supply agreements. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;">On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). After giving effect to the sales under the Sales Agreement in January 2025, no shares of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;) remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $20.0&#160;million. As of June&#160;30, 2025, approximately $15.7&#160;million in shares of Common Stock remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel. In October 2023 Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and attacked civilian and military targets. The infiltration was accompanied by extensive rocket attacks by Hamas on industrial, civilian and military targets throughout Israel. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#8217;s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel, as discussed above. In June 2025, Israel launched significant aerial attacks on military and related sites in Iran, and the Iranian military responded with missile and drone attacks in Israel, which was followed by strategic bombing by the U.S. Air Force. The U.S. action was followed by a cease fire with Iran which remains in effect as of the date hereof. Although ceasefire negotiations are on-going with Hamas and the level of military activity has decreased in recent months compared to previous levels, it is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The Company&#8217;s facilities are recognized as an &#8220;essential enterprise&#8221; in Israel which means the Company operates or can be operated for the purposes of state defense or public security or for the maintenance of essential supplies or services, allowing the Company to maintain operations during emergencies. However, the situation could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of June&#160;30, 2025, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;) on March&#160;17, 2025. The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Net earnings (loss) per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of Common Stock outstanding for each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">New accounting </b><b style="font-weight:bold;">pronouncements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2024, the FASB issued ASU&#160;2024-03 &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures<span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at June&#160;30, 2025 and December&#160;31, 2024 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is identical or close to their carrying value.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 4 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the three months ended March&#160;31, 2025, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">908,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from such exercises. The remaining warrants expired on March&#160;11, 2025. Accordingly, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as of March&#160;12, 2025, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants remained outstanding</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the six months ended June&#160;30, 2025, the Company sold, in the aggregate, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2,775,215</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock under the Sales Agreement. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company generated </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">gross proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$7.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in connection with such sales (issuance costs were </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the six months ended June&#160;30, 2025, the Company issued, in the aggregate, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">198,625</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of options to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">198,625</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock by certain current and former employees of the Company. The Company received cash proceeds equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in connection with such exercises.</span></td></tr></table><div style="margin-top:10pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; EARNINGS (LOSS) PER SHARE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted earnings (loss) per share attributable to common stockholders were calculated as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for basic and diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,455)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,798)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,203)</p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,651,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,172,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,663,884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,308,281</p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of stock options and restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,607,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,651,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,172,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,271,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,308,281</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include 12,936,429 shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock and warrants for the six months ended June&#160;30, 2025 because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include 2,365,709 shares of Common Stock underlying outstanding stock options for the three months ended June&#160;30, 2025 because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include 31,744,960 and 31,791,645 shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock, warrants and the 2024 Notes for the three and six months ended June&#160;30, 2024, respectively, because the effect would be anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (TAX BENEFIT)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME (TAX BENEFIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME (TAX BENEFIT)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; TAXES ON INCOME (TAX BENEFIT)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:50.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (207)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (69)</p></td></tr><tr><td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income (tax benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (207)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (69)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of 13% for the six months ended June&#160;30, 2025 compared to an effective tax rate of (3)% for the six months ended June&#160;30, 2024. For the six months ended June&#160;30, 2025, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of forecasted profits derived primarily from U.S.&#160;taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;), which was enacted in December 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On July&#160;4, 2025, tax reform legislation was enacted in the United States through the passage of H.R.1, One Big Beautiful Bill Act (&#8220;HR1&#8221;), which includes significant corporate tax changes, including a restoration of the current deductibility for domestic research expenditures beginning in 2025, with transition options for previously capitalized amounts. The Company continues to evaluate the impact that the new legislation will have on the consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SEGMENT INFORMATION</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company operates in Israel as a </span><span style="-sec-ix-hidden:Hidden_aiZWtzxgnU-JSOrCWSBBBw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> operating segment. The Company&#8217;s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Segment information:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from customers</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,474</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee salaries and related expenses</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,649</p></td><td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,357</p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,444</p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,213</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-contractors expense</p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,463</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,764</p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,773</p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,609</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 761</p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 379</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (528)</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (757)</p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (272)</p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (374)</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 706</p></td><td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 641</p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 360</p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 319</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment expenses*</p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,552</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,461</p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,692</p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,600</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income (loss) before taxes on income</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,071)</p></td><td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,005)</p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 661</p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,272)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxes on income (tax benefit)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (207)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69)</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net income (loss)</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,455)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,798)</p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,203)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;">* Other expenses included in net income includes raw materials, rent and utilities and others.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Gaucher disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer (Ireland)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12,626</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6,874</p></td></tr><tr><td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiocruz (Brazil)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,716</p></td></tr><tr><td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Fabry disease:</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi (Italy)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,714</p></td></tr><tr><td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">25,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">16,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13,304</p></td></tr><tr><td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">170</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Long lived assets are located in Israel.</span></td></tr></table><div style="margin-top:10pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,343</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,811</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,568</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,080</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,476</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable to customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">-</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,056</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,588</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 9 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the end of the quarter ended June&#160;30, 2025, the Company collected approximately $1.4&#160;million from sales to Pfizer and approximately $7.8&#160;million from sales to Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On July&#160;20, 2025, the Company granted, with the approval of the Company&#8217;s compensation committee, 10-year options to purchase 597,990 shares of Common Stock, in the aggregate, to the Company&#8217;s incoming Sr.&#160;Vice President and Chief Financial Officer under the under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The options have an exercise price equal to $1.45 per share and vest over a three-year period in 12&#160;equal quarterly increments. Vesting of the options is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<span style="direction:rtl;">0.6</span>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="num">$ (2,203)<span></span>
</td>
<td class="num">$ (3,455)<span></span>
</td>
<td class="num">$ (6,798)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#8220;Company&#8221;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients and children four years of age and greater with Gaucher disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Elelyso was first approved by the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. In May 2023, both the European Commission (&#8220;EC&#8221;) and the FDA announced the approval of Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia, Singapore, Australia and Taiwan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases (neutrophil extracellular traps).</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio through two exclusive global licensing and supply agreements. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;">On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). After giving effect to the sales under the Sales Agreement in January 2025, no shares of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;) remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $20.0&#160;million. As of June&#160;30, 2025, approximately $15.7&#160;million in shares of Common Stock remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel. In October 2023 Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and attacked civilian and military targets. The infiltration was accompanied by extensive rocket attacks by Hamas on industrial, civilian and military targets throughout Israel. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#8217;s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel, as discussed above. In June 2025, Israel launched significant aerial attacks on military and related sites in Iran, and the Iranian military responded with missile and drone attacks in Israel, which was followed by strategic bombing by the U.S. Air Force. The U.S. action was followed by a cease fire with Iran which remains in effect as of the date hereof. Although ceasefire negotiations are on-going with Hamas and the level of military activity has decreased in recent months compared to previous levels, it is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The Company&#8217;s facilities are recognized as an &#8220;essential enterprise&#8221; in Israel which means the Company operates or can be operated for the purposes of state defense or public security or for the maintenance of essential supplies or services, allowing the Company to maintain operations during emergencies. However, the situation could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of June&#160;30, 2025, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;) on March&#160;17, 2025. The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net earnings (loss) per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Net earnings (loss) per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of Common Stock outstanding for each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible notes</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2024, the FASB issued ASU&#160;2024-03 &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures<span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at June&#160;30, 2025 and December&#160;31, 2024 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings (Loss) per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted earnings (loss) per share attributable to common stockholders were calculated as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for basic and diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,455)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,798)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,203)</p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,651,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,172,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,663,884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,308,281</p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of stock options and restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,607,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,651,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,172,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,271,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,308,281</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (TAX BENEFIT) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME (TAX BENEFIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Taxes on Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:50.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (207)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (69)</p></td></tr><tr><td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income (tax benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (207)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (69)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Segment information:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from customers</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,474</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee salaries and related expenses</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,649</p></td><td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,357</p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,444</p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,213</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-contractors expense</p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,463</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,764</p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,773</p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,609</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 761</p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 379</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (528)</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (757)</p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (272)</p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (374)</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 706</p></td><td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 641</p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 360</p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 319</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment expenses*</p></td><td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,552</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,461</p></td><td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,692</p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,600</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income (loss) before taxes on income</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,071)</p></td><td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,005)</p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 661</p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,272)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:51.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxes on income (tax benefit)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (207)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (69)</p></td></tr><tr><td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net income (loss)</p></td><td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,455)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,798)</p></td><td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,203)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;">* Other expenses included in net income includes raw materials, rent and utilities and others.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Disaggregation of Revenues</a></td>
<td class="text"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Gaucher disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer (Ireland)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12,626</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6,874</p></td></tr><tr><td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiocruz (Brazil)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,716</p></td></tr><tr><td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Fabry disease:</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi (Italy)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,714</p></td></tr><tr><td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">25,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">16,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13,304</p></td></tr><tr><td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">170</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock', window );">Schedule of Supplemental Information of Balance Sheets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,343</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,811</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,568</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,080</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,476</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable to customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">-</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,056</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td></tr><tr><td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,588</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental balance sheets information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryBalanceSheetsInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfGlobalLicensingAndSupplyAgreements', window );">Number of global licensing and supply agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings (loss) per share, amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,365,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares remain for sale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance', window );">Increase in aggregate gross sales price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance', window );">Shares remain available, total gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative arrangement revenues and expenses sharing percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in gross sales price of shares available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfGlobalLicensingAndSupplyAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of global licensing and supply agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfGlobalLicensingAndSupplyAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 4,357<span></span>
</td>
<td class="nump">$ 4,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">8,144<span></span>
</td>
<td class="nump">11,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">8,630<span></span>
</td>
<td class="nump">5,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 21,131<span></span>
</td>
<td class="nump">$ 21,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 12, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,775,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GrossProceedsFromIssuanceOfCommonStock', window );">Gross stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for basic and diluted calculation</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="num">$ (2,203)<span></span>
</td>
<td class="num">$ (3,455)<span></span>
</td>
<td class="num">$ (6,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of Common Stock outstanding for basic calculation</a></td>
<td class="nump">78,663,884<span></span>
</td>
<td class="nump">73,308,281<span></span>
</td>
<td class="nump">77,651,330<span></span>
</td>
<td class="nump">73,172,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average dilutive effect of stock options and restricted stock</a></td>
<td class="nump">2,607,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of Common Stock outstanding for diluted calculation</a></td>
<td class="nump">81,271,610<span></span>
</td>
<td class="nump">73,308,281<span></span>
</td>
<td class="nump">77,651,330<span></span>
</td>
<td class="nump">73,172,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings (loss) per share, amount</a></td>
<td class="nump">2,365,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember', window );">Outstanding Stock Options, Unvested Restricted Stock and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings (loss) per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,936,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember', window );">Outstanding Stock Options, Unvested Restricted Stock, Warrants and Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings (loss) per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,744,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,791,645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME (TAX BENEFIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current taxes on income</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes on income</a></td>
<td class="nump">231<span></span>
</td>
<td class="num">$ (69)<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="num">$ (207)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total taxes on income (tax benefit)</a></td>
<td class="nump">$ 497<span></span>
</td>
<td class="num">$ (69)<span></span>
</td>
<td class="nump">$ 384<span></span>
</td>
<td class="num">$ (207)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME (TAX BENEFIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate (as a percent)</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Schedule of Segment Information) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues from customers</a></td>
<td class="nump">$ 15,658<span></span>
</td>
<td class="nump">$ 13,474<span></span>
</td>
<td class="nump">$ 25,771<span></span>
</td>
<td class="nump">$ 17,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE TAXES ON INCOME</a></td>
<td class="nump">661<span></span>
</td>
<td class="num">(2,272)<span></span>
</td>
<td class="num">(3,071)<span></span>
</td>
<td class="num">(7,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income (tax benefit)</a></td>
<td class="nump">497<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="num">$ (2,203)<span></span>
</td>
<td class="num">$ (3,455)<span></span>
</td>
<td class="num">$ (6,798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemCompositionDescription', window );">Segment reporting description</a></td>
<td class="text">Other expenses included in net income includes raw materials, rent and utilities and others.<span></span>
</td>
<td class="text">Other expenses included in net income includes raw materials, rent and utilities and others.<span></span>
</td>
<td class="text">Other expenses included in net income includes raw materials, rent and utilities and others.<span></span>
</td>
<td class="text">Other expenses included in net income includes raw materials, rent and utilities and others.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=plx_SingleReportableSegmentMember', window );">Single operating segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues from customers</a></td>
<td class="nump">$ 15,658<span></span>
</td>
<td class="nump">$ 13,474<span></span>
</td>
<td class="nump">$ 25,771<span></span>
</td>
<td class="nump">$ 17,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Employee salaries and related expenses</a></td>
<td class="nump">5,444<span></span>
</td>
<td class="nump">5,213<span></span>
</td>
<td class="nump">10,649<span></span>
</td>
<td class="nump">10,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Sub-contractors expense</a></td>
<td class="nump">4,773<span></span>
</td>
<td class="nump">2,609<span></span>
</td>
<td class="nump">7,463<span></span>
</td>
<td class="nump">4,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(272)<span></span>
</td>
<td class="num">(374)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
<td class="num">(757)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="nump">706<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment expenses</a></td>
<td class="nump">4,692<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">10,552<span></span>
</td>
<td class="nump">8,461<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE TAXES ON INCOME</a></td>
<td class="nump">661<span></span>
</td>
<td class="num">(2,272)<span></span>
</td>
<td class="num">(3,071)<span></span>
</td>
<td class="num">(7,005)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income (tax benefit)</a></td>
<td class="nump">497<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="num">$ (2,203)<span></span>
</td>
<td class="num">$ (3,455)<span></span>
</td>
<td class="num">$ (6,798)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemCompositionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of composition of other segment item not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemCompositionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=plx_SingleReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=plx_SingleReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 15,658<span></span>
</td>
<td class="nump">$ 13,474<span></span>
</td>
<td class="nump">$ 25,771<span></span>
</td>
<td class="nump">$ 17,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">15,440<span></span>
</td>
<td class="nump">13,304<span></span>
</td>
<td class="nump">25,435<span></span>
</td>
<td class="nump">16,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">LICENSE AND R&amp;D SERVICES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_PfizerMember', window );">Pfizer | GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">5,647<span></span>
</td>
<td class="nump">6,874<span></span>
</td>
<td class="nump">12,626<span></span>
</td>
<td class="nump">8,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_FiocruzMember', window );">Fiocruz | GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,716<span></span>
</td>
<td class="nump">3,016<span></span>
</td>
<td class="nump">7,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_ChiesiMember', window );">Chiesi | GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 9,793<span></span>
</td>
<td class="nump">$ 1,714<span></span>
</td>
<td class="nump">$ 9,793<span></span>
</td>
<td class="nump">$ 1,714<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_FiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_FiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals - other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 1,527<span></span>
</td>
<td class="nump">$ 1,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
<td class="nump">2,209<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,311<span></span>
</td>
<td class="nump">9,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
<td class="nump">763<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">3,742<span></span>
</td>
<td class="nump">3,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PayableToCustomerCurrent', window );">Payable to customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent', window );">Property and equipment suppliers</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent', window );">Accounts payable and accruals - other</a></td>
<td class="nump">$ 15,930<span></span>
</td>
<td class="nump">$ 19,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PayableToCustomerCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable to customers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PayableToCustomerCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 20, 2025 </div>
<div>USD ($) </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 14, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Senior Vice President And Chief Financial Officer | Options | Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase shares | shares</a></td>
<td class="nump">597,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | installment</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Total proceeds from sale of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Total proceeds from sale of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receipts from customers during the current period which are usually for sales of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_SeniorVicePresidentAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>83</ContextCount>
  <ElementCount>168</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>25</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShare</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - TAXES ON INCOME (TAX BENEFIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit</Role>
      <ShortName>TAXES ON INCOME (TAX BENEFIT)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformation</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>99930203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShareTables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureEarningsLossPerShare</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables</Role>
      <ShortName>TAXES ON INCOME (TAX BENEFIT) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformationTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSegmentInformation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureEarningsLossPerShareTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails</Role>
      <ShortName>TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99940602 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails</Role>
      <ShortName>TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails</Role>
      <ShortName>SEGMENT INFORMATION (Schedule of Segment Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99940702 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails</Role>
      <ShortName>SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="plx-20250630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>plx-20250630.xsd</File>
    <File>plx-20250630_cal.xml</File>
    <File>plx-20250630_def.xml</File>
    <File>plx-20250630_lab.xml</File>
    <File>plx-20250630_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="plx-20250630x10q.htm">plx-20250630x10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20250630x10q005.jpg</File>
    <File>plx-20250630x10q006.jpg</File>
    <File>plx-20250630x10q007.jpg</File>
    <File>plx-20250630x10q008.jpg</File>
    <File>plx-20250630x10q009.jpg</File>
    <File>plx-20250630x10q010.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="362">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>57
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "plx-20250630x10q.htm": {
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20250630",
   "dts": {
    "schema": {
     "local": [
      "plx-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "plx-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20250630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20250630x10q.htm"
     ]
    }
   },
   "keyStandard": 146,
   "keyCustom": 22,
   "axisStandard": 16,
   "axisCustom": 0,
   "memberStandard": 11,
   "memberCustom": 14,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://fasb.org/us-gaap/2025": 3
   },
   "contextCount": 83,
   "entityCount": 1,
   "segmentCount": 25,
   "elementCount": 370,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 362,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "longName": "995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FH48IkEeXkKYk6m4HHmdOg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FH48IkEeXkKYk6m4HHmdOg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
     "longName": "995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "longName": "995210201 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "longName": "995210301 - Disclosure - FAIR VALUE MEASUREMENT",
     "shortName": "FAIR VALUE MEASUREMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "longName": "995210401 - Disclosure - STOCK TRANSACTIONS",
     "shortName": "STOCK TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShare",
     "longName": "995210501 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit",
     "longName": "995210601 - Disclosure - TAXES ON INCOME (TAX BENEFIT)",
     "shortName": "TAXES ON INCOME (TAX BENEFIT)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformation",
     "longName": "995210701 - Disclosure - SEGMENT INFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation",
     "longName": "995210801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "longName": "995210901 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R17": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "longName": "99930203 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShareTables",
     "longName": "99930503 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables",
     "longName": "99930603 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Tables)",
     "shortName": "TAXES ON INCOME (TAX BENEFIT) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformationTables",
     "longName": "99930703 - Disclosure - SEGMENT INFORMATION (Tables)",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables",
     "longName": "99930803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "longName": "99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_R6tg8LdwCUeUoAN2h0xL2A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_R6tg8LdwCUeUoAN2h0xL2A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "longName": "99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)",
     "shortName": "INVENTORIES (Schedule of Inventory) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "longName": "99940401 - Disclosure - STOCK TRANSACTIONS (Details)",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_H8A_3lY72U6nRHPcehodwA",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_H8A_3lY72U6nRHPcehodwA",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
     "longName": "99940501 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails",
     "longName": "99940601 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)",
     "shortName": "TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails",
     "longName": "99940602 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)",
     "shortName": "TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
     "longName": "99940701 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)",
     "shortName": "SEGMENT INFORMATION (Schedule of Segment Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ",
      "name": "us-gaap:SegmentReportingOtherItemCompositionDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingOtherItemCompositionDescription",
       "us-gaap:SegmentReportingOtherItemCompositionDescription",
       "us-gaap:SegmentReportingOtherItemCompositionDescription",
       "p",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
     "longName": "99940702 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)",
     "shortName": "SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_6_coWg2e90CjjtM9azRMBg",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
     "longName": "99940801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99940901 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250630x10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "ASU 2020-06",
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:",
        "verboseLabel": "Accounts payable and accruals - other:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "AccountsPayableAndAccruedLiabilitiesOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).",
        "label": "Accounts Payable and Accrued Liabilities, Other, Current",
        "terseLabel": "Other",
        "totalLabel": "Accounts payable and accruals - other"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "AccountsPayablePropertyAndEquipmentSuppliersCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Property And Equipment Suppliers, Current",
        "terseLabel": "Property and equipment suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r34"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable - Trade",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r608"
     ]
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation, Current",
        "terseLabel": "Provision for vacation",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r36"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r834",
      "r835",
      "r836",
      "r837",
      "r884",
      "r929"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r116",
      "r117",
      "r118",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r148",
      "r208",
      "r209",
      "r212",
      "r213",
      "r214",
      "r215",
      "r227",
      "r228",
      "r230",
      "r258",
      "r259",
      "r260",
      "r261",
      "r318",
      "r319",
      "r320",
      "r321",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r409",
      "r410",
      "r419",
      "r420",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation related to stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r694",
      "r704",
      "r714",
      "r746"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r707",
      "r717",
      "r749"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r708",
      "r718",
      "r742",
      "r750",
      "r754",
      "r762"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "plx_AmendedPfizerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "AmendedPfizerAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings (loss) per share, amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "NET EARNINGS (LOSS) PER SHARE",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r79",
      "r99",
      "r125",
      "r126",
      "r127",
      "r170",
      "r178",
      "r196",
      "r200",
      "r211",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r366",
      "r370",
      "r411",
      "r474",
      "r475",
      "r480",
      "r554",
      "r627",
      "r628",
      "r638",
      "r655",
      "r672",
      "r673",
      "r685",
      "r853",
      "r854",
      "r892"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r105",
      "r125",
      "r126",
      "r127",
      "r211",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r366",
      "r370",
      "r411",
      "r655",
      "r853",
      "r854",
      "r892"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "country_BR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "BR",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Purchase of property and equipment",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r15"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r98",
      "r606"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r57",
      "r124"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r57"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in operating lease right of use assets, net"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "plx_ChiesiAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "ChiesiAgreementsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements",
        "terseLabel": "Chiesi Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "ChiesiMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "STOCK TRANSACTIONS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r172",
      "r265",
      "r270",
      "r271",
      "r272",
      "r274",
      "r277",
      "r282",
      "r284",
      "r372",
      "r522",
      "r523",
      "r524",
      "r525",
      "r639",
      "r772",
      "r826",
      "r828"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants and rights outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative arrangement revenues and expenses sharing percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r72",
      "r481",
      "r541"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares remain for sale",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in gross sales price of shares available for future issuance.",
        "label": "Common Stock, Increase in Gross Sales Price of Shares Reserved for Future Issuance",
        "terseLabel": "Increase in aggregate gross sales price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r682",
      "r834",
      "r835",
      "r837",
      "r884",
      "r926",
      "r929"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r542"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "CommonStockValueOfCapitalSharesReservedForFutureIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of common shares reserved for future issuance.",
        "label": "Common Stock, Value of Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares remain available, total gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "ConvertibleNotesDue2021And2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r125",
      "r126",
      "r127",
      "r211",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r411",
      "r627",
      "r853"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Adjustment"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r133",
      "r141",
      "r148",
      "r212",
      "r215",
      "r228",
      "r334",
      "r335",
      "r348",
      "r350",
      "r375",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r391",
      "r394",
      "r396",
      "r397",
      "r429"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r133",
      "r141",
      "r148",
      "r212",
      "r215",
      "r228",
      "r334",
      "r335",
      "r348",
      "r350",
      "r375",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r391",
      "r394",
      "r396",
      "r397",
      "r429"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r133",
      "r141",
      "r148",
      "r212",
      "r215",
      "r228",
      "r334",
      "r335",
      "r348",
      "r350",
      "r375",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r391",
      "r394",
      "r396",
      "r397",
      "r429"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current taxes on income",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r826",
      "r832"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r35",
      "r36",
      "r70",
      "r71",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r653",
      "r826",
      "r827",
      "r829",
      "r833",
      "r848",
      "r849",
      "r850",
      "r889",
      "r890",
      "r895"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r243"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r653",
      "r826",
      "r827",
      "r829",
      "r833",
      "r848",
      "r849",
      "r850",
      "r889",
      "r890",
      "r895"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible notes",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Changes in deferred income tax asset",
        "verboseLabel": "Deferred taxes on income",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r81",
      "r826",
      "r832"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement",
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r286",
      "r287",
      "r288",
      "r289",
      "r553",
      "r644",
      "r896"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r24",
      "r115",
      "r612",
      "r613",
      "r615",
      "r617"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r112",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r150",
      "r152",
      "r162",
      "r163",
      "r164",
      "r169",
      "r261",
      "r320",
      "r352",
      "r363",
      "r397",
      "r398",
      "r473",
      "r488",
      "r619"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r112",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r152",
      "r162",
      "r163",
      "r164",
      "r169",
      "r261",
      "r320",
      "r352",
      "r363",
      "r397",
      "r398",
      "r473",
      "r488",
      "r619"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net earnings (loss) per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r166"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r165",
      "r167",
      "r168"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedLabel": "Effective income tax rate (as a percent)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r647"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r128",
      "r327",
      "r339",
      "r647"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "plx_EmployeeStockIncentivePlan2006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "EmployeeStockIncentivePlan2006Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent the employee stock incentive plan for the particular period.",
        "label": "2006 Employee Stock Incentive Plan",
        "terseLabel": "Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Entities [Member]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r85",
      "r92",
      "r93",
      "r108",
      "r109",
      "r110",
      "r130",
      "r131",
      "r132",
      "r135",
      "r143",
      "r145",
      "r147",
      "r171",
      "r212",
      "r215",
      "r228",
      "r260",
      "r285",
      "r320",
      "r334",
      "r335",
      "r348",
      "r349",
      "r350",
      "r353",
      "r362",
      "r363",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r396",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r421",
      "r431",
      "r487",
      "r510",
      "r511",
      "r512",
      "r528",
      "r579"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r694",
      "r704",
      "r714",
      "r746"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r691",
      "r701",
      "r711",
      "r743"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r471",
      "r651",
      "r652"
     ]
    },
    "plx_FiocruzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "FiocruzMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiocruz"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Financial expenses (income), net",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r561",
      "r683",
      "r886",
      "r887",
      "r928"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r708",
      "r718",
      "r750"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r708",
      "r718",
      "r750"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r708",
      "r718",
      "r750"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r708",
      "r718",
      "r750"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r708",
      "r718",
      "r750"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Gain on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross cash inflow from the additional capital contribution to the entity.",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Gross stock issuance proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "INCOME (LOSS) BEFORE TAXES ON INCOME",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r74",
      "r78",
      "r474",
      "r476",
      "r484",
      "r614",
      "r616",
      "r618",
      "r622",
      "r627",
      "r839",
      "r841",
      "r842",
      "r843",
      "r844"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME (TAX BENEFIT)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES ON INCOME (TAX BENEFIT)",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r128",
      "r323",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r340",
      "r342",
      "r343",
      "r344",
      "r479",
      "r520",
      "r526",
      "r647"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Taxes on income (tax benefit)",
        "totalLabel": "Total taxes on income (tax benefit)",
        "verboseLabel": "TAXES ON INCOME (TAX BENEFIT)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r82",
      "r125",
      "r146",
      "r147",
      "r170",
      "r186",
      "r200",
      "r326",
      "r327",
      "r341",
      "r489",
      "r614",
      "r616",
      "r618",
      "r647"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase (decrease) in accounts payable and accruals",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable-trade and other assets",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Increase in contracts liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r823"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Weighted average dilutive effect of stock options and restricted stock",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r164",
      "r291"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r708",
      "r718",
      "r742",
      "r750",
      "r754",
      "r762"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r690",
      "r766"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r690",
      "r766"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r690",
      "r766"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Nonoperating",
        "terseLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r614",
      "r618",
      "r778"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r122",
      "r123"
     ]
    },
    "plx_InterestReceivedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "InterestReceivedNet",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r609"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r607",
      "r655"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r611"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r610"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r181",
      "r200",
      "r627",
      "r777"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "terseLabel": "Employee salaries and related expenses",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r616",
      "r776"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r35",
      "r36",
      "r37",
      "r39",
      "r40",
      "r41",
      "r42",
      "r125",
      "r126",
      "r127",
      "r211",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r367",
      "r370",
      "r371",
      "r411",
      "r540",
      "r621",
      "r638",
      "r685",
      "r853",
      "r892",
      "r893"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r73",
      "r482",
      "r655",
      "r672",
      "r673",
      "r826",
      "r831",
      "r847",
      "r885"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r97",
      "r125",
      "r126",
      "r127",
      "r211",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r367",
      "r370",
      "r371",
      "r411",
      "r655",
      "r853",
      "r892",
      "r893"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r39",
      "r40",
      "r41",
      "r42",
      "r125",
      "r126",
      "r127",
      "r211",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r367",
      "r370",
      "r371",
      "r411",
      "r853",
      "r892",
      "r893"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Service [Member]",
        "terseLabel": "LICENSE AND R&amp;D SERVICES",
        "verboseLabel": "License and R&amp;D Services",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r855",
      "r856"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r640",
      "r643",
      "r665",
      "r670",
      "r897",
      "r898",
      "r899",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r640",
      "r643",
      "r665",
      "r670",
      "r897",
      "r898",
      "r899",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "NatureOfOperationsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r60"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCOME (LOSS)",
        "verboseLabel": "Net income (loss) for basic and diluted calculation",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r60",
      "r75",
      "r93",
      "r95",
      "r106",
      "r107",
      "r110",
      "r125",
      "r126",
      "r127",
      "r129",
      "r134",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r146",
      "r147",
      "r160",
      "r211",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r261",
      "r264",
      "r266",
      "r268",
      "r320",
      "r352",
      "r363",
      "r398",
      "r411",
      "r486",
      "r562",
      "r577",
      "r578",
      "r614",
      "r616",
      "r618",
      "r683",
      "r853"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net income (loss) for diluted calculation",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r151",
      "r156",
      "r157",
      "r158",
      "r159",
      "r161",
      "r164"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "New accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r708",
      "r718",
      "r742",
      "r750"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL INCOME (EXPENSES), NET",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "plx_NumberOfGlobalLicensingAndSupplyAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "NumberOfGlobalLicensingAndSupplyAgreements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of global licensing and supply agreements.",
        "label": "Number Of Global Licensing And Supply Agreements",
        "terseLabel": "Number of global licensing and supply agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r840"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r614",
      "r618",
      "r622",
      "r839",
      "r841",
      "r842",
      "r843",
      "r844"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r655"
     ]
    },
    "plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other, net of amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.",
        "label": "Other Nonoperating Expense, Net of Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "FINANCIAL EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r696",
      "r706",
      "r716",
      "r748"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r699",
      "r709",
      "r719",
      "r751"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r699",
      "r709",
      "r719",
      "r751"
     ]
    },
    "plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to outstanding stock options, unvested shares of restricted stock and warrants.",
        "label": "Outstanding Stock Options, Unvested Restricted Stock and Warrants [Member]",
        "terseLabel": "Outstanding Stock Options, Unvested Restricted Stock and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to outstanding stock options, unvested shares of restricted stock, warrants and convertible notes.",
        "label": "Outstanding Stock Options, Unvested Restricted Stock, Warrants and Convertible Notes [Member]",
        "terseLabel": "Outstanding Stock Options, Unvested Restricted Stock, Warrants and Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "plx_PayableToCustomerCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "PayableToCustomerCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable to customers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Payable To Customer, Current",
        "terseLabel": "Payable to customer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts funded in respect of employee rights upon retirement, net",
        "documentation": "Amount of cash (inflow) outflow from investing activity, classified as other."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r821"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement",
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r40",
      "r67"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement",
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "plx_PfizerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "PfizerAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Agreement",
        "label": "Pfizer Agreement [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PfizerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "PfizerMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromCustomers",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Customers",
        "verboseLabel": "Total proceeds from sale of products",
        "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash proceeds from stock options exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "plx_ProceedsFromWarrantsAndStockOptionExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "ProceedsFromWarrantsAndStockOptionExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants and stock options.",
        "label": "Proceeds from Warrants and Stock Option Exercises",
        "terseLabel": "Exercise of warrants and options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "terseLabel": "GOODS",
        "verboseLabel": "Goods",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r618",
      "r640",
      "r641"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r436",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r604",
      "r613",
      "r616",
      "r618",
      "r640",
      "r641",
      "r664",
      "r666",
      "r667",
      "r671",
      "r674",
      "r774",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r817",
      "r818",
      "r819",
      "r820",
      "r851",
      "r852",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r436",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r604",
      "r613",
      "r616",
      "r618",
      "r640",
      "r641",
      "r664",
      "r666",
      "r667",
      "r671",
      "r674",
      "r774",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r817",
      "r818",
      "r819",
      "r820",
      "r851",
      "r852",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional and Contract Services Expense",
        "terseLabel": "Sub-contractors expense",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r95",
      "r106",
      "r107",
      "r120",
      "r125",
      "r126",
      "r127",
      "r129",
      "r134",
      "r143",
      "r146",
      "r147",
      "r211",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r261",
      "r320",
      "r352",
      "r363",
      "r365",
      "r368",
      "r369",
      "r398",
      "r411",
      "r474",
      "r476",
      "r485",
      "r527",
      "r562",
      "r577",
      "r578",
      "r648",
      "r649",
      "r684",
      "r775",
      "r853"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r425",
      "r478",
      "r483",
      "r655"
     ]
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Segment Information",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r691",
      "r701",
      "r711",
      "r743"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r603",
      "r614",
      "r615",
      "r627",
      "r894"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r692",
      "r702",
      "r712",
      "r744"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r693",
      "r703",
      "r713",
      "r745"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r710",
      "r720",
      "r752"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r92",
      "r93",
      "r130",
      "r131",
      "r132",
      "r135",
      "r143",
      "r145",
      "r147",
      "r212",
      "r215",
      "r228",
      "r260",
      "r320",
      "r334",
      "r335",
      "r348",
      "r349",
      "r350",
      "r353",
      "r362",
      "r363",
      "r375",
      "r378",
      "r379",
      "r382",
      "r396",
      "r419",
      "r421",
      "r510",
      "r512",
      "r528",
      "r929"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues from customers",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r111",
      "r125",
      "r126",
      "r127",
      "r170",
      "r179",
      "r180",
      "r194",
      "r200",
      "r203",
      "r205",
      "r207",
      "r211",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r411",
      "r474",
      "r476",
      "r627",
      "r650",
      "r672",
      "r673",
      "r853"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right of use assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r654"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "plx_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to sales agreement.",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Taxes on Income",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Earnings (Loss) per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenues",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r48",
      "r49",
      "r50"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r64",
      "r65",
      "r66",
      "r100",
      "r101",
      "r102",
      "r172",
      "r270",
      "r271",
      "r272",
      "r274",
      "r277",
      "r282",
      "r284",
      "r372",
      "r522",
      "r523",
      "r524",
      "r525",
      "r639",
      "r772",
      "r826",
      "r828"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r79",
      "r170",
      "r175",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r207",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r231",
      "r232",
      "r357",
      "r358",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r624",
      "r627",
      "r628",
      "r632",
      "r669",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r173",
      "r205",
      "r206",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r474",
      "r475",
      "r476",
      "r477",
      "r531",
      "r532",
      "r533",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r605",
      "r620",
      "r640",
      "r642",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r668",
      "r677",
      "r897",
      "r898",
      "r899",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r170",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r190",
      "r192",
      "r193",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r207",
      "r623",
      "r625",
      "r626",
      "r627",
      "r629",
      "r630",
      "r631"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "SEGMENT INFORMATION",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment expenses",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r192",
      "r193",
      "r200",
      "r627"
     ]
    },
    "us-gaap_SegmentReportingOtherItemCompositionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemCompositionDescription",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Composition, Description",
        "terseLabel": "Segment reporting description",
        "documentation": "Description of composition of other segment item not separately disclosed."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r192",
      "r193",
      "r200",
      "r627"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r613",
      "r614",
      "r615",
      "r618",
      "r816"
     ]
    },
    "plx_SeniorVicePresidentAndChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "SeniorVicePresidentAndChiefFinancialOfficerMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sr. Vice President And Chief Financial Officer",
        "label": "Senior Vice President And Chief Financial Officer"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value",
        "terseLabel": "Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal quarterly increments over which the awards vest under the share based payment arrangement.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments",
        "terseLabel": "Number of equal quarterly increments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options to purchase shares",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercise price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "verboseLabel": "Term of award",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "plx_ShortTermBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "ShortTermBankDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SingleReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "SingleReportableSegmentMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to single reportable segment.",
        "label": "Single Reportable Segment [Member]",
        "terseLabel": "Single operating segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r79",
      "r94",
      "r170",
      "r175",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r207",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r231",
      "r232",
      "r357",
      "r358",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r624",
      "r627",
      "r628",
      "r632",
      "r669",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r44",
      "r45",
      "r46",
      "r85",
      "r92",
      "r93",
      "r108",
      "r109",
      "r110",
      "r130",
      "r131",
      "r132",
      "r135",
      "r143",
      "r145",
      "r147",
      "r171",
      "r212",
      "r215",
      "r228",
      "r260",
      "r285",
      "r320",
      "r334",
      "r335",
      "r348",
      "r349",
      "r350",
      "r353",
      "r362",
      "r363",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r396",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r421",
      "r431",
      "r487",
      "r510",
      "r511",
      "r512",
      "r528",
      "r579"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r173",
      "r205",
      "r206",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r474",
      "r475",
      "r476",
      "r477",
      "r531",
      "r532",
      "r533",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r605",
      "r620",
      "r640",
      "r642",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r668",
      "r677",
      "r897",
      "r898",
      "r899",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r171",
      "r262",
      "r263",
      "r265",
      "r267",
      "r421",
      "r436",
      "r521",
      "r529",
      "r530",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r542",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r579",
      "r616",
      "r618",
      "r678",
      "r927"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r171",
      "r210",
      "r262",
      "r263",
      "r265",
      "r267",
      "r421",
      "r436",
      "r521",
      "r529",
      "r530",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r542",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r579",
      "r616",
      "r618",
      "r678",
      "r927"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r695",
      "r705",
      "r715",
      "r747"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock under the Sales Agreement, net (in shares)",
        "verboseLabel": "Number of shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44",
      "r66",
      "r522",
      "r579",
      "r588"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of options",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44",
      "r66",
      "r300"
     ]
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued as a result of exercise of warrants and stock options.",
        "label": "Stock Issued During Period, Shares, Warrants and Stock Options Exercised",
        "terseLabel": "Exercise of warrants and options (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock under the Sales Agreement, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44",
      "r66",
      "r528",
      "r579",
      "r588",
      "r684"
     ]
    },
    "plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants and stock options.",
        "label": "Stock Issued During Period, Value, Warrants and Stock Options Exercised",
        "terseLabel": "Exercise of warrants and options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r61",
      "r543",
      "r560",
      "r580",
      "r581",
      "r655",
      "r685",
      "r826",
      "r830",
      "r831",
      "r847",
      "r885",
      "r929"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "STOCK TRANSACTIONS",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r269",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r285",
      "r372",
      "r387",
      "r582",
      "r583",
      "r589"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r433"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r433"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r433"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r433"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r433"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r434"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementalInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "SupplementalInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementaryBalanceSheetsInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20250630",
     "localname": "SupplementaryBalanceSheetsInformationTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for supplemental balance sheets information.",
        "label": "Supplementary Balance Sheets Information [Table Text Block]",
        "verboseLabel": "Schedule of Supplemental Information of Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r891"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r116",
      "r117",
      "r118",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r148",
      "r208",
      "r209",
      "r212",
      "r213",
      "r214",
      "r215",
      "r227",
      "r228",
      "r230",
      "r258",
      "r259",
      "r260",
      "r261",
      "r318",
      "r319",
      "r320",
      "r321",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r409",
      "r410",
      "r419",
      "r420",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares)",
        "totalLabel": "Weighted average shares of Common Stock outstanding for diluted calculation",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r164"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares)",
        "verboseLabel": "Weighted average shares of Common Stock outstanding for basic calculation",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r164"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0001558370-25-011471-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-011471-xbrl.zip
M4$L#!!0    ( +DX#EM:B=!&@ T  ,YQ   0    <&QX+3(P,C4P-C,P+GAS
M9.U=6Y/BMA)^3]7Y#SZ\G.P#PS"SL]F9VMF486"6.@PFP&PV3REA"U"ML5E)
MWH'\^M.2+_A^ 29AZ[A2E3!6J]7=7ZO5+=G*AU^W:U/YCBDCMG7?:%]<-A1L
MZ;9!K.5]P^&+YOO&KQ__]=.'?S>;7SJ3H6+8NK/&%E=TBA''AO)"^$J9V9L-
MLI0G3"DQ3:5#B;'$BM(&?O#/M=)L?I0L.HA!%]M2)*^KB[;?T/6XV=:=\K[5
M?MNZNKRZ4=[?O;VYNWJOJ$\^W1-(MB!%A%MFW#%]A==( ?4L=H>W^NJ^L>)\
M<]=J;>?4O&!8OUC:WUNB1?)H>*1;DUA? ]J7EY>+E^L+FRY;[=O;VY9L]4EU
MV[$XW:4S]AHCO"U$=)9.+ILBQ(SHZ:30$)48&@T>I14"7UU>WK3<1I_48<TE
M0IN =H'87-)Z#1&^"4.$.5^W1/,<\ R+07+HB<4XLO2 GO$-S5 06B*2@'1\
MM\$L56[9$K4<Y4E*>!C#.4?6+\,PS ZE,">R</9:/>8<T27F([3&;(-T'!EC
M0VV.3+*]T.VU)+]\=RWFFXG%C.K;=/V %\@Q0?IO#A *1P_IE&6#H"FJ'S/2
MO!C4:[>^/ VG<GKXQ :G,>X1FT!S2S2+ =XV+]O-Z[;?<V-NR^CH34/+65^E
M.>K5)4Q$CBU&YB9N"C),$8>0Q)I7%Y<A-Z"VF>$&LB5B 8H7F1"_:T%KV+89
MC(.FJ#]RFLGYM@6MP83'2Q'6<H@%\Y9'YO="G%,R=SB.N(1C)9QBRT@QQLWX
MQ#/PAF*]C%Q[RKU"O%@9OA^)I$\::(@8U,@UJ+$WJ QG)#76O7-C'8G%NB:>
M9\<[T1@11-\93;1H,F>>,=N#]D@WK!OI]- 0)\QF[C6Z'3[^I"AR(4.6!5-*
M3 ;QR'^XV1!K8;M/X)D(QG?"_#.8IHKX\3P99$],"=0#8;II,X?B*?B'@:BA
M6D;78=Q>JUO"'NPU(I;G?JRA$%"Q6A=?.E\^ R^(1:0FL)9>7BI-9<\0_O!Y
M*L!4<;DJ@JWB\E5\QA]:<7:Q@1S(,C3KH_P-'LP@NDH#BJCN=?9(<CKJR-0=
MLWJ_O5B9W;R'/EY'H0A&XW+]Z-J6 1$4&_"#V28QQ+SM(%-,_>D*8Q_#*AUR
M$;P1<4:B&+"$WUUM]- ;37L/XM=4&PX>U!G\T5&'ZJC;4Z:?>KW9M$:P-()!
M*],6VL9?%LM F=&S$-.KLIA.9_"?I]YH-E6TOJ*->Q-U-@""&MV#T.TBMNJ;
M]DME</<="[%]>QBV777Z2>D/M=]K;--7T('U'12U*<%,9%V&8V)MX3_</6".
MB)E80\MURE]%W\)T;<<7TL'H,R"G30:]J?*SSUJQ%TK _(WRL\?_38UH*J(]
M1"UB+=G09FR,Z72%*,[ ,8^T"+V;)'H]=3(:C!X!NJ$VG;Y1(*["LJE.>C5F
M!9C-T!8SS1I8T";^Z& +1.%39[U&=*<M(NT98![$HPCE=TF49^H7F)W:""9K
M5WL";.&!TNF->OW!#&:G-YZ8M')$L6GFCEE/W<)R!B_%XC:  HFNI=S[\)IL
MR_"#PY@4.<(O24>8]A[%.@M^T-<F3S*#B@9M;S0E-%SM X4^X&PV[KX:S*(^
ML:"H(<@,$I^0+55=;M6R,=JAN8FA]H0GU$$FT_@*TRSW.#7_(L]YG^(YS^/Q
M4"9IZN0/I3\8084U4(?[W"WJ4[X@BB>) M6VXLL"[*0XM6<=G<:OD+7$;&!-
MN:U_7=FF@2GK?7,(WU5.['-8%:;ZUP>F^I_4T2.L3(,1-&C=_W[2A@^]R?0_
M2N^WY\'LC]HI3NT48\@6+9AZG(#6)_20*-\2[G+S"NZB_!P1HXXI&:L565ID
M 1:RN!>EH9X8 ^ ZU(99*U"9/D6K2CME51D\C@;]05>%]4/M=K7GT0RJ$64,
M#M"5!66]/A1LIL-,G%%D,:3+';<L_++HBC![FX*9F'K*;**.IFI7[L'5,!U6
M*ZJ&(:5!9G&)< B+XDKQJF*EN!^NKA!.524"%5HNJ3B6A>?:8H*_8\O)#L5'
ML"JN&!,.45@Q1L<43_Q1:[<H+ASG#']S0-F>V"O-A#R#K C.V[0RKC.%;$D@
MVOLL\ZH:HU2,O%?/_/]")=V#I(?O0O/.@ZD,96%&#%@)J/P7WD(_1>'L,@R'
MW!JLZKEMI:2V"++V >EL#5K1>5;.J54Q(/F'4[7Q4XW?1X1^1J:#GS 2?XN8
M$T<AE:80CNLD''UU,%$^J\/GGO+44Z?/$UG;U\B4J^T*B[IB3$J5<S4>I0]I
MRYS.%J-2Y5RV!J=*A5VRBBZ&J.JA:@U3R3JXN+PM!J?<06<-R9&'EX<?2Q9#
M>.R)8PUNJ0V&HIV%8J#*["G48%0O3@\J4LL5J[=0&*5L[!4=O?C,Z[6LL&R=
MB5<<\HI7CR ?IFNH8*]S7Z]TV=2 E$_0TY')H2R"Z"8)4<X[E#5@!R3MZ9CE
M$Q?!]BX)6\%15PU=M40^';5,NB+ ?DD"EGH45<-TFN0^ [ZJ_8M@?9\":[4W
M"_\O !?_$M^[3_!"D=< W(E/HN\;C*P!CX;W;"6_.MZ8VZ;_\?.?H.G%=FWZ
M%()[SJ?GTEOBQO'&]5D@JB>X)&XI ";V!E,.J4[+E[VAM$ZD%%BSJE)1 ,Y/
M)1/-JZH$7;!YGMK -*FJ36QFG5RG#ZW8I\O>@\@'SO+S9E#.IERQHM<HL-BE
M ==AB9OMBW9#<6_]&-JZ?+;O%M,XV?4"AO4$S9$@^_/NK(%3R>67WN+'8:/N
MOYXO-:I/+GY4&S7O$H^TH5.[B+^".PB:XE&S?=6\KFCQQ(4F)<?W.XB!#U<\
M?D]#F<%-2B.]A 2W0O7VN\/D2+V%HY3#I_24?[/2@F3=M)'K@*FWR[2PR5G
MIIH_9EQ7<X00\A*(PV387RA3;GR?WAU;7"QR> 2(7BY4*@J$N_A_'"%!Y*Z*
M Z(?]$T=W;L,1PY_WY"[ /+2J*Z]WF"+2?X3S#@ENGP5WM:_JB^(&FR$N;;H
MVW2!"8<D%M)F=Z&4UQ+=K6T+BWQY $FR2.T:"IH#$Z3S^\8"F?(6(TD(BQ>Q
MC9GL:CC4VV2WB&F*'/>^P:GCG3#":OOG4?*!"1B'/T271VH[&U]8 D+Z\LS=
M^QCN&SK%AC@\2YKJ!,+(KB#2T58/&,4,%L:"29H]$J7LD(Y+MC$>$;'$5I)F
MJ6OYU5/?L0QL#(0:&ZR#U#U(H.P=QA.R7''VO!$:<N*_;>%:XF@N.69(NN01
MABCM+*Y>[F<C \N[%L):#K%(]H0.VN*9894Q>5_(WS"%RHIRJMGB&F"$A+N&
M[\606^N[&=[RC@GN[>L>W(QUQ_VF$QN@A"@%NF=&S[QS"EFSQR8FS&]KF::>
M*_%!$;*$#!GJ&?QN!:-0W9GC0:ZB*OR&:3E>D+\P59<4R\8GO)YCF@32D+<)
MG5;-? D.Q&_L[2)UB#U;@7-L,'#0F=ANI;!&2Y'^3B6KR/,:+@M%J70$]@^[
M;4B.RFH&8<\6 TNC?<<JI2(("@+_1?W>5BR\[H(JAH9I(#:$EMA?FHYAD+HJ
M[7UGX]*^\@KMSA7?7SR/CSXKD#/NXP5B5O&+;+']!5\F0>#ZT 8 C&'=$7?0
M1=4I27N.:J;G@"$_Z^SV)&.TDZ_9BY3P$2CX Q2\P1NJ^6GEH2Q?-[-R]RMX
M(J\P\+P@"=_OSH<__U(]4 );%)+E)="Q@/?W.$3XV"%R2US\Q"&4N"24K="U
M8%:DI&.O&*822WHX7B4;SW%&]XFM4^>OJ +QA^<H>.P"C;&[P[P3'_5\<\A&
MT$H/(YBRKKR--YAFAW7]9T)+<8'?74'R0:( QIZ=(W[3E4WY#--U!UE?'_#&
M9H2']AK2&\\UO!^ZAHT<@9"V^,U!E&-J[B =<'<)"K9=CN:=8TEB<;S$])4C
MJ.NB09!D:0Z<TGJ.KCP @U',(,G6,61RQ@@'H2:]Z1_:_RGV8VP1FWXF.L1$
M,+_A?B0IL%@$KQ1H"RB XAGZ(1W/$<FI*)/&-LR ODC)@^K(U6^*=8?*6U>^
MB\-,$'YD<\P>'"Q.4.(6.0&G<S*17U^F2=P&L,."[\O9,M1'JA6W4IY:<1-D
M;@1ZL?/1M&'V#,%O+0;)-0@N$X/=/C"%=NPJ]#DFW!;K&ZQCB9W(S#TE-Q.:
MV>[]VI@&:4^0\&92'!6]CE&FXN9NQHUKV!@2-"<F$6\GR,O.$KI7[_FCV,3=
M@F ,='EPO TA&$56T[\CD6-P)AQ8D&D;N0W=VT(L(TR<=P=1\R@NKVRKM,E_
M4F.YAUM'6ZLLFR/.S(XR5LYVM(ZQP?K47J=+[PO/(GO&Y3N=C8-DYD^>?R 3
MLT35'\">VGJ&:Q^4&6!E?W.2BG.W@1B;,:G"F,+*IBU<=YU@ABFDM7V;]AUQ
M8"7\VGT3:)\#G(3=CQ)10^K*^"?N8=\0CLQ##%:1PX]B(XE^. 3X*H"J>^7W
M%BE+_Z,$"LWAPI+B_Z86#O+/D"PSCHWX*Q66X8?(>$PYFM$9AI\I*&/B"1:O
M&PG>WG<)B7":3W:&BE4#*[0JQJNHX[R@!.-S-)Y(KT>V9?OO@W@'F?)-HZ7W
M/@Z$1$R65M?[?Z^%+MSHX(4M/TP*6>UD',\P[+BO4+OOWWW\'U!+ P04
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M;U 92])]6HDY7FRC2\AS4+SF1YHZ4R^)YPF6@\=G;((N#.$\FBV)2;@E-/.
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M96&4)5YKJBT(RT"J:.LU7 G=8%6FAE_,A5&45GNDN-?N6X4TSYKU78!:Z%<
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MF^NS!6C#4B\*6?[%G-"070Q/'I%[@\E-S)+"6+*)'3CP(P7*]>C.JF^F_A:
M!_'L/5>3P"'(#M$D^$1P&"8]^HS0T)/?7":KX@[KU9U_W\;C.Q' L":0I)9-
MEXT<NUU5NE/E.U&T(F9S(_O,)E.2[%BDV8;YE93UL1PNJ3L=OK/H#4,T3*$C
M"L]E]Q'2,4>RZD0%SH8:CA^[U""3RZ\WVSA*]E^GR^K]HZ,-$Q"4D-1-W;H3
MJ-L914=",,QLRFO6^=7F]]3>4Z,'1_=-*M"=EMO. %20&I##RZ)7,==+.6_W
M+2=OEUW6:2WN1W?ST57RJFV;5-WVJZ'.&KGQ?O7J<G?EVR$WGU>JA(ZHS4[8
ML)Q)T>5=91HSDG<55% *HF4L^N,?_QQ4,8'R<G>@F=F[9%>5H3A "=R9;P>U
MV\?]-&70HCW7F$L+];U(0+\1C3=;'^\0*IRG$29X"^B-V13HT2]*E\7"HM"O
MUY>_*PK=O:(6M;]OB1H07;]OB0X8_4S9$FWM'3/B/=+)"0W$#JR0.F+=6VO-
MU%*'2K]RDJB; 3J:>E:7W?BT>F]=$P(HQ2-1A_.2;V'[M[N3"' ]>4V_S&N)
M9@0["+G)*X'9"?G\1#RD0G$1W=O7RHH3PS%,71FJC,\IN6?O\]2_4U1?3/>V
ML[+:ZB$9ICIA@)"Y\*--1;JWF+L-I_HN<$GVMHL1(]_HG"X+FV><<;]L0=U;
MQ-**4@%EF"=FJS8YO)SI*QP>)>/)%=&]ZZO>YPGAF*:N@H&IQ$F)<KIW9EL-
M5II&P=ZWX/(M8':MS_Z=3]5=N'?'NW#CT?W=Y.[3W/K+[70^_ZLU&]];\U]&
M]V-#-N-:[I3+[=]UT\C+2]2XW/$K$&T@]MFBJ=N171IAAVD@8F'J[V3XW-7N
M;=87,V@E?0 /K+>8_L_<%B:!Q2[R2_"(P@BYU;L^ S>_&1!<M&]=HRGK^[)6
MG@_P6P,W0<.%BQ^KYU$[TKA$"Z:L9_9K 1*",#742X?!H_%YMZ..6U/V.+H6
M$W];I)OAR@O=22E=@#IZH*YD.U N,D!K=ESIQEH Z(8M4[R$ZWH!5Q?:89L;
M>W6ZTZ/M^2PZ+'!A+3)[4>F:62JX<-2@'E/<L)DFY3 :INW?$-OQ0>Z(#C/L
M%<H/$Z<[!(5A2TU<5:_&E!W./D.NNE1>J'5<VJ'GM#2-K Y3HGE3QVBB_PRZ
M8<I/SJ*RH9[M9_$LX7L4T;G* W6()-(=9_$6DGP!B^BB8E.ZBB[,I MY&&8[
M@%BR7O!(.FJA Z[%E$ZEQ^ !@S?,!+X?*95.U^ES##+4P=/^CR2FZPZ38(G)
M)N&VD!9Z])OR3NG?..<5QY\^C^\6UN3N9GK_><1.+%I_R1NU\-+*FK4*[?[5
MD%W4C+5[M,6$G5$ML'BYRWZ4/.HH7Y.6?+#LKN3+.*1N$(891Z(=S9HRINY)
M*JN4^W8U'[/^[B+C1WSFIDQCT*:@E!F6]%&&TM?M=\'*1ZG!,,/(&H6/U8CI
M39F:<4WE<,&=$(,QALYSX[I-$;FB>C<\5. !9SSDX]Q+W;'(QO)3VAO8#&(>
M+:"E5)C>E'EP4[4+H!DVG\GOWP-T=/C9E$EH4Y4<D!BF@5MV+>(H<.^1SVY,
MR2Y"!/0!$9LRYVNJ'0B78;J:$;RDPZ"$@32/(5GHR%[]#L6ZDRULRGF,IKJ4
MQ6F8;O/+BS+^[G" \^@-KO@*2IAR6*.I%H7@C%,=RSA*UTK8OF7..Z@WB-R4
MPQK-E08A,TQCUVA+D.,EB  ME4E,.8W15#-E-(9IHPIJ&JT185"$R]6UI71?
M;==Z\E8'T# U'I(VT@5P=HU?S/A. S<.PDM$D:.4;F$_L\Z8]LU4>EY@DUTB
M"!KHV4R32ME/1%4327ML<?B%F?.NHW&/TC'2]BB&;+QPB0*J,;'=<*B'UWG'
M"SX@,L/T]2(R$KM>E3$Z0Q'L;=A.)@Z]=/\O=(BW%8R:E&L97JL=+^PH(S9[
MTY=2V:L50:MLZSI?MVJP]?M:>>NWW#C[)F_^^PYP!XAKWOO];/\3DZLXC&B(
M(KRM7HCHWVIO%P*IYPWF]$ZU$C_@&\P"6@,V=<46EDM>@*&G-^*7WA^(P*_
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ME23Q\MJ.T(WMD:^V'U>[KLYK-^8VHKYM@@>^:;9R]C7[#QO.__S_4$L#!!0
M   ( +DX#EO;9T_L%D$   59 P 4    <&QX+3(P,C4P-C,P7VQA8BYX;6SE
M?6%SX[B1Z/=4O?^ VU?U;J9*WMG9W*6R^Y)<R;+L5<4C*9(\F]S6U19-0C8O
M-*F0E#W*KW]H *1($0!!B5)C[M7E=FRSN]D-=C<:0'?C#__QY24BKS3-PB3^
MXS<?O_WN&T)C/PG"^.F/WVSS]=7OO_F//_VOW_SA7ZZN_GJ]N"=!XF]?:)P3
M/Z5>3@/R%N;/9)5L-EY,/M$T#:.(7*=A\$0)^<CHL?_[+;FZ^A,G<>UE#"6)
M":?U_;<?BP<C22V)?R2___#QWSY\_]WW_TY^_^.__?N/W_^>##\5<)\89^NP
M#3 *X[__"/]Y9.\C3,(X^^,WSWF^^?'#A[>WMV^_/*;1MTGZQ)"_^^V' O ;
M ?GCERRL0;_]MH#]^.&OG^Z7_C-]\:[".,N]V-]C 1D5WL<??OCA W_*0+/P
MQXSCWR>^E_,Q;^6+:"'@MZL"[ K^=/7Q^ZO??OSV2Q84?#78:A&>/0WR$J$*
M_.\?Q,-O_O0;0L08ITE$%W1-N'@_YKL-_>,W6?BRB8 >_]MS2M?JUT=I^@'P
M/\3T";X]\/\#\/_Q=\#__Y9_OO<>:?0- <B'Q40KR0\U6A+IPY[3"/YRSWZJ
M\4J_Y#0.:%!P"S0,@\5?P;\D$"Y))WZ-: 2?-DF;(Y 5 YI1_]NGY/5#0$.N
MO_##%?S !6>__#I*F$T.'[,\]?R\H,1E^.,WBN<?:OP V#"M,^6E?D&&_=@B
MIX3XX"=,P3?Y522&4Z"OT^1%R81\7:)X^&OT&*FXK+&8TBS9IC[M]#&JG.G&
M1[R=Z3># +=&XZN'Y3=_NBE<F1<'9!SG8;XCDWB=I"_<,O_P84_TW)^[8&7%
M*"JDJ3_&^=@J%HMO77UV\4_=?+G^2P,,QG?]R]9+<YI&NP7=)*G*H+60N%];
MP_CAAS\ 0],!)1]Z=2C!B8#'4(TY3<,D&,?!#9NX#*(=P.&JA9+I0Z6H :&I
MA((+O4((8#89! 3 4:: U(NS$":@5E_1!$6>&C2L-Z:) SB\*4/)B&'Z*.$1
M'(:(4&[#B$ZW+X\T5<C5!,%1"!VKA2(</K^X J@9:'SX)?6W*?O>-"-#/R<
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M(&$!Z-"NG<TFC3.[=*V[<_B[<G:[<<@::\.Q4%E?[AZZ,"$(KJ=,9SIL.*O
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MJ1/5VC,>X#NGJ&H&CU/9 =E3PPX]>I1]#^;,"8Y(_)ADV5:;5*Z%=N(T1R6
MYDRG"HI]LM/DQ7A&,I 960,B4!RXO*Z;,/4;["Z7%V5YFUTW81I7VEG)<[D+
M* 7S-]L4MK+X 'SVHBV=TC?^1)\Q8H6+?$VEK7"-FRO;$/$NL[3CK-G]DI_\
M"F0BL.5<.B"< #3B>A, 9[[3U2(M^Q1)X2&W,Q8C^,(M\FOER#8.:$KR9TJ6
M7D0S,GQ**=^TY8W=G#1%X5^.M,4&LG/&J!'/PAH/,%TR1R5K?6FI4\43)PW
M/G]<I@6'PC<Y,SM6CGQ6B>9,GHOZZ&4T@,0K&F<\6WD!%U=F84[E-2AB6!;4
M3YYB3H7[L?:3IC.]UHF#PK,.J>9L\2SOQ#Z./*-0S37I?#*2JXNK:Z!,YMZ.
MK[N':<H I9^:Q'Y*V6.>S<\OLZC0QSX4P!DY,6:<)KC[DFBU%ZWP_V*3X+1;
M7Y2MF8LB^$.ILCP-?2CK@-</W^"8A'<PO4W2-0WS;=J(.TZFAM. N8<!*'HN
MGT *K<WRR3P;.BNGP@J@V[&XM%FEZH%8=4!H(U;:W#^D)0/2 #S. E(?Y/X'
MB5,DPEM6:9(]49F6*\CR?LBS-:E01G*99QR/%D^HT0FG?**(<OL=LH+F5^<?
MZX/1@Y<4!+]&7UGE_!S.0&[N?G7N\7_$N)S+5[8/SG$>L[?5M-I[&G;I?O9@
M12!NVP:PF0AKQU]HZH=9X_SH=')(/K.'(2C=Y0FT\#SER4PW])WC\HTAKLER
M7\C+B =JOHUXQ E1))6$X/<W^2[>OZZVDL**)/L?&(L]_)^KPR#@)7%24L=T
MD?T/REBG!.=;2)NV/?OS>[;TG')\W0:AQ?/9$7/-]77AVGI7_,#[?8V>[Z1Q
M,;F^(MOAZ_1])PU+F_-SYS2EDC0Q]])9RKLB",=?M!ML3[?08SJ17M0FF";5
M2(>&G79DYJLE!8DADR0E EU$)_N&E^@GEQ>1TLENEXWDI>$V?TY2V+JU37>J
M8CAA=SI!C*E]>W!L.U/S8Y7B1_98V/DK9<NED9<]WT;)6V;?&4N!XD#+(8,H
MFCY8#7CL]E<:AH[L>C5<_D1N[V<_(U]$.*4YR#5/D]<PH,'U[H$%2).XO UW
M6%[CV:*!QQ!"O3;A2+$/[E;H2 7GRK<CV51>=0"42$&*/.[(.Z!&PO@]*0F2
M/47R2T$3NX*QMU'8FRZY7<P^D?U]T,/1:O)YLIJ,ES_B6C43<AWFAOM+J@!X
M5MADLVI=^Z<H5G/X>J4UU&XNX\DZT9;GV\^3E!\K#/,\#1^WN?<843A;P+FL
MK,TVK&2%RTT<RB*$9*'8#R-:NZ1EE?0SG9WG58YD"_8\=-H,P9[>@Y\5V*L@
MANJT#%Q$^3+2\##P^*N=@)%&-(4DJK0XV2V&-I8.C=];SW[V850WU5'=%J.J
MNM,>>7Y7GX[KEC :8,15H9']VGI0"8FS$C2PHDDS,*3U0AP *B<ORT,VS2-D
M:Z90X)K$#=TPZPY-AE 'P5-_%:M5I:\^1U'U)@,-):B"("NO4]Q:[)?WQ>]%
MS.HV26GX%(^V:4IC?[=B+BR#:3")[[PPACG[(4ZI%QGVO+N1P#/+8T2MFFT7
M?!2S[LY@0S'W  1PRH6O)$T*VJ1"?%!<V[WROIS)^'X0PL?T"<Z.3,;7PQC<
MAK''@D@O(E1,WOQD&$+8]PX4O\X91] 8(PYF^3--YPD+E&G. F"(.^2=O#+H
MT&T&=*& N'G47=#:[I(].L[V4U?^&GHJ*? 4!DZ#U(D02243967O%I1-7AE3
M:WZG3(9^V??I(S!ZAH [8ZLXMG3S4TAWB4+O,8R@NS_4R]"7393L*"4IW*Z3
MD>V&9P(7+\&.:->4>:F@Y=+Y1G31@H49]UH)5 ^%C2A(T;$%3XJ03F 5&SH,
MKUC\D7?7E[F4OCV2/D:RBI4%A9#R0FRXH-[+,L.<>+F@^Z2/Q@2!R[9B*5C_
M>;!%]#&+12%@=@N]"QB["YIMJ)_/UF/IJQ;<53ULH!JB<%2*#+E3">)DPO8S
M#$4J[&G4T')A^V"[H<HB7!<7U$-0("B3-2<-MIL*XCPCUCPM(J7"GF]8@"J9
MQ432)8(P\]1$DH;RJ((X$=0)D">+]ECAW"N;\P[-B:J"&T$5O1-NJ/BW<I0@
MNQ.TG )V(8 75W47LQIBV6.C1%M=V6LV!RH::+PK2+P''=Z?E94WUKAR4':R
MR)6(K')X!7&82&@O%D'X!UE-44>0'<%$^SG,GT?;+&?15GI?+-JL!ZR%BDNV
M:B6PV6"-)!RQ6@L>;4VW($7>&"U2$!N0DIQS]GN2\$QB7^)G^_T+U^Q67A"0
M+:A/PU=(=[(>'16J2Q:J%\ULEDT\1VQ1QYBM 1;X9$\ ?6._#RG%/J$0+2VQ
MKICI!514@O%M5#&3]K\'(*;MRFQ_#USQB'VV?LCHD+]7$?[;(N*LZ;N)5:S=
M[;#0UNA=V#/T>N(9U9Q4/2;EU,1*$]:>6_:+H(BT]CY)W$X"HJZC>Q#S(.J.
MN)Q\<0S?&^04[L.!H\*FRYS$KTSGDS34ML=MP7%IVE8(8YZO*PB.3-0-CFQG
MZ JB@S-SNU@%+#]9WXL56HB%'/_.O1T$#<,X&(HCQ_O]8KMSZ&(FYI*Q=1'?
M+FHV47+$/.U9[1Q92Y(\ZI1$284J^GG:F08CJ Y&&8MO*H/!#_*]"-G^[8O)
M-./7A<#74":ILFU[;,?+(OLKASSSSE22>Y'):GL1N6.IA).&"A%(UD=]LY&0
M<X9K(;:% 1NHN&3(K6QV->B2H)/E5;V-PF%]\V3Z>;QTK+Y9E-1 UWF?5W<Q
MJ9GKR7=S)DG.0H\Q^^M&D1ES# '$%-?.8M8R7*VQ<1)<.[+7S&^5!*"$3Y(@
M!8T!X50&/&0L":$OA4^7F3'U[(D>91N)RV6DK3)>U#!ODY2)YE,:9+=,I7D"
MK\(3M0R3-15\$^THL,I.+4F@&FLG'O46"[G7[PI"!$;TO4Q15\VQSICM:=(/
M3\BC<F"WV#Z^.#E ^3HBY],B9L<CY?XB9#>7O-U$YDM>N<KEF]#9U[#(E85J
MIR]RC82<,U4+L2U,UD#%)=-M9;.K"9<$OZ9%;O=1.%SDWDZFP^G(K45N)=0H
M;KB<K2N]+G712CL>:LLO.Z$..H&9D; :A-EPU8R"JW$OJ=Y=6NU*BEU\V8MP
M(<+UP<K4JJHXZO;@1?=O57Y5)VR<)*LC!"PRK3J@HJ5;=>:QH9@KIFL\C OC
M=92\019. ATVV+3'TXA!%T6EBTS]8P^X#C\G$=/5K+@F0-ZZ%Z92DYV[,>#T
MH:K;L/8F@/(B ,Q[HDZ7]JQWGEPPM#\Y8OHZ0OG30GC'0_?^0G8W5]W=1&X<
M-*]+05U9>8_7:U%>^<7GV9\+-J',8A =_A]V\U]9?,.3T(L[Y> !\U#U/U0@
MRQZR-V&V23(ONDN3[89AL-^A#B2,MS20)_;,/6D^@ N,X;D3%Z1ONBE\KE#<
MGRMB-V=^SAC,^P5K!'B#FF=XWT#XW,IK!]4K- 4(! H'?ZQC[%M"%[P2SBS'
MK+)+]OPBK_W<_6"WM^/1"JY/&/]U]--P>C<FB^%J3,3/2S*;BGL5AM,;\</X
M+P^3S\-[N'0!^::84P9/W&W5S+B40UK]3.+3:;[KI9E O,\&9;AK5^1<E .<
M6W<01&SNX_;FJ 5'1)&8777B]9E"L(8<:SOQ':;C%;D9CQ;CX7),)O\S_? Y
MQO^K]9*].[VOSX>=V26=UZULN.&/8V/BRSF&YWIX/YR.QN4E6"HG088K,F9_
M9S#S\6(RN[G$6"QS+\U='8WK\=UD.H7SR?8QN9@GA=O09"/[?3Y%'"AV>2#,
MCY)LF]*6#(33R>+ZTSZ&Y-"EGD(3S:N>SK32L1*@N[\^89]P!,Y4F;NP)^].
M&L.9!FCY,)_?\SL&AXN_L2CL=K;X-%Q-V+*8_:^2QL]\C"K?@4QG*P";W7^&
M!_L4">1$"-GTBG?L#,*<C0/L)T '[^!ZFT^3_&\TGWNA]LY5:W1,U]%-Q+J+
ML,-%<@5=F%.8O.C-5L4G!0'RN,V9)\C)CN8$B*!7Q9XHK>O9_0>-,&:/N1?&
M<*Y3+!-OD[3>.J.M<]M)%/',M8>!J%KP">10C/ID?AN:SRE>)>NKAZ(1#"FH
M0LIMN>L"A0.'361<:?O6_ZCL)=6VD2%)99AH=9AB^M;H0Q-9=!"XS 5FV\TF
MX@E?7E0$0Y.8L?W"#P#:;KNVQ4:\XJR;@+4[S^Q0<2Y!Z\);,SZM8),RFB<5
M A<+T2TF\Q-EK<7B-Y/EZ'ZV?%B,RT,J!R[_+FZ?A9!D2O5-D ^@,/O.*!FN
M-Y2I@2!UBE'PH.AZ(J!XZ#J .4Z>,<@HDM^R5  -,-I)M#<Z[23GQA2B'YW:
M6Y!?R*S-IB)KH7!2=0T,%RFY"A"TU%LM+X:VAGQO9I]&RZ*14%)!2HJU%Z+4
MU@)T $T:$3-<CV"]&'GDV[I%^R;FL>9)%/H6=VX;$!!OSFX5HW;_M18:YQ;K
M%G::8<OD;CJYG8R&TQ49CD:SARG?,IS/[B>CR1@Y7KGVLC";K>=LE J'!;G>
MX5,<KD,?.B@TQ%W1+_EUI"^6.HTDGE;V,115O3V%'HIFG\YP\RP.2,+T524J
MRA[V9,F>+BD(DU^ -.&T\=<M9Q@9I[U"T4UT9WW(:,3 7-VT"E)?Z6C!D58]
M+?PT Y;I9[8^GBU<5*&VB<.,XI02&1V_"=X5-6IS3R5*[;#7)9]\C%"N&,>M
M%Z:?O6A+][RW1?)F%,0KOBU$J5WI;8#'N<*[E:'F==7#R8)\'MX_C,FG\1"V
M(&%3TCV5:G.X+3AN*971Y1H1G%&K-O\$.(0C5;RN8Z'P47(Y:"^\G%D6HD-.
M8;Z;)GE;E-N&A'@X9B5.[4S,B(%S%&;!4G,AM9J-_DQ6B^%T"7E7LRGRW*X6
MPCX*[H#OFKI9QL?6R XIH7V0*7 NZ+1;SY1.E<@U"QM[:1S&3U!HLWSV6K<F
M]."(U=0M(M1JG#6P.)7'1F::QC!<0(;]DKR[GRV7[R'-GBQ_&B[&;FE0FT\V
MP+NC0T:?JP5V0HM:?:J$AXI"PC%<\J^=I7'3*":QG[S0E?>EPZ:O 0/U*J4V
M00[N2]*!8UV*9.:GV8AK^%=1JC^9CF:?QN0=^P.Y'D_'MY/5>^>4JGT;V(3B
ME%JU; /KX5U1K/9M8$ A# =G']CF8NBN,CEL+4OZ!'E#"[I)4EZ\U+(=H05'
M7!FVB%!;"&I@<=9]1F::BZ+Q'6QB54O"W-*=#CL.-ICN:)3M+D,[FA-ZUF$=
M+C!)B>JH3SY!PIZ-2IG=6DU";R^0L,+ R7JU%*3(@&T!OZ@Q6//34@0@:VZ'
M]V2Y&J[&;GGD81"$()$7R0KDFISV_OD(.HBYG<<*74OY[$H$)Q/T."Z;2=XE
M'5(2JE7PN.GF^Q+_*[+HY?8QH__8,I<UAN23MIP-/3AF%9U9A'K9G!H6J4[.
MQ(Q"JZZ7X[\\@/J,/^-WR3KDOC4FU\.[HSOF^%L'[(3VM#JE$IX(!)<\;V=A
M>K4%95 ]]: UPVR];SC*$Z%W.CVWQ,$)K*V%*4+K5@2T4C-+SIK-!SD>F:TK
M/71%<OZ9>P+H5@N]"O*+P"4N)%:=(MP=C1E"Y$0)T4$)Q,YL_UV1T<N"+,53
M% "U8&*6^EBQIB_JV:,/I&]PRK+Z%793*?YQ*WO!SM):L=S)9+"PK184)[(:
M[!2LF=N 9TR=4QTLYV":$UJ(^2Y*LNP]83,=R8 $KBW=T,?<SGZ4D'@V8V"\
M:B<*,!3;T/+14!: =-@"[ 49)3&;G/+P,:(D3G+L_E!3^E:9 =,D9C_Z?/L]
MZQ*P=2>#>076<2+7+\+J1@/I.JQCF%3XZ;=:+7:-D-,A7H\#X.T'8%,CA+R!
MZ#_38!NQ16)9^#B"+IAQOO*8AVG=3[1&1]Q>["AB;;?1$A=G\[$3<\WM.XD.
MJY"2P(!($N073L0I<SR'P*Z8WV$(# M$GU^[%&US&G2TQH[47##.HP9 ;:N=
M2"&;[A&\&A5;M>[C-.4U9ISJQ8V[_>SA; /2%+X<HG?WY9IQB;]FW _!*'G9
M)#$$!^#I9"8J;U6=T6L:TW78=78^@J(+/N'H@5#[A<[DD'W#D?P:S6%/4TR#
M92*VI$O>2<KO7782YQ@91H%F<*6D((C<P)V"H811R#>&RR,<O@IAPH'C@HNT
M94YDMDI&29RQQ4@ ]Z2W^86^B".V=>]U>&H=WGNAC-/LO4?6FWW?:\3!7O9M
M;@7]8CKE=]$7+R%Y0JJO<<^IG'74JOZER+.N9+.Y$G",XSS,=S^' :TPMZ!L
MB;2E(/SX"QO&V(M&VRQGKC'-KG=L=(*MGV?0L(ZFKZ'?WA?FC.]S(5@YTR!J
MECC]O@Q[$70.:10NC!,4#JH@24J:<&]]057TDI1TW?-9EQZYJAN["3/OZ2FE
M3^5$(%]WVDYF6TU%NKOV&$\^73Y3"M=4E](:ET)'4T&OO>@JL*(>PY8$6AK9
MT;PVJR^?*<F]QVWDI238Y[5#0_.L>I?%HW@)R?A;2+A_#5*_\_Z&H$:)2%)$
MT*K?W.'.SF[/(U"-MJI?O2H]WQ*JCLT9W):Q@R](HAH&"R0DIV0M3NF#6C'P
M7(XE:TWE:NTL#<C_A>5&SBP6[DIEQ6C/UL,TA3NSX.L.OX2Z2[XUL'@K!"/S
MU>A>"8@2F1LX4>2C1 P[@37S*R45'!Y#5W^?Y<\T)?FS%Y,ZTB] 'EG%*HQ"
M9#Q-8F__EQ7[*?-\GD+]B;X\TE0S<)VI(%94'B=PK9ZR&PF<:LIC>#R+DM\D
M+UX8GZ;FRG!CR%X<T&"^#O])TR%;FG%.E'K:#HX38MB(4 07)EBTL**=*<4E
M3!R%"!Q2(I%?!-J9HW)=)-&C)/UY](SZWSXEKQ\"&@IGSG[8^W#VRZ_W],F+
MQ&Z((CA00EQ>U0V,@G8K'E_49VK?W_CB'(H(L-ZG[_:/+5XL'*I"AOICG,^L
M8K'XQM5G%__ S9<W[3F2WY8O -J\T='SUCQ-X/+$+]=ALF*3IK>AVSSTX1[N
M)-TDHF)-.XMU0<:9T[J+5\QP]IAH\UU7%ILWJ$L"A%$@51*D1J-4/Z1U]:7D
M/,/B)TOSRL*'_;;WH>R77Y?LV_)9^HXF3XRKY]#W(L74V0)[>=NR8AY,R0AX
M4;]KP8FB"'</=KX5<IN2B#/K*B_*6;<%%DE)VI@OE40'>'DE,7/2HB1]K#"5
MD1C?%DQW0E/D+WM%D7_X]7IQ(%'UP>55H,D6?._]7R_Z<0]?VRP(7@S_<W*/
M=*[<SEWJ_3-$;@@ )7*3.,O3;<L.L H0MZ)2S?9A064="JV>4L6&LIR2["&=
MV,*M,S_U7JARKFH'=T59FB+H568/ZX#B'#+3ICX# AAGW"*M%,W")279S98R
MF(_#.&#__)MVD6F'AK.\[")2L;"TP4%;4MHSI\CLDFTT:AD=4-B1,WV"\\P\
M(?YAX30)MI3 *_@F/KP$:9%Y@N0<OB[$&?(9(,%KGH1Q?AN^TCEE8K//^$27
M- Z3=$G];4H#M1!ZV^J#*%(^1&_#4>9+G$P1+Y^B)]9--IT_4X-=9\ !V0 +
M9 TG;9N2"?8,N&#_<#;T+@#+\L\V>@! IOCM(:"G8!B$7KI;>I"ORB\-,\3N
M!GC<!I5&(0X;5"J!T1I4&KAII@-Y,GT.X)R(ZBM\0Y X6U<.[8WQO0TBHDY9
MBU53KE8L'"VS9*M-W<X6_\-[LO;4"#484I1A8+F,&Q0P>)& EIGCXO4,Z!&O
M((@U0]M+Q4$OGL>AW=0[C?L+9T7?AS&=Y/3E,"[H@NA@=G1#+*L,Z1+K\I=G
M=&"K>RHQ$""< JI-G"3CY&XZN9V,AM,5&8Y&LX?I:C*](_/9_60T&9^C _86
M;':VOHN21R^Z#]D"(8-KI.* 5SCL2H-564X79*2>V)W%*YMC6V/B=<GNR&+;
M&CCF]"!>>N(42520Y)L_O-!IMY\Q,Z0I\V2Q!0%HKBU(D)(&&4)=II!S3P;1
MF?0EJ_4W/<?>>"5-N9+*7)1URK8:&;3( 4]9;E(H=S*/IH6UBWZB\/NM]2,)
M(>ZWG\1Q2XY\)<N>I)(BUV@J^\QD@FQEMPYM]_V<XU"M#2@H%KUV,B)IDCU1
MU%),7)7(%#J!N_<T2EY>DIAO3HR\39A[$>\3EBW8I)R^TN V26^W<,?"),NV
M4%*JV1\Y@@[>SM310E<WJCH30=FW.I)+A9X#';&+-2"2E.@IEY&"&"]&%^1(
M00^YCT1?\DM)4PK;=Z+HWHM.LUU-J%+R.XG]E'H9G<1W:9)E?/=BGK+8:;;N
M9J,]TL4*87H<E'TXTP-1Q-"F-^X5Q4ZP90 !>RA)LQ_($Q"76Y8;( \ F3 +
M[]4+(]YR 2QC+3Q *-^"%O2<;X3JWG!2&27^ B)V&N?%*+GK)L\]4-6A*7KJ
MT*8JG=6/?O:B+314/":\.8T4NK<\2G2%@^Q$QP6?> 3#33=8ZNLK4 -#]H7=
M9T4P4+%GYYQ>'T-0]W.?BV%P/_P[PUC4(\!RQAN0',J?I$_;I(E/:8"<DC*,
M\S" 5M!L3<HS;'B=X_B+'VT#)C#S%-!==IO+?I"'_:C%_*\)J'NBC=@5HL_!
MJ?6*Z(,P3@>)_CAO>M$*;;(G3@KJHE=AA;ZNQ;MX"_;5W9<:J6P_4K0V4GY]
MI+2W@PV(9QXPA(*%2<P&F&;Y@DVJO%@PT&ZU'T/ E:(&&S'U90XF; <*']K9
M:R^%*&@0(#(@@HP+.\2]B5Q*F$+\^,YC2^1BR_<]KD66U\(LO+=/C+DT]*)L
M2O/96@9$NKQ5&T0\"[07JVIY[5@H%F?+ED+MRDN.&"HI<0<$;I+DC6P%/O(T
M>K2 (-5+@>"((?V<I'^?Q'.(_+-NEF3"=,"4V@53VI(>#=>8VO@R61/@PAZ6
MQ';6GCK+6 C&%JY/C#57;.HVC,/LF09W21)TLRD3I@,VU2Z8TJ;T:+@VU<:7
MR:8*7,*1G36ISB*6<CT!ABL78/!]L.O=*/(R98-F*PP7+J'0"J*^1J(!CGP1
MA(:?YG:C/&D'N$K]B N]BL<OFRC94<I9FFVT3<PLX/$4JE6(JCII@<^F3!:+
MU!:F&AHE0) =TCP-7UG\/H\\7U^HU :,IS5F]JLJHX9$<3XF5A3=W#@P*:&Q
MBWSZD0(YRPZ\N/3]]YHZH!98Q&PY$_.UC#@5($[6FYZ3YAGGP0Q[CU["<XP4
MR]5L]&>R6@RGR^%H-9E-3RO4Z<'/BX-0.!+YF:?%YN,O-/7#3+N$,Z-@^OQV
M4>J>7P^/Y/_;&%+U].0HXLQ)(I$2"WTJZ"Q0\1P,_4V@($="TKHE_[-T$3X]
MY[-MGN5>'(3QD]DI&-#09XI6D123AA8'<_YH84H_E10&DZ2$HPY(!=F-6:6K
M;!)>E#.D@,,DM1#J,ML</'DQR[8TN-G*NHTP"43*3F5]E!5N(-"MTX\@A+@I
M<K38M;V2SE1PME".9%.=R'5U[3$(GG="XTRD4U0+F1YWI HW]W;\ST,V=P3,
MFL6;!OL9D1\.<(:P+\[L:YBJ,V;2P]:!,DV7IQE7I_,B"8]?@%ZD[QV(V@41
M)P6WFUA%PJT=%EIZ;1?VE+=7BA1)W\N>H2=*E+R)Z!+JOKT@".&U7L2>B^12
M-L1Y&CYNN6GF"0>C_&8'I-S:D^07=0%E6 WH98XLE(%7,VT1<V9[D#'CR^@B
M#]J1C%CIOXO5="'5*,D:727L4!"7HQ:BU):C!GB<Y6@K0\WEJ$39;].4ML/1
ML->CW25:UJW$-TIQ\1V;+B&S!9X;>S?6 7$K$OHN3I<XKKZ5(_1.HI;A*W;0
M>JQL(X@E-C4!Q?0C U9"6P6\\#'\B0GD=B?W_;S$A</^/H=+G1_0QQN04PKZ
M$\&J>F,WV!=OC.=+,O(B?QM5+U['ONCVM/&XWJD)&'KZGO6-7VVIE,U ]EA
M97K=UUA6U2Z/=;&5"UV.U<*TWF'2CN::?9CO-&G#<4A36^\XT:C;V>\ZJ9Q6
M5*/%A_B59CD-%NR_:>BSGT0O\#@H#B^T;9%/IHBSS]C30!0;D">20]N9[(7O
MXZ]GJ!R#U9<? [*5+!0M Y(U= V0W$A@.% KCJ21MC;/,X 5JO5UYX 4E,F>
MM 2!T2C/&AWH+^WHT& [U8(/)O#AY1T].5F+-WP-3M=ZH(YSPJWDOQ*G;"D'
MEI,>E!Z:6V'CEIVOPF\?.\;'.*L!J26,5-XG[NSY^ER[2Z/GXDK.>EU[WY(
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MN[2GY$)E3&?!->TQ;<E@M\WLQF=3D24EOBP6X*0D1BK4!KSU@X1PHIR%7SD
M[%QOLS"F62:Y,Q6DM.!@MBRQ$*;>G<2 @-2(I)6CIOI)$"<J,20SQK*+ QA$
MA5$Q6U.0*@".0C0Y,"C V:HBELR3150X-7!;\I7:=-P6>)SD6BLABE19(S!:
MXJL%5Z8T5GT*:\8)D[2D3#)!&BG[]!A!!0[9(^WG6OR$T!,$2L0*'9*+!9(3
M+EX5+MVWI%_:H:)/"%:B*>8)(Q[F]&'!F&Y644>R+B4QGB+C^.[3>+HBD^GM
M;/%I"+UMD9.RY(GVK##Y8F[7I;CHX1&3K-J$J"53Z8!QDJ;,W*B2^63^1(E1
M3#K(B?3,8I)T& <+&L$.L3QVT8BM \;3(3/[50520Z)HCXF5ANIP8'XX+,&+
MHSMD=]I)B.*>"+APW4LA&UZ<=@N!J,#%;SZU9BMIW@%0%-CPW* E35]#'[+=
M399ABXS:AJJ#> >]J"PPL1I26;.FZDI5(A<U3AR=%/B.F-I)4BZWCU>^Q$C2
MK# V['PV<3>I9'V:Q.7B19NH8\# S$!K%:2>6J8%1\H9:^%'?ZNL1!F0*A)Z
M-M?1XCAB%E",^5+FP13<:<75@>/>,F@2X?!J014LVGV">F:4EP@*<'DBN[]2
M&CV5H[,HT@9<R)XZ7*7/\F>:PMI<W%MON;9O8+FS5Z01R+1-=(#BQ Z1DJ?V
MS:$!X8CECBM0&!!!P['](3L)A3ARP]61E8Q6$JC233+>Y?R&9GX:;A3G!T=3
M<=#&S );V9R:A%LV:.+Q6)NLT!R0"E57K?2H,4C+3>O 0L+CC3=+\XKALM_V
M1LM^^?63]]]).MIF.9M^4U5.A0[H\B9G9A<L2@UQ48,QL:!((A<PY\N+:/GZ
MT*EPMJ[QJ\R+:('%T856Y@N5T )>7#-:.#$HR-GR)N;K\)\TU:9)U!_C9$6H
M6"R2(*K/T'(>FDPT;P>)DD<O8E$:",JKLZ]3[Y]AA).[8,&P .E?WV[#Q$^W
M_]0JW,%S'(U3,EFH7.WA15V(YNV-;R=A^O]XH^>09J'VV]4?XWPZ%8O%EZL^
M0W,6329:G(5P%/R88))[T0['95BP+4"0BVSD<9\\&[P/O<<PXCVC9,6>)KBW
MP$,LD+$5JE;^TH:$4]QBQY7V&/>J.+FM8+(5H\#%+D0Y4K:YMV,OB!P\F![Z
M;!ZAP6?/Y][,;$(Z8,0^A$;V:UT%E9 X/0(-K#0[_@E@4D"[8@J=A)BGR6L(
M9\P\+GZ5.$YHOO7\88!'UW^[^4(+C&D%UCZT, 0'IX5C17%J"E@D.R^R-H,F
M-+H1Z 10F, A**8!J'G1ZDP)[ICR6XI1@I&-MX,:!%S=7T%SC[G@Q*SW2D@\
MG3<P7M5W!1B*KFOY:%ZDS-NM2%!7=-R>_<F^C+P/!5=OZ K"JZ38/%9KKAD4
M::.WA?5RTU<#A[<!;&1(<7%GFN[@Z._5B[:4>/S2!;C X=&+^(6XV3.E.0F@
M,X-\DCQ&X9-H@@+),D ^8 _29/OTS/[U)#0L(:5F0<V<7QQ"?4L>H T:^Q-3
MG B:@ %17S8QXB>1HALX_#G:1RKD7< 8? OSYY ]CBG942\E+$J7?P+P&&I9
MHDH-F+_SV>O#-8F2^(FF[Y$*]#I^% E.5@DI$+ =S E25#Y^_RZ&3>J0EU+X
M/+9^@U+-W3 .QO_8AANPE.5VLXE")IC>^QQ%!<<QG2!PX;..(('FSH[F]51/
MI_1R!SYM([GA?Z<%/R0K&/K_T=7U]\$*2OL8JR!&&#52DB,E/1><9'_RSUNT
M"SF];ON8,:881^-7VM+:1PF*F"AG8+V6#:> PTEYTS*B*G21H(3#.M(YYT
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MN-!.7&HG72P6*1:(_$,FR__X_U!+ P04    " "Y. Y;H&UJ7X2+ 0 20!
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MHSQM:MMMGC3P0:?O%MIJ#24TD$];QO [JI2(:VT1I%8EPNOE;&V$^J2_8Z+
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MBPZA/#(PHL#)CW&9HDSXR[='#FW?Y);=0I/(2_S4&EEDS&VGV@H$,BI(@4]
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MGZ@%]K\8&?SRKR?T?L0V8F=9WKQP_=4SW6_9(@?+C:0D5)*()P92G^XS$DU
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MB%XNMW?"X-;BA5! 1!@3Y(Q1B0%H!<=V902@V,$N5YFD6O!MG.Z"T"4:C]G
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MB;!T3JLL,N"Z6K!15&GVM-;3W9'&QW2(2S+&.720:K_,T[6FLR94KM$I$-7
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MV<*EKC#."%#C;]]8>;Y)V15>+,A\U9QF,DQVPP$]0LQ8&/&!ELH;'4$JZX[
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M29NE_I0BCTR#.+[NHO,X3NB2_TA'$NZHD$02X%];N,P/J4/L#NYF&?RH">$
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M,80+Y7A+,WZ?S>BZ-DA7B9;$;@SN*SG%3G#R"IAXM3;\<-PX1D2 FEN2GT^
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M>=8.HXKS"-0CS$5Z-%[;< WD\>VE"Q\MC^$O8/U^%+^=S+#?*+\]FX_^,@?
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M\QSG76!#Q*O$KXW;S-++\[N9T$-JCJD'@B[C"@@E#(SOT7>3WK!,_9:E5G.
M@9&60*?JP;H#DJ]H)JE&ORJ\0(0FKUN>JV;'I#9C6JFKX\KC/$GAU$AL2^BL
MIZW.83#6U^*'R;=:7^9;+?.M?KQ\JY^./4W[H^P<EVDC@5U3&&1!=07C0Z(S
MJZA:+W2#$0>3V>H#0>2C)>+V)N(!<S/; V"IL69P"DF2H\]/26E@J4=!1?H1
M)L^7M#@,\,&/:1:8HFX_PZIQ'FG;%?0K3([VT1,9])9J1U$\V<8H1?/I4_X5
MJ"(@D4RNDW&5DM.@X  E(U;Y3K4[@8-UY4"=!>C R #+,[$]F^X(0>4X:4E9
M]ARMIT-P4U;;Z!^H H*"H;,&4C DLSHJW*3_PZ4B/KBD>D/UG %%:C+FGB3!
M"$NDQW5\+6O7/A(KF5_ JUP.W)>9(_&V&ZSLC.*<W"P):^CI<+G7!7\$N2\#
MLC[>!'$OR;\P1P&J-' ))H4EM2K*7R?NER!T-"2*;<)**HM*L% FK3*:L&R*
MKP39NV$:6U$6E7]F.2;9ZE<O^JF/D-/#!E& HCQ";\,-FBQI,6$0WC>,0SRI
M4.=4J?,)"#!EQ(6!N-EAT =)38S,IQ@ER(R?=H^1BP-?QDPY8AR1G>'%F3]!
MXM51G$XXJPUVF?4L/[D.>F)V2PRS<"QXL>)<I*T<23EZ*6/\M-O//C9,JL8X
MQLQD(^46H1SR)!]@*G&&IU2(8^FLI6PR]DD>4/6J>O+GWF1Q+?8+'B8,QG,2
M"I?0<C1&A30ROS>,XC"FA&*X"JS-<QIJ\!,3;65$5MS(N,%$H(HD-6;:3[M=
M)IJC3,\P4)8.;25[S7E7B;'V.-JFXF].B"1+WZE-#Z(T3XA%]V+&"_EIM]<D
M+DG\M(]1"]Q VD-;@.G$)$S>C6P3'95O F;,^9BXTQAY<$Q=C.'*; !U\=_X
M$C4<G07%22LR#3  IJ4EY8(@2@%&58"1]]13\R>BDYS4DBAV#$,^Z>$_W[.?
M;5"!S.389@^%(&J--2?)0U\ER%.\DS$E6"M$. .X6.<99Q<DIMRI4>6ZU:MO
MB>.3?_/4^<D'F): \TW]HI)0<R:F\@Q]'+#=/4K-SZF@BVV>6#T[KPYB5PDX
M'>P9NJ /]OR<TFQI [M!K*7C1$7U\!&RA-!3X*/[S-;<4S]#_SN-"O81SH>R
MS)&AU>'] W\Z9033ZR7CP+IM8 )3;8#CNPDFSHDRJ3V(1;.Y'U 6 D>SR;(J
MO:;A(!@#A@S[[G7,CKQ,\$?(Y@8+@L-/5)1598!C<+X@]VHZXQ1>B@DIF*,X
M(\J.-B&>&,<D*<>"$T3(HL0P&C$R$_BGH#_ESKCELX&'BT<C13,ZS=6>Y%-"
M,33O5TUZYF,81T.B[%FQ;UW0^=-)- (-G881MAP\GG;Y#%T@!$QV<CW/>.W.
M<I U8>BL-9O-)\JII\)E>4W[Z5YS"#MWB^Q-9V59M4R7C?.&RN_KA5A8$MM;
MU]Y26^>FY!!6S^&'>O(!OP'WELMFL%!6Y515\/X?0+!:+\4XYB-1I(:Q;<V@
M2 K(Q""/E&UU$(1 GL?N*(ROZ-A P<%L%(;U<>X/\6@??R<?@+"1J:RKJ9!*
MY9/?87^"=<5Y-X@:SD4,^E6*608N"""8"";447J#E!T<*[Q)F>40IODIIK(!
MY2^DM"M,:TEU=H$;QB!1,-BCGY<7=DA88443J(3TWG0F;J4?>6FM- *'F51!
MJ,)KNG9A)R59!0:,?%0?4;CE\#L8L)?%71@0M^(Y:2MS6?\)$,-KR?)96/'^
M!W:*N(7,;-(]0&R69*D1G3W*557H6T9&U90D50D5E<5-R%%&73S]3'P,] ;*
MP_1!GY=!X W7@:M,AS%H4U3A<)K$N\"F]F^?B,%BE3!P3WA%G6")U;14*2 N
M(IVDH!U2A2SN'M6V!4F:24Y5:-0,H$^T48JU-J0=J6'U8K-A$N>#X?0$K!?#
M[],\Q?0>Y,4.DDP>!9]S?WIV6,^-F404?"(N,_)!Q^("'\M]9I^&/@%422.M
MQL)V$? 5!B%![7L:-0DS'6*J2*WI8MB"72ASQIVZB6UZ589ES<&4!]Q==G3C
MT?C1E\D(%7Y2_[E"5KNU5O;/+M+5E]^EVF[U_B5U+E69!%27XP7N((H5?HI=
M:T>TMQ_ZX21]LH4@3,0@!&I-'K8,8@7#(/024,SZ>*,1HX+-A '/7%76T(H/
M7#!+X ]96D.MR[D!9L\W[<>"O=I8IF$MT[!^O#2LI]8^=.&'5-2CE 31<^Q.
M8%6MMM(R00DW-2)]G5S-^=-.>TTGUYI8&P>G:U* :=+RT;DAW%[%0V]0//3]
M))%\W]0Y/?L3SJ.MBCPP%FX'24@_JI%FS);FS*E-^='8#:(+$N [U+D/D/?!
ME /TZ-2<<^"!7_P$U "OYISZ2:Z642,;+7#A)_ "=QPGJ/UCIFH(BA*N\<(-
M;MR(%!,2H%(GJ>H=R6F:Q06US#?,-4Y"[P:5^!6I$<4R(][)51.W4#GM*@$
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M]R@=D:$>@TFCD[?1V=*-/1H#\QT1>)Q4.=IO6!IN&FEY47S-$#$Q809@Z[K
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M5@EM%IH(QNDTBBLC#P>@"5'ZGQQ%86OJ*C!H;XG!*)^-1"@G:BS/TME>R+[
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MO9<,72=<,6M:3+@_6,/LC66<=AFG?>(X+7!FA>':WMANM'CA/UKHUJ0L:<B
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M,2Z2W_W)=",EQ)9^R 4D4]]5$$CI2YJYQ=\?8>Y*4;(^(6EA_:V@P4GEP>*
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M8)5UD-^1R_JWM^Y_TKPX?:OU(WE"E0\4]4OEC2_UA(2/R0'9VEI'_V,^_HW
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M&PN8-J.= :<B3W5);YI_542J$+EH^?]_V[O6YK:-9/O]_@J44]EKUR4I/$E
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M 4(8OF_FGYF+N?AG+N=_S]E7^YSS[/7N_:ZUWN<YE].72X!;^MIZV@"R:P
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M/][51I,9-I\.!/WUVB[W+[$B&&/S>E69NY+NP2-'PM92=RL37EM#OQ 3KLC
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M2+BXI'B+'@YF'6F DC7@-; S_I7%*0C:=#Q_+':Z-^BI=-O[MS#"A8?'Z4>
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M509BKIP+,K$/_TB>_B B$!A)"?3;W*2^V^N2DY5:5N;)+/_ZDU<*#Q.__"1
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MJ2/[!37@TJ@CTGX"4,^TIJ$=2-P>W;M!V^?0H*,=!P+0W'/RU.(M(RC,4NB
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MH55*%PL"K=RONFKU&K7N&J%CB *:HO\@65R:0O\Y:J045E6KXNX5/;T!-[J
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M7U3/_.!-1%J!%T'@HST0<:52*(\HG&\QF8R+)"Y6@<?<J)2IE("^=L1MCX-
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M]@\0:.+&';:K\H_<:>E7V]$U\#YZUTF<^Y<)0+TQ7NX?4<ZB)D<\@68'>8\
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M1;(]E:?RA69X>6--"<J@Q-EJ/5'E=24:[.N (&F#I)OM.KLG6W]I=;R[_-9
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MI>8%Y8["EIM-W 6D"35:"9U6^#V<6.(L_C!.1:S>0-1/UTE.>\,:J14?964
M?QU+5+N_*_>47D[>RSLF@R45>1RU954)#N\5WQ*G4/!'*NK"[,P6LFF[A#,0
M+*R>G1$-@KNRV!AG&%IR:PS./N.*ZS@=>8.],=#8Y.DS^C'% MX[I!(%)$&M
MAM?\-:O[^_00!@\V0&:5#-1U^L8LH4XMY+I1*EC_:3=>G2_%&+(T"&=O]"PT
MWT#QR6.JB(2*&1%;C=HQ1#YJ*/EM1]&R+?PZ^UA9<9'UXQW'GG*6ZS&H">6%
M5%=6=!H\R*&+41=5VC6"6[$WFZR 1LJZ?'M\GC:DZ33:F=TBZELB.?1=7^/=
MR*S4I2)SNZ4)CL3'R-VHCTJ7DDQ>C_<4)WQF'UA@-@HHA5PRG^O;X<NY8<K;
M6W.IB(&WH3_.H0EP3XEVF&93/NBUU MY,&]IGJ\T&R9_@W?KHO=5MN'0(_-#
M"0,= J!ME(;?\CZ4HT3G!V<9JL3J\:W\'*S.$2M;=1[RKE'*,T\X$[-@^($
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ML%ZOO<0'MU.I2.?;V)+/?2'MOCP6MMV0$Q6C$CP+5[%TLU,)M(=#AET>]/Q
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MD[AGU5,0 &P@T)M2#"M?@RU\VL #*L2U69T E.7AZA,,)IZ0@XUC68-WD($
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MC#KQJ)!\ ^SHL'DN<5O>:8'5M69G;>>DR:X_R^;/P;-9C#^(8)M@?/6RTY@
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MB/.J%=<J$2;V:M=\R?]L#3"=):%2TQZ#BVO7]CB[44LW:,PO=M=A 2<,7^D
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M<1)D#4;M1HH:E4RZ@M?I&@KVG81T%X\8[MMLED:!BCGVP$,=H/Q/XY.36
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M%^!9V9^'8!>/3] NTM_S*XVSV^X%X=!=E^)W]CAY/4<9X ),C<%1X*L-#!:
M(JJ#(EHGS\&6J"V.+YI  X$_#ST6]SY=N!/BY&5SO'5M$0N03",-R =?6;QD
M\OONZ5]6C_#GU>([N7B1HT1HQ!^Y(#X,6O3YCRPYJ1OLKW5;*#5XS^ZUR3K[
MC2#EN5X0[-/J.AQOZOHS8/'"8=7?.*%O'63WE19\A^6(05G7;@N)ZF6LI3SP
M_Z^@ROND@%\$MJ][8YS_2 5N>'/WA/3$[6.@ 1V0_Y(9N(@G"T1R8%YHP/[(
MC!^&0Q,PTW;(%E=AX.1WEI_LC=[++W4*<0CXA@3S)<'K\D>1N]N4?Z"S.$7P
MGB3JP_7Z98WDXY=.X> N^1><$E&49'D;\6J-#-IUO!E3^Z?DY3XI\=3?XAXR
MH['NM=_JB[!O/OD"A/.0QU>6[[^2/;A94[8X/XO\/\A>M#D/$Q: DR*C?"QE
M=GX1D7J\B0\+$,W%23@N$GZQ_>\U_0FA^R(?O.DD<-([LS"HVFUR6'0RY8C0
M/).-FP<$<.CWC/MQ!(9"S9I*G2+_PQ$Q#L0-D*T-NU(GM)M<@)&8(R;>5_M_
MET1>99P1W,K]7E#%'B4!NPXKXX]WGB?)?=]Y_HM7NG )^'?$&2-Q?2NW?,YP
M$"<T^K^CW<]XK(3I\S>SNO'M)H#V^';(+XF"]S<4@M?/0D';7MZ&!YN%W[?O
MTH.E3<L=I5&I3:@/?J\ZYTOA)P,&!&(]>EMS[;=AR(U^9A@2A_I]T)/9/+-R
MQ"RAP5C @P6(?VMB*'^$LE]LOH.A9YS1/#J5 _UN\X^CO&J:I5N&ERI^WQ5]
M-.':R_@)("X]"=KY1BF_,,C?8TW_V..R+:X:)=A2K^ML<&1\_8>].ER&</U7
M&4*."S<95#@NW++ ?X3?CV.+3>Z?6"C+D6Y*TB'>[7LS<@+T3_\-Z'^L(%1P
MH7WT'SNBQ?NV";>X"JRALX/W/=U^*=I@J"=6;\ [),5_Q-Y/PYJMP\>X>*']
M@[__S[U0]668A#+$R1L+4"HXMG'6ICB&CJL@U@9R>1.7%U"27\1Q_#/BXI\!
MM^O_LRXZ8>3D/V.D$JU$@M655<"+;SR\-;K^*^]B 3\O^A7/%MCY)RH-<D6X
M.$@[%HDX5.[(FM-[,@M<*C"*]RAV'%4)A+S@T2-/(V#\UO3LI9SDX-IX1 OT
M/&SIO-D?'/S3T./P1-[_MPK)@Q4; 1OJ(7Q1^&?0GC9%VED57,J>8?DOZ.UO
M\7,'L$*55?%^P[8<UWJU,/M:@7QN_]P[G(1YVK^"><\3G!/'3]>>B:M4GQGA
M^@2[%5PA_4L%@RN8_I(X I6N^%159G_;UA[?;E5,GM%8UN&D&X"TN/YGO0SE
M7T/RT8G*^[_99Z%7; B.;_+ZHTU=5DJB<P1S+7+$'/-&D!C%Q$D%MX_O^_D+
MG.],.2N!T>O\[E&Z]=*)_TG68(B15G#1?$0$1*YR03G_.0;_2)HNT^G'4MX^
M2U_REJ)L;GT6F?R[/. .3MP.PTG=IJ!/K?!6@13B-#JF%6MGK-*O]O?RREYI
M%<AOG;NHJA]M(#PF6:TA3<]R3J85>@W0HV\L5Q%JYU8XDJ:HYO7243J*/;&0
M[Y_=T/NO?(AR8QB!M>#M35QZ395]V\XUC,%5<?$>N&PE;$%;C+/GYKH"6[_E
M%6UA([2K"9?%6$#=/W!B4ISO%@B& ;B)RJ+18!0E^GP]KAG(1^,@4_Q@$T,:
M?%Q#D =/<>]_'8(B=*'-U;U^0DM0EF/0(OKW5/^>ZO_)J3@PC&RU$K-K!QL>
MH,)@5"^NOGCB3(KQV)U$TP*1>=K]T#GC/MAJ+X[DI+QR5;ND]H''R"@6QX+Q
MY$838<[,@A CS#\H=TS0K3B./5R%H;A L_I?I"_N@$*.V0A_9 :T.(.C >A4
MW&V<=B'_J5TPZEDP'K2K!D<27K,8_K7^?T_T?_]$(] !4'?/G\P&1HR(X]JW
M.(;C0/RV>U) ^3ET\=6W,[& )LT,55DQRCE<,0'8<P[>1\$00!1;Q''DH8@P
MSA;'.J'5@2>$Z*?\J9(Z."7#IH#[T[_G"O(A]"<QKN$7[+HQLL>U)*7):]P2
M^.,J=9P>+E8GE%(]*4A]Y>&?+.4\[-_&_9EQSL180/OOL<$'^SG<+(9O8@']
MP3F*OYX;\#/>)&$867X$/C?^/S?0N0LM(/L<MCB)JX/K;+[5M06B_XE]0X5_
MHN:_I_I?FJKEQR Z[@=_"N'LR=7X%;-W_[?$\;]TDOYO&?<K(O1';E+FF/_K
M<>*_)_J?G,@<[E!1ZO>DL^V"\-SCJ8 >92;VW =%BYXL%G?TF1#,L(P1P:"-
MWDZMQ*=ZM;?4)%M<][GO'R76<"[K$_>A/:#BX1DH<YU98\[2M^?T&L)B\ *>
M6TN*S]24H'P2QE"1M0<;X2:%ZTX1MI*T[T<U[:[CLWW*"]_I&H'.1"1-C8-J
M#U)3$LTP-%X[$ZW=(G(B/%-8 *4@P93-8+4H8W+87L2XU:C.\!;/Y\)W'N%[
M;DZ]0V)@7%E=//02S9VNHZ6S#,\M%8W(U[]WTT#M<M!O%'>,?44>G1^-*[;X
M[2BSZGHN*NQ>WZ72*@4/M8&-G,VY899]:G\6\A$R$MY9)IMA;WUC),N>[% *
M,N @\F5GH%N:KG;+LTN#+YZ6P/VB(^<OQ; +?155WV3 M,&;6AJ 9&9PIO$0
MI'BTS<U26@"I<XR\^.-*S0 #V?MQRL46:PA+GB%-E!4L*3^RJ,5.'MGC8E4R
M41$KY3FB3Z-X>E1%6""W;T)7E,:1ISF0LU8-SV;;R%*)R%9R)A]SR7- =05V
MAKL8"SA=!7]:; 0E+/Z2FG3J XOF^("M)!&31Z9O,.A)X-W9!@R)^,4PQ;)^
M>Q%)PH&XU#.E%;9.E4_(MIK*9@/LFIZV'[(Y)[MS#.Q,WI$1O]R?]S&ZM5B2
ML(I'MFS6^7Y^NQ.UZBMR;;E=-#=&.^3Z;.S,T,CRQ&3LCMCY1MRR.OFBJ6U,
M4L8>F6LO9$98CTTR\5(_*1UGR+\IQW0[;#FNF MVJ..L\%LQ8G[,T34HP2SW
M;F_]7D^&Z>?\NP')<R73 61#5#/*(^TM4: WNYPZ=5%![S)RS3(,TAO2S[_?
M\F-E=XP);'OKNM?DTM)(^8HAOH'R OHRHC,6:GFP=8]9)./">^GV,6-;RJN2
MM<O=]FE*031)?LJ:BW.;RY!3#DC[I&N#_NU?= 8/QK[:'.JC]-"4Z<Z!]M6J
MBCYKCIK"[J_]A6^_@D^ZT>T3K\8,"$(A(*)V!P=+.-OK<X_"OOQVR! 1SA-;
M>[J5;I$-G[IVW/.S^)UJ!.V;Q(K*W@4D<VEFG3.RA>,F\9N%4"?(ROU8GKYJ
M1\?C*TR*P$;2+\8U]<_F$!D]85];G.+W#("*,"=KT0/'=.MZUEU85YMG*>?#
MYE*FF]6B<'1VI_^CHVPT?2KJ@?1@S@RL/WG@P^"D4LD;Q5IVQT\&E?CQ=C$!
MZNI'>:)LW"^L1.5HXC-N:^DV6=BE"5]1IG_+HS'_Z>&:I1V\*@%F!*/)\W87
M5E-DAMC=+WO?;NRXMM?WVY=RE]$AH=86S^(D[K7H&1A*O:(F=F%I$O'67+/[
MOD&Q*MG9)CIHI+7$H_G#H &E"'((5_4!&/U:/?_+*J/9: ZL*V')57/=[J/%
M9A9\V%2[NQ]R4WMO NYFS; L0;"FTK@C4EU[+=NS W:1/SA 0+A\T'Z$<Z$D
MTE9/&D_!\.643+9<.T7:"@?;/13EC @X8"_NZH?L,#E%0KX6#A[>,]+IK]]6
MNC!6+J8\\_P")G4W1H3V:?;LCA2U[6B^ZS(=M/S"_5ZY0^>&8"WP=7;JI\\Q
MY7<*5A<V($J/TM28>_<J:^+D)P,[N)DQ_0=#/NX>,T *LSABS)@B TC<[?6F
M']59]9OS[H7/[[A&;?#EP67K[)QII9#7\C)D$W*S&/D<[<)8,]7]!.N][A$P
M6_/RZ$-FH"-*6, ,47,PE4748 *G[ZO-?KK.:%N:Z582@8H"JE+O XW( ) )
MI[(4$OBJ&'Q*,F5,>^G /LJZS\$7DBR.;BO#C[@F8U2[X'OQ9A+=1"?\:-1Q
M8#35ZT&SC%UX'F.EQZJZA1CUP8KKJPQD0^V!0$CR2J3^E1(]D8=<G%QO;R?[
M\)0]P0]XXM!D T(,>9Z&,C0E-MEN/H9T?,DLN!7LB?=H0&"#U4M)"=#B.OWQ
MZ-UN.X1T>N^#C4!\1EWJJMJ*<)$R"W%5!L/%%CJ.;?+\4B(FBY(!<7(+.+A%
M 4KK[#EZSX,$(F2_O,[V],U'"< U?G4<<K7,;ZIE3"=Y6,%T(*43.EG^$9D"
M*%>PQ\$.ASO_4;9]'F/7#&.UVN?1ACA@K]<,9F:GLK5C6')^WV@3T.)E$V!4
M;8^Y<I10)43;H.C65$-?48H$[MT+_E*DQ4!#./=POZ <7*5DT\G1E@,UCK^@
MB(A;E8I:5/9^I.B\TGT]/([^@:E>[MTYYNK@54TNF DWG84P6Z/%:E^RUJKG
MM2#BCWW/C*T*?SOW:"RTR>/L%,!\7IED?&8]<W5Y?W79T.@!722'YJ2.*T;;
M=6R'FQP-#7Z$+$[U=S,V284K)$IG*SA=71XG=E:[FR*/]Z*2L=1Q64_3NX8/
MQ=$"SXYZZCU#"KF[?P'V-B'\@ZQ:Y?,QHF+GV*]K;3-Z%HT%7VSL3,R,N'VF
M>SHRKC_5ZB7N1I?-.UU>%..0G8ZO!=(LZPLC7N7DQ5ZI;Z_?4S:CW-,-ZM4_
M=_&T>WK+Y.*P8:K]IR_ZO(.3B[@BS//JW=SK?#%6>?L>X^#/+;U\JM(N)KD7
M5*4!)P_#%= 6[_+D[K(=%I!0IWDC+@D+8.&*Q0+T(T$'%ZEM_[%?=Y_!5N*7
MS+[_*-!]VO@?>"$@[=KWKE!E! O( &I'_4/SW'Z*!>AB 0_NIWW!E&-2/_SM
M+"0P9P\+M8*AXWKS'[[+@["GUX](GAW/-'M?5"Q%@45D.<)R3>$V'[$<6P;;
MA4F43%'P :$6=$H8Z@,P4]6:;8"KW/6^7TA\[ZIGYWM6$Z*T<O0R])-]URW0
MGD,J D ^QR6!CQ_C:B-!NY2-G%Z_*=,3*- AT\@#OGSK7B<%SRC;-M\)H>HN
M.ZL*&3-Q%H^>1K&\GPN]U>$K-!47KHFARF'!O-  HRCBIY7 %,OWZ+@^/,4G
MNT6SW-II[;R+O_7MH;0H)WGV"\L1QIJLW"-]^&)N#^+O]CT)E86(]\3=CS0Z
M%;HO)"2X&&=Z:I<Z&@L@'@PYOAZ,J[B4$4D_RI=@>*CAZNPD']B0^N%I-H44
M9\4ID#R1[TX^HPS?* _CV2;WEW4L@H(MS^([ND_[4$N8"C\.N6@V^**/4:=5
M-U?X\6S  ] T0R]HB=H8"WB^C#E^[BS.??7\R=#N&^VX&.U#LV,!+RWN'5_.
MC,3@IZ&.GUPK6<3$,Q<RJE1D$B8R7%O^;+>MA<^W :XJX7N_D/W,9=P"$\RR
MI7U"I^/?]?OR\^FJ/QOSD?P&AZBSFSS5.P;C]W>EJ+?.$P1,S3(O;O-E?5SV
M9[7D6Y5 SAH1TW($O1><><[=@_-CQ:]^A"$"S8 [) 6X*M8>"R#Y]I3AGZR:
M1VR\^S":JI4K0\'9_<35_KL'W!1XLDT4"]F3/^&<?*99B6<-=%G>GNE6:]=1
MK%EU87F53UN7;HS31](=#2LTB[;LT:EL&(()5!]\,KB0SE"%5[^%B@ET"IU]
MI?GH+#5+ M$%2HIE29) WH[KE\(/<0N=9@[(2L<"6MO3H$,I71A?0MULB*Q4
M'W3Z4E\BIJMX"]-FL^7"$<1\T29X+WI;O-@$0S7.@7D1 ?WNY@L:4#1+A>81
M_DU<S8[3(0:G9W-^K'!W8FB=NT\M&[U@RR>T#T _,0-JL%R)\YP)?/.2UX3\
MW-SCO9UDX=/O52[WY9"<N@>^;'VF65G98%^%<(4#].,<LC_)?\['GHDOT5L?
MS@#YJ+%"0.I]\."5;QJ'3(-R,3EP[ KUY^TXP=E018!>8CHYOH*Z\7]\30U:
M+Y("[>;M^AX\N C ?7KI='P]W#C^. (>A$GVL0@I"O?($1@_5JVC8TE+^$C:
MKX[_T<SX%)- GRFKSQ8M(*ZZVG=>B>%:S,6R3\44#S.LKMIYW9)5>C^[+$%K
MFHT%H&3M\PY.:^$Z7IP+@(B@9? .6>$?[N_^M@BUS=#"=3O@F+@\NFHQ2' N
M#-5+CG]?I=9L\/D=,@+2+D]GW+3?L'! H-N^Y2%YFO8MR6+)%TH]H=:"NZP8
M_HMQS+TO(5C N79Q7XP>SA:\=^K -<X[F!=[\5^GH?61A^>5X+1K-)62G:+A
MS= ;@$KIAPS2SR&3AJ7CI9;N*9T\ ?;+0==APU&.X[#'Q:,QLVVZ)EL?28M^
MDA+\P^?GW*H/7[U)8W]\DU/"P(N HW5U>>VZ4F!:;/R2P.2E>LR\I[Y="W-R
M]_$[RO<$XN[@UG34?9;\,'R_O$O4KO7"Y E9T$]%DP=$<.BD#VY9U'OLYX1T
M2-4%6:Y07Z3RAA^_*1F6S[=>Z5EG42K4$EK6-2]_P!5_N?V1#D\M_:V,*3*\
MOM[C=W/_) 7TXP!0+?U F"O.<:%^>)T./)9W<3%(3)%[3\RW"^,#.:SS/>I%
MCRW&"<WAXU!C(/X@9#<CZ\:H9!_K"RFSP0#:2T\)!8]N@']R)<!4%??I9W^"
MU\AO7@:OC2HFS^6]Q6EYO-E;]K<^?U\!FI1:$L8VW6--4P53 _$5B#4/!?K,
M+H5OT1($Q59W+1Z#^=\&2WJN=^JEQQ4.B;YTCR_IRTC6S?;CH]28\!6,U84A
M">I+9*0MR\=S4GXT"Q4162X)6+/5^J@FM[LLA\.RC>.-.NV@[UA&\G-&*6,:
M^DI]<<D] <"K"F\%/*:(BU$AA-]XW<U7ZW,ZUO3L6_E]4B\9:U>W^,Z0(G+.
M3AW%(J/GO(\?U-(QI9\ZHH[_67[2"43XEC)W8P6ZTW$JOCAX$"W5%SOWM&]=
M*_EPS4"W5&@QR&7A^97H([LC1=[,+XEFHR/B=1;%CZ;=PVN/;H#^*E2L>^P1
M/H0^G^Y*<LSEGJ&O6]Z "@/*I1\PB#UW@'X:M=0UJ$II;;EO(_'GWU/%U/=!
MEX!F6( G+9K]IP&.SE2+_(F<' M*3=PWC<[-%[9U7>Q3>I-&3;I'JO<QE"BT
MC AF97#\0FOEQ.4M$9%AG=OY;4]]Y-B&4MCV:'!4*'&H?(B 34O0IF>"AK6M
MCO#709OU6("/J.D>WD!3^*<GS8-;D2Q,/$T G<0,<EHE8DU<ALH1Y(66L=JO
MX_1C_*TOFC&;4^GT:0-]HOGCB7X2 _QQ  "#J\2+,W01/?8SU.0^&1*VM&VZ
MIVSB)AJV<J02EE/&.^/-];;+J\)Q/($\%L4FV4=F08\#VNLW:5MQWPP+<*-L
M?0"=9NJ%+=&;_,ZP"=*X3S^"Y'69%RDO;_"-2B1[:;;JGA-V_'I\OT)RQ;68
M8,8<G\PJY^%Z:D)K6YZ6BWV@OQ'%_C/6'C\B_]Z2JYDC=.U0;SVF-+1<:#7N
M.H5W*ET]TZ_4D2[^(J6U*5JQZ*F8W LY4 K;248XF4MB]F)"# )ZXOU\4.O7
MFAR=SK-!+L?XAO?1S#P[2;&(9%SBA3547J.;KX6$4:GH<1()&6EM)PY=V;9Q
MV'N"T8)/ L%#I1>I%XCM5^\^#_V^F'W#G@^3?NOSCCPDS-TBB=C29*7R$L95
M;(Q2*1?823[B/2<"J$J02MN":-"XOIO,D]'9NXEGA"OQ0"^_C":'+8*U#I_Q
MD\U0]] K,&8X:M(7+93=GNM,P0G2+^[CY/?G$-PUN$GK6#@F2WQ-DHZGX(,L
MH2+'#E-%O$J//KG'H81S0X,GT ]B5>L('87')=!$)RR[ZI=%<KAQG.;25[Y)
M/  @B&&NSG*J P%G815A]Y EW@Y3T'-)NI#",DK^ZL]2P ^L;SO/<J3KANVT
M\#6ZSE//,G"ORTXKE" =$S+&FI)11M*'9TH&C'F?(G0;G^A*?[HE:GW:5F@F
MRQQ<#//B1-M,!=*TJWAA 8I(T7-*4<F02X\^+0@VC\<W7:F("2FUXEO/\4[I
MLDZL&I(_2A9G6'5T/1J(]'^6YGTWH-US2G K3' ,#QQC$I#K<LF)NM.9="^V
M3YQ5"ZW0SR?"5]5;==6RE&;HK@:X%)\L]*SZ6SJ$T>ADKID]K$-X> _.4;\&
M-4L);9GV6-\(B(B(NY5?7E/^5C?R\)34F7=3!!TQ^,L:]IOPM'KAH8!S?<K]
MSTP0_:[W*V('"UF[Z%\FZ*9%&"WZZCN9L-%]$2C7B]\]>G1'[JM8KM]6R.$#
M=P[Q\^*LN,BM[S"[LKCF:2 GVB7"6++OYK2S*-@L,NC3M7X>,3&D@CAZ%\?Y
MZ5"FFD$AS>=F^PTA>/(GNOMQXH9"70F)M:[\U(W.3K.:7NY:LXI2]:[*KR%6
M59(&E5V%P8XR?;X-5,5^85YX@GDBJ)Q#A4D4K=H0I A,+IF;&@XU2.$+G7Q/
M$!EYZ5. H0#@BD\;6Q:>GUY5[=<*C@6.2?@V^-6C(O8J0F)DA47(4J3P_8JR
M+>JYP.3 7AMZ@K/)9Q\:QH$@A'U%8B"=(5&V:Q]2N)*<DLP+FESV@O,G&GU"
M+F0:2H=]%#UK5]<$')K'F(+RNM ?=@:HOSCC-T;%OT&3IEA$-8<=!4)=GG&!
ME>3(<LX:A*LY!D?3M;80S%2M3F,!Z_0VLQ#:EHJ ./+^M61$$QR>&N';45U^
M\V-@SQ2!I8R,TFE;YX1E^X-3@QU[F1P+^U +G39Q<F>GYFYG.V6OS4<#QGTU
M31GF,W!B:H+DUNV"Q] L_)"!YU\<Q<^@9J$Y%LP4!4-\L0+-H O:8VTF3BDK
MB0= 81JV]HET:F^9.Z<H562NC^K@]]D-+27Z2?Q9BWI\N&PV<U/K.C,V'$2^
MAEP)<HN]+5U3$73=+O\#&2M^D$V3NR060,F*A!V1NK(M<F,!U&!#SS[@UGU1
M=2S <"(%"RBRV"*PM1BL4_5Y5&-LU]PRE"&OJN(H7H$%^(8Z3V)\JL]O1V(!
M?DD89KE9Z '-CG(G&'.CQA7)5I\CVP"B6D/3VSA9<![U:65VT5NQ>R2PV'?*
M.)\C0P[/\OO/3)[1=Y9JTF[VMBE9F+U?&=$I]YA,%7[G1I,M7K.LC5[F*R9X
M.W1U5_3KZ\:L"1W/M#X<+FTI,V(!W:6)GK;?+ZRTB5IA 7<GWNRW'U_%:3M#
M%FIB>-LH][3-W0:6#&,98Z9[]*?R5HJ@[X)SAC!&JU"4"UL@%K"DTP,2@J(R
M0=-SQT5;@M5OZ'DL8"9K+KPT?,BV<=XFQD<P)U"J+BHU>CH0"(ZB.HK/DA-U
M[$B[>?^JU)PC4+ ECZ\F1]+C[:,J*;ALW^3?J74%;MCTFY*6"XM9:]Y=Q)TZ
M<G!+E'AT^LBDEDZ3AYN-X1LAZ\^(T0_#,=>GTFN_IMR@<^8RXR0)8CM_IYW>
MW"T-+1K6C 7L<"[%Q\".+T/]-)OZEL0K*7KK !4HC2!Z-0GE,<6Q^;KF6FG/
M,V,_N-E,G'K4U*T X@271T_PVZC>BK6F(OK/05H,;FI<4;S*V95R8@G23W@V
M[P/ZS)2B\@SP]6Q/$>SR-?9M!1L'=C]2Y[?&<R%=))FGY?C[4<%3T68U=/W%
MXY1-%93^Z_8EDNFRR6W<T<^RZZ3"0_G&HE\S1K)$?5!I:!I)G'W=V*9W;P]'
M7'_M"6\ROQ>?;TGUO)[JF9,KRXL8]54-D@8/F&(!U^,'5[$ GEW87R_+-EL@
MFBK377QH5':0Y5Z>!IT)!Z.E2H%, ;=XI:[)Q*?K-_G/<*0'SN13.=K^74!+
M)\8?S\Q>4PK>#\Z%_:QK!B.&1'KVJ1IHFK%'B&[U6QJQJ,I^.\'#$K8-U((V
M-%7AZJV[&_Y80,@W8V<F^' "G*1Q_2=.=?=H::!Z$CIA%Z=&AP>N1::D0:8=
MD59P8Z1_=XF_<Q_&9YP6"[CRS>.0"QX:P5N^W]<A$BVJTQR_P[4$VZ?]KCKG
MK/(!K3T8[?\M^(I4=[5!GX$Z>>B603 ":<4 [:Y,Q +FP,>/UW,N#00MZ?5
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MB#OA?Z?8"S=>1&U-6?_0@UK8P[OGBA&\E.>\LNIXSDI+!\W>ZQ2:_A9A\IH
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MX?BO9O/^<F>F4EY%+FCK*.>Z12M!T4K63OGW.[2C!M7]!_0Q=I]Y@Y6LWF<
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M_-Q3BMAS/J"O3V5\ X[D[0E H!&^#4%.N^;SI\ZD/7MHS@\=98J;^Z'1'WW
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M^H+H177H)A/!@?L/"-_K6>GO#DIXU2(BDKR_,[^1_7MOJ?R,*L5?*-^#@-$
MC(H\$KBM/2SL1+357:$+=?^()W=!_"; &#N:(H74,U<A^7_!U2S(1"3(Q"+1
ME*6V#K7]ND?0/S+8S@./.[1)P=>\YPUXZW"8@_G!B?\$84>F#8ZH'X :Y;"
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M06"KMK8 %^5E=)6#VD*&X\V63(IPTC&>//4^V@Q2 N!]'-C[\O_KH96D7PD
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M>*B9(_D,EH< =?\_]B?[=0T5!0!.&/Y?4$L#!!0    ( +DX#EN0XN2.+,T
M %/D   7    <&QX+3(P,C4P-C,P>#$P<3 P-BYJ<&?DN6507-&:-MIHHR&X
M2Y 0/+A[L! T01L)[NX>($!P"R1X@@:"!.O&">ZN:=PM2"-- TUS.:=FOCMG
MZJN9;^Z?6W7OVGM7UZZU]M[O\\KSKJ?Z8?%A'?#TM;*:,@ -'0! >SP #TL
M10 &.OH_SL>!^7ABX6!A86)BX0&!V#@$> 0$^'CX^(1/2)X2/B%^@H__E.(I
M,2D9.3DY 1$E%049%0D9.=D_7H*&\?@,)A8N%A8N&2$^(=G_>#S\!A#CH'&B
MSV&@,0/0B=$PB-$>>@&,CW9BH?US /YMH*$_VH@-Q,'%PW]<T/@4@(Z&@8&.
MB?$/JQ]G0Q[G 9C$6"3/^.6Q274L@,P>9 +AJ=]Q6!1JN\AUI\Y8!2T](W#Q
M*"BIJ&G8GK._X. 4$A81%1.74'REI*RBJO;Z[3L]?0-#(V,K:QM;.WL'1R]O
M'U\__X# R(]1T3&?8N/2TC]G9'[YFI5=6%1<4EKVH[RBKKZA$0QI:F[I[NGM
MZQ\8'!J>GIF=FU]8_ /=V-S:WMG=VS\XA)U?7%[!KQ$WM__ A0; 0/OW\;_%
M1?R("QT3$P,3^ ]<:.A^_UA C(GUC!^;1%X':.%!RBP0CD.FD/J]M@N715#W
MC-S2<PJ/@E5H@PWV#VC_1/9_!BSB_Q&R_P7L_\8%!1!@H#T&#X,8( NXUTJS
M^>CJB]=1Z:$*P1DVE,@8%\SGRD8D_U0L1'B<V+FDQJ:X(AT;JPXA,<?/P2DX
M>U_<6:_&O.XMOS1D\+H%L$+/;9HTE#2A@L42\.S:L6>S/ J*J2S47W"3FL6W
MR D8.*>JHRWF_CYGJ%TN"F,Q<]CB(9$<PS#X0$RZ FIP/HJ<K9'9;2OJZK0\
MLTOD%:+=58]W0>F:<!XS[6%X/@#"-QL]U:J\0]ZDGS9?8:+X)JMRG*'S><27
M00V,HW->6P\  BX7&99I^:/($(JP2\XSQK@"0MW-38YGR1'NJO1<>WR,_OIN
M1.;T@WH?!N:<Q,>U,RJ%9F05!I*1+U>D5(H+2B[-D7J2*-).PK#)GI*P=><P
MI%ZHI;'JR'-QAKD?%QEQM8;1MS3G19=9;2$;GW7'-GG8WA&DN14"PK9F4Y%R
M9[T_Z!]?(\&0 )EZ&@8[1/; Z$_&L/_N99H6P82EBP@E7S=^I'-.P-!8<##K
MUFF5U7@ ;$B=+=P32!B@L <> 'VZR73^'BU.MT:W9BJ/MP:[E'#P_-U<$>4G
MW6D,H30L)=.^9 NC>QLX5\H]MXSXV6;+]X7+7\=3H7\8M#9::I:. D-VI>*/
M'"YF1K) -S3(GK."3\4M<SF@]AM/$>/N'DD6%%Q:(X1GW?R)$\U*2G,3)/Y-
M8JH9AG\)3?"YR'OK;6O8@7%_^TJE[<SKO?EGX=1 8>K6CP+)P@(# %>Z GES
MJ;6)G_X@M8;6ULZV.DI1[&F<XYUTC_04@2< S,@QO_I#?3/RNOI9'_POS9TO
M)EG?[WGQ[Q=!6&H0^ND_:3R\\F/1XUU8 ^5:8TOXN7],?Z#Z9I%"I!B7M/:V
ML57W?5/T^R>XB3WO4>3K+07)/K%2BHXMPM^;.F:],UIB*9/7/W\;6@^90QY]
MBNUX!DET/0X6AJMZCZC[I&VJ#_D"<W@^FWLEEP08)G17O7CM7A8$\LW<LY$2
MR/ULP^4:XLQ;9$/ JE#6Y,I1$X(9=#U&\]?T.).1\[; E3!8W@E&N;E2MDCG
MX$?2Q7KJPJWD^_F]\C3:(<X@=B2LH/_XQ]K2ZG[@9\_1TK$4://PQ;C'!QG;
MO<6%CTU)U05-G<5?4O<? #:B0>_,YR8@M.\:U#(I6L)M;*$L H2]MU;S96D;
MSTQ:.8GTF0S&:8!QKE(:FV$$(774+C6LLS9&WYW+E=\E,'J,!2K8@TG5MH"9
M:\>$=,Y J&D)X-BMA2JEO<6R8SQ1RPE+TG@O1JQ)K2\_F;S7*\+*)P4C0J]>
MBYW<0+T^8KB?ZG@C"1/Z9''VQ;ATA=&:8_9B^I;;DMFY@PR3_?RN_DN5,J#A
MQ7FT QUILLD+Y,\Q*;6S!D30AE],L-5](3M-6S]?78!D<*7;GF_ 74=DE=\:
M^%V'76^((*JK0O:<-4-S8+,S7#@LJH/^[$OL997E^L&;Z8!, 6;T;8AG )4C
MO+R94]M#-E_0V#!8V2,I^KDC[^I1N@-'4'M;S>3FY5HX2F0.^5)*WJE0*MOB
MTWBUM?8I%8HI:X@N4.]K!P"Q&R*KU1ZO0@):^S36R@W;Z4E($K4K8Y_TJ3$[
M@QQK;!#A[\\;V]3$-%(Q02 B.Y']?=$OJ?*+MY;U*:-18H:'H;((URE1>$A^
M\GMGWAS=SRIH5M18$(+P28#JY3A0J+W$J1U=W%;1T>.VYW->>OTA5,NGKAVE
MDG=8@!;L4S1A@34>W1UTD+VZ*I1!5?]!;=^?"G.OQ-I_;2,FMH-^R+4%_A7N
MY%' J63!S$^OO,-J!^W(0R3#BGHZ"9^?E4^=5/DT\[CN96Z.0\],!%28P6JA
M[IY;@'L)@P+_:WA#V^SS>G,"HQS_C67K=+W$Y[R:8GAB5%<E>(TE=B/?#9%%
M+-V<*?Y9'/WSZJNK"\>A[7H)54"X1<';,^$OG_B"U9Q*V_]B;U(9K^0+FUB[
MI=#Q,:SE<\7-A (12P9G1TZ^@:SI!TM&\TH^*\Q/*N,T#3T6O:#MBK\?  WC
MD1L\=/Q35V_+R:R$*_VB*LLRFNUPMO\.#74GW1\F/B;:1B>QO43 /%(R[+Z^
M]/<9Z'E.\/Q\KPA_7C%QPA/QHNP6-_EWW>[WK[5W?H[PFCJOUFB '):J,Z7@
M1(\1;3YKAA$$LN0)#HFB(7M7K?K]G,<]DAT7Y\/LQ@)YS%5F&J2AR]>WUH$Y
M*1'DX8:IT6RU2S7D^]GLQRH;[7S=+_>/OIEUL<,=&E(+K6W6(+1UH5;Y;?ES
M%+%W[QP"E<OMP^I.:0;N: @E?!4B]#(%!@+WF!+XUV>\JD*(/480OOQQF6RM
MT-/Z(Q>)F]6!*/_T+HF)2)_+J:L1T9E3JG+HXGN]) ST)S@/ #QX 7'H$,F!
MA&V1=%D<<VMK;;BK-3AMK(CV25B\!_6-U@ZT[0&P1=3W"<7N#YW0CYL'@;C$
MIE^DV1)R ?ZPU?9K!AJHP^S@:;-(AW(5MT)3,X=5.GLKM;]YVD()N#R9U&(L
M=+;E=T8OEE1F+\Y@@V?GO14+Y633T54BC:W[#3/FOR=@P+\KFR!S*I-]8Q)Z
M=Q"H3PJBI(^IL9[2*>BS-5][>?KG 3"077Q])O^]-KO?PTW*18!#GXEX]ORE
M_.!FNRT?M*S'=Y5EKE'^F]D8VZC( >D7C=_]+^6!3!B'XO></%KPPDG7G?GB
M&,U9*Q<%^/1.Z#ZT%J<'(_KT%\J'[FH^4YIZ!RG)-69),[=?H.'B5*-YE^_G
M<"?A7VB.[Y]NT/+TCWIA*VNFP%-KSXK* ?'?:""FB_RYK#/(!MT:L8N/R^L]
M/<AD@S0/ALF:"4<PZ3AZA*370E/U1:]Y V_D)I<LXZ+)@>BQW28PSLE6C=Q,
M5-5*OC,_IPB8L$UGP'CV91.<MSY&:7X&[RQ5+]^G&0X76)(9T@Y/(J*S6FNT
MSS,S")F0\!8PM'K13]HNJ9X%OG+H /WA8B]=P3[LQ! VDGK[)'4CZ$B+DA6^
M><#K;*V'4W Y27K.H/)V/ P/4H2:R-XNZX4Y.4/9YA.M(87/$UY#\/R\WR^B
M&-H6]#8*H%P]9D0PI[%"Q)N#;-I%GO0<SXA#96"LX27K$_&CV?3I:B?9QB<Y
M5:;^7T9GW'17K]5-92:\N&3^-O,B/\B<K0?2C.M6U:GX<+,3K4'?556MM=2,
M.'F[@<RKD,G\B,2S7TA9V$Y,]'@AG\:LNQH\_,E8AQ5Q8FN21[+Q91@I:G#!
M6#.]7*L4D<3S&M4OG/%WN_'E">$DD%O9HP#5Z-Y)WO'"T/]Z4SEGDTO28;T1
M'+<JDN3L)@,B\8A,BF[1B@UK )=LGI(L/?:8%;,__A;&V#E:-DH!>"]Y,NG6
MMTH]].]_ZD!&MTON8S0-:YR;,Z:C<MKS3N;;Z2&=W\=,0L<[G_(TXCNQ3UYX
M>#055O7:1?4;(I?14H=.E-YJA8>*I?>F[2LJ?+E3?B$S/6R*'A# ]#)X_9Q_
MH2H0(W1:PBM8=T%XR/MH*1&H/S/===SVN_X5^@<C37?Q"<75!J)CI2*U$.&/
MV?0;9T/38?7$^A[PMC#_SJ;?1ZGS9?EU^RYT0"*UUDW6*BZ_EM.SO]>=B@FP
MFK];FXP$$\R+=8>IH$6VXZ647U]%*6C=#?=HM9CK+.X+D'X>U5K% X69K1%D
M^6_WF)0,QI?!'NF1_5YF91YWNOZ^%V]G0V>^FX^4K#IX& DIZ)%@*VPC_VP_
M[<EO>^L3!@WK"67JF'>^(B35<0'J1F"Y,5O0[</VI"(GD>WW(0X<"Z9/XA:?
MT.<V?__D8.YT(\M>Y+MP)L9#"W>&V19MW(?IML1)B[AP<7+OLHQF?<!<WP.\
MWQ/?:U3ZB9H(?6;JVZ,^613B"$J4X%%6>?&KDG/[ RZWBIZLF7]5N^Q60?2,
M)BP_PZ/04:WX2*<_<Q\R)E3[F0HK;T@JEX&HT4WE3L/^K19;QDERB$B\3]'2
MP0+#NWBZ0]CI" ?P.^&AA/:.\;7J)PO_0.]9&_V)]I7+]//&;##XAL'-[DX6
M<7Y[CIKFP47-6.^GOSHO3&T]24V/X%\.-&#<=",X#"6:/Q%*-)ZK$L;WQ.CM
M92ABBA!CBC2[+P^=,W8M=ZGL]?XYHI<+4G*HG?NJ0NO*-J["GI^Q9R:*R"CT
M7]B2DN'*']^W[UH/X#'DR]X4QJ#W&&)HK&37&UE5^9+<94-VH'+HLUR\G=EJ
M!*D><1$^6JR' >&A<\$8ZSR,O>FF^.G^5J!XI8^1SN/-VIJ:)_[[XGWV#HQU
MIW&\;7SECMDIJ*&6*.)CYQV\_BT_RZX.Q=PG(4YU\P\ QWO27K#Q;D'01G,A
MN$E/))TK)F3?BU8B/3R"["S$$1+W ' X!O8R4,'HV\')/XP<;_N*/1K&!-K4
MF!,(",Z O_:F:_=J7)(=#67H]-ATA6O(Z5E\V[>SW5Q;A&>V TP*,) .M&8_
M[?="2J!&JA'OAK(B,O2H;YK>>XIU_11=JW\ )#6LJ*O7-D\%-U]QT'"%K?6_
M:U+840,"-D U)7XHEOO2R_O0,&!#B]0$X<<COXJ!C+<^G/W$JEW;3[3$]K&\
M)6*.K39&CL9(7DTUXEC-^&"W+'U"6?.K?B"P @H\D6Z9$Y\WM]Z--N^9WGV$
MXC@&,DM:.)B2#"P:]:[YDS,@FHTJ*%TS?/[Y2Q3,1RAN/SP4KI ^\>U46_U.
M#+&IX64P\U>H$UQ:()JVP.#(/'0>;6+3DO'>8TEXA1'JI9[HS:XA<6O$+1Q[
MNOUD6%2)/2L**"V7$N1A$,QSI^&OT@T)K,S,IY^-61(F#61-4UTY^^V&F9\;
M(<?P37>ONK&VTEU*_'GA44/-SP[PSM(&>"_=7A8=Z;'YJL6)_HDR!830@2/M
ME48=1P_1UX3U:W+>G#/@0';G4F+UQ_.JW FW9Q?:V-YB-B8%.< DKOVUZ$Y2
M)/_FG?K(L:).[735^GSQ[+>X"VV*"Y64 )_]GEUI7*#P*!0U#U6.]:HT A?X
M!1!(1/7.&U"X_H#@C/?Y65O['$I:EBWINY20%MT1,9>\SC->S/Q<4S4//@<7
ME&_ PS#;G$*^J5<J%0YR;SU135-2PU%0W,!==I<_-N$]O!55O2]O6 P6#W'Y
M<6"PL$ I$^#$8<;!HY8:[ZZZ"IC0=-IC$.^.HM[GJL@M7=I3&;3]&MSQT4&*
MT$!DH3TT68N5]U!45P?$*///7SG\EL39S]KH)T4^;&2 UA\K:DJ __D$=8W;
M?7)U2<SF;6^:@(IP0K<2,+I_6A 1!\.#N_UA0W8FB.RA<O=0"K552)$0(B*1
M>F=11.IUW&5A#KYKH@;YQ=Z5VL8:V*R9/284UVRU]YV Z6\9C]01 _H-QMBD
M4"Q_/FW_? ?C$S$C*R9^%K'^T,AVA[ N>=;S,#MI^1C& _C:+7D 8X_E]0.@
M?B)ZEG_%S8]^.'P9R!F6%XQB3L\+;/OI7]-5OU3RHE*8UVTO+$V:2P51[E)]
MY">AODQ5W.2'3U;DJOGN Y%"2'BIJ;_OYN-.:?GM<K%?IHQ=FH4OY[MH6P)^
M!-[Y P!_PLUK\R<N>ZR-?/ V]E_WCS2'4K(P]XD[);7"C%CDT1JOJ"P7P39*
M&K U7S=\&,0MI'\P<BDX,&6VT@27[GP'J_?_NC2P<4\B&>_OMCH.=]K:J0R2
M@4\320>B,OCZM"*@HO%M7"$\)349Y<5LF]Z>\K_OVH,6B*W9:L]L6YD+> ]-
M]3<Z3OP=GI+?OL]V2^JTESR-]O75SS:/ED+00P4]6/A56"(_2/B>KG;$EK8?
M[?LOO+D1T6 [WK6VY6+5M$I5W>]II*Q5HY/M7O8S+MG4^E3^$S'PMAWTKB[I
MUESH]\>,Q-NG@HNSUZ+Q$KC!$8;5HC]]:V2/)9V=P>(/@*>2(1%L*80U @1/
MO"9>UX>Q]0Z+*%,FY73]:&1\#C_IQA[^8*SQ<3WW"5?NO/ ?YQ,CEGPEP%G9
M;NF-;CU)^TG\%_4 XJ$H^&V2$_.>B>EK;[!?7P.[0,+]IFS,@5'+6GPC3A5<
MA8F':6G7N;]K><'\3+W[):+P5N#PE2.M1XH5%1.)0W\N:#)&G,JX+$'_!;R'
M:5D,0'-[ 5>=1ZK V+LAD, ^Y(0+YB[^^_7@5)PFO<$=SW</@-]*_CS5\26+
M3E]LOD&:;=QXI:> >V&,(U4AH#.)6T)@#\5+SC[ .;/+-W=!FJ2UUP/Y5*&.
M:7\H'?0<\<M/=8:>I!;*9>K'"Z:-"X@M&V:Z]<7*)@:\NVW/ZZAW*7?DK1,
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MEH;9;$B%6PLE3C@@:?=Z.51,Z[!')Y>UW<7 >4$/ +FSQV9@<(/_ "#H/%M
M1?U;21:AJ,,V:N[QUVZ$11\ E$8H;L383]!^/G?]3,.B2YM2$<AL\.3B) KS
MI1*3-YN,U1T"I0M4'NIS12HBPLL183WI R7R="U-4[S"BD(GQ"S$%><RNM20
MES>:0""K]N'LZY,WYHM_[.XQ>AX :.;;NH_ S1%.#P"%:Y2&Q@.@;^H_V5/J
M$$9KTZX>D4UX/TIQ(";*Y2+QLPT_"S>,:Z0+VN7;S/H!A[KT,(SA6_2ATHRW
MTXKQ'WVCK?QQW+*+C<0,ZA0EVO4OJT4>VKX^N\E..B'?'P#_J";"_X-J,I@,
MY5L;<JL4@BO I3D#K%N_=GX>06O-?I'QE&.YRY)UCUXR7;\4,13@8N'BQ1O[
MU&E3IC\^(*_GV&.)]-F?\PO.7_W^@^M3QXZR#8R+S6[_#ECT7_VK\J\V_%Q&
M^A2\5D9-3<9)"IUU@[VDNP(L6^,6$W\R')>4ZN)@KC-(F\B(FU*Z!TL+H4/_
MG%3W;:2MS%&L*[QQ8+7($5\6Q=I*(F28+ZD9[7G,[*7#R7\&F?0_9_+^?W;[
M@L'9M?ELFV+98;JC@VL:Z/"+;RJ^+RM545:J5XIX]P5*R>>]SK%CF"#17Q,(
M*GSC ?"AYERJ[+\$TPXBLTQV^E<&VY'];^CD<+&(+,BXX)_F_WMA)G/\=UE2
MH]_W3^:R_8^N#M#Z+P,<"'[1]P\*>/D?2I%E..S1'MJP?Z4 >BG)?[?N\NN_
M$N3_5UWP7]+@7*WR"WBC;-:_$ G#V_^:2<RJXOC_,\F?%_S7S'?EK!,G7:6U
M:_$?FJ_*YT= _UTV_[1,^/]-MOZ_$RKS*1D\?]'?$A&.4(94N.05-C]? 0NR
M:M;B:]QEL!Z]7;S> R!8U^?YI?-T_ML/1<*Z>3CE/-EQD_7V7J[1<>I\B*OD
M@WO[R@G#FWH4'M.2K&V[ZMZC>.V\):ZA12A6LB7_KL&J?\GAX>O"Z*?8;)@\
M^ZB>$2^L^<?N1!PC0.$N5!U@*Q:6EXRB[FC"%P:1KM_BX=YGD8VS#@3&;3R[
M8LXB@K]_L[,?F-EHVL_E+IS7C%Z^G_W1S7=3L.WFSZ>K(=GK&[&A6&<NI00J
M5=6[Y\I -')+J/0%W6O.<JJ5G:2(*N[VT^T=33<$JP<X66TV68/SN4V7>68=
MJ^ZWW_:'=%4+;H7^J#=##&+DM 8-_0JT,1-A',6[^#'M?79>PINLU710KO.Z
M[D<KO4'$ \"!QY*6D&% 1Z45,KM.F;0L2&''"I'VUS%;VI)68*1R,L-JC CR
M7V]-4R%BR0"<OHT :GLJ2W-M$C(:8RB>\7:72U'P_Q1;/_9@&M@/DSB58H2A
M!\G2(VS_5!O>1]\?\S\;3DW[?<>0,:-)SJ$YE3%WU>E$-V>E6>SF)(RR^Q;L
MB7"P*?*_/7&B_6$\O:LEP4^%YIL?_8,>V\E%;(@V^D4SCASK5F.(0,$?62HI
M:OO;K%\NSI3,AM^@PW&: -IF:B"LAA/VBD8_&;.07N?Y9_I"ML3PRUL#Q\@5
MQR1"'M>RB98,5)%(2=F$6UFE?77HU%ZUJFD9K=A1]F$'7>@XB@71_P5R"SH
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M(WKR70H'+FK8R;ETTE3*/L;!4WVE\\.>TOY,C@E:OB\0;&N#)0N?R9Y6-<;
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M7[7NIHQU&SDV)#XA[:0C1?Q=A;2WQ:8S$_X L/;ARIMRY6G8JQGMW:O6#%S
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M;."VF2Q0BG/J1KE;T246 +E[DZ\M\,HRY>]*0AT)[C5[>7G.ADKTREYJE:V
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M5U?"LX68VM_>HWW XN%!QWM1&!Y%IB.']3^]M.?#MJ;"ULA#?SC)PO8[3^,
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M#)@&@U<]QI\KQST"F14]JS_3M,BW+:^S8_JRAF=>N#(O&:V<WKC,7&F?!E+
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M%9,P/'F@_LJK+W5W.N'7K&YQU&RY5-'Y"IZ/3#(*?0TWQ'\D^<H%1E0QUGQ
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M],ZK7! :"PD?ZM :NI2B++6]PZ$!*7SZ8X3OR=H^!M^>I\/'5.-SOZ4(.IM
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M7]6Y]7WWUOV#*KJ>7K_5W:O[M[JIAYF%1TON4YHP\D[-3="LQ,L2YM>,C\^
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M$@GXK\!\0NJ/6(D_^FO0566-@:\0]445N;^_SYZR*9L7L2WI^&J4!4!/<<M
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M-Q\S;],0ST/^E=2E'EF(K=4)^Q&;?,/YTY+DRM6P3OTM3DG9]4"O +B7LU.
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MDU\*FI*&[D%58-#CG@'DM[[?[I+I)EHWR?[VIPP VP+T@UOK*<;FNRO%VF=
M=.K)(^S=ZV81-*<@FOH5K +PF!1+.U_H4I--?!7WKU@=^>9"G=PD1X/ (W:D
MD3ZGB)U)FJID>2:VK/I-82QO+6:.@Q*VQ4)+.-.EU($"ZQMR+.%W)J3OJG5I
MZ,P:(X JGX_>VMY5]"E/76AHT08TB1;\UDF5E)#CVZ,UC;3J5]OZ+3UJ)-+;
M6F*Q1X;F(BM[V63F-_*-8F()C_2VAZ']6I6XU+/I3/;'<0O9_KFE5@J6)-N@
M.:\>+]5,<^[OQS[5;V)0SO/34]H01A?D8HZ<YH!110?&^9R210=I\^[S!^S
M]DO89A_,U50N7:I.+ERG%9U]MH[B$A?7]IS8;5I&$=B%/,LK^\5^S:S0!BUI
M=L_H,;H^SGG'E*BN]\2CJW4<*Y5[@2KUK75>[NM6413JUEA#FC^M'+Y_WUM4
M1Z8](MC<[;B6@S%.^C!*G=DR^)3T*_CS02U[?86]7P&,*.+[@9W9LLM!$O%,
MJT$-9BW<]YC)+ OX1114@LAJ7^Y92=",=1\%3DO.?XVN#;^S]X/#TNQI%U$5
M09#\\I%,'+8&)C,PUUNW=MI93OMS9)_X4P+R@Y*L/;:X(]#9RM%A"GO$H>\+
M.7'X77S!@]1MLHTEW>716^GJR8QD?J_KIF0/:G5NMH\]Y)C<=)BL1 'IB?:L
M@4?)9O[5$4*#:K7@I?>_IDL)MR]U>\)I3%_7?7F-!Z.J@NJLF)("/B #N.LK
MD,^[>\E"**;;0T<X.Q$8,6#SC>1]I*^R9!<EW_[RMFR9!??PV[W6D73S2LJ0
M+9A'6EXD=UQ;9DV \5N(J(>R\>:][Q[6Z^UH(,UTR=3265EN=W%Q0*N!]JV'
MHFL4L7U)+!-OVRF !;J&K6*@]%K7'JP=,8I4H?B_J8HRC\U]-"YK5IWR)7)W
M4FN8_%(WR:2')ICK7H)*9_">&87U VM*^$ZD]%6&)$8.=*RL$+%. ?W'Y :&
M_07G[@5\>1W76H?UUF" =_,BW<-O"CDKLGGT;5WYW25S!['<EE"7(ES9YHFF
M#[Q 4K/!(*-\(1V2/($:S_ TM-/',NN37WN'UY4<8V^MOW8=+B0E1"+;2I,H
M<,HH! MA)'X"GK9$KINM,!_@CUSOQ)Y?W/R$W@M5FZMG=L\]&D_7'"S!5R^]
M0G).%5-Y@&EH:'[:GI866%D*ZC,8?VP6)7&=2J._;2WZO3_Q>]<3K7GS\X&]
M>8F#F\?62=(T0?!8=J$_>>?CBDN+CK'@D"_<Z:)Z\!$'&BNS6W::XSRY3_\-
M$<^(>L61TO :VJL3->A,@N3DUA2$(:RW5HQYZR'/E3W&/W !&Z2?\/@&VEK6
M=CZL</U#CH\!^:T('N41JA'/B:_[\4>YEPZ0X'.=$BSNHCL_Z[!.\^T3<VI9
M;Y9<1B?U5>=/;6.[? )*;@9&!S8IZ.?7F=D/G4Z&\BJD#(VQ:[U?O]1KKG1J
MB8U\8Z#2E- @QFSOS:3:52@1 GV#XC8VU-<G=#;H0/"TF_;T1MC.-P,6(MD<
M5=X>(^80(HJ-DFU$5AB7Z5DD^.)PXUG0W!Y5WZ5YX.($X\924WYYWV" ;4)/
MHND^;/:444.7UQ#3Q(SV2R0!N78O1*-IX:L%-25[%53PEDB**'@;%NAIY2U\
MVA7,MDPZ,1JODFM#=>?J5Q3)TP; ,*"W?81?"[OMT+D%?4H%O,:5E9HS8&<A
MCDQR$U:W4Q8AU<_R]IFV<RG@F!DO/CZV+3.KG<1:/LUV+)0F5P,KY=GUOR7%
MJ72(;'+30[Z-I0UM$B_8P_.4W;W!+=CN)KX(!JN@JM2. 7H<@B5<R,.CW4ND
M6\ANU3870[P%<Z1L\0EN-'N\.WCAZS:?+(]CUG3Q1.J3-^0FK*OO=F"^Q,\O
M&9O!5I"CAC)CE$1XTF=$Z8PW2RHASOS;?]Q=Y2P*FL.8YQYO\)Y(-[UMST"<
MP$RVL":SU.V<308H=C-QNQ5DV5]EP^;G!B-FGLC6H5^V?:CGS5,R\9PP<1@&
M\(4:QGC:$N2]0@,P82N*_(LAT8\/"31%^_"KJ?'Z^UBIBQV<I)-UL'ZY#E-7
M3'X_?4 >V:= O2S$^Q_/ &?E5-@"N%<8)3K4_=348TF221JW*/I3Z2I@N@Q_
M53^D(D+PD*^?>L:CP%,:IS"FQ/L:46SZFZ#J8E'8"EN,IXNHGI:HJ+7IKUK%
M-_1HQ8I2/2*4U>$R^%=/V^Q1L\L-7MH\1Q0:63KD^)NQZ5VS>E181<!BI\D\
M.NG&E(1O0O@6R4S-E9B,11@,ME_L*.2=NCP6[M5-OE,!Z  P\ZF02)Z<4I*1
M(.S:UW2_ @)"Z3+@\G=J0[?9P#V5F?NE&:'QH8#B>Y?J2(*,D$345Y^Q$'/>
M_Z98U!Z(<B*.K79T2JZ0#@7X,QI$V?89ZV!U6L($>*:7J$P(\.?MJEE8&5M'
M?X@< 1#PAP!3TCQC[V92L6%4JQ?4HPPAWW./NC\9$USUEB#*U_!?V&&NW#P#
M7(7LRDJTLK/A6.?%B,/WL!C#64:P7TG6YY:F6N%3V*R+B"):PD1[AE:)L[RK
M_6GY>[B)*3;-F,3'0JMG:?[#.!4!"QD=^MJNC^4P-HSZ(6[W9R+W\FRVB$!
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MP?$9EJEUD];K&0" ?O@UZRUJM;9KL[SC)3C4@401A-+/^!5W/L.+@<P@^[K
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M_8S1!&_VU?309(G,_"6=ZNM*?3DB/05+)5-7%'LWRA#CC2$3GD6^2"2$QF<
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MQE=]AC=OXI5=I:L)J,7*^'88 =Q6H\.@16#VO'<KYB\#W+:,]J113#M/3U&
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M;>4;]-G\_&"7JK@VNU=[N;JZ8JKA9E=MLXMDPMAI%*:E&O=,WW*H-VK_//O
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MSE-#6 _ZD!OXUV9J[ERJC=<&BT_\4D'4*FV[V79J_W9G/G96NITWNJK/K2(
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MH$F]1).#-9<N5!H-AG"97S\TPJJT' W"/4NEXQ=4H[>H+\A:_':NMCS,N&
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M_MEXK@DRIAY8CX[J%[WS2_+,N>;N112C_?,S^B+C,$D\NJ[RY_*>AF+9W/1
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MZP.E&>:X'>+Z=4P1?KM31=#<E:@"D=3(#X?-U($K,NTGO!DA39I'=[Y+Q8@
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MI+G/=B.;9L")$SR$3LTW4VU-R:B4588WV+0HKV5\[HWK,:D MLEH4G)%![C
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MW7S+-;PB07H=SC O*+F73A/D>$Z/0FMJDRB<N,*NSHHL@.H@TV[I^<#0;:H
MPK+HT@5-N$,^EA2&OMX>L@H>7(MW&1:]+#ZG1Z7CXA>G*8I-C04D'<%M7NY
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M*9.(![I$\JZT']4K0CVX.BJ\/J."UI<YOB1]@LW:'U>:OV$.4W[WMO%92ZM
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MY \=FXO=J!M,0%%$>09 D7H\7Y^)98-YN 1$K=/!U-W2KU7=IYVMBX[;V/)
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MF"KT>@6/UWMFK&'4O_A8EI001L/NIP[N(V,"]?R_R889UU[,9'H@1/IT/Q=
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MVW.^(OAQ<I!@N2Z^I\QS*YD[/WHSEKUNM98B]E)-M:O&])">RI".C+.^%^C
MZ<HD1Q0S0VO!OK ,P=B-^^DFWUYYN&42WJKO9XH0+IQ@R8ZZ4$U)LPP6BGQD
MY6'"_T.8GJC(^(7/SQ+QE;??:T-*X%-CED(DA^_P0*(R3GQOQ_*8L1+]!DQ"
MZ2'>\6*4?9*(.RS%\U8XX2MK+#EE([01:/V3+O5F^ANA5JR+6M-#@I#J@M"^
M(X^@;\3)!:A5>DR9;'YQE#N'96B 'V9FA!_K2FCG8\?JV]: #.PT>'9HZH@4
M3J6%<S4U3W/-;E.#P/TZEMA,Q702D5'JJ.&UQ6/B0_W'E6KHQ/&(X>F)HX52
M(#AH:F>Y3^[%"XZ>?RH^3G[8QCQ7"<UTDVL./E>;=E^TB9S]\(NEQXZ)_PF
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M0["S@(977KF'!+!&.4C=K]T;*TG:_3-33:C 4XF;(^&=L,G;S]/NS'<?EE\
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M>=<R'P&WIH'>GM_=SL)N6/J3:]=,)A^69OQ,R(;O=#+S;_<+05,' .0BHGK
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M1MC[M*X(. )BBAP%<YJI.$Q,U#1JG!<L89EM1X,*FQ"*N2N(/K4+,H&.Z\2
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M[5<0,:RKIB41+&EXB,(@<YBHPJJBE)W&3206N1O:>P'HR)$Y[$?JX1?Z37.
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M3++@:'X.EF_M*EMWUV0X416'4<7&0!7GXC8E2W<2.61^>?901UX\A6.VGGW
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MTP93[$= Y2$+>N(N=H;115;%JT9& C_:7 &?V7"(HF6'&2,)(&+#-\$SS5'
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M/;(-7'U#2$YMP4BV5C20<JW!KY,KL9&FY$;F3-1"<IO /$+SU,V-H>T31,G
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M5_=EIUX[;"D$@%(K$8:YA.B+I-'[Y+\[&<CX:$GIPP.#:2/HE7?%3:[.#/4
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MK[<.2B=B^OR1!>QH\Z$<$7"E2>C*"U];Z]N=A+XQ9*,R^HVLMS(?;^.I[)%
MN:.7B"W28,?YEBMVHR,3\J[<]SW8.9G&"7.7^]*C*4XGE"<0#];WI'=EY[)K
M>"1><Q+1E0Z&]"F[\S!)M\%MU&R,$,V*+PK*R9U^\1R(&I4V:T]O'RBG&$>?
MBV.[R[T"/]E;KR? 7'D1XYFI-_W\./9(>$/3I%ZI,LSB+Q)"8'TL6J! I?0F
MYK9T^AV^#U-E%TY9:, XN?)Z%42M;+X07NAFH[1V%/36?]3&SG:VZI*3LSBG
ME6]/OCTVHYW7["Y.+KK4;J9-NG/*;/88*IQB]^CJ/A]B\](HF;D7**>#H(RM
M@:/L=3J]YJA=Q:6D'':15C,92@U1%&.LO:U14)A08H5?W*R\_L1C/?^?95/W
M<Y%J#SXY!C0':[$TS#A>DWRL>97ZFDD=W<NCPI'_%;R;7VSS<_TFM\'JI[K8
MQTG\?C1 K(K;%B2I)\'TJ"-+!JN-8$W,";E0KAOUG-_U2O]C/9.=NUP!V>2J
M3#H5]&JZ(WGCUE\E,LU-C4_?G:>M(2V2G7*M\RNR76G3OM*(/[BJ!7P)3]QO
MI8=X6N(MT<;,^#B-"4EE>Y^B 5Y$9Z6N9'CZ=R45  >\Y)Q'JUASP9Y6]LF*
MJ>U#YN/L8'^ETQ\4AEHL$0O,=TFV'-1/'[H<VD2WT3//VFLU&"B!Y$3(6,7V
M) -Y*^T]HU2OVT#R;#*,8Y&Z[\AN5]UQC'0O?,&3T[L*_GA6N)U3C:?$R-6Y
M%TV*A\^DW!1SDS<7\%@=@E%K9\6@@D.,49+O\]<V6)N;!^,#Q1OQ3R\E9ZVH
M@)4.0^79SNDRC#]B' MG]=P =C>1/X^;C9LU3]6@FC6XZ# 9I:<1'3**T.N,
M_ V]81KIEX+C&9'UW,8LD*0V( .BU%U:*\3'>+PBOE2B@C6 9$]8*/YD*L^(
MN9CJ+=_:/&AO7W$U=#?UU:[SCU^?X1PXG=B6&P[6G2>PR-%N]:M.\SYU;Q2C
MR!!^V93*#\\EL-/V1KM$@(OX(.^,*6Y)EUZ4XO&:7=K-KX7&2+G,W0!"I*CD
MK>7ZN=^KK__61,IJ9MH:K?\U<SOD_.'=JN>F/4!UB[6RG#":V_0/M-4_T2ME
M8^!1IFQ/P370IV3/OS$?E'#!MLAR9@UK(!Z/[MZVTK85PL)UWFM]R9+3J0I+
MJQ,8X)D(!E&ML1GQ\2K.<M \U18FRZS&-^>L5\Y*Q-DIXS3VR--)/T5R5AAW
M9#%.-KFCZ@B&4K%^2H;/5F5J*MODIEVTC29$XAE[!)M=UM*C%!AL[X5-.;K?
MO:VT#Y<'4OEM*2+=@7HXVY]X_V=/W ?K G,MUHM6/IWL?PJAK @56D?Z;GQ&
MKKJC>2WZ)YZ-/T6\>Q*K?&0:>O@"PCJ0'8=,.$I(V5,?DSPHY:R&5W.KR3YA
MO%U/^^%H(:F]P38[0AYIOE:'[6Y"&F>[I=>**6MXWI0B^1HDIS0Q3PWEK\%^
M7'D/ANRP_Z1-9I+ZWIGR?67=R,O OFO\<S;7$-PSOR LQP[,E;947Y\R-635
M%$'A.M,3O\A';N&96!XLF>R:#PE:)P(>MDIK3T:9)_6F2#65&>_E#B_4Y*!6
MJT\3R!S8%,N;I#ROC]K&,+G\&GA4O*H-D0WN@%W&8)?K<]<=38-C-@<[AG:%
MI/LDY>5K]1_5\&(]N\_Y<1]L<%/[=?M[KB'7&:\L67[C.*93Q$RU@#/P!0W1
MX0=Q]N:R6X]W*N ,6HGB$J@9,O'PPON[X!]-S OOX5?<@C830FOEN"('['M(
MDFB9:^<& BI@]GB3T@UFT 4F;#<6A7B?>"H&BURC%SYXZ--+P>+JVY&GHLA&
M3W7S6M@#;T6N$$VP1[K_CS:.=NTPEF"2,+,'UR^LB^S?JT9- UT7,J9_>PY3
MLR9TNAP+0/S[,YAGJR <&C8GF_]OJ2<0U)/-"ZE%;8>[ET# ^E7C"TQE 1I+
MO2)U*%VRFJ"I$LOW4"<\PA%;>A]1-U[-/?ML:-U8(J'L\02WFO#SDZRW)#V:
M<*A?0Y2"9?L<^],7O#Z0X*,UAZG<YOU,PSPWDQZZ3XZ7(2@%+:@WR3Z<,^GP
MXV^YFW@?=$(=A@W# 7\V@F N7;.H+9@ST%0&"Z7>Z2C0T=RYR[Z6(O5;?+U8
M<GQB;K86(/ "![9P&Z &W3VST#S\O8TY&M>S?9QOIX[']IWEA@);.T& X4)Q
M3YD;T=D\AC&<])PF/]X$]@0=N.7]^;QRC_7%^XBW&1HW6*^/K4/[3JD@,A#-
MCBSARDSK_*P!TY1!MM4GNAA>$MZJ*=*63VP/1$O*A'.,EDAT*,8M8PD<0ZFX
M5'36VY]44V_FM-5^^1(!C YH,>C]#R7U 54$RMSZ1RFKERQ3-JCF:52O=91>
MG<X!)UYK,#EZDEUU2N: ")NLA-JB2CW9\*%[]QOL/O=%>JQWO.F8X<ID9;GA
M^GS?V5#!NU$E:[G_CB]-TRMIHW6Q[Z%L> R;]*KB1']/Z9I/2'+'!TX=[$W>
M7;&QL%YT5:G>Z/LXEH6%S:[<6+';__ROOO]K=/E#0%Y8+/V:.7P[<W14+UWP
MW1LF1L7L?">%;D;O]#Y:L>KDIQ]^T+Z0!S)MFPJ)?0*)D5]GYPF5C?L$M9B0
M7'GG(=,G.<Y'_G4WJ[M%#LZQ)%.J$9$OUG^RVX^$M@I,1)G'?N 9-\_() *D
M)V\-N0E=&-$E]]OBT;GI@.SVND7<P> L F7(M4W)'[9H\8:&Z?+=BM__DD1;
M[<F.YY4],UVVEFWL#)PVE_X"]N_[YO""%-V21Y&8DQ2-Z&CL:<XD<.E\M(A?
M;;$N5=NHW,K+E_]N>BI/.^N5!>[%X'IBMBOFM;%C:R<YH^5,MLT:Q^_/!!2^
M&3;W\FZ\K<3MO"988AY.$)3<P=PMB0XN\$5/23D=!0!=4_A@P#O@O<2W"$R0
M<]<P V30MQ1([WK(L)YJ(SL[-J_$D4?5]:(Q4.'J0<D7Z%.<9'/1*E([K= 5
MNSXEY47>UQ"PFPNI3*E;#$>^5*DMO[5HU3O3YOWB-GB@A0+,)SQQ%7<-)[&$
M^%4[[A0K[5G'TGT[3ZUCS<$91X].*XR!!G^:T82W.16X!HW[MX\;1GVLG]M6
M:U"D4MR-]@_1U+HMPF:5/%(K #"/]C+^^WF^&1WE G3^6SCXM_KAI83+GZ'
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M-6L7O@!F8TC[E-$A>2.KS70K,@<9=(L_8(1D<_ENV$L4471_"5,F=04S7EU
M+\[R_MEAR+]OL*ZC)]WD.IX^0'L6@IP/V']&!,31R= DS)_-;3V$&$7M+E[[
M^BJ&UR@B^_1O&0O55%O,E0SZ_R8#?/]//N2+V7UK=B+U^2,$:3]M47UE?95
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M[*JQI-V265I7!!OE'[LRU/^_"0!02P,$%     @ N3@.6TY\G@+RQP  ,MT
M !<   !P;'@M,C R-3 V,S!X,3!Q,# Y+FIP9]2[!U137=<N&D1$04&D@Q 1
M1*6*]!H1Z0(B)?2(B)0(D1YJ4 2DBP@H5;I(B930B_0FO02"A-Y;0@T0DLO[
MG>^_W_?^][SO.>?>>\;][R)S#!A[[[7F\\RY9LEBD\?),X"K6FJ::@"*<P
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M$8R7VLH;>"P?PBJ%PYYH']"HP[3J\=2MI3'!Q[_-.D(E+VZ841LG/DF[__,
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MQ1\3L#*F?Z-'C<GFO">2B1"'+P#C0:U%9[%4\73L<R5;N*CPP8_W[A>*HX3
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M8^BD/\F6VH/*Z-'U$G4E]'QE(3T>QN"?]X'A1C'%JF"51V['FN:.>!'>L8S
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MJ>UYA.IG#O%9D\J^RK%KQI5,KX9!QP1$7&278:13FJ1_LN=Q8FQ&V2G /E7
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MF[)%7-^'SX"0+F%[?\ 9_OH$Y>3/#SL3O.HV="OX*),L!)9HN%#S6(7?%U?
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MTG9=2C\%!%K%=?\[!3!#<QJXCJ;Z4Z9S<!Z_3O!"^Z \3Y>N2C&CU\6*C#D
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ML?$=CW]GD8=Y+,5R?DT671NK^9.8F">835$ -E]9'L(;E<-LVPD4Z6U'FT3
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M+FU"5G $(B]T!@G.+Z9S&P1_WEE/&#-AP@Q&*P$/OF0Y)BXA3QB7A%TBTX6
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M!&,3V:0QREN>>U?[-EE.QGO7L*'%S(B2Z5^3%4HC,JC?Y8A!PL(H?(,;2@3
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M=2?0#$OWLTJ=-Z\%V!!WN.NZX]+_]L^AF^+-S1\K:2>-)&]=1 :FE+V_^^6
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M303PW!9;2%$95@WB*5;[\GAE)^'P8:$@BD&VI,8.5HNI^;Q4DO6]J^R;\UL
M9\V[B+GN&+I9;*F5_%)7/F;>'&V--?IQ9-3>6=#6_2M6_4F0Q4*U$BON6G6"
M1]D6YC$JX]D'>S)RSCV&X.0-6*>?UP:8,?FY\>RWT]W@G9-B#&>86PH=9KJO
MU:M13"D?^N'UJ+"UNCQGN,3@2S+/!4I4XL$\U$3H ]+B >U!]H8@B-E2J2@
MDOW#KT[);L4GAMWSI+QX@;0VA"O&U1!P[;C\"B_6VLX2 :E>7B?IYI=]6$?N
MRP':??#AW\[M<HD8$Q2%=!J:/F%DN2$WE=KJ;<+] Q.<[F[Y BY+##^7?\FL
MXU\%)JMB=3?W2KTN*4DN+HV77G/ !\7[@+\:M>4-*ZLC%L2C,$\0BN\Z@P1^
M/)?7]R(=B9-%2N"FEZ%EMS1JAHYMLCK\9R]3!IA*7UYNTGYGR!=\6R)UXT3B
MRQC7RF^W=1!+BT"T_>7Z^R8)T4W: RNKN.@]QF:4X0, U;5.3Q -G@YZ<-&6
MXJ_:VM\C,RB^+5R88GLB-08WG[QCI*5U&V>;0P2 /M-GCZRE[,,/_Y!1('Y/
M>/=17^_<.[F5AZI53CR4!HF9'Q4IJ&# B+O5[$!-21'2@_.\O@_VP..!@"#H
M0)&Y)%ITOW*N:$QOV/F"C2*:P&^*\_<>+7T=9&.>%+7C&OR:MN3.F:KM)OJ*
M13!9JQ?#9I8'*7U5<MO0==&COF>QWDJW#QB3%^ONN;Q">_!+6/4=:0N<\#58
M&FO%%+<XHWW!66\?WS_)FA]"+,P(R>HS<YLN*X<;,0,,VQ&Z6>:AIX19W5J_
MO<*X!9Y[$)Z7V<%\C3D-W#GS=Y2<!:X>2OM9Z3$E]K\A\\O,QV8[^X(+<3+/
MTSM\W^U*/!!PB9P?M&G+CEQR:UY^3-8=BZKG>?<EEA]L>Y]D.MZXO#-B]:Q$
MR6@6.4]P(/2EFC4&.T348ZMT0K'5\]='ECL:RCU63<MM_WY@-:V% AL?WY/4
MZ=]Z*OUEC@BPW]0)5<_M)3!L-#!%>+52F8F4?[:ECJ%4VM&@6 N83,<KX_;)
MDTJ 5#BUWB8C3*^2'L3-DZ'U0K]5E60$%:X:;*D0[&Y"T/@-B]*WWJK%$-0N
MU_&<-B1X$._QE?81D1>>W"\'A/QI=G3\?B1U$0'5VA@0"B;T0SB8")AK:;4I
M/! H&R0/O%DWAHIJ,L"R7!#N@F^3M+"J$0'QVF)VNN_C#:S[$=S/Q2AE 33)
M=TN8Y0L'1/>/9;.J.^3'AGVV+I_3DN)(5' !N07I7Z>Z'=U:8=_Z>@*J9/2A
M.8-E8N!\P"3=WXL9#3-_*^'-KM93Y0K]OZ@)^Y^%]'J3?#>P$A36%(0)F/<A
MG)DA]K!G/35GOZ-HY&G&]WBPZN35X68C@4,^#E("7<75X\-'TF47%##1;7":
MO(Z))6(U]<Q=ZJ(A;$\(].0R#"^7I".-+-ZR2[[%8FZCV267V)W5UE*4T]#2
M&H6JGQX\$5;<_Q7_!;04CB?U=U;B( )^)DUZ8&Q(+&&/9MOD(B-%',<-VE]E
M2\?S;>:'3%*IL)?*398$?WI=OS598OSK;7/LIEZAUA[EI$+!=A<[%RY:?%32
MBO)"?=3ZIO[AD7'D+Y=D3F/Q+^N*VPA$G^D$GG]ID*1["3I+K:[3%+XGMA(E
MT@1EM>N)QZNVE@7=RWRP)T2_,S!X_<H;B^G9O%^0JB+T?43/.X\,W ]0\F/J
MUV<.IN][58R[UV118(FS)@),4ZV57/,[JY]JS'HI^VC (R'([)MY@UHF&ZS.
ML,(V]VM;F8S8#@H]U&N. [PTVJG+4+.5]]HIPT@@4]RV[LA)D.AIV]8O#%HO
M4V=4_7V"5:^QRMSK9BZ$;TN.PN&1:M-$B\2,M:5%_<AQA@*J*49)12&2-/X-
M:@.6GQ.70E-[!7A"PO_)B.MGL\NPG'+ WU[;%*9=,[Z_)\J-0M4V/AG^$_?F
M)L5(T_(2>VVY.O8!3@S#%%Y]S<_;_G1;.YI5HVUWKQ!QW!I/!-PZ 2$6;H5I
M#9\P>_7A1)<;XC#>PME?!Y6MI?AW5K$Y< 8+6"R!:[/0M.;=K*K'J<.O+O\8
M_;A8]/G0VUGPML%6"9O<I';M;;-9%<CMQW?:0I@.&=SJB( (%OX/Q[24G1#,
M[FL17].[XM"Z%SG)BN1"WXMYR=["Z;ZFN)-N#3",U73)LO6^7ZRA>'Y:7N;\
M^+5FKM.*40+SJ^0(979,_G;V1,P1DFE+HOT@<[(GBXG:W<6^?0E?:2COOWQO
MK0PO#[.=;-)Q+>RIW+S=1SO]2\/JFD *8.6L?+K4-<.G^L[#Z=7%;&[WL^#,
M,;.I60B6N:P,4Q-?WO/B 3Y<?JMSF+N#"'".=5;D;I>3K)77OW$B:]?KD4B_
M6G?*8+[DM4T$1%XYO0_<G_JX^MRYRC%O2  W[IO07=A/6UH[SW"F0D;;_CB3
M1D;8_E9W+_.O_9%%8[&IQ- T'.P0\K3(@#.8D@B 74([!E8C.YI$9&4&_<JJ
MQZVV@\;C;<BL\^E7,'^,LERSMBQ'6L3->O-F>,M3B[:8KO/J<]9PV%W+U#$Z
M"(\H6D8RZR"A$_JS9E-5ZK:.TB"?@!22$I,B"W,51TKUNX)<@.QK4Y0)KPU)
M!4,R-4B*RHSOYLTI5N_EEB56MFJ?4<3FDX%>@9/[M&M]DA;F(\/>D0NR-M;M
ME*VD&=]B$7@-SBYL*F%A=*#,MEN9C(41 99CJ/F7/PNJJZ;*Z<X$?21\2<^0
M0E$2/79U-LXYZ]([.;6M 3Y6S[_+RL04]0;P-LH/DILW']?ZK_ZX7%T.W@ N
MQ7@QC,[-=3O2]4E$8?12'#:$Y,&9(D#EFH#)N.G7[_UB5AY84JZ(X2V*86.]
MKY:B7]0XKJ0:--C,+[<,+S1;5H:V+W$TH'P6=INM"([27($G%IN5Q^:<7NE3
M"F98W4.O9/O:$=<.O6L]HFC89.XDT\'13SH<'VL4"T8^[W-,K.C<8W=DOD_R
M]OU5-@M#U+#D;/I%KS$K%-:?J+$. $A8@P^BG]=C)Z/V"5Q;V$=!A=+GJDUA
MESIUH$!:XV\M_ LZ6)FN*XI3O<EL^M1XVR)3HJV+QECX'.7O4%3F1" ?YH86
MY514UCY)0.H"?E#*3WKE??_DS@_1#.HCT*YXS!MFH-M:03CR34P=B"%0KW84
M":^4U/:9].Y:M+ XK+AH]+I>P7)Q->T83/,3^Y9:J6NI/3@Z!]J(@$K0>Y8M
MKV:)JX]4U2/14C69S7:9&.4UC2#33!V8LY&'Z)A1:C!RF,7:VRLBNO4/L[EZ
MN_R V[FB19>OS8SORSU$IVQMV"RP SK"%<L1JT?/=>U=[CLR/]19=\:=5>ES
MW@PB(&K/G^S[NT_\ET>=1H117 8FSN7X GC+O!9?W>0NYP)OD!WP]WI[IFEM
M;E/BWSIY(+<4\<9\<\O_4Q7/#6NU&[F)FC\8NJ%HYD#^I3]4,BS5!G.GM:C^
M2N!/Z'50Z%OHW9M->A@=L$5P >FG=MI1YQ.&:2<@+5YQZ:^VS1E55#V!"$BY
ME=5Q9'6_SAE._R4K)7H?OF)5U.T+5UD'QMJPX"$>0:_X(X51.JQ:W"N)VF]9
M? 8/D1H'-FT7:#8((\M@O-C>B=#G%QJ2$TJ6XN?7<Y'+UAVG'W\!8'H_-IA)
M$)_>/"3S&NL6LV<Q?)DS:=2*KB^MN)6@=@?5<"*PF6:4&>N<<FI<8?XC][KL
MQP? 9$,L"%&-)-^D<_8?.)8+BN$6$1X(.68OJ+/Y &*3W*>P+OB0.ZN) 3."
M#]OSI_"=X+,\1?H@:-9!ZT\VBR[_:G9^W%=80_YAUJ-9E?=9%3/^UUN[VL<F
M6?(+JTMWLA8&1;V_Y"U3VRPV/Y]NTERVF:$Q1ATLUAU$AC+OIII^%O?T;^Y0
MP2F?($UP\(/N]JMA/TZPSS$K?3XWX,D_(#DPGQ'/,VE >F?V64)7]'WGA]_"
M +1/!"T-=:N@B93#NX2@;DI!L33=PWV"LIJ 4RG-NQS$W_?'_SMRK;DXOZO0
MT>Z"OR&"O\NGZ1UP;+Q]T]H6LS]]T:XD,;$^[GW3&XC2B6T3JC%B/F8K<18O
M%# O3;/6(@)6+.DMSN839M&P$K515YZ&NK'=UZ&\<WL.UA3K9M9,N/PE.'.[
M<)IQE:MLU.Z;W_3Q/R:_.%_-=\=PT>K9J-(]%+/HYQMQFFZ?QRTJA.:,:4/@
MMO,@'>TD#)LNM-LVJC,F]@8)>J)98[AO7GK>S&;TN'7+NQ@6;#PW?TF;#:_U
MVEFTF4DB JQ,\- ,+!$0ZQ8HZS4 TJK6OG0W_-0)I8I% 4B$=^ -9!ZVIP8'
MK[_\2?MVQ3[6RK)88+I$@$I2V_E$F*MHD71( U^5GX3P4,.NB_A66]/6\%?6
M (':A2UTR>-U9MX]>7RT/WO%<BS0JK8*RY8<2\AZ6XJ>D3.UMWA-[L'AMH I
M& V6@H&-)[E'.5KAC\RH'LXI"'_76B[.30B%WEWO9'^ ^R ^ZC5 ?O1D9.$*
MT6P;1W&+"SXMM55JWHZ-UIT\&:3$>?X@ @X0UI"S--<Y$8\BC7<6.6K3C[C/
M1"ZAGYW'^^^-;X"JR3_R-==.VDM7=19IVR&IG@]S15S3KE7E:P#?QML=M$9(
MJ8WNB]GY+0/ZAYZ.\ ".'SUD-C\B G!/O55QX&5%!8@^ZT6SL5E.]$NTX&?Z
M"."[;[M+$W@J@L@HL*VV818ZL#8S-\OA1' *W?F4U5@]4GLRYYBS#6+&2WW=
M>CC5ZRDU/C=4UN$Q_6,D-;;A8;=SY!)%QP:!WZFV-LL^;7IW+R_2)>'1]>Q%
M6T5=N4F!@ZP?YLAP!=>;K34.<6SDK.XH6X$U]]XG02'E\8L=3#/6GTLV?<]=
MQS\-.4OT5#[_*\[(A^<1.]X U7K'ZR+._<I1,@6J%#HWS'>F03P@:5*_9C5M
MO?I%]ZIBJH/GL-O6O5"/TQ)3AQF#?M6@PF\]OZD#US'N9(-\^9@'4L ;:"@[
M3W,CQ&O>^<Y?.9;Q8B)9J>X%0ALZ=V^ENS+^8ITFG4QHBY8,PWVYEO1G)+Z-
MUO,IXD'!/UMUZ]]%* H[L+N2=@4;)*,#&J-9 S;Y), NLS8KS\,I:B6OS8ZP
M'$XKV!?3O@_3OUL[B[]: Y?903M^C3*7'A:$&TU_*UW%F* X=S8TI<F4+-7G
M%BAG%QIP] 0H&SPE-Z)45W-'3J1#@/6/^Y?ZK1O'#+D'C:>)!_L17S50UQ0;
M-%G\&KD>W?[I$6(5WYWUK@]+UR'=4(::JTE]SGC3\Z;7JZD8=M2ZS4&W>>HE
M.?Q0K[6K^8N22<)8H5:^F>QOZF:QIN2,8\=&7=0]O942_F+M/5_U83F9KM8;
MVYFLZ99AAK'"2Z0-_4^UQ D_'TM%%@2/M%!.?*V#:J_??::TTKN:<FXW^643
M5!G\V74IH$][K:Y^P@Y4UZ3Q61]4O)X6_1->:1^1"A?.Y$P),A\KN,O,Z=3C
M;KF&P%F2?AN+%?S]:&,7WDY@7D:T==8*M?0,$ 'ALP5;F8*P\A/MB%J_[TN>
MW\N#-]8:11Q/,PXFPQWB^G2KCVQGI*G3?;(\+9/C=Q ?<>&BHN[YZ5ITC%"C
MVI=K"I?STY?.W=%$@%V)*]A$PLE$ N+#^H3Q:O4]5/SM:2VJU_Z8W4!?/]9/
M9]#LL?/^M-*'ELA@H7OJ3 ]46TSS*XT509HUU=C4Z1,P/2RTS?2OFURCKQJ4
M[X;US _R-5H,,N.@[0W/DS)TVUCEO>:,!3XNTCZAE5IM@.],+T(5'Y$UC7C?
M*XP37^LO_<4<TML%*SX_VQE>G-=^5A>O.8K<0>:!Y^9ZS,9IB^ZM-:N"R7XG
MI:,NQ(X4H/HM>PN1VI +<*!2P_>Z1KE&BSQ^,KZHDMJ+W&:_]0[WF>(M,)6U
M)<Y&);G,COVIS8(&-T?MM62)-,=0D#VUO&9S)OB.Y'EG(Q\W@MG\45EF_8"7
M-=_E9P7.8@B=Q68*2T0ZS"]N,701^ :L=<)]F?RT ;527CM[S%<F:)"1*YV[
MB5SPD_F9%7<*I&VB#JQEW/7$S/85^)67LW(]\9>0J<WW)@"QKMT(]TDC.4]<
MNA&_N.:W_IK3-_"&O'5L&?)&\"_KNZ/'-=$=*3+F)\M*2QQJL2_\ =1>P(,!
M(/63'P>H#2*@)A&.->J,(0R6?4AV](/F!(@E[_W6U ^_9YZXAIC9/];X[*)@
M@[$G,<$6?%ZZL.V>KHY\^L/?G:^Z&AEN35:5[-C:'&W90*'DD^_/NSY)BJD$
M+7TFL,*'D %$ -R.", 4?20,M%+M<=]57RJ94!GZ\+=G)?Q1X64W99$\J=MO
M+UOX[>F;V5I5QH7%JJFE[S#D=V6X,F]4:++$#XTC<1J2R/.;YG#T,1' <@C&
M.< CT,=""T0 >AJ$*_[/[RI)*!8SX3^#_Q1?+\.7[!,![_S1>!X6FTO2,M#^
M.3P6>/ 1 C^^^[=L4)L$J96L@WXT=>N&2<O5]THXUA#>+A$H301\M;X@$'J)
M@$[]U:_XP3TB(/3^>&OR%0$\H)GL;&4.%%N<NZRYM!>ZEP:N3$[J4\;K#%YO
MZH)'$41P9Q*F>%"<SJVVO)TZK-0(0Z+RW)-(Y$3.!,C>G:*FB&$M.;<7< NU
MV!2[%O-E15K&FST2<;)_8\8<IOVL>MA5I-Q,Q/9'A^R6YQ?'."AT.)_A 51,
M*8M;U'R<%[()%#L2")3&J2]=43ICMP87$0^XS(!GD67&&5WMVWYXLB_'ZV]P
MYZP_1XU7_;&Y] >A=$'+O_<)E_"3;83^I_F5O=]U70\M*XS5PAFR+DOAZ__R
MVP9A G2T[DL$!+>>G_"FT1O#3RN(@"SYUHL3(F"R0*DFH8';?)X\F-[/"FX.
M&,VI(@)0\?@_\U=C@"0T V>Z"8%7-MJ?) *LWTD^*"4"=FV) "5?^-D59T.J
M_Z.N;&I*(="%*1$PF(&^/"<"MD=Y)T88R';=/M&%7)03 1D R+ 9$?"/&N/_
M4=D3EO_4N-Q_5#9$_O_8K>-K7U4=5,IY.UYK[+I]IGW*];=W_X=N )ST_F=O
M_LQ8D^0^#?6:-2VZG'PJ[UU(!$"!_S84@*'_H=D>;D=5ECI,; =0A:S"3S;_
M8U/_6;,/_X.52)XB!@F33WJ0[A[LIY3WEG_TXJ%/_U]W@\3_+1#G_'MP!K3^
M:R@N]O_7V SX]W/K"( 0O]7!?&34$D)^(R:4#\TJQ& OVTUJC**_%A7(G5^3
M?DKBK-2]ZJ>DJSM?/[B>>2(=N=1'2],N[//PSVOC>6X)1@?%QWPHIVRJ>;#A
MJ(M=B-C>UY#I,+7*.M*$.>/0[_:D]\-ZI%9:[W!+$_C'5QI#\A#[:A>*<5?-
MO)PGO_9STSIA:<JA]H#PF>%W\%#*<.GG[;H'@]M/9S#;MOI7D.&U_K JP"AS
M;=I>&Y*OFOCFJ=I Z/+]1:, :EO=QL^[(J)+::9J$P@9TG+9<HDN%HE>+%V[
M20JV9Z3:5VODK1'(-_ST_N3C12$_5M.#ZMMMV 53=2\IZ8>?5I*JQ;F_I#%F
M'ROF_"LZH92+0+W*V[FPGY.>_<W4_T;B13DR?\92U:[V#<_.HX_[]SB.NB?J
MD CSB71'J98LWIR^(G3;4/[8=XEN]WL7_1H4%$,F] UFHY@QR6\*LV5/H;,R
MHWLLC,)#W^Z]G%JDNC^$HOBZ/_:OIT1,FIK#P+60/0<-3INFP_O7#'DFJZ.=
MEIL#+KSBX F\CZB4Y"G#.D?-9C>=SX8DAVXR457XY?#MK :$6 OES&CG66DJ
M%9&FLCQ/6.B$2E@D\B;$&=78K@XJ'V?3?N5.L%?U>OFKG3.DARNO/."'\:1Q
M)LT(9Q.5J/Z\2L268OR2%1FM^BL1H\ZKKC,;N_XN+'PVTBLU)NA*NW_O2_ V
M=VL!Y+P_M6+35Z?P61+ZQF#2_5B4MD_OK@UH:F-F(2,(J91?H$.O8E#9T)R<
M=]21+8!^1\%=J"4W)6=YSM)%0.N'.*(^BW*ZQ;/:&:4M$9A+F%&S?PWG?J\?
MLTL<UJ)G??@8<$PZZ?$OU]7LM<L@!@NL3(WAY7J5K^:/KC]>0T$[3OI8H^4S
MC,5H-?T\2JP'03-E>]D_8N_1]A<"GWL^86]^56;J7*#LZ$O=&[/45$C!X-^4
MM=3@1^ >S:\*_UI3,ZR_<"3._#/KS>(*56;39*F!\X\KJW-0Y@:4FFY6JJ6:
MZ%DT1=ZH?$@ZOH5%LD'.HI<5S3$^R<MIOQE&LV^G:MI1'W'*+A_G?F,O="_>
M_.![F4$]!X38_'E9+D-S*:35)*&,:KQPR+#EK5)'JI>S?NZ)BOUN>X&[:&Z8
MK*?YY%7WM]JTUPQ1(J_[-&*M3]?D[6S?V<D.6)6K8UP2D>&.<0OHP?HZKYJ8
MJ+-/"V\L9DD41HY)=&GIG#[<![/G0BLWH[EODM]?)T7,4"C$J<(B/U0S!TKX
M%4/ZG)\;0.Y80+YRB%T,H:5OW+]_9-V>JRXLIQCC>>5?3+E-!L]"8P@H*U&R
M\P<Y'\E4)7O=Z32YB]5RA?O? (J@*;@DJC-VRG&NFI!R>UC;CDH/:P2X16YY
M)HFL/F^&$/>2:8V [E59_;/P\@<_RFG62M7ON@YIM+#NH_)(#L2!!:N9<*"R
M:]!;:R+@2<2)>0"R\I.ZDO'P13;H_5FGOV];24 T_$;W>JY:)5CX8V[Y2$4J
MKYJ\QW.:7W]?8H*/D_K#1WG<]!_)'6=3 F=9K):U0@]O4E>@.6B4GOM*26>5
MF&UA)6M,Q*W4"LER7[Z!KI?9*D^(N;RJ'OGTU_'&'EF?L&AB3_Y19,_*R6;:
M\7ZDO6B@9KGU5-?PYB,5MP3"1E>!*C@=$*+C3*LR?.7<GOR7%#/_(/_4.:W_
MB83EDTY&$X;@MU#NS%-*586P=OV#C5%7'D]WNR=F4:1'UIH'%#\:KD)"^PHN
MO!BW;]'\P;7<7.=AC_3'[#CFLR(KBPW&V?Z+NQ\G!Y38+W-=%*@/EG^,BB:7
M;*M8^7&]UW[4ZU''?DWQT!EO@ZK2/>_*5* H(P+:5/)7][PJJBN?D6M7>9$P
M@)^H#]-G"'65MT(RR$&1:< /9<)N^^7>13K-*<DWV+V2:(HVN\O<\"*X/G<L
MXX7^B-MQ>BLM+$R7<I+%=>]6<6;,C46$\-X0,G]0,Z?)YO0C-O-KWO05Q#=7
M;)]QMN88LZTY6I:UB[IM ]3KU%D&QC_$R72F$&B'\: B&-*TMM;,+;>RZV4\
MT._#EM.F1^;/L>$8EC\VBZ"NSSL*;,M$P%TH<,8\3:6DTL+,5>SA;P]FMOKR
MR?:LZKYMEJ["'&<EVK%J'9^)GR?,PFX9GAXLL7-WAC#QAZU;;&#OG":?H]/8
MD46<>CYL@5H.&O9M@*W:W+GN[@>SFAW^,6/=KQ?@YX$J ?E.F93C4J>CB++C
ME$J.0\MW6N'\(C&GN65A^8.^W&4 +R0EKG,Y0_MG0VO[/M.326E_[_F1*?3F
MD4?X)RI&X )Y\_!]N8C[H8\$++2COVT]R/FK[;^QZ_2_DW\N4=G_1!XJN-M+
M$0'OI=*AL!G(6G4R=ZQ_%0/'-6N# YN?,Q-A%U*]7[=87"8:ZJL;E!TYVO=>
MSJHO6V]J:^=:M5WX =EQ[DLV5_:S"?T^F#W/O2E3J1E8FGO)IBDK,N!K3A'B
MO>T>"V(XT?0J&FG7'WUO[$NF-IT.838_OS\<!R$"?N)5:Y=P\EFT?1=*N)(7
M./'%>OYA]\R+9V/E? TCK])[ZA.9W"J^*TCY#^Y,'\Q04UB/>Y\>Q#4OE7S(
MN2V<ME9X^IG7<IW4I[LLB'8A3/>\ANVN4M!E@3 :C,UJ%[O[G>]WN[&I@UM?
MZSOPLI&"3BZN<2FKV\JB2XX_0E3!K  Z 7'K==I"DD8/_:TL9D#A![QX :Y;
M(U5[W#5EZ_?3TA?84!IEB@KRZMUL"R?N<(E**<KZQ[(D]"G1^WBU$R69@_U0
M@N"&#76@(U]6CB5D9N"T3G1A0B1'4V10F$NIN<J<"*#$4V,T"$J0!?XQ!?YB
M"(OD^?.:D=XBRYLKQETW$ZJZ_# MM9W*OE"&D]*)(^KAY[&L,<L<,2S:.B8G
M^2';EWYSN/4?2G?JQEM <S 1GKC]MF#V,;N)A)R7?:E P?L>[<:176B M3/A
MX7CA2##+]@'4 'CLZOELC%1/8S[3B"(_"+@H%AY\#P>A'H'!=2RD&UR/M$RK
MZL]L![S'SGFG?,=;UG^U,DNZ!H/#T52!_.7@TWVZ!><4C(-!RA^:-9X+FI,3
MWFHEU2:]L P$TR%S:<G^#8AY852I5&/)*]'<US$IAS)<BO,:["TG-0]:"&XK
ML^Z\KYQR$.3_)U_[S\C_;W[Y_T[X%N41 ',!&5H]M:6M!]><\N845<G>[3VX
M!KE1:L.(2Z2]@7,C DSK67-0,?4O/.J.2;"RY09+)AUEZMV56W?0FZ<^1(#C
M3*]TEH\H]SJ..2Y.'L'XM6)CS"1A/M!N/!M+FMC]M8UP-U*/Q7+F0UU'V_/%
M[^"]L!"+06S?#\0H$L]3XQ=B]L6^#K"X'*>A&,XFRN;B.V9"5QQH?V#]P=[6
M+P C)"N"S#TJ6^'YN'FY1T&RK=N"R\HSG5<6LIHMCW-IF1?-[G]:3/>^N]R)
MI#JG"?X<=T6"D+ ,%\EOKUI&T7H1O6)WINSD&$5"Y6*\D"K8PFAA_)VE6!7+
M%OZ=&KU[EF(&<6.*#%,IY3USUU.:PIY>YBE(?-LZM$!;SVY.)"J[2^6-5#G8
M2#J2VL:P2U@%HAD#N=W]X%"^1N>J*0%H,@]A@\I;MMOCR9D\I5 TB!G/W )D
MF9[<A5<]SS3).'*$G_DL^\ I?XZU@&#NFEB=_.2%7"ACK&_A90V;NN?M]>#Y
M.I)\=N4U_V2&[BWXE?+<+48?D[3+/!D9!)*2D?]M[?QC$@#0O[\6UYMKQF9_
MTE<2)+C0]T+Z84^_Q6\.DH^ LVQ:E9R_[;BRRP/O! HW_'J6H';4=]?/Q?11
MR6U6;'G;?YM0&9!7O0!%(O[E[O[_UT+%\>6H$^;8$1^.IE?0Q#26H&D"GQ+:
M1U8HN2LOI'?_NO_E8K*!'2+>#9ZH*-&2LNWC(^@@>X[?R)[7!YD8?WH]:WR6
MF'B1YH1E@RXY=D03 0 (BTYA?&QY,Y3S?RU[KO^)\_.6+WI\:_J!^5S[E#.J
M\K:R;?_(^#6[>W>Q[)IY#O&;[;\?7UN=[V7@'WQP3=U:OE3MO29WY[ZW.6H5
MM/@TMWE]D_G>]XNW7MKONW;AYV.-'[P?K9NY]D;L_9K@6=_.24Y]NLWL *>(
M7+C=5_M^.XX_GA_E.]]OY55_E'ILXO(S-_N.*K*X&5XV_<+_T'-^UOQ5P4^?
M[MZ^^C^#<?W7;NFW4U,EBE7S'QZZ]F7K^N<[GV^NL=EWY9^P>:MI;\"K7=W1
M'$_V335\ML.2M7WA ='V!_VL/^8?OC7WVT:UWL4OMZO=L[;X\M<N=J,/<['V
MG-HW)>_C]HB4,$LL7OA]W8VCCI'RYF%+5OM>F?=V^[+9/TMLO#X_7-XM'[SK
MPB5=FQ]!KT/_7:T^-N7GRQ/)$GY_^K;J-7Y(^NX[^>!;T[6=_\[LV#/M=:MU
MR\[;MR>?K8X5N=9UQ-9_HDWBLOM_5"/?I/1[[]ESU>3FVGWG:_H.,I9I/YFP
M1*B<?WI?]@63^:U6[Q9^^';-:=O+U<>V%=V.NO.?875J:_W5_0M4KN\\F\YZ
MTGT:Q],4RZ 7G/'+JD*>+^5VD?6?N^Q'ZN,K5Y=_%+%RZ]DU.VO:]]/+#Q=N
MTETI&<2=O-[TY>4;/R8?J^<O[;6/O9SS96W8*TG%+@GUSXN?U"S99IN]9U'[
MJ@VZLN>9-_TP7Q?[0D[5^[>LG:QSP*6W.0]""A[*F1[\N?' 8U.QA1^XPZ[:
M\#ZR-7S6=C]@SQ6EO4T>2V[%**VX=8;-S</T_=^C+!>^_MN7%!7QLTG^YNWX
M>*Y[DCF/=UQ-W^79(IQU[KQ$Z('4Z7G,=;+:RS[4'XP7R'R7>FW>N5_Q;S2_
M?-%M,SSQQFM=X3G&IZOO55^<E_%OOX-=\<8?NH]YQ=WGNP'[;.]SMV9'*.S:
MLZLH=7-*C.R<FL.7MBS^8?THG^_5Z=69&S-_K3VZ]TFK;O[])Y/4>X/K"@_S
MA.\+]/MU)YWS0_:AJ.E->\1FE:V9]O'>[)G+4K98]CKO3&!_'GM7)*BJ 4?Q
MSMB^@O_+3_N[49K?E<_NF?(K(="!.[WPF^7-Z+_1\T]<VV'YI$C;ZMD-LRR.
MU'G7&S\O_QYQ@>VLZ*S2I,6SB^>GB<R_'?_EW?WO%Q;P6FD;_\[^-_?VOU\B
M];GUEW?7WW=J,'FQYOS;];_*\W^_"/R[]3^#W]O_#+5<H)$Z^VW[7][=_WZA
M^[?K?ZVW__VBP>S7=>;?K?\,RX%5Q;Y6^5%CAZZQ6E$4V[;D:-I_!JBB?JB"
M +:YHC,1BF#.<9 J"4N'.0EA+VC %I8X%\/L95SNFE8_)(V=DFWYGV$Z5&UH
M]NZ%^9+VQZJX5I5JJDIX?/L].? X\VFUEWS/OB]@NJ5T*N*KS2RM-P$/,Q;P
M_[\) %!+ P04    " "Y. Y;K((Q2\)Y   :G0  %P   '!L>"TR,#(U,#8S
M,'@Q,'$P,3 N:G!GS'L'5%/KMFX0%10049 FH'2I2E-I$140D-Y#D]X,H7>(
M@A2IT@6$B/0N)?2B]-YKZ*'WW@(D+^Q][CGJO=M]SAUOO/$6,,8:K/7/?Y;O
M^^;\!P$S@ID&7)>6D)( X%P  '"P7P#,&. 9 /?"A?-O['41^WT)_]*EBQ<O
M7<7#NXQ/>)60D. J 0'1M1O7B:Z17",@N'[K.LE-4C(R,D)B<HI;I!0W2,E(
MSXW@X&+77+QTY=*E*Z1$!$2D__&%^08@P0?,7(#CXM #+I#@X)+@8!H =%@_
M+^'\<0'^<>%<P/IX&0__RE4"[ OPZX +.+BX%R[BGGN-?>J!?0ZX2'+IQMT'
M8I=O*NKCT=N0\KP-2\)G>%KPG4RI=XN1U\#6Z\K56^04E%1,S"RL]]CX^ 4>
M/GHL^.RYN(3D"REI9155-74-39"AD;&)J9FYA9V]@Z.3LXNK]SL?7S__]P'A
M$9%1T3$?8^.^)*>DIJ5G9&85%A7#2TK+RBOJZAL:FYI;6MOZ^@<&AX9'1A$S
MR-FY^87%I>65[9W=O?V#PZ-CU'E<. !<G/^Z_L>X2+!Q7;AX$?<BWGE<.!><
MSE\@N7CI[H/+-\04\?1M;M+SO,4G?1J65/#]"@.OTA:9@6WOU5N,?#-,V^>A
M_1'9OQ>8U_\JLG\&]J^X$ !"7!QL\7!) $  JGZ6SI^_FAWIFWLINC1#\_O<
M6)DOY=?/D8^_-=I@ %NQSO%H7QUU- :  >QGIQPM8@!,AFH80+XEY PP3*2G
M[)>.)\V96K ]$A<1;)[*4IZ- 5R)>5^[9#P(W3Q?! H]>EDEBP$\X\(^@6(
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M>Y0'<A\3KD /VC$ ,?[_& 2T;<"_+NM_)ZO;O]@7O:]'Y1QK/Q8NC*7/W7.
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M LT)&0YC:AO<S.94<<,M@UGE<!7X]BV84(/UBG]#+IU&/0;P JK6@ &\W/8
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M'![<5Y:WQN4%W[^+ $^Z'R[BXE;+_K3-!/7^C7PKOQSU&.>3^HK<X4"CZM*
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MQP!Z3>"62:KS4AIS4;3F#^U::V>8^C& Q2(,8"H& T">NQR#34QB-W8@UL,
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M;I*P*[*3DK4A8M$%<X!/F5L]WDY':(AC <[\L!^E_0[I7)EY4@#5OE>7AGG
M =SI?:.9/6&7?#XL.[E"J$644X9-7]8S"331$*B_*8@>2 E3-'[+FPPA9K=D
M"-)8KTBYJ7X_+1V=Z$ VN/5VJM*3<8+^A:C+06[WJL:*B:^0*0\D&VB$B@<]
M Q;#ND0Z8A]TLC"#BERG8@6EGHL5$#=QUS'XXNP-&M,H&4KU<MJP+Y0%7VX
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M,R3)+*6/B![<O_ZC0O^7M'8X5R0A$<-(R7:21$_0HZ7!:E)1"<W 9 /,3ZD
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MJM30 3#A\]Y-F99.3;SSD24^;CI&$^2J"F$S$6&$O=JP'#G\AJXH)A92PC3
MHT?TX>DSM<1(RL8C\-B>OPG80K#8W<!:-K ^8[X/T4.9'Z+A%_8#"R Y!CJ@
MH4NF[2SA&?*DEN$89:HZU$ I%H#?50_<PP>AD%C L3)QSLM[O$:7R&M_N<^P
MG7/\ )?+*;C$#,8"&A4VDNA_2/W]=BS^8@Q(]\ZV@82^" 'SLL_AX8>*3@S.
M);CI71UIC'DOBP5 &+  O^31YG<(WONL4"P J>).C2-^1<A4,Q8PFX$%>!K/
MQ!]=8D$?0S#W@BVN(4C_\V;9I%,S6(#W6..!??,+I?.CR3['0W5O)MSW\7/4
M7*BO]VAB ;\:\HNA]*.WUYE>*_Q?-%2FLYGI\N;<TQ97VVN4)9V44B$5>X(O
M W0^49KW00:4C@3W.Q>?MI@Z7Z,3_:2 $:^8[+VK0.<\R(^B[2[T^3 ,!H@%
MD$N7^+A04Y&IX(2Q PEQE1\;< M'N_!7_]CLZM]NIK3/[8UA\&^\R5]AVI;?
M5D3YA'TF/R'@>*#\5_,&[_R]>%U'_7WI_]!,V7=Z"J=/S?;Q#2W3=HZ<G?,=
M[$O>MR#D](,"92[4.@VV_[/F_Q,%9KMP"A3U33OR+?A&+_+=-73_M"-V@I=8
MZKO60NP0#'F\%V29+/X CG-%%O 76(\]=?]WTN7OMF,.W\8"ZG<=8[3?[RV8
MZ%US,C%TY7H9%AQ3C:N9SA@FD4V&'Q#U7A+\RWWI7]SA8N*='_(WFS4[_K/W
MY*$@,AQ=C^LP]-/Q%1/F%^#]Q,4?:@HA<N4;-4RFX[QZ/Q%8!=D,1F2B3(9U
MFE1Y,_X*/#@&1'\*P/]K'XO^DU;U ^XXYF&X8?*.^5LVX:3#UP^J]7J\#W:=
MN[,:/R8S\?I-_8+47U1!])#H,9[_'VPE-^-P[!/M@.K% I:-_$!>%=K0R(\<
MTQ\8N)A"+3++X+OQSNQ!*I7"B=N)N'5<R%Q#_.8HKFF1^N2M;9,A$?69#I-Q
M)VD9TZ^2I6)&^V.XXD+JU!/';.G7FX[-WNX75W6HA_+ .?O:@H:-#7V^#"^4
MWL49.9+:S?%K]"%>Y_>^Z4OOVW?)@,DD1PM7^M)6C'-D202F>\XO!3\[P)\5
MXS,?PE CP=FK0H;-(]Q)KZYW% MT=&9_8]!7*BPP+4$_U_U4>V6KYN9/GX,*
MBX["[_-80+(:QP,!(0JKP1PMUX=PHKQ 6*"Q+/Q2=6I$CCY*/F7P@]2/W*GP
MHB9)JYOI#0S7'9F/=F4K!L>TGER"]NKXA# %M+)*!18TNP[LHU,ETPKR-,R$
MV&#^(#_9V^AM7E#^^[XT8C?'=)>MQ;ON<9+:#Q JL%Y.6,N&G1YA:8_(?2TF
MANJ !UO"0>Z6CIE\D)$XB_.=C'IY.4*?'!0[B_CS#<;N6-B-@N;-S>;FI J,
MTU8R!=Z_Y8]]-BUA?EZ74:(X#=V)2Z5FL^8*= JW06EII/SVU&B!'N?^:'6=
M+JLD<S,^Q'_4WQ93Z56)!6C[KD.,^F%]*@/['[DW+68YWEP0>Y6Z&^PZ6X2Y
MX\H OQSU+KK6\SHW['*_485)S)M/04^'ZRY/][\[-H+?G<S,*H9+6Z1+9XUH
MCCEQ$,9I999EDZQIW(1LD$/XJX8$W6DI$(&F#C;F=\8O\SH12IP7-B835=U?
MO8D%Z%H5I!PSUE8@'R4Y&NW W\*$'^E7\&9Y*X=HU?!,Y;+9 M^#4QTC>A$6
M)N.F$:6%9B]'?,Z7E5GMDJ*?H90MS!$?O.4*^IGE'AI&3$YVR@RDUSG$.ESJ
M@EE)(/S@E#[1[&/L5'MHSCVGS7GMZ;;"9N8?JJ+2,.'5J7VT"5-QZ3[:S!FO
MD>&#TK'4H%@?NI@3JDTJZ*5I&)(T:E/!LAI@%CM4)P<KKXRN;[@\,7I$)SZ1
MXB$L?8>KKQ)5Y_=A"/$^',PY4/R1*R+LNQ[_W/.+DZX^5^Z(I;JMR<UL-?EC
M 52.?FU-N^(WW5*/;:JA/SII2[\L:#*6F-[M@6@_*1TZ6G[3BGHXT9PF09[G
M*U(Y^&%Q<'%63MF*PX9'WQ-H^\&YOX8!*>AD#)=X5AW!+$\IVS?KT])YI:I,
M<C3T+9U P'ZN9PWG>#-_GURZ5(2IC9TI37;HPHSV"&/W  $60(%,?U[1!\-3
MB92+'C T>D4C9L Q(I9<FI_H0%-9813L7T.UIM$<D,=?S:@;+">W=JEO\XV+
M'CO5=Y9[((D."<-MKA\_VK6*O#8^W0R*H?B6;L)-]=C][4'KH^S\8TE*9Y4P
MR-L=7K<28>&,^><4DP_UCM>ZETLBR$<=,+50DM@JA6WNQILZ,>C,=#/9/,</
M5S<,WFOP^RKK*99]GX:OZ01O"_YPSOMX? -A8:HB*C6[:I[)*$[<L?'-JGE!
MQU-2>),Q;AMRW(0%K+,!,>W:1#:39YY2IG.V!GW7NK340-/B^D1$C@PX4G+T
M2<-F24S/@7I<^+4J1*NCV<,6%?AN59YISG;%&C%3:]^;\:. OCAB84_(C#7I
M<Y!+4^T.,6YEEC<,B;7E[W(<PCP9U-U'D>SF>L6,D)8:DV<Z'KFQ-VA 8SNB
M&XV-]1#%8?8:$K4F]#_"%. #B,C,Y9>@-_Y@EXMA\ER;GOI3,$ES<QV"PL'<
M/,L4#BZN'$S3"_>7E:47@K5PU/B#A6BY9Z$6++0$"DQ63,<?BS0W<&.SY9;#
M G2DN#VJG.QFVVNG)&GO@_!&;VGGY*K:"Z-G-MGZ'#_JZE*.KWQV"YH=G1S)
M-;3(H7YP0"F65FP;?VYDN<@IXH#RW""0F:XKGEETS"^OQ&P5:2VL#O//5M5S
MR<@@W*'UO&V?*^I)TO*TAGJ($4[O:9S1))"S$EKSB?;ZX<=7IT]NS#KPVI,Y
M%DX<6>FA:S]OP;DJVPJ,XI<:PDC'3!WM@M#X4+N[>T(W69,2DKW@P4'<Q=H:
MLX-MK-0<ZS43[XPZU1TV1LNVM&-C6ZJ*/LQ(4:@-/A9+YO><Y;XPXABZI]7!
MMRTL.?_L]MNK^A.5YBY&%5?>J-V6^6SQ]&66*&!::5E K*CJS($R)H-G3FM,
MM)0;%CG[0'#0P1LR?RX-,I2C>P2 WJ2?+KE34:8IIYYNJ<)D#'S\0$OUX[&-
M&]1,Y>5DX_G&# W81&W8MZ3L.:(X9.ZLS*#:"*VE"A5C_\TE5^"T)C?Q%,%7
MHSC[H >$[ _FQ3U+R76;0L=SO64ER5XRQ@W4SK_KAHR7X>1*XK!B-K7ST 2X
MJ059OE-QL[0[O!)_L4IOEKV:?DZV(%\M<#'Y@52PF#VK\KALHRTL>):;\/LL
M4\GNW8A1%U.1%N/W^<M6'X,S,CB)MNUK)IFW-](2EAE#Y;\/.%]6N6>UT6BA
M3$0B5;J-B03KF5WY</U]V?RW;Z%N.V9H@5MG3TSL'A*=YCZDP-5&4R<?A3-S
MHP::TA&1*2@JU$%^?*_"3!KNZ&':;W[MA7?%U#*X]%'G8LKCD8_? DN)DPR_
M?;1"U!9NHH=B \#-4-O^(Z*M!%7A.?#AI3'(T#CPB-Q6N1,YAGEB/[5_0(+Q
M?"$<PAGDY\>:R5H/3_>)^3%)5]Y__6+H[5>2EC%1'P)0-B\=Y1HHG5.;,O7=
M"]R*0%^EM@#"5/=;&/DS<TU*,+=ZE_(K"/6^$(8_O/7QLW39G6RD2_T[1WOA
M>"Y32^/RL)_13F-<2U341_@F;D3.K$GO:1%GCBLLWZ#!2&U=1W/6[EW0)GID
M^=P>?\95;RY[@E*UHJ3([[)?4P>82V1]X4N9=G;0_H2JX"S#^6&D'Q:PH20G
MPM%SA5E-\[Q:O>7H5*"LV80\2O.]G3GAZOW".V4,"M$1,;3FA.8WB3(26.D]
ME#*NA\UV'5+L,QS-#H!QQ=AGY4BT%0A]41E$ 6DIQ95R0Q39SJ#C#SFU:WZX
M^&>OA_6GSW;HS#W91F^@H:6C:1\$K*@MDCU>@&!ZZLCVEX,15_C6'&]NK\ G
MVI=XK@0@ZS!&%=5R('_EOLVWBUWA5C12)U\,^9ZK@IKYJ63I-;KC(JR>$]&F
MXHEH4Q9;(5H+(I)UIG1EF&6?,!M2$%209!Q]T9TR>+BS5+=:?C!;R.E^>Y*.
M0*4_-R?YD^F1+RSTUHB8VBUCL5I^6QV&[3:D?2>!&I@E](KC*U=]JA7UHTB/
MZ;)>\#IG"D]CAHY;UGQYZZ-;^0R?$_B$OEC=86=KRV_A?P^%M(S-3*$<<7!G
M=WLEE95U/^O^I=?FNCL"2 ?,)*Z.+]M\6O([%43 O7VY^6(VN$%]@S<<7 UN
M+^&997'-]0T65['D0G[(SHQQRB0$='X*ISMW\>.1G['/,3=X%E18%29O+EKT
M0)*_4L]KQHM!_!XB.&5LV=FB.C K_ /Y:/DCH 9%O6$;:])7OS@ KFQ\,82I
MZ#C9.\FZC7?L9U^[/PA&$_:HMUO/%3Z2UVUL?HI\/TOU(M;.)KSD=M(%AM4.
M((;B,:Y4Y<0"YH%-68XQF&?$.*+3VL#A1WFMAFR.-:U+3/DN-5\@$*E^ >-1
MB@LT%G"S:^A8(=TQ6::L=U^7:%)G6(MKY/5GHIP'<4U1DJJ%WF_<BE%?1^V"
M/Q7'"FG2Z%[LH,OI+)3Y9#G>9IT2VK!M^J9X^XM0^&)"S96P#0>35C[/!]6:
M6X0WWL>;#2<%&_YV>,1W;<;OF<EB7T2(N(=O@AXV!L_M3U0R[F:W8:B#R'U=
MJ7F;2M):[B5<:&6Y*[3'$MW]?_JUW4>^FN3OV=::=*'Z6C.9QN/3^: ?/X)-
MA)^0YVD<T5=I,NL&__S7'-Z\Q+6-<>;B?J)?A/%*XFV^^==CKGB#XEI%+MT9
M>][2R]S7"JJPJ12QSY0*F6[TN]+\WN JOHA5AL[Y\O:@ZJO055;$RW7Z4;>?
MB22>4D7$.2+DW(A/]\B9AWD!5+3&U!=J-2K35J/I@_E32MQOE)6&=@O5M23S
M>#]RM1D?\/MM__2H6PN-2H\V-62&O.)<:BBX0@P5(&RW*BFO/VLNIRTPV*E-
M?+3"^;F91B;[<XH^G=O#U/]C8T+DJ'Q98=!0?6G)8$DI@^DUJ63SUJ"KK1O:
ME,<<[W'K14TLH 42:*0@7>3A8NJ F[1F#$B.SD]A)$X.M/3\#%PF@!R2P'/:
M?K=!7P0XIVX[M<$M*(D+O4QUZ(S ^P--*HPR;H%&< O238$%[##,J7]10EBY
M7<SJL/O7X[&YL-HSE$2EG^XG_8M*A=ZO$7W4L\";[5D:8\W$_BX5PCX+PAZT
M;(NPVO\>UIS7S_VW4RC&^TX)2#Z-U2+6U/7$8?=1H_C3 ABV"_'0YW#+V-L8
M_BA)^C:ZCV//3P^1\]75G,.=N;Q6B',K[&Y%PT/JED?I/:"1YOSJ'%0TY(_>
M?) ?+0Q[EVJ/O9&#AF357X1)S@[TBR[)(Q+Y+J:G!^!74H'OZJRHEL"72R<-
MNJO,/_.$IN#GG6P+/[&K( 5YF%.<S>[$I[G%2Z4H4$?5\I)(\Y?H_+93NN-,
MY@%/^TCT[ZD54 //*:6_U;NE*EF] XUX>7@!R#O]YO^)N^,)D(/:#%)^@VX4
M!S]5K.T]I#ED,+9';*B'&WHNZI,'_P-8.CV$.4M#G$"D<J$7JZWF1+N(-5T=
M\;G6D_@VVM[(%NS_'[;NGSN[[]B<,[<Z>U+,WV5!^XK]:\+CK"<=YF?@A#XY
MN.1_))%(;K@^)46ZHX$%>9&VSWD?9POI-KRNL$C" O1U:<4_)F"6<T"DD);S
M*$PYOWH?9)[&%$?NN"+H";E.)\5PO+EP3/R_P#RY6!N=WUGO_C/R..LQ@U5Z
M_H@UG5[PC1.DN4[\CK1X2: Q>;?.(#CSSPR2P[D/7?SG:,?[.SX1VO)2W7":
M]J?&=#%ISG]==S5P7?2#_-@ZO,ZW=9#ZVR%-C>S:L=M(A8XU=[*:P9I;2#\U
M.Z\B2<W7C)H&D$,CEVC@C(Z9[AXO$'-.&L/?^\OANR!3IM#G[2/?2T8?@I&J
MT9%HPF LP$,!"PBTTN$=XJBZFC6V<I3GRW^IK.SVFQW;D#N5]'Y7MC9T)K1T
M&[BO3CE&*F^'-\9'+JQ$)TUT5>?;7V(,5NH F@M#)8;[AB2Z.(Z5TU9O]JVH
M8!C[TRJ"%"[&V+Y6IO5XUS$&-:\7#6_VWQ*Y'\=CDZ/1N"1',GSCG%4<L=/#
M#;4((*&K<K(K:(@_HWBPHK"ZOV->43K;2>9:!@.?VCS\%=3]LF/;D%8)7!71
MH+C&G=EN9Y,6KL 0?NO>*[G^&:M&%A5[22&^@8X\?/,(';Y^BCXY.'TBVYOO
M1FZW.*1-O]?'"?DM6Q135L$O+?I3^AE8B/<R1:MA?GQCMWW48<-P2>PF,K[.
M^<OU50T;: 7U1RTNZ**DUQNIV\UTYHG]MB#*90@YOZB+="\GOZCP2YC71+1F
MP8VFESM606;5.<7]\?I$MGQ#WR,YA>M$U-),FG1X+"@6Z%.,_0)=[VU8]@53
MB[]6&36X)E',\'P)ZN3F70>D&D'V-6@TCZFH5@9-?^<K?:L<\'%!*L">OCPG
MCQC3)<;;^]90\.7(E#0":=D9>7?D6MM%0S52H=<[]]QRUH'ZS_=B*<R!UT3$
MNYH(V^_(K#&.2&5^LH"VBL$J1%C8-:.: QCO7QXU0(EH/MGK=!X*&\5TU=S3
M):I_W6I^%741T4'F@&=6-'X5@-<'=@Z>I:QWDZASMHU4&=4TNRF(@%4W(UX1
M;@8EB>9H$3\FZB NCM1=G5EGFVRE3\XQ@2\+\55 #P+FO$$^'D.7!^\DA 48
MB\',&*ZVO^MA<N>6"GU%>H? I)0W;MHX]9T[)=(F$YF,L(QY$@]2XR>(2BGS
M&EP/!SA5?J'=>;B?L>&.[QCEJFQN-Z\^)HVH="G(2&VGANI+UFO>V[OG9HJ2
MG>SP'^Z#]0H>&V:88BY4E)8,'.MQ*'6F20:)/M+Z1*==T",-U>F=*1P$+Q46
MP7\^T)*@M:X@,"E3I988JGZ)G-ENUH:G08U=DM5'NSCLM\YW(<+ ?!P@K3W;
M?24MV%)=/%F]4Z;V=XIX.X@(!2E![8,V7OESA]WONP6AK /Q*H)2\4^=E:<\
M#0I*(YR.=4(:J6]'09.H;AG3.:.4Y?%D0:0F<#-[L?OJ'//:,Z.]=^M:J6_%
M/2+_OJI[^5@_JQ[1/L8IAG#B%Z[,Y"OG\O%^FT%.XY 5-Q"9?,PYN%?M\AU#
M-;QR8^3.VJ2,/D FA9M^:%FVA6Q _0!/*EYBI+E^0V9'1&8>,O0-@N,*]@XY
MC)<T%E#'B@4T57J^S )0 5XK]FRPC.LTB0;S=KO>SC;3'14S]AEVB]N1LVO\
M!K&S"L+LXY;6^+N*N*(Z! O8Q@?"H<%X6,!/,.8'CD?78=U]X;*ZUOK/*(9G
M:D^Q!HY+J_IKEPT@Q^>#C\W+<RTA]*:(HYD^=9:[1IH.95=1J2%>XC?6Y$9!
MY3I-= %Y9XF$83N/G_N(F@$+ "3C:'#3Y+<M853V(LT-.B0#Q96:3HQPFAMW
M&ZQH1YJ[XZ%F6,!I:?JGG]CPH5-R8"PCXBA:P;,."#XKTH$?I#+ N:<M,'NT
M4O+D_.8;(?0]T1Q4^+K>\/R_-BQA>\N/LTH2\2F(#9I>.K;XY%VEM@1A9G,B
M>1'H=Y5_Y4C#^ADB'1"IEAK#]=)PNHHVDN&Y3MEFJ+.%S>"I(X.?I<#Z(Y_=
M--$_8]G)!.24">ENP0*0EQB00S:2W*9B"_]$R"_^&X+C!7&X"CN7]#6+]%ZI
M.B1D*Y.DMRJOOFSNSD9ATOM4.*3.4"SA! BB <*TH+-^REJ=Q!O@**YL_P2G
MB?2B_$Q2(-W/)@9;MHN=Y3X$F$'VU[@Q'B;*QFZMMGH608*RVV*9+JDCXT"?
M<9'N%&\TL5CJD_ULW;,*K?[RB.9$-#F5IK[760-[?D%>[J0LQ<.1X0UE:I9N
M5> ,%D"KAO3;7=^6Q"W=H]Z8AIF$7[#@J$GF<Y$]8!]N+@CYI7LRAGP1-_])
M,&(!TV20.>T.,EQ#$GWBYJ]3CA(JI4-[[7?A-%2;*HK-ZU;S%EI!^]F_(C]0
M$R--A(=N#T9?5)60[X^(#LT4WY+X*ZT7"T4D9C4AQ,W@Q6;^AB&2A49"@O+Q
M.98+*PH;AN-Y. 6$_T)3'?\<S;51 TI$RE=F:NWZBS8?2&HD=;(089OT371!
M-&=;J^M0;[M#LY?AVG*S L0_I]\;,Q@Q#HU6"Y5OG8.T%($QQ_%'-$J(T))Y
M%*NN/L/9SK^R1#3;;\ZL+ZB'_&L@#N8=LT1#$#-]): &+, 0]:)KPJFL\^?1
MD*QT<?P[Q/WU=U-GX]\.I_RX;\'52?T&3D-A.A>PV"GV:6ZP6J!\B@;2PC6&
MJ<'%MCNS*66KG#>5X*W!GXC^/0?F$#S_(.-,#3-@'CU0ZKU7OK79?N7.!6$I
M6:9I@*@L/Y[WL32>#V,9CR1_U>#60OO%-5CW'"/C"DYM*Q25_:.NOTE+[:!M
M+ZA=[NJ@Q:S ]=%#85Q2+UF'N@RFG_5F"1_XD*9*>J_DY,&E+=^"HL/XUU[/
MDK_(WDWSV-_SUY73.,A)^\UNJHG2.U]!B_')C_ST@]IM./_^J8? M/X<9LL.
M[( G^Y=CE7]/<GK363!@50%7.0?[Q'KX!DT5-#TX&HCEGL&DC%HDTC.^(V2U
M0CS$ BI$UW+^^ZC8TA1<G7FO'5.6COG AE(?LW8+X"YH^7.&>AZM_($EI+/_
ML7IP OE_:6L%_)-(Y<ULT0PC_;;'ZLFV*Z67GAK))ZGM!K:O/M F5_WG8&KK
M%[F=K;%6H1R-# QPT+&<0SQ$CI;3K?5EQPW6SEML;Z&K(,MD<XK:K>&LFG\+
M[PP%P7])11\;=%A+MJ=&(M32RJ(7HMYX33@(OS8,$@5D5[S(O Q+?^)B-I80
MY<#&>#GX!)_WUZUU_\3J\9[_RA1]5]Z"N*[O%/=;[1!>LLST1G51AUUF]PX\
M@/-*N/H[MPBR;.37!%(Q)T^ZUWBV+O]: 6>.3W/<:I"U>R#5H*E_\.))@['(
M>Y7:&8&>VJ4-+&"K(?Y87A%4(-*N+3_*3H"Y84&#<9_"',O^UWG>)8%8 !"W
M$G)G.CF=?L'M8Y3#(S =<JZA0C>0KXO$T0;49YE641RZ,=_/9 NXW71Y<FFR
M += &KW9O)ZTJU2*NELE9#,QWDQ:U));>&CX:H^1WZ4I6NSC+-J^736XP3DB
MV,6<8,R70]^.(\ )CUV]8YKAPI6++Z<F'R?5#5NJS7,6U^S,AR_X*RZ$E]S;
MWGS;"$?51PI)Q;M8@#,F9)TW"T:^O]6Q*MKB>>E\;A(J#Z^O?[=FM?*3^[[.
M0X-*U*.=V^%-*H*6/]W8 XN0VM,= FT#'#"T2B_FJL$7LVN^%$I5>I&;K\\+
MXU=RUV,!E^2A!(L#^XP7Y.@:$,^9>+2>?R1@#*R*=LU%X?&Y1'+5FFQ<'%GE
M--3/!(E65S=TYT0T*D[7UV>5.#4^27/O1LB_.3A*]6S\=GYP4,_R<Q&H0M^#
MY]OUN"\%2);O/*-CFNB:E>3W7)_=5U\\/9PZ%CM6U@1[NQ-Z70J2-\(LA%N$
M_0P59+E&FX J9JU)9"$.6+6-#YRD'[PYR2?7PA*Y :@7N43_X$J[%UV0D+*\
M-.+C=DFD7;($3Q46X)N5_'B-I$WP&ZNE(],@,VP;"_A>4=4EM*;A&=@^WO'.
MJ$26O-:Y4EML2YR==VX:QRF;W,5K8=FKMX:;\:5B:#-Y:!,7'($OBEFKN6IS
MDZR#I<P<(0B?CZ_*///V#GHYQ7I<R(*M T/S"3>5^M:BA[$ KT_;;::1E-;?
M,Q]O%S.N%XZ&\/FS-5AFQ[V*V_>J)18A'B+N6W4H%=BX^_/#J,S\:(UC_?L=
M#%\$A-B5$DQ $&BL4%NV>\NPK%R=>N#VHR">'72/K.2*5;ETLG"@X&Q)8):C
M%*J!I]F!'/H%>G&[XZIZJ.1K_/#]5K) .._HJLQ&SH:1T$?0 HVYYW#;^2V6
MG15U]C1'!3YYX^>4!_12V?9#80S,S[V-+K[?V9M6,H9M'PO-:S3&)<SN&\MJ
M_OP@GRK^EG'S@.Q05\]&.ID(;Q8+&+O+L_I9(IV!7_IK8XGGH^EYMVDI4?:"
MWF.9TM%]3$1;D@RC[)SM(U*I"9(EK7@?#E>V6693YNIHMFAYC,$[F2M4WW4K
MN_V*$B=-G%^4.KF#01T7[?-O?0"%,M$:+ZS*T^;E/\+9MOHW4LSS9V4($HC1
MAR#(XG$S9ZY7F2Z^8[WL1Y3^SW*[J8R?:U^9YFE?HT<GL(!/8U)80'PI%E!+
M"H'S*_K7_ @(+Q4T[\H38Y@"S5+/R]Z^:=&43)&T+KM[X593M]#K(=E_$/CK
M*"*Y!P5:[>8QQ2J4Q\RC@L?H6C0R[+?3N,\HWH8BB')@/+V]XEW-?;A7F)6^
M"6.YPYU-YH<?7GCLHV"5OPHT*]>.^+"HZAP#"YQ%XV%(P413IHG');'W<YPO
M7[P>W_ *LAUC,K6+P (.9D$GQZ#+%X,/41 4G.7D*P!M*+*4B%(VI'1]Z:AE
M<N:JL[\XU]93&?U2IJ0<\V+:N,6*Z!^_6(2KSBV2(5UC6,"4+Q 9S8'"AV]:
M#HF:XYBR8POME([Q5#S;XD<IW"NTYD'5E_':B$&?Q"I?GM@)L0TMI2%QK8CH
MV %RS[_V81[.A>6><]P7==<TJCL&_.M($>WK#PX;%BC=-]J#8"/#8P3"PB[O
MK&\'ZN,-72 /^ZL1^:PK->H7M3M&S^Z( )V)R0"12Y.S2 5]DJ_MSPZ+6Q=:
MPD)?80%%\I)3;[3"2P5^W1/!DH#LDO:7Z O9C%*W2+[H1/K./AB!6S:=B7IB
MX]1K197QX8I2S4KU!'W/<&IBT2N-5O1$VV*)2:L1#W1:SWF_*#:7@S"%:JOO
MEA?UG;SX\V?NU\IS(8FRL+'W^XLP/=)]O:C=L@\^I.5C.. "[EW' :PB/8 O
M2D0UZ5DIE_[3>!LG4JMP*LS-?\B#%]SR5Q5/ /83V5Y?Z@QK"G-[_4;0V;;C
MCC3/;37>#<8[)Y\+."T,>&8Z!+&OZ_)N"G^/OH TKK>/=@V]>C?81IA;_F=C
MD&@YM.(O%%<Y2> 86)<C 48R!G(PCW/V:,JO*GI.QU.9"F#H/CRRU*85B5*Z
M&#\%1I@=:L=]VF6'OEC]*^?$J0[G&HXO8@$SNE,0,,^NWDWU@<O9E2P=4\'E
M05\[G(GT(']B'VWN8/YAI(W]F<HZ2_=,HJGI_);,:6,Y#ESSVD\;KC MTZ!'
MK?QK&MJ>C?V='. KU]7;Y9J9 Q.7^KD*VJ0WK='F*O?$I"V\KA<;?T5_O1O,
M5QFH@@6\Y"'H$#<,2?8(]2%_=UD>]->94/,=Y]^_9"<\WDWI9$C+Q"PPM13C
M89Z82RF+,XC!S^[PYD*#-8$;=%ZV\]H2TMSA; H]XT+A\ZJ,3^22-(E=KAV$
M^5?ZL]U2RUL?[)SK9&&]X#5>ACAY1^^TJZ3/*)*YX.:'2U07.2MS<T+ O)2?
M!_KR/;._QHSC <L_+:K9H^&" <6^54!W7^N?&S< %TEML("@ 2AW4[20:8G?
MT',J<8_@.Z#-X!/XE%#RUBS)O]35\%^C\3=ZJ)YLTKK7TFCPIVB79E]7Y=W4
M<Q3\+N05F*6AI2N+%ZEO\!;:P!2ZJBD<(TK,7I'#_2<&)W7EY]$O;MB<_DK"
M/^(]&S>#A37>)/2W7F#</1 ,8:%^ ?3*99O2>_;WX(2C5!QFK>,#J@1=LG5-
M-;R^Z0FJ,#\FM18OK-@0%?;KV0[R<N6?&>/D_R;3?9NP/I$IU H9[?^7DZWW
MW\$2;J;CJSJ'!=R)S4/;Q> 6"GS*$&_5;2U'L5Y)_>)V 4%V-M12 9F*=76'
M?L'0=RR 80BRS;"@XL::Y('_-RYV=4A[,]H.O*)BDN3%1/\%GS5!3Y+LY25M
M";069+\'$JN1Y.<&N(0')7OEH2!)5G>O$(>/)UC VE>,K<)C"I,D/P K[KK'
MGH=$Q*#KCS.2/ ATD0AO]/?C+ W6A/-^OU_X?9#F_=J>VG#U)+^W3R3)%*EP
M@P&4+80Q(GUPC)$?Z_*=#C*%QS].FF?K8@&9N@=#ASV2_&51N-]2[B?YL0)P
MU_EB!CC*#K=@P2@;_7[GM[LT7<C]2'0?R!O]'++IQYK>K2W=(TGF1:8@"2#7
M@"#1N 7)>RS@'FN"9#1KTGM/G)Q+N(N<HW9N #()7I(D>U4D68 =^?\ 4$L#
M!!0    ( +DX#EOZNR88:P@  #HP   7    <&QX+3(P,C4P-C,P>&5X,S%D
M,2YH=&WM6FMOV[@2_2N\*;I- ,N//':S<AH@35-L@-M]%%[@?J4E*B)"BUJ2
MLN/]]?<,*=FRX[1)-[EU<],BML7GD'-FY@S%DW]%T461\R(1*?ME]/'?+-5)
M-1&%8XD1W*%T)EW.1KHL><$^"F.D4NR=D>F58&PPZ/;Q?W XB*+3$XQU7G?2
M1<R.>X/#WGY__XCUC^/#HWBPS\X^LMT_1^=[U#IW$X5/P=/3DXEPG"4Y-U:X
MMSM_CCY$QSNG)TXZ)4Y/>LUW:#O6Z?ST))539MU<B;<[$VZN9!$Y7<8'_=(-
MT;.'ZK4V-]%,IBZ/!_W^ZV')TU065Y$2F8N/NL?'RR(CK_)%F;;22:S%",6=
MG H:NS5JH@0W\5B[?+@^P::>9=,OTX6+,CZ1:AZ_&<F)L.Q7,6.?](07;SJA
M!-]6&)F]&?K65OXM,#26Y\2-B[B25QB<9!V&]<>H8_0WJ'_0C..5&6?"KVVL
M58K*B__\<OGN<O3#J\&/_>'!H#LXZ8VQ<^43R)D 3\)\K:#G%Y]&EQ\NS\]&
ME[_]^LA"WBW298>]-]JP=]S"/#HL$<;);,Y<SEWL)7!\K 0;:Y,*\W:GOX,F
M2M4P6CS;DB?U,WH8_*6-X%,:,>&JWB2_7P#Q<)9+)R+J*.)"SPQ'D4?6P8^0
MK)X@KC?N,;<A I*=GJP4D56%J09=O^J>2]N+^&;B7+*<3P4S8BK%#!['Y=*R
MORIN@#0U1WFIC8,?8A^TF4"QT1],9^QWHQVV^X:]DWJ4"^RMJ* $VV&71=(=
M+E?8(UWUO(K_[S2]OUV:A@7ZB,(F<W:-;5("L:<3%%ZK.=68M= (6AB>RX+Q
M8LZJPIE*0$Q$)!_1H'_.)G@RDBN6\01%ANF)=,SIT.Y6@T(DPEINYM1DPJ\%
MYFV-:5&60AA,J<AGT1S4()$&813-$%@M) %P&+2=Y,Q6]+'L/Q-&U(/0 B;2
M(JC01H? :X0M1>(%I'%+B*93+!.0PJ:,Y^UM>(&OG^K@.X&O8)DL !#"VA(0
M'6 7S5%M6O6RR.#&.%$*_$Y4E6),@*ZE_0X *\GUE< ,P9W, %QM@><:2G9M
M:IA,ZKE*AUI4"@T 8@VD^>FLER=!%&29TC/;(-R(*VF=X9B(4V&0&U)V6D"U
MC3"WI'W!JI_J<+NP.EI1[ ^OCO<'/PUMC<:: 9%KTEDF\>A5?LFX$1Y< (LD
M[0$$3%C2I+0Y-:=F$[AE<LWTG$J;*&TK]".';;0**"N-1AZ"8LMV :I4 *4!
M.1<WR X*I!QG\(6?*H46@P,>#8YVQ9[O.CA*PU-XE$0XBX!N&I^1PVR!/H"0
M9+GW1-G*1!DFHG6NFP):$"^)GPC>=V-V#4+?F1WPO:VR@_?"8M> "!^MOPS7
M#A&)A%?V_ETHHH\%H%?/%#B"K@P&@/.<2NM=,EJ)PH]#B<?2F;<#0L@Q@>6:
M)"SQV*F#!55*.';(8K62J<_1;36V,I7<2%J #%3&AZB"1JHLT0MO^M9S$>_
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MW*0M8F%#DD^EDFY)&<ZF9<E^/;@];H/IK9%VLGH? J^:#56UJ6 WUF=D20)
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M'+\I\6_Q+WZO)=CW6*_+Q!_8['V?ZXGGZD*WK-0\4T@<(3<)[-() IU%)%(
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M/A[WAX<;LJG'?/>$I/Y"9."^3_D+4$L! A0#%     @ N3@.6UJ)T$: #0
MSG$  !               ( !     '!L>"TR,#(U,#8S,"YX<V102P$"% ,4
M    " "Y. Y;J+E"J(L-  !UJ@  %               @ &N#0  <&QX+3(P
M,C4P-C,P7V-A;"YX;6Q02P$"% ,4    " "Y. Y;]U%S*P4>  ":H $ %
M            @ %K&P  <&QX+3(P,C4P-C,P7V1E9BYX;6Q02P$"% ,4
M" "Y. Y;VV=/[!9!   %60, %               @ &B.0  <&QX+3(P,C4P
M-C,P7VQA8BYX;6Q02P$"% ,4    " "Y. Y;Q.0R?ILK  "YN@( %
M        @ 'J>@  <&QX+3(P,C4P-C,P7W!R92YX;6Q02P$"% ,4    " "Y
M. Y;H&UJ7X2+ 0 20!  %               @ &WI@  <&QX+3(P,C4P-C,P
M>#$P<2YH=&U02P$"% ,4    " "Y. Y;[10W:/WW   $3 $ %P
M    @ %M,@( <&QX+3(P,C4P-C,P>#$P<3 P-2YJ<&=02P$"% ,4    " "Y
M. Y;D.+DCBS-  !3Y   %P              @ &?*@, <&QX+3(P,C4P-C,P
M>#$P<3 P-BYJ<&=02P$"% ,4    " "Y. Y;1L=_$OS&   BS   %P
M        @ $ ^ , <&QX+3(P,C4P-C,P>#$P<3 P-RYJ<&=02P$"% ,4
M" "Y. Y;>/O(T!F%  #WE0  %P              @ $QOP0 <&QX+3(P,C4P
M-C,P>#$P<3 P."YJ<&=02P$"% ,4    " "Y. Y;3GR> O+'   RW0  %P
M            @ %_1 4 <&QX+3(P,C4P-C,P>#$P<3 P.2YJ<&=02P$"% ,4
M    " "Y. Y;K((Q2\)Y   :G0  %P              @ &F# 8 <&QX+3(P
M,C4P-C,P>#$P<3 Q,"YJ<&=02P$"% ,4    " "Y. Y;^KLF&&L(   Z,
M%P              @ &=A@8 <&QX+3(P,C4P-C,P>&5X,S%D,2YH=&U02P$"
M% ,4    " "Y. Y;/-XGV) (  #B,   %P              @ $]CP8 <&QX
M+3(P,C4P-C,P>&5X,S%D,BYH=&U02P$"% ,4    " "Y. Y;TNIWG*$%  "Z
M&0  %P              @ $"F 8 <&QX+3(P,C4P-C,P>&5X,S)D,2YH=&U0
M2P$"% ,4    " "Y. Y;_[[]]*D%  #0&0  %P              @ '8G08
M<&QX+3(P,C4P-C,P>&5X,S)D,BYH=&U02P4&     !  $  Z!   MJ,&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>plx-20250630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20250630"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20250630.xsd" xlink:type="simple"/>
    <context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gv3VRwsmA06TTm6sQUN6DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BEtiHKEg5kuzpUuHsr_wSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qLRTrEx8eUKQia7ENmBkMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2LLqvubzfE2_bgUOB4p5ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_Jmty4GTo6k21zaIY9WJ2NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_z3i-FDaHlE-BZ9GIL0jWNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n5C0Tv5uoUusGQMN1w0I-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oBjoUu4mDkqIlAPbHCD0BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YOsx-bZkqUqqRJ-r5Udi3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9h5JLRuXP0SrzhRzTBu5HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bNcrB3tI4keRMneOxkJ39w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_AdauIPbP4UuVFiRvmL4s7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ShmDYwDjqEWRMkqNQoAC2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FH48IkEeXkKYk6m4HHmdOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_NTtOh_tj50iF28Xo4DEnjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JAoE3eeC006wm5kUxnCZQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_afsyJr4hf0OEKhekB3AHYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_6_coWg2e90CjjtM9azRMBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_mBt_DhnwSkaQSv72fYtQQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_iejKZn67F0Sf2DaGIlWrig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Ry9eJBFRY0aWUriRJJoWPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_lOvXmD6MgESV0B-omrPS4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_YHDGlfD_AUaicoScEusHeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_GrF2myzJiEqbTvJY60IqmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_c_PLLEX5ekOtxFhMT3jjag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_W2wc6JkTt0WlVF693XXzxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_Nr4z7GCvjkSm2YfF7bwdZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember__Vfwx-5_M0Cu0g0xtW7Dkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_LpkP8tV3j0qgmNzcnf0nig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_r_xBq1FYmEe1hu9bPCmlCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_71I2lv4f9kWJWcfI-ONvvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_yAabyI-paEuRtn18CZC1RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_Qa6aQzsVJ062wE77uGETpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_vu813cbeqECqUyYxxfs3Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_ls4KWM6TWU2ieTyrmZgYpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_rUd6RnaD1Ea21Qe6MwDvwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_BskKyxhG5ketf2PCSTzhyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_6_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFHYyBQEPE2I_t5p2bioTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_8_14_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_kUAPHqMvy0ainpcMZtiRig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-08-14</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_8_14_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_DphnniDSq0SBx-JnoOYjZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-08-14</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yRXKgj1-r0me-ISDulhcmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iTnaGMElH0yBObH0OL-TXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rW77dB4dWESXNLR4EYGmyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GYqZURE_wUWCBx0IiGtJdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_J-bqAQI5xUiCwzpV-Gys5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIdlrBTkX0WJBo8z2nuPEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5IUo4MDNeU-PF-knaxHuhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tD6aS3nTtkSRjdsTuc_j0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gnSYRAKnVUCk2W-avLWlNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F5dDIxgUX02lMffBZpl-QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K54wRCnebE-ZiUifv4iNAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_YPPSNBqug0mazz_yBXPpwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="As_Of_3_12_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_KdZmUKvKIEagwl1U2B1ZLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-12</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_wf2iuAS66kiC7r9Ko2A7aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_SSEd4QlqZ0ixMnchHstv9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_6_30_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_OSrevicPJEyApi98O9HZYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_H3oHw-vHw0emnoAUC9JBzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_xTNzdzPaT0qCf53ldUBTUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cCx29kPpekObSCYrlCS5HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaZNoHa79k-oQmE30hl7Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M2e2ab-8O0Wf_GeW-n8L5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BTZY9KQhX0ONpZ7wFZENbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IMn_qGh8rUiSVtUpQ531fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wzsUdUWAf0Cbd6Wi9_SGbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ETC7kP5_4Eeir_fPIkYRjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CkeeA2C0XEG0WPbHArw-rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-20</startDate>
            <endDate>2025-07-20</endDate>
        </period>
    </context>
    <context id="As_Of_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2W9cGUF6_ESGJ2hjWELYOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:SeniorVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-20</instant>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_H8A_3lY72U6nRHPcehodwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_FzEf68MnnECijIQBxIjdcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_17_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_DSLkWT434UONxCiW0FQpqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-17</instant>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_1NEZJ566u0G9wZB2EoTpTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_8_1_2025_fYC8XQZBJkm4PqOx0h4hqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_R6tg8LdwCUeUoAN2h0xL2A">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Standard_installment_ZMevQBZ1KEOi7rMSOC56JQ">
        <measure>plx:installment</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_EaaV5hI0qEadWpzP0cmK2A">
        <measure>plx:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      id="Hidden_cOJM3k19jEKfhTTecRZJkg"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      id="Hidden_4U70dJ4GK0W4puB6oxSofA"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tc_kZ_6tRgi40qD0m3HqGY9Fw_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tc_DmY_RMzHM0ifweaXqHkASQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tc_8ep4FMvZY06pYa_cC5vnAQ_4_1">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tc_6j1qiv0cgEyyA-yQJOpFqg_5_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tc_BKs-kREKDUWBkH2Mur8iHA_6_1">false</dei:AmendmentFlag>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="INF"
      id="Hidden_aiZWtzxgnU-JSOrCWSBBBw"
      unitRef="Unit_Standard_segment_EaaV5hI0qEadWpzP0cmK2A">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_v27Ua5ytwkWaXkxlsYTPMw">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_zpqmh-1sTkCN4NwzSGoAiw">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_Hs2UOoK0EkigRFJdicpwyA">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_aFaMN9W0W0ac3zsKbgntyw">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_XMIFlgmdrEO8CCTcJ4rV4g">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_hpZWivxxXUa7ed8wORdmYQ">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tc_qvBBsVyFRki5h1sXt7PfKg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_ib9PUXWHf0eMIWSckxY2Rg">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_D7S7SqupzU-pjDTiH3Pxtg">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_KmDWrM7ETkuOXmgEVElzxw">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_27_-6j2Ui0CHoSY0LN-hGQ">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_K_GVvhQSWkGVKY5MVuNdWg">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tc_mzC_mhp5Y0ujYWsWhuZOzg_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_ViFkkS48QUu655tpdOeRJA">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_-75lLX_ZpkmddED0v0XeYA">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tc_pz2-9OcpxEq2CkmxLTP1zA_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tc_4QDRQsKIQEexJ0DXR7wWYA_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tc_NEeTDIuDCU2ywFpiyNKlhA_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_g510MsPjukCHIbrQHDHSkQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_VRta75Evbku7IxM7K13mzA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tc_BObzVYBzUkCtPQN9DP6aTA_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tc_IodOZtfmgkGJMgydISo8BA_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tc_Kze4C0xGg0mNTqXm4mYTkg_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_jTcWcpimbEGL0py4rt-7vQ">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_8_1_2025_fYC8XQZBJkm4PqOx0h4hqA"
      decimals="INF"
      id="Narr_CT8oyPXhc0KUPIXEvwKF1g"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">79732115</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_XfAfRvdhsUOoizLeLGejAQ_6_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">17895000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_v1W4phlgE02DkDq58-I5pA_6_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">19760000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_qNIKoWPI3U6uprF3Bl5i4g_7_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">15503000</plx:ShortTermBankDeposits>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_cdm9dUmhSEGuTRYuiVRxiQ_7_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">15070000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_BK2F2gXxX0-r480hVimJSA_8_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">9443000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_wIHtag8aYEO4eqaAMcnifQ_8_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">2909000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_Vb84A8yWaUW5HCok-Tjl5A_9_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1513000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_6dxKD7sKtkepYRV6Nv5vCA_9_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1096000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_Mh-YSV3sA0iWnPmGu4-pZA_10_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">21131000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_0JvZdd0Xpka1XrcmUWqs4w_10_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">21243000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_krv5d6X93ka8Be34jAc6KQ_11_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">65485000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_doCgr-5_Kki-ifknwp36nQ_11_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">60078000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_Q8m0TvZJpkWEomDFO8I6XQ_14_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">520000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_PE6oGEJ5skG5810NjfUgbw_14_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">462000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_U9WoFAu_L0yro9tEuAgJ6A_15_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">4746000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_Cak5XelPv06qMvxnDm8a4w_15_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">4591000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_R4qXwVESIE-ELF0x0nYeYA_16_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">2738000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_kBLWp95tPEaMB0mWobx_tQ_16_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">2856000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_L17wekQGHkOZ9B_iWHBsXg_17_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">4997000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_PYGiS7XGVUO-DsY3oooB6g_17_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">5430000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_XeouVCUKw0as3cFsx8ZL_g_18_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">78486000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_ODLBcq1A70C61-Zvja3KnQ_18_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">73417000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_TPtzeHpuUkSZ3cutDUqQBw_24_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">6689000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_XmcRuLU3O0umxwwHKKfUgA_24_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">4533000</us-gaap:AccountsPayableTradeCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_sI50Z7KyfUKtBffgtQ2Dew_25_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">15930000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_xYi1yx6MPU6f6xpniwWL-w_25_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">19588000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_qng1FHGABki1GYCtUqzAFA_26_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1472000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_KNSMm4m6gUKt6PjkJf69pQ_26_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_tiGR7UPWZkCYVCXQH8-jEQ_27_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">24091000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_zh-CofGns0iRxLUCMbWbSg_27_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">25621000</us-gaap:LiabilitiesCurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_r8MSCMCXhUq8TLe3KnvLYw_30_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">615000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_c6d38trI4USXCzyo_FrQUw_30_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">559000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_IW3EQgYK_Eewhq1YMlQ5DA_31_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">3877000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_v9IqnyB7GEmJruy5LcPKWw_31_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">4026000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_dcFk0a5cTEOZEjx8vhjiTA_32_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">4492000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_6S2zxPPrREOxkLjDJp4oGQ_32_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">4585000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_rGyYIR1H_Eqnhn2-sWBWcQ_33_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">28583000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_czI1t7LEdESqvSuOEvcclg_33_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">30206000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_aEsDXpMdsUOVTdRA3_GQvg_37_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">49903000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_Bf4gkZIyz0CUZpjHJGI7kQ_37_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">43211000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_qgnLB2nZoUOy6uh7rc3QeQ_38_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">78486000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_QmpbyklLgkaa-6iAAXf-jQ_38_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">73417000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_c_PLLEX5ekOtxFhMT3jjag"
      decimals="-3"
      id="Tc_aYvIVecp9kGKZ16a1ynqdQ_3_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">25435000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_ls4KWM6TWU2ieTyrmZgYpw"
      decimals="-3"
      id="Tc_aaM7xZBmIUaO0xoajaMfdQ_3_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">16981000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_iejKZn67F0Sf2DaGIlWrig"
      decimals="-3"
      id="Tc_JjN9mxVvYk25xGleGcylkQ_3_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">15440000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_r_xBq1FYmEe1hu9bPCmlCg"
      decimals="-3"
      id="Tc_3Mj_gVSNs0SR6bil_Xlhjg_3_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">13304000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_W2wc6JkTt0WlVF693XXzxw"
      decimals="-3"
      id="Tc_LwCqYSRcYkKq3znyCmThxg_4_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">336000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_rUd6RnaD1Ea21Qe6MwDvwg"
      decimals="-3"
      id="Tc_XQCYccu6v0mdI_0oBGnhGQ_4_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">241000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Ry9eJBFRY0aWUriRJJoWPw"
      decimals="-3"
      id="Tc_orv1hfT9j0Cfvhw57_nW3Q_4_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">218000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_71I2lv4f9kWJWcfI-ONvvA"
      decimals="-3"
      id="Tc_BKT6pk9df0mY7Qwt-wLGSg_4_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">170000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_Pmfw0Ct390KvWLUgBSacNQ_5_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">25771000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc__xmdKYGzjEWf460DxWO6Vg_5_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">17222000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_3WwxLKj3Qk2aUCH79GDufQ_5_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">15658000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_JNXura3V8U2MPnDx_p0s4Q_5_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">13474000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_1BRXHpcsjU2pq6Fr4jQOAA_6_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">14050000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_9tWH2TaIhESbW2ZU1uW2bQ_6_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">12058000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_xX8N4tb6E0a5hSWcIR_mCw_6_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">5870000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_nPJZFkZ8EU-33-R5xc5g1A_6_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">9456000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_9hlBhEXU3EaTTGQauGdKMg_7_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">9467000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_hPusIP1hokK08EBdm12crg_7_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">5848000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_6FDSy3QAV0OqyBjiAs6p1w_7_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">5992000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_2YKlNncOfkWKjYhaN2oUOw_7_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">2961000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_bOdZaVYWi0Wq6JqP5gxU-A_8_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">5227000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_G9iPz86CWk-wcHvVDg7w6g_8_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">6599000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_ZLqzMca8FUaU4ZORHpag7w_8_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">2624000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_HqQUnxkYLkyijh6QGpfHFw_8_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">3484000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_NZjsDLRfSU21RRfu9UP0cQ_9_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-2973000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_uLupgl8y4UyAOJei55sRqA_9_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-7283000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_cbU8MA8PoEWVRCYM2oKabA_9_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1172000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc__97YrPCNF06mCIfPYfcypA_9_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-2427000</us-gaap:OperatingIncomeLoss>
    <plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_0hCx40NqxEaw6rjkd3QRnw_10_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">628000</plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax>
    <plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_03gVTmHJYku5Mt_VeBXGBg_10_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">757000</plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax>
    <plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_jIMahEj0WEqo3Ku9VJHoGQ_10_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">783000</plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax>
    <plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_Yr0kBO_VeEaUeMfOR55M6w_10_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">367000</plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_DHEHG-GdvEC_PGP6mbYsBw_11_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">530000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_hk_YM8lkEUujW-eryseAnA_11_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1035000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_JNmegZ8T5E2zb-3pFoTzsA_11_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">272000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_UnjcR7XEK0mpo7yNJHj6Fw_11_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">522000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_1ykIRShRWUWN0QU3P--wPw_12_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-98000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_-RrNtfQA5UOI2-alZbDv7Q_12_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">278000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_fsc6GCcAG0Gp-YJuV90hPw_12_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-511000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc__EYne7KCNE6y_bCR-ARAsw_12_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">155000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_BQtW1CMkrEGBZ3-eNcdOhw_13_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-3071000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_gZISIvjn6UyS8XRvXhCkdw_13_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-7005000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_JVRi3LlGlkSAoyu6qh0_dA_13_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">661000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_EN3y4vyNEEKVaPyd-3TPqg_13_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-2272000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_cc6v-05UtEyDtUrNn_zBjQ_14_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">384000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_xLcSIa1SF0ykiVabl9QYvQ_14_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-207000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_XIxVB7PP7kSnuN73hb5g4g_14_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">497000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_rL74p3mtL0Sn1zZgijORog_14_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-69000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_EsNW05bpYUS7_RB0E3sAKA_15_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-3455000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_MMF2DVfJJkqILiE7KOgFWw_15_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-6798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_Bf-vhMBgzkKstI7fcmkKHw_15_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">164000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_MuOzqmiF2keLl9eP4kxunQ_15_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-2203000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="2"
      id="Tc_YeAEsMS6VkW0-f91KshgKw_17_3"
      unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="2"
      id="Tc_h7sy8-KJl02XngE6yiyY8w_17_6"
      unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="2"
      id="Tc_mDd4W2sJIk-3Dk-T-vqEJA_17_9"
      unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="2"
      id="Tc_u8UHjIL9MEirauk6mYkJSQ_17_12"
      unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="2"
      id="Tc_T_08yqbWhkyZh__tB8shgg_18_3"
      unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="2"
      id="Tc_NzVpyhRH8EqSWRF0JcWzVQ_18_6"
      unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="2"
      id="Tc_Gd_0H_MeGEeTLvwqbidR4g_18_9"
      unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="2"
      id="Tc_Q0e1DPDBnEiA3KRBQu5dDQ_18_12"
      unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="0"
      id="Tc_GlyPTYfi00ilVlOyCGA9tg_21_3"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">77651330</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="0"
      id="Tc_nHy8My-5eky9bVAyUWK9pQ_21_6"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">73172980</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="0"
      id="Tc_EOzH8LpQ5EytCVdpWSGV6A_21_9"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">78663884</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="0"
      id="Tc_TDp3qo6_xkmoP2vgR6DymQ_21_12"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">73308281</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="0"
      id="Tc_njYHuMqUxEiBHR6ZRK5Qlw_22_3"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">77651330</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="0"
      id="Tc_quolZDTcykCWeOo1LBB3TQ_22_6"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">73172980</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="0"
      id="Tc_FzOtwOkcKEGzkyYZcuft4Q_22_9"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">81271610</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="0"
      id="Tc_rEWI0Rc3n0WSygxudIa9CA_22_12"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">73308281</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K54wRCnebE-ZiUifv4iNAw"
      decimals="INF"
      id="Tc_JUsHG8EYSEWT6N4MJbloMQ_6_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">72952124</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_K54wRCnebE-ZiUifv4iNAw"
      decimals="-3"
      id="Tc_wVAWmRz2R0WhnzUJRLTW7g_6_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_afsyJr4hf0OEKhekB3AHYw"
      decimals="-3"
      id="Tc_dafjpgEgbEaePj8ew_tZqQ_6_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">415045000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JAoE3eeC006wm5kUxnCZQQ"
      decimals="-3"
      id="Tc_neWuVlVj0UyXIYUFm9FZ0w_6_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-381549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_SSEd4QlqZ0ixMnchHstv9w"
      decimals="-3"
      id="Tc_UETTfFw0vEyIp_7WcG6xqg_6_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">33569000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FH48IkEeXkKYk6m4HHmdOg"
      decimals="-3"
      id="Tc_DroN6LvDykepkfZqSLzfgg_8_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ShmDYwDjqEWRMkqNQoAC2A"
      decimals="-3"
      id="Tc_Smlu03_nxEORDotXYV2WMw_8_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_NTtOh_tj50iF28Xo4DEnjQ"
      decimals="-3"
      id="Tc_XaK73bei1kSehfec9M63fw_8_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-169000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CkeeA2C0XEG0WPbHArw-rw"
      decimals="-3"
      id="Tc_024ACbkg60mMaJ5TsYefOA_9_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">833000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_XC331I4PNk-GwW17yixA0A_9_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">833000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BTZY9KQhX0ONpZ7wFZENbQ"
      decimals="INF"
      id="Tc_8DGpfWJ6u0yrb1j10aB90g_10_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">340550</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CkeeA2C0XEG0WPbHArw-rw"
      decimals="-3"
      id="Tc_8PvpoFgHh0K2U-SyPiXp0A_10_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1146000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_5Ox-l6gSPU6nEOm2tpCDiQ_10_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1146000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GYqZURE_wUWCBx0IiGtJdw"
      decimals="-3"
      id="Tc_L2Qb1ipAxUaBtkjgvKhtMQ_11_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-6798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_0PxDgtXTe0Gjyj7GsXjrOQ_11_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-6798000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gnSYRAKnVUCk2W-avLWlNQ"
      decimals="INF"
      id="Tc_MHpHHWRQRUW2J_oQ3TlEYQ_12_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">73292674</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gnSYRAKnVUCk2W-avLWlNQ"
      decimals="-3"
      id="Tc_hp_X0lNc_Ua5A9jHJngLFg_12_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YOsx-bZkqUqqRJ-r5Udi3g"
      decimals="-3"
      id="Tc_dRyswdDTIkiOmohrr50rOQ_12_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">416631000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oBjoUu4mDkqIlAPbHCD0BA"
      decimals="-3"
      id="Tc_J3qrhMI2CUW76e4WevLapw_12_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-388123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_wf2iuAS66kiC7r9Ko2A7aQ"
      decimals="-3"
      id="Tc_BKD_2YVxL0ynwllJc9ml6w_12_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">28581000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tD6aS3nTtkSRjdsTuc_j0A"
      decimals="INF"
      id="Tc_5YdKmLQiKkezM06rF9KC3g_13_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">75850275</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tD6aS3nTtkSRjdsTuc_j0A"
      decimals="-3"
      id="Tc_b7MRCZq5qEeLIbhHF-wyJQ_13_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">76000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_n5C0Tv5uoUusGQMN1w0I-g"
      decimals="-3"
      id="Tc_XkeB1vuIWkaSnOVVf5B_vQ_13_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">421528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_z3i-FDaHlE-BZ9GIL0jWNQ"
      decimals="-3"
      id="Tc_pg_vAhydcEa5NKDfUQXwSQ_13_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-378393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_YyfMm_hW5kej_HurtyXrrg_13_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">43211000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaZNoHa79k-oQmE30hl7Ug"
      decimals="INF"
      id="Tc_R6K5a9hlw0WIYzXuvs9mOw_15_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">2775215</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaZNoHa79k-oQmE30hl7Ug"
      decimals="-3"
      id="Tc_pKRXtES6lkabiiGmpU366w_15_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wzsUdUWAf0Cbd6Wi9_SGbA"
      decimals="-3"
      id="Tc_XSTyTSg9kkWAnWTnIu9NRg_15_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">6809000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_3atokn--906d5NvXCjp19w_15_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">6812000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wzsUdUWAf0Cbd6Wi9_SGbA"
      decimals="-3"
      id="Tc_QQwy7x0Mj0K3398oDj_HKg_16_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">599000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_mPCCyholUEGckpWdiV8CGw_16_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">599000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wzsUdUWAf0Cbd6Wi9_SGbA"
      decimals="-3"
      id="Tc_5hGR7ZUm0kKIgewaCWG3tg_17_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">368000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_iNjsc0j0xk2LXOLDTRoluA_17_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">368000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaZNoHa79k-oQmE30hl7Ug"
      decimals="INF"
      id="Tc_1cUpthGGJEqf6itNfIU1ZA_18_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">1106625</plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaZNoHa79k-oQmE30hl7Ug"
      decimals="-3"
      id="Tc_-17LUgHRR0eAU8w_F1adnQ_18_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1000</plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wzsUdUWAf0Cbd6Wi9_SGbA"
      decimals="-3"
      id="Tc_bq83yUut00a35SpWOk6_ZA_18_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">2367000</plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_VhY-mc0t30WWOHErsUYtRg_18_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">2368000</plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iTnaGMElH0yBObH0OL-TXw"
      decimals="-3"
      id="Tc_fVcPjO4bGU2LyzSU_7EY-A_19_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-3455000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_XvKZb8U8Qk6M6j-0vOWTQw_19_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-3455000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIdlrBTkX0WJBo8z2nuPEQ"
      decimals="INF"
      id="Tc_SimVJaL030ORTwulZYu9zw_20_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">79732115</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIdlrBTkX0WJBo8z2nuPEQ"
      decimals="-3"
      id="Tc_gSNky3RM0EyVL8PB-IlLwQ_20_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BEtiHKEg5kuzpUuHsr_wSw"
      decimals="-3"
      id="Tc_fYwS2feQ4E2DMjYPxkr0XQ_20_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">431671000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gv3VRwsmA06TTm6sQUN6DA"
      decimals="-3"
      id="Tc_tVaM6n_N0U-KgsLWkpru7Q_20_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-381848000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_pu3sH4OGekSPemHL-HJXgQ_20_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">49903000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F5dDIxgUX02lMffBZpl-QQ"
      decimals="INF"
      id="Tc_rM1xId7NxkWW208M0pKjng_21_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">73052124</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F5dDIxgUX02lMffBZpl-QQ"
      decimals="-3"
      id="Tc_MYKC3NQox0aAPVG0MuodEw_21_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bNcrB3tI4keRMneOxkJ39w"
      decimals="-3"
      id="Tc_SFyPkt0_n02jwWgkYcyZ4g_21_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">415633000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9h5JLRuXP0SrzhRzTBu5HA"
      decimals="-3"
      id="Tc_JHxUCz8cEUi-mAQrTrtB1A_21_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-385920000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_AdauIPbP4UuVFiRvmL4s7Q"
      decimals="-3"
      id="Tc_Ptwxd6jwCUapH71ACmK_AQ_21_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">29786000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ETC7kP5_4Eeir_fPIkYRjg"
      decimals="-3"
      id="Tc_UYHKzzfeL0m41hz4jQuj2g_23_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">333000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_9FnxX2lprUaSxyU_zKIBAQ_23_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">333000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_M2e2ab-8O0Wf_GeW-n8L5g"
      decimals="INF"
      id="Tc_E59k4yziiUa67x_HxpXThA_24_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">240550</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ETC7kP5_4Eeir_fPIkYRjg"
      decimals="-3"
      id="Tc_hRTLFcl9b0-f6gVr4hw-7g_24_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">665000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_ZcMMEWxX0kuJVketf1a_IQ_24_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">665000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rW77dB4dWESXNLR4EYGmyw"
      decimals="-3"
      id="Tc_OOf1DqKce06fQt1ZcYdMiw_25_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-2203000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_HWY7xmTnFUmvR0kL0nq4xA_25_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-2203000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gnSYRAKnVUCk2W-avLWlNQ"
      decimals="INF"
      id="Tc_qBTNBNI8cE-e-oypr6TgsQ_26_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">73292674</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gnSYRAKnVUCk2W-avLWlNQ"
      decimals="-3"
      id="Tc_MkDmt2w8_EWnEUUVoHf_pQ_26_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YOsx-bZkqUqqRJ-r5Udi3g"
      decimals="-3"
      id="Tc_VFQsudWaw0K8ZnsqGWdzHw_26_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">416631000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oBjoUu4mDkqIlAPbHCD0BA"
      decimals="-3"
      id="Tc_5NvzsooDJ0yznifj2pF0IQ_26_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-388123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_wf2iuAS66kiC7r9Ko2A7aQ"
      decimals="-3"
      id="Tc_6cljebF3bk2DCYkIlMPRCQ_26_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">28581000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5IUo4MDNeU-PF-knaxHuhQ"
      decimals="INF"
      id="Tc_hlYrSjoLfkmyEVTMYIoDcw_27_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">78133829</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5IUo4MDNeU-PF-knaxHuhQ"
      decimals="-3"
      id="Tc_DxOt82Pe8UmcAkIJ8ymGoA_27_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2LLqvubzfE2_bgUOB4p5ug"
      decimals="-3"
      id="Tc_3wGWKwRDLEKoPp9RBviVQg_27_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">427142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qLRTrEx8eUKQia7ENmBkMA"
      decimals="-3"
      id="Tc_BnqkcfDNI06hjrBL25Aqow_27_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-382012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_Jmty4GTo6k21zaIY9WJ2NA"
      decimals="-3"
      id="Tc_p1Afo8yRFku2tJvhIRVXNQ_27_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">45208000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cCx29kPpekObSCYrlCS5HA"
      decimals="INF"
      id="Tc_iNSN0warEkSepi8qJ6f5lw_29_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">1450036</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cCx29kPpekObSCYrlCS5HA"
      decimals="-3"
      id="Tc_1okrwUogoESMoT03D1jHKg_29_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IMn_qGh8rUiSVtUpQ531fQ"
      decimals="-3"
      id="Tc_SyTDUcgsvEuw3Ebtz-Nekg_29_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">3949000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_XNbvdWSA3EqYfUe8Yw0DoA_29_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">3951000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IMn_qGh8rUiSVtUpQ531fQ"
      decimals="-3"
      id="Tc_ozla6umCkEa8EEHl-zxZiw_30_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">263000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_w_2cLLxW10yw9J6_7Aksmw_30_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">263000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IMn_qGh8rUiSVtUpQ531fQ"
      decimals="-3"
      id="Tc_Im2Eg-CobEu6El_MFOJ3Fg_31_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">164000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_B5pj9YStXUONAb1Hw3XVhw_31_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">164000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cCx29kPpekObSCYrlCS5HA"
      decimals="INF"
      id="Tc_1gTmG3hllU66Zqf80x33Nw_32_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">148250</plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_IMn_qGh8rUiSVtUpQ531fQ"
      decimals="-3"
      id="Tc_F-7taEekIEGt88QCc5Siuw_32_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">153000</plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_aYMRxPZCkE2JG_Ci7IiuKg_32_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">153000</plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yRXKgj1-r0me-ISDulhcmw"
      decimals="-3"
      id="Tc_BFBZM0UuHkuS9Jgrohxpzg_33_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">164000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_FShQEj2z7UqBmmkVT7k_7A_33_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">164000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIdlrBTkX0WJBo8z2nuPEQ"
      decimals="INF"
      id="Tc_VvyQGZl5rE-JlitgqqJ8gg_34_2"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">79732115</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IIdlrBTkX0WJBo8z2nuPEQ"
      decimals="-3"
      id="Tc_hldhgVHRTES4iWt7EItNNA_34_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BEtiHKEg5kuzpUuHsr_wSw"
      decimals="-3"
      id="Tc_q6omSpG8HkCq4Smi2mOwWQ_34_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">431671000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gv3VRwsmA06TTm6sQUN6DA"
      decimals="-3"
      id="Tc_kbBsgg10DU-akIkg9nymRg_34_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-381848000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_skaKqIx8bEWWu2EAuJNrKA_34_14"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">49903000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="INF"
      id="Narr_s3SehukV90C99J1peCHZZA"
      unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="INF"
      id="Narr_Sswona3ipEOnprl2xSkUnQ"
      unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="INF"
      id="Narr_d1JvnhEV7EKBaeakZOwTqQ"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="INF"
      id="Narr_WVVDxZeTMUmavnJxHQ39Bg"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_xoBNeGDTb0qnuGX1zydAng_4_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-3455000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_E6TxyAqxn0aC-A5kL9SR1Q_4_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-6798000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_6NdSqOVbh0ev9ztC9tQhfw_6_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">967000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_OTCnovG2GkydY8dpIc-C6w_6_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1979000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_QCROzJ6UH0iFBIDFcD8ksA_7_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">706000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_s4jxBl1j3kKLvvFdBISJIw_7_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">641000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_XuUSspnRekyDF63hRd3Ybg_8_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-108000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_DMt0raUWakSyVkHMM9DUkg_8_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">975000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_U-IX74UbOEmS4oK2GuSUHw_9_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">10000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_pvBtU-g3gEmVrmJVAvSZeQ_9_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">16000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_4n3x1VIbwk6WL15XjSgXgg_10_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">118000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_T4eLBi7QTUyJN5SMbhOYxA_10_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-207000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_GaUaYmhREU6ca9bZ70LZwg_11_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">6000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_bPHUPQXuFEKUMylZ-YjyrA_11_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">10000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_itGeyFW9y0aBkjQWTHWgdg_13_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">12695000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_ug_HVYlOIkWUCbkqbGcqpQ_14_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">6919000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_oZv3JsJeUkGNNRdgseHpsQ_14_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">5308000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_EceABrrcakCBfMo4rUjiJA_15_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">38000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_gTVi4FqW-kiz6yIeK6UD4w_15_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-20000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_ieg84KiavUSIoNUAWt8cRg_16_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-112000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_iDgU_sH2TkuIuaFjlveIjw_16_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1674000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_ApmJ0Y3rRUewruzak9OdDQ_17_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-1894000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_37C5tQvawU-g3EjTasHxCg_17_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">199000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_-Jb-HXlMA0yj2-j5b4kxZA_18_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-10291000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_xy9Hq5vaNky9uMuhIFciLA_18_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">578000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_pvbDJoXv6kWhb71jwIHD2Q_21_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">737000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_7ud9DQBwTESYugTJPTYkzg_21_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">770000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_MwlVo52WU0W551YEoD8OCw_22_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">13000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_LIVg8kR2G0Kbt15htrPqiA_22_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">16000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_4HXYCX6A6kOp0MQcK3E-Zg_23_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-750000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_MJYPFfBpzUK43W2dNNKoIQ_23_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-786000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_3DKu_9q6wE2AuztEMlRZcQ_26_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">6812000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:ProceedsFromWarrantsAndStockOptionExercises
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_EmDYICjHPkaCg1xuTRsoyg_27_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">2368000</plx:ProceedsFromWarrantsAndStockOptionExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_vHO_jOCF1U-4A2WR45N5WQ_28_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">9180000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_06OcfJGy-ky0uwKfs6s6Mg_29_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-4000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_7liFiRmH80yoD_yF0Ya9RQ_29_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-27000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_yxhmdiG4f020A_V3ymh5uA_30_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-1865000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_0xbnDcCwEkCANPyqgl5Vvg_30_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-235000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_JvJL961hFk2oK_5TJay7XQ_31_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">19760000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_SSEd4QlqZ0ixMnchHstv9w"
      decimals="-3"
      id="Tc_DfTt87h7MU6guM_5P81ZJg_31_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">23634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_GdCuc5FiVESKgoE6AuotSg_32_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">17895000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2024_wf2iuAS66kiC7r9Ko2A7aQ"
      decimals="-3"
      id="Tc_v9GY2soSUkW7-8FjnqErCA_32_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">23399000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_DLolvX-r9Eqwj-VYD-CXpA_4_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">378000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_lf5kNO5dPkS300lLYQev9w_4_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">121000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_i63YZGj-uEmfsc8S1yX06g_5_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">33000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_vrMnariiQ0OZbl7JIhmOXw_5_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">258000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc__vfFgxvVu0iwfyX9owP0zg_8_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">766000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_aCQoKK2NYkKPDsOra0-5gA_9_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">220000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_lkrzcdELk0O-B5pZgqXYSg_9_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">56000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_woFg3WAEqkeXrFIy2yvMAQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#x201c;Company&#x201d;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients and children four years of age and greater with Gaucher disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Elelyso was first approved by the U.S.&#160;Food and Drug Administration (&#x201c;FDA&#x201d;) in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. In May 2023, both the European Commission (&#x201c;EC&#x201d;) and the FDA announced the approval of Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia, Singapore, Australia and Taiwan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is committed to leveraging its record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat uncontrolled gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases (neutrophil extracellular traps).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio through two exclusive global licensing and supply agreements. On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;), with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). After giving effect to the sales under the Sales Agreement in January 2025, no shares of common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;) remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $20.0&#160;million. As of June&#160;30, 2025, approximately $15.7&#160;million in shares of Common Stock remain available to be sold under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel. In October 2023 Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and attacked civilian and military targets. The infiltration was accompanied by extensive rocket attacks by Hamas on industrial, civilian and military targets throughout Israel. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#x2019;s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel, as discussed above. In June 2025, Israel launched significant aerial attacks on military and related sites in Iran, and the Iranian military responded with missile and drone attacks in Israel, which was followed by strategic bombing by the U.S. Air Force. The U.S. action was followed by a cease fire with Iran which remains in effect as of the date hereof. Although ceasefire negotiations are on-going with Hamas and the level of military activity has decreased in recent months compared to previous levels, it is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#x2019;s business, operations and financial conditions. The Company&#x2019;s facilities are recognized as an &#x201c;essential enterprise&#x201d; in Israel which means the Company operates or can be operated for the purposes of state defense or public security or for the maintenance of essential supplies or services, allowing the Company to maintain operations during emergencies. However, the situation could disrupt certain of the Company&#x2019;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#x2019;s operations.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of June&#160;30, 2025, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;) on March&#160;17, 2025. The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Net earnings (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of Common Stock outstanding for each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#x201c;if-converted&#x201d; method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;d.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#x201c;2024 Notes&#x201d;). The repayment of the convertible notes at maturity was financed entirely with available cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to January&#160;1, 2024, the Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;e.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;New accounting &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;pronouncements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In November 2024, the FASB issued ASU&#160;2024-03 &#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures&lt;span style="font-family:'Palatino Linotype';background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_E4UhmIKRuEKi86osR_ioLA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#x201c;Company&#x201d;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients and children four years of age and greater with Gaucher disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Elelyso was first approved by the U.S.&#160;Food and Drug Administration (&#x201c;FDA&#x201d;) in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. In May 2023, both the European Commission (&#x201c;EC&#x201d;) and the FDA announced the approval of Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia, Singapore, Australia and Taiwan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is committed to leveraging its record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat uncontrolled gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases (neutrophil extracellular traps).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio through two exclusive global licensing and supply agreements. On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;), with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). After giving effect to the sales under the Sales Agreement in January 2025, no shares of common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;) remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $20.0&#160;million. As of June&#160;30, 2025, approximately $15.7&#160;million in shares of Common Stock remain available to be sold under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel. In October 2023 Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and attacked civilian and military targets. The infiltration was accompanied by extensive rocket attacks by Hamas on industrial, civilian and military targets throughout Israel. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#x2019;s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel, as discussed above. In June 2025, Israel launched significant aerial attacks on military and related sites in Iran, and the Iranian military responded with missile and drone attacks in Israel, which was followed by strategic bombing by the U.S. Air Force. The U.S. action was followed by a cease fire with Iran which remains in effect as of the date hereof. Although ceasefire negotiations are on-going with Hamas and the level of military activity has decreased in recent months compared to previous levels, it is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#x2019;s business, operations and financial conditions. The Company&#x2019;s facilities are recognized as an &#x201c;essential enterprise&#x201d; in Israel which means the Company operates or can be operated for the purposes of state defense or public security or for the maintenance of essential supplies or services, allowing the Company to maintain operations during emergencies. However, the situation could disrupt certain of the Company&#x2019;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#x2019;s operations.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of June&#160;30, 2025, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <plx:NumberOfGlobalLicensingAndSupplyAgreements
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="INF"
      id="Narr_Mr0ik3J3UkepsdGTd-vlEg"
      unitRef="Unit_Standard_agreement_R6tg8LdwCUeUoAN2h0xL2A">2</plx:NumberOfGlobalLicensingAndSupplyAgreements>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_1NEZJ566u0G9wZB2EoTpTg"
      decimals="2"
      id="Narr_SnVcygBGO0S1QcQLV3_y5Q"
      unitRef="Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_YPPSNBqug0mazz_yBXPpwQ"
      decimals="INF"
      id="Narr_2r_2E-D9QEiR5vZrhruxDQ"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_YPPSNBqug0mazz_yBXPpwQ"
      decimals="INF"
      id="Narr_qKxxs9zHK0uRxEO4new4Jw"
      unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance
      contextRef="As_Of_3_17_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_DSLkWT434UONxCiW0FQpqQ"
      decimals="-5"
      id="Narr_3jS8bLUjb0-BfKsW9QUP7g"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">20000000</plx:CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance>
    <plx:CommonStockValueOfCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_FzEf68MnnECijIQBxIjdcg"
      decimals="-5"
      id="Narr_geruRghsR0SAZ0STM8urlw"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">15700000</plx:CommonStockValueOfCapitalSharesReservedForFutureIssuance>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_5SXqhbhMS0uObp36imacdw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;) on March&#160;17, 2025. The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_vgtdJKXbhk2vRNOntGDOVw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Net earnings (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of Common Stock outstanding for each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#x201c;if-converted&#x201d; method.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_CDiL3nD89k6p_RihxvSkNw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;d.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#x201c;2024 Notes&#x201d;). The repayment of the convertible notes at maturity was financed entirely with available cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to January&#160;1, 2024, the Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_J-bqAQI5xUiCwzpV-Gys5Q"
      decimals="INF"
      id="Narr_vFkCTZvdIEe6BoIjZU3H7w"
      unitRef="Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_9uP82DbmvkOUi92sJ_m10A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In November 2024, the FASB issued ASU&#160;2024-03 &#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures&lt;span style="font-family:'Palatino Linotype';background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_XFtGlW-Vu028LI60m-_aKg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at June&#160;30, 2025 and December&#160;31, 2024 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,357&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,144&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,630&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Group_5mfmd0-jrECNWCRmPNfXFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at June&#160;30, 2025 and December&#160;31, 2024 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,357&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,144&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,630&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_8Fl06kS0AUqy2MBWAg2jDQ_3_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">4357000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_oApzV49rx0CejzqKWauFKA_3_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">4549000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_7P0U4pJG0EK0v2Ru8t9hsg_4_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">8144000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_uYFprKC6P0aSDZZI3wYKng_4_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">11245000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_6IdiTZWt4EmowQpLF3I0QA_5_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">8630000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_aiO6wd1_uk2CozCciC7UVQ_5_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">5449000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_Q8pHAirHek6-VX6dj4lnsg_6_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">21131000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_lMC-_FSEf0iD6bnu93x7yw_6_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">21243000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_HL45UST1nUOytQfUPOQ5MQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is identical or close to their carrying value.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_5DyqU5yZk0Wa69eXONBmDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 4 &#x2013; STOCK TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;During the three months ended March&#160;31, 2025, the Company issued &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;908,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million from such exercises. The remaining warrants expired on March&#160;11, 2025. Accordingly, &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;as of March&#160;12, 2025, &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; warrants remained outstanding&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;During the six months ended June&#160;30, 2025, the Company sold, in the aggregate, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2,775,215&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock under the Sales Agreement. &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company generated &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;gross proceeds equal to approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$7.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million in connection with such sales (issuance costs were &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;During the six months ended June&#160;30, 2025, the Company issued, in the aggregate, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;198,625&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock in connection with the exercise of options to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;198,625&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock by certain current and former employees of the Company. The Company received cash proceeds equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.3&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million in connection with such exercises.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_BskKyxhG5ketf2PCSTzhyw"
      decimals="INF"
      id="Narr_1ANNu_dmGEa0Bss_ldBkfw"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">908000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_BskKyxhG5ketf2PCSTzhyw"
      decimals="-5"
      id="Narr_SGba7zzPS0yrrgfnPXvGIw"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">2100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_12_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_KdZmUKvKIEagwl1U2B1ZLA"
      decimals="INF"
      id="Narr_NDIoPPH0vkKQLi0JhqYy3w"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_H8A_3lY72U6nRHPcehodwA"
      decimals="INF"
      id="Narr_-Jd1WUEGkEa8QVFPpdJh-Q"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">2775215</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <plx:GrossProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_H8A_3lY72U6nRHPcehodwA"
      decimals="-5"
      id="Narr_snts2Gr8FU26Qjj8lMja2w"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">7000000</plx:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_H8A_3lY72U6nRHPcehodwA"
      decimals="-5"
      id="Narr_B4oD44dAfkSgd6pOosMmYA"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFHYyBQEPE2I_t5p2bioTg"
      decimals="INF"
      id="Narr_unrLzfg3YEm7Ih0sCra2nw"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">198625</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFHYyBQEPE2I_t5p2bioTg"
      decimals="INF"
      id="Narr_EABleRMm1US_tPFTPRXrlQ"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">198625</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dFHYyBQEPE2I_t5p2bioTg"
      decimals="-5"
      id="Narr_DFOAMuSDGkiZ5dqLoL2rPw"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_iHyEK0sxdkK7rnVEbWHBXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; EARNINGS (LOSS) PER SHARE&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Basic and diluted earnings (loss) per share attributable to common stockholders were calculated as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss) for basic and diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,455)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,798)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,203)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,651,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,172,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,663,884&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,308,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of stock options and restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,607,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,651,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,172,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,271,610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,308,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;"&gt;Diluted earnings (loss) per share do not include 12,936,429 shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock and warrants for the six months ended June&#160;30, 2025 because the effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Diluted earnings (loss) per share do not include 2,365,709 shares of Common Stock underlying outstanding stock options for the three months ended June&#160;30, 2025 because the effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Diluted earnings (loss) per share do not include 31,744,960 and 31,791,645 shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock, warrants and the 2024 Notes for the three and six months ended June&#160;30, 2024, respectively, because the effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_9mGTyPMlQEOe6S7rlCyzjg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Basic and diluted earnings (loss) per share attributable to common stockholders were calculated as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss) for basic and diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,455)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,798)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,203)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,651,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,172,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,663,884&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,308,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of stock options and restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,607,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,651,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,172,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,271,610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,308,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_F8freIaE3EqGzySL814VRA_4_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-3455000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_3zW86VaBSkustABP0kNpeg_4_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-6798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_-79aeVUiz0eW6mccYTuxAQ_4_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">164000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_BVASvn3xrEaN4btBP2gcWw_4_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-2203000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="0"
      id="Tc_Ng4HO3U-KUGfcod_5rrA4w_6_3"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">77651330</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="0"
      id="Tc_tCDLG7wul0KoJvAX76bAgw_6_6"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">73172980</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="0"
      id="Tc_EUZkuQmzM06Tx1M1mQ9PqQ_6_9"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">78663884</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="0"
      id="Tc_oa4q9Z7AdUuj9o9LIJOaWQ_6_12"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">73308281</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="0"
      id="Tc_dLptJM0nQ0enRPxRlbPcIQ_7_9"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">2607726</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="0"
      id="Tc_d_rUZt_qw0ier9Bd21WHug_8_3"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">77651330</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="0"
      id="Tc_8E5eeyc6FUy8U1PQZXqcLA_8_6"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">73172980</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="0"
      id="Tc_t0QVohfS7kmpUC12Dtma0A_8_9"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">81271610</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="0"
      id="Tc_7eIHHKFy00qS9JYLdW-ltw_8_12"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">73308281</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_OSrevicPJEyApi98O9HZYw"
      decimals="INF"
      id="Narr_BQKWBlougUShm6K6mFWGOQ"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">12936429</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="INF"
      id="Narr_Jd2vQXzHM0yf_bHD3xyvTw"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">2365709</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_H3oHw-vHw0emnoAUC9JBzA"
      decimals="INF"
      id="Narr_r7UWY4uXQk21FKhtN2u54Q"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">31744960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_xTNzdzPaT0qCf53ldUBTUQ"
      decimals="INF"
      id="Narr_A2kbDg8J9U-gSDeP39oQmA"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">31791645</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_HqmhOi8HjUej0VtXhdaGOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; TAXES ON INCOME (TAX BENEFIT)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 118&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (207)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (69)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income (tax benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 384&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (207)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (69)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company had an effective tax rate of 13% for the six months ended June&#160;30, 2025 compared to an effective tax rate of (3)% for the six months ended June&#160;30, 2024. For the six months ended June&#160;30, 2025, the difference between the Company&#x2019;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of forecasted profits derived primarily from U.S.&#160;taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act of 2017 (the &#x201c;TCJA&#x201d;), which was enacted in December 2017.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On July&#160;4, 2025, tax reform legislation was enacted in the United States through the passage of H.R.1, One Big Beautiful Bill Act (&#x201c;HR1&#x201d;), which includes significant corporate tax changes, including a restoration of the current deductibility for domestic research expenditures beginning in 2025, with transition options for previously capitalized amounts. The Company continues to evaluate the impact that the new legislation will have on the consolidated financial statements.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Group_BNfUwtRf8ku4ofF0J65BZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 118&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (207)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (69)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income (tax benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 384&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (207)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (69)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_xZgT5HmG0E69Fj7_8vDu-g_3_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">266000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_NAtsWuunT0SqQWPHVzyRXA_3_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">266000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_kfx4rB8H6kaAwrozXXp6XQ_4_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">118000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_ZfisHjACr0-ArwFeOFj0Ug_4_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-207000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_dpgudmlYU0iOo3_z6-FwGw_4_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">231000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_mBdbZW4ar0Gc8VMZd3FfMw_4_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-69000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="-3"
      id="Tc_TzACwMOSB0y-3iAsPB59iA_5_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">384000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="-3"
      id="Tc_G11UkH6hX0aReEWTU5jAKw_5_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-207000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      decimals="-3"
      id="Tc_VViQ9mCPAEeDkxtavF4RJg_5_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">497000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      decimals="-3"
      id="Tc_Ei-LXCaPk02D_XCxC_8hRg_5_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-69000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="2"
      id="Narr_nr698p2f5EGCpYf4mmo0DA"
      unitRef="Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ">-0.13</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      decimals="2"
      id="Narr_KRHB0nQFHUS651PGpgl6XA"
      unitRef="Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ">0.03</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      decimals="2"
      id="Narr_DPyuy7_V402Rv_Eq5c3YAg"
      unitRef="Unit_Standard_pure_NuK_Fi-SGEODoqsPDKzMuQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_VgaFp2RcoUWjw-HW_nJLvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 7 &#x2013; &lt;/b&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;SEGMENT INFORMATION&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company operates in Israel as a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_aiZWtzxgnU-JSOrCWSBBBw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; operating segment. The Company&#x2019;s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Segment information:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from customers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,771&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,474&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee salaries and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,649&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,357&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sub-contractors expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,463&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,609&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (528)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (757)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (272)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (374)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 706&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 360&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment expenses*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,552&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income (loss) before taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,071)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,005)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,272)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Taxes on income (tax benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 384&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (207)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,455)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,798)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,203)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;"&gt;* Other expenses included in net income includes raw materials, rent and utilities and others.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Gaucher disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer (Ireland)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;12,626&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5,647&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6,874&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fiocruz (Brazil)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4,716&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fabry disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi (Italy)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,714&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;25,435&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;16,981&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;15,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;13,304&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;336&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;170&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;d.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Long lived assets are located in Israel.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_Q1vpxTm6702NDGaaGPgumQ">&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Segment information:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from customers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,771&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,474&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee salaries and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,649&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,357&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sub-contractors expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,463&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,609&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (528)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (757)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (272)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (374)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 706&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 360&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment expenses*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,552&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income (loss) before taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,071)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,005)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,272)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:51.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Taxes on income (tax benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 384&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (207)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (69)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,455)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,798)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,203)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;"&gt;* Other expenses included in net income includes raw materials, rent and utilities and others.&lt;/p&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg"
      decimals="-3"
      id="Tc_hZJ4MqPiuE2r1MBzkHKigA_3_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">25771000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q"
      decimals="-3"
      id="Tc_f8kmu7iFy0ayRKShU9uOVA_3_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">17222000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA"
      decimals="-3"
      id="Tc_tzhbvyn8MkC52y2g-uY0EA_3_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">15658000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA"
      decimals="-3"
      id="Tc_r2rRQR-GAEWQWJtz4b31Ww_3_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">13474000</us-gaap:Revenues>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg"
      decimals="-3"
      id="Tc_0i9a4FtZDUutXu3qR3BqOw_5_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">10649000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q"
      decimals="-3"
      id="Tc_NqPKTRWLYEiAesJv0-NEfA_5_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">10357000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA"
      decimals="-3"
      id="Tc_iKvV-I1pakylOU2EYgWFzw_5_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">5444000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA"
      decimals="-3"
      id="Tc_ER0RH9SlnEGgMSO3EwBaQw_5_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">5213000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg"
      decimals="-3"
      id="Tc_I-0D9zV0B0GUzOOwqkN4kQ_6_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">7463000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q"
      decimals="-3"
      id="Tc_o4F8azEvE0isM8UXQ9xYgw_6_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">4764000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA"
      decimals="-3"
      id="Tc_Fwc67k2etU6rb7PRV96NFw_6_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">4773000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA"
      decimals="-3"
      id="Tc_BpOF2D1s60yfjx8kyXN7cQ_6_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">2609000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q"
      decimals="-3"
      id="Tc_SJoliR-fpEaQ53c822d2ZA_7_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">761000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA"
      decimals="-3"
      id="Tc__pu69sqn-0u46gWuhZE8nA_7_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">379000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg"
      decimals="-3"
      id="Tc_NcFTSI0GOE-V_OfR0AktfA_8_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">528000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q"
      decimals="-3"
      id="Tc_fOLh-NQWWUONYxnCZ9veJw_8_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">757000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA"
      decimals="-3"
      id="Tc_8c1b9ZTlVEajjyKwWEgqcA_8_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">272000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA"
      decimals="-3"
      id="Tc_epPbcno_20qjWi_F2RCJpA_8_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">374000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg"
      decimals="-3"
      id="Tc_-4ijikXqx0ajeD3KP3PxdA_9_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">706000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q"
      decimals="-3"
      id="Tc_CRcfRlLwg0---noMOe8IFg_9_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">641000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA"
      decimals="-3"
      id="Tc_9Gv3da9OK0Gqctu2KkMG9Q_9_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">360000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA"
      decimals="-3"
      id="Tc_2GKLzywQ002OuX7Qw8k82w_9_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">319000</us-gaap:Depreciation>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg"
      decimals="-3"
      id="Tc_KXpaHKcDBEu25-4UpyaH6Q_10_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">10552000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q"
      decimals="-3"
      id="Tc_dF2qORBR5UuORH9T3cYghg_10_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">8461000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA"
      decimals="-3"
      id="Tc_1cw5eeoLPkGKCd5vPu4pIQ_10_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">4692000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA"
      decimals="-3"
      id="Tc_ysunOtYrZEqwMpEXGAWg1A_10_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">7600000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg"
      decimals="-3"
      id="Tc_7Jf8pvOSO0ykUO8QLptDcA_11_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-3071000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q"
      decimals="-3"
      id="Tc_yWAGsCiJHEOL6aiuqAUt2w_11_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-7005000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA"
      decimals="-3"
      id="Tc_RGqQP3oiN0unyiqhV8FVfA_11_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">661000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA"
      decimals="-3"
      id="Tc_wd8HhYEvckK7Hz5i1NpFLA_11_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-2272000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg"
      decimals="-3"
      id="Tc_S7saCiF1CUSB2ceFk5M4_w_12_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">384000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q"
      decimals="-3"
      id="Tc_4oeC_D-wPUCJBNPxRPCb4g_12_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-207000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA"
      decimals="-3"
      id="Tc_s9uMJuMMIkeC0FhChiNZMg_12_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">497000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA"
      decimals="-3"
      id="Tc_IDRwQRpqwEaaN_XlRRah3w_12_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-69000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_GNu7sO8RFkqVBKR7qCGBvg"
      decimals="-3"
      id="Tc_7zBAfkjxvk2c_lh4txk0pA_13_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-3455000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_ujXm5NkehkWgpepAMSx33Q"
      decimals="-3"
      id="Tc_7kBV7VjuSkOK8d4Xb-7-gw_13_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-6798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2025_To_6_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_2v02UjgOX0GGzPjwPPaLhA"
      decimals="-3"
      id="Tc_yW65z1RslU6mR7-LRxQjvg_13_9"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">164000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_H7Clwrc3GUm2p1KktOWGxA"
      decimals="-3"
      id="Tc_j_2C1Us46EysWCi1_LYr-Q_13_12"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">-2203000</us-gaap:NetIncomeLoss>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2024_To_6_30_2024_Y4_SgclmxUWHvg1l_fXhAA"
      id="Narr_yb07mZVDHUulKOJ25TrVaw">Other expenses included in net income includes raw materials, rent and utilities and others.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_4_1_2024_To_6_30_2024_8WIM05YkWku3b2l9LS0NMQ"
      id="Narr_kSbwOFa_rEKTjIBPrR1TAQ">Other expenses included in net income includes raw materials, rent and utilities and others.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Narr_oVKpKdrwhka1akezzI6fsA">Other expenses included in net income includes raw materials, rent and utilities and others.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      id="Narr_qC9n0gkZ9k-H5PHkg6Z4SA">Other expenses included in net income includes raw materials, rent and utilities and others.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_5w6SzUPYgUW7zyptUDZ3kA">&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Gaucher disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer (Ireland)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;12,626&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5,647&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6,874&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fiocruz (Brazil)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;7,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4,716&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fabry disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi (Italy)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,714&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;25,435&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;16,981&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;15,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;13,304&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:47.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;336&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;170&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_lOvXmD6MgESV0B-omrPS4Q"
      decimals="-3"
      id="Tc_s4-KtEov1UKtU4C3M-pt2g_4_2"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">12626000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_yAabyI-paEuRtn18CZC1RA"
      decimals="-3"
      id="Tc_sNoob_g9nUuJps3Mevt26A_4_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">8001000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_6_coWg2e90CjjtM9azRMBg"
      decimals="-3"
      id="Tc_DPFTb9DNGkCSBSckbmV_BA_4_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">5647000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_Nr4z7GCvjkSm2YfF7bwdZg"
      decimals="-3"
      id="Tc_N27CjTqen0-mA8X67_UZHQ_4_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">6874000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_YHDGlfD_AUaicoScEusHeg"
      decimals="-3"
      id="Tc_hxfKIqEXUUm3cYlD94FxrA_5_2"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">3016000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_Qa6aQzsVJ062wE77uGETpQ"
      decimals="-3"
      id="Tc_uRFFP769RkiRl9CpB5DuJQ_5_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">7266000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember__Vfwx-5_M0Cu0g0xtW7Dkg"
      decimals="-3"
      id="Tc_46bWuVZzG0ybOv3TF8-X1g_5_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">4716000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_GrF2myzJiEqbTvJY60IqmQ"
      decimals="-3"
      id="Tc_Y2WplVQKuEGD1R5G-hxMlw_7_2"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">9793000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_vu813cbeqECqUyYxxfs3Wg"
      decimals="-3"
      id="Tc_eIyFfjOUkEKy2hJN6BQo9g_7_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1714000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2025_To_6_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_mBt_DhnwSkaQSv72fYtQQg"
      decimals="-3"
      id="Tc_cO504aYBmkyA7UF2tZkSYg_7_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">9793000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_LpkP8tV3j0qgmNzcnf0nig"
      decimals="-3"
      id="Tc_fymEMkZquUq1pZvzDnwh9w_7_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1714000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_c_PLLEX5ekOtxFhMT3jjag"
      decimals="-3"
      id="Tc_FVKkpoihTkOlMfebkyOhUg_8_2"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">25435000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_ls4KWM6TWU2ieTyrmZgYpw"
      decimals="-3"
      id="Tc_od5hk-9rgUuFchs8-FPReQ_8_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">16981000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_iejKZn67F0Sf2DaGIlWrig"
      decimals="-3"
      id="Tc_ynvn_rT9Tk6go1ZMwUPVlA_8_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">15440000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_r_xBq1FYmEe1hu9bPCmlCg"
      decimals="-3"
      id="Tc_WxAv5RoqCEWNbagHxiCUWA_8_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">13304000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_W2wc6JkTt0WlVF693XXzxw"
      decimals="-3"
      id="Tc_GNGekzq-EUG7ssbqA_8k4Q_9_2"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">336000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_rUd6RnaD1Ea21Qe6MwDvwg"
      decimals="-3"
      id="Tc_IJYuAfgwTU22KrpaN-KWbw_9_5"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">241000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2025_To_6_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Ry9eJBFRY0aWUriRJJoWPw"
      decimals="-3"
      id="Tc_yvVR1HQvkUmEZUSV_Gq50g_9_8"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">218000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_71I2lv4f9kWJWcfI-ONvvA"
      decimals="-3"
      id="Tc_vBuIp_qYKEaClaLQaLB8JQ_9_11"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">170000</us-gaap:Revenues>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_eTJ64BGxZkCu3snMM-ee3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 8 &#x2013; &lt;/b&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance sheets:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,209&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,811&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 763&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,080&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,742&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payable to customer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,056&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <plx:SupplementaryBalanceSheetsInformationTableTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_OhOEhaaVrkaWpDPW1fu8wQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,209&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,811&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 763&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,080&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,742&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payable to customer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,056&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:SupplementaryBalanceSheetsInformationTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_MqZQx3rTDEGBuuZwKm59sw_4_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1527000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_O_CV6GcgSEq2P22tfLuR8Q_4_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1343000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_srsKrp2LakqzQjqjhbQULQ_5_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">2209000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_hNpL06ST9k674XLaI_dmsQ_5_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1811000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_hDQCssK0x06vGHDW7nqPng_6_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">7311000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_OufxySyxGkCoyAFZFm1XTw_6_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">9568000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_KQ7LXB_b2UC0XZwTKnkyhA_7_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">763000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_KX8ig6UbBUa9C2A4OCgVbw_7_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1080000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_NEVP0yvPHU-QjhCPfSaAZg_8_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">3742000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_qpFTtn3YbEWJs8x9YOGgUw_8_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">3476000</us-gaap:TaxesPayableCurrent>
    <plx:PayableToCustomerCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_OXt8nZ9g8kGup90mUftlUw_9_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">2056000</plx:PayableToCustomerCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_HXeOHaoTakOb7MbeKpg6sw_10_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">378000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_BWM9oTSnXE2WqwLzbzE9eg_10_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">254000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_6_30_2025_Kpy5nLCIGUCMkj996ByAeg"
      decimals="-3"
      id="Tc_dYud74kTMkehs6HAisjrUg_11_3"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">15930000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_12_31_2024_bDT5zRnxv06LzEDvXIwRlw"
      decimals="-3"
      id="Tc_-akLPMdizkeKP6tMhWHU_w_11_6"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">19588000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2025_To_6_30_2025_cj-e6eT7c0mo0g0-ee5uQQ"
      id="Tb_2UTDmpAotk-CpVb4PZEtsw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 9 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Since the end of the quarter ended June&#160;30, 2025, the Company collected approximately $1.4&#160;million from sales to Pfizer and approximately $7.8&#160;million from sales to Chiesi.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;On July&#160;20, 2025, the Company granted, with the approval of the Company&#x2019;s compensation committee, 10-year options to purchase 597,990 shares of Common Stock, in the aggregate, to the Company&#x2019;s incoming Sr.&#160;Vice President and Chief Financial Officer under the under the Company&#x2019;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#x201c;Plan&#x201d;). The options have an exercise price equal to $1.45 per share and vest over a three-year period in 12&#160;equal quarterly increments. Vesting of the options is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $&lt;span style="direction:rtl;"&gt;0.6&lt;/span&gt;&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromCustomers
      contextRef="Duration_7_1_2025_To_8_14_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_kUAPHqMvy0ainpcMZtiRig"
      decimals="-5"
      id="Narr_j4UXtjX8dUeCdjKMNTAGMg"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">1400000</us-gaap:ProceedsFromCustomers>
    <us-gaap:ProceedsFromCustomers
      contextRef="Duration_7_1_2025_To_8_14_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_DphnniDSq0SBx-JnoOYjZA"
      decimals="-5"
      id="Narr_QtWXhi5sDUKbQZSzHcehwA"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">7800000</us-gaap:ProceedsFromCustomers>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg"
      id="Narr_xbkGmc7wDUiQZVFhWFt7qg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg"
      decimals="INF"
      id="Narr_t-mbo8lje0-oOlRRA1bbgw"
      unitRef="Unit_Standard_shares_ItwuuLCJpUiObxYBYL2gsQ">597990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg"
      decimals="2"
      id="Narr__ifj5iKkPk6OiGhy_4qAvg"
      unitRef="Unit_Divide_USD_shares_OikgtHpiRkujRkVT4fNV2g">1.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg"
      id="Narr_F1MsSGRD2Eyc-qX-JLaR3w">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_7_20_2025_To_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qVgZ2rpdFUGyZJEP_OamVg"
      decimals="INF"
      id="Narr_81y6vS_Xoky14KrpnzmMOQ"
      unitRef="Unit_Standard_installment_ZMevQBZ1KEOi7rMSOC56JQ">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_7_20_2025_srt_TitleOfIndividualAxis_plx_SeniorVicePresidentAndChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2W9cGUF6_ESGJ2hjWELYOw"
      decimals="-5"
      id="Narr_cIRC1Eshu0-VKfibNPlUbQ"
      unitRef="Unit_Standard_USD_z3XlW9HYx0--Nwg6A5i8bA">600000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      id="Narr_DF_iPi24eUao-E3ffWckYg">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      id="Narr_rpVsv0R8aUK_juQKVZm8Cw">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      id="Narr_qBfL0My1k0upycp94DX_wQ">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_4_1_2025_To_6_30_2025_mt9nqjrloEiyCB8yKHslOQ"
      id="Narr_9P1rdKXnjESZreQD-QmO5A">false</ecd:Rule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_8DGpfWJ6u0yrb1j10aB90g_10_2"
          xlink:label="Tc_8DGpfWJ6u0yrb1j10aB90g_10_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; Authorized &#x2013; as of June&#160;30, 2025 and December&#160;31, 2024 &#x2013; 185,000,000 shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_8DGpfWJ6u0yrb1j10aB90g_10_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_E59k4yziiUa67x_HxpXThA_24_2"
          xlink:label="Tc_E59k4yziiUa67x_HxpXThA_24_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_E59k4yziiUa67x_HxpXThA_24_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_1cUpthGGJEqf6itNfIU1ZA_18_2"
          xlink:label="Tc_1cUpthGGJEqf6itNfIU1ZA_18_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_1cUpthGGJEqf6itNfIU1ZA_18_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_1gTmG3hllU66Zqf80x33Nw_32_2"
          xlink:label="Tc_1gTmG3hllU66Zqf80x33Nw_32_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_1gTmG3hllU66Zqf80x33Nw_32_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_JUsHG8EYSEWT6N4MJbloMQ_6_2"
          xlink:label="Tc_JUsHG8EYSEWT6N4MJbloMQ_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_JUsHG8EYSEWT6N4MJbloMQ_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_rM1xId7NxkWW208M0pKjng_21_2"
          xlink:label="Tc_rM1xId7NxkWW208M0pKjng_21_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_rM1xId7NxkWW208M0pKjng_21_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_qBTNBNI8cE-e-oypr6TgsQ_26_2"
          xlink:label="Tc_qBTNBNI8cE-e-oypr6TgsQ_26_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_qBTNBNI8cE-e-oypr6TgsQ_26_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_MHpHHWRQRUW2J_oQ3TlEYQ_12_2"
          xlink:label="Tc_MHpHHWRQRUW2J_oQ3TlEYQ_12_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_MHpHHWRQRUW2J_oQ3TlEYQ_12_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_5YdKmLQiKkezM06rF9KC3g_13_2"
          xlink:label="Tc_5YdKmLQiKkezM06rF9KC3g_13_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_5YdKmLQiKkezM06rF9KC3g_13_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_hlYrSjoLfkmyEVTMYIoDcw_27_2"
          xlink:label="Tc_hlYrSjoLfkmyEVTMYIoDcw_27_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_hlYrSjoLfkmyEVTMYIoDcw_27_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_VvyQGZl5rE-JlitgqqJ8gg_34_2"
          xlink:label="Tc_VvyQGZl5rE-JlitgqqJ8gg_34_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_VvyQGZl5rE-JlitgqqJ8gg_34_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_SimVJaL030ORTwulZYu9zw_20_2"
          xlink:label="Tc_SimVJaL030ORTwulZYu9zw_20_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_SimVJaL030ORTwulZYu9zw_20_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_R6K5a9hlw0WIYzXuvs9mOw_15_2"
          xlink:label="Tc_R6K5a9hlw0WIYzXuvs9mOw_15_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_R6K5a9hlw0WIYzXuvs9mOw_15_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_iNSN0warEkSepi8qJ6f5lw_29_2"
          xlink:label="Tc_iNSN0warEkSepi8qJ6f5lw_29_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_iNSN0warEkSepi8qJ6f5lw_29_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
